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There are multiple similarities between the central canal region of the spinal cord and 
the adult neurogenic niches in the mammalian brain. The central canal region 
displays increased proliferation after injury with migration of the newly-proliferated 
cells to the site of injury and differentiation into astrocytes and oligodendrocytes. This 
study will look at the role of purinergic signalling in the ependymal cells and CSF-
contacting cells (CSFcCs) as the CSFcCs present in this area express P2X receptors 
containing the P2X2 subunit. 
Local application of ATP elicited fast depolarisations via activation of suramin-
sensitive channels in a subgroup of CSFcCs comprising both spiking and non-spiking 
subtypes of CSFcC (types 1, 2 and 3). The P2X2/3,3-specific antagonist A-317491 had 
no effect in the majority of CSFcCs but produced a reduction in depolarisation in a 
subgroup of CSFcCs predominantly located ventral to the central canal, with the 
ventral expression of the P2X3 subunit supported by immunohistochemistry.  
Ependymal cells and the remainder of CSFcCs produced a suramin-insensitive 
hyperpolarisation to the application of ATP or UTP, while producing a small 
depolarisation to the dinucleotide polyphosphate Ap4A.  
Modulation of purinergic signalling had no effect on proliferation rate in spinal cord 
slices over a 4 hour time period, nor did it affect the survival rate of the newly-
proliferated cells over 5 days in organotypic slice cultures. In this model, inhibition of 
purinergic signalling with suramin reduced the migration of newly-proliferated 
ependymal cells away from the central canal, while inhibition of the breakdown of 
ATP by ARL 67156 facilitated this migration.  
The presence of fast acute responses to ATP including spatial variation in receptor 
subtypes indicates the importance of purinergic signalling in this area and the release 
of ATP known to be triggered by spinal cord injury could now have a role in the 
necessary migration of newly-proliferated ependymal cells.   
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Chapter 1 - General Introduction
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1.1 Introduction to the central canal region of the spinal cord 
 
The spinal cord is a bundle of neural fibres and cells which runs down the vertebral 
column, extending from the medulla oblongata in the brainstem to the lumbar region. 
The primary function of the spinal cord is to relay messages between the peripheral 
nervous system (PNS) and the central nervous system (CNS), however there are 
also several other functions independent of the brain. The spinal cord has many 
neural circuits, controlling both reflexes and central pattern generators for locomotion.  
The core of the spinal cord is made up of the cellular grey matter, surrounded by the 
neuronal tracts of the white matter (De Leener et al., 2016). Through the centre of the 
grey matter is the central canal through which the cerebrospinal fluid flows. There are 
31 segments in the human spinal cord, 8 cervical segments, 12 thoracic segments, 5 
lumbar and 5 sacral segments, with each segment having two dorsal and two lateral 
roots which combine to form a single pair of spinal nerves. The dorsal roots consist of 
a bundle of the axons of sensory neurons with their cell bodies in the dorsal root 
ganglia. The ventral roots have efferent fibres containing axons from autonomic pre-
ganglionic neurons and motor neurons with their cell bodies sitting in the ventral horn. 
There are also many interneurons and non-neuronal cells within the spinal cord.  
The spinal cord is contained within 3 protective layers of membrane, known as the 
meninges. The innermost of these is the pia mater which closely wraps around spinal 
cord and roots. The next layer is the arachnoid mater, with the space between the pia 
and the arachnoid mater called the subarchnoid space. Outside the arachnoid mater 
is a final tough protective layer, called the dura mater (Russi and Brown, 2015). 
The grey matter of the spinal cord is organised into 10 layers called the Rexed 
laminae (Rexed, 1952; Molander et al., 1984) (Figure 1.1). Laminae I-VI are located 
in the dorsal horn, lamina VII forms the intermediate zone, laminae VIII and IX are in 
the ventral horn and lamina X sits around the central canal. This work focuses on the 
area immediately surrounding the central canal and the cell types and characteristics 




Figure 1.1 Rexed laminae of the spinal cord showing the central canal in the 
centre of lamina X 
Diagram of a transverse spinal cord section showing the white matter surrounding the 
grey matter. The grey matter is divided into 10 layers (I-X) as identified by Bror 
Rexed, with each layer corresponding to a column of cells defined by their cell 
structure. The central canal (CC), through with the CSF flows, is shown in the centre 
of lamina X. 
 
1.2 The components of the central canal region 
 
The key components of the central canal region are the cells that form the ependymal 
cell layer that line the central canal, the cerebrospinal fluid (CSF) which flows through 
the central canal and the tanycytes and CSF-contacting cells which sit within or just 





Figure 1.2 The components of the spinal cord central canal region 
Schematic of the location and cellular components in the central canal as shown on a 
transverse view of the spinal cord. The close view of the central canal shows 
ependymal cells surrounding the central canal through which the CSF flows. 
Interspersed in the ependymal layer and just outside it are cerebrospinal fluid 
contacting cells (CSFcCs) and tanycytes.  
1.2.1 The cerebrospinal fluid 
The cerebrospinal fluid (CSF) is part of the extracellular fluid in the central nervous 
system (CNS). CSF is secreted by the choroid plexus of the cerebral ventricles 
(Spector et al., 2015). The choroid plexus is a highly vascularised region of the 
ventricles with modified ependymal cells which are highly tight-junction coupled. 
Plasma is filtered from the blood through the choroid plexus cells, which then also 
actively transport many small molecules into the CSF.  
The net flow of CSF is caudal, from the choroid plexus predominantly in the lateral 
ventricles, to the 4th ventricle and down the central canal of the spinal cord and 
5 
 
through the caudal opening; however a large proportion is absorbed by the lateral 
apertures of Luschka into the sub-arachnoid space without going down the central 
canal. The CSF that flows down the spinal cord is subject to two biphasic tides, the 
caudal flow and the cephalic ebb (Whedon and Glassey, 2009). 
In adult humans, approximately 500 ml is produced each day with a maximum of 
150 ml present at any point. Of this, only about 30 ml is present within the ventricles 
and central canal. The remaining 110 ml sits within the subarachnoid space, between 
the dura and pia maters. In mice, the total CSF volume is only approximately 40 μl 
(Oshio et al., 2005).  
Although there are turbulences and ebbs, the CSF has been measured to flow at 
approximately 1 cm/minute (Cifuentes et al., 1994). At the filum terminale, one or 
several openings allow the CSF to pass into the subarachnoid space (Nakayama, 
1976). Whilst some CSF is absorbed into the spinal cord tissue, most is released into 
lymphatic vessels or veins (Maillot, 1990). 
Despite the tight junctions in the choroid plexus, the majority of the ependymal cell 
layer lining the central canal of the spinal cord does not possess tight junctions, and 
thus allows for considerable flow between the CSF and the extracellular fluid of the 
spinal cord tissue. The level of permeability is lower in foetal stages and increases 
into adulthood to the extent that it is permeable to 70 kDa plasma proteins (Whish et 
al., 2015). Approximately 75 % of the CSF is produced by the choroid plexuses in the 
lateral ventricle, while the other 25 % passes into the CSF system through the 
ependymal surfaces in the brain and spinal cord after being produced by the CNS 
parenchyma (Veening and Barendregt, 2010). 
The CSF contains ions (Na+, Cl-, HCO3-, and lower concentrations of K+, Mg2+ and 
Ca2+), peptides, proteins, and micronutrients such as vitamin C and folate (Spector et 
al., 2015) with the overall concentration of salts high and the protein concentration 
relatively low. The CSF also carries signalling molecules such as hormones (e.g. 
leptin) and growth factors (e.g. brain-derived neurotrophic factor). Some 
neuropeptides are produced by the choroid plexus such as the thyroid hormone 
carrier, transthyretin (Veening and Barendregt, 2010). Cells of the choroid plexus 
bordering the CSF also release neuropeptides into the CSF, which could then have 
actions on other parts of the CNS (Nilsson et al., 1992). Many fibres are observed in 
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the sub-ependymal layer of the lateral ventricles, such as serotonergic fibres, and are 
also thought to be releasing substances into the CSF. 
The main functions of the CSF, in addition to signalling, are buoyancy, reducing the 
effective mass of the brain from 1200 g to 45 g (Spector et al., 2015) and thus 
preventing the damage that would occur with that weight of brain tissue, protection 
from impacts and chemical and fluid stability. Both the volume and the composition of 
the CSF can adapt to the needs of the central nervous system (Johanson et al., 
2008), providing homeostasis for the extracellular fluid in the brain and spinal cord. A 
last important function of the CSF is as the clearance mechanism for the CNS. As the 
CNS lacks a lymphatic clearance system, metabolites and toxins are cleared by the 
CSF and either via active absorption by cells or by draining of the CSF into venous 
and lymphatic systems (Johanson et al., 2008). The CSF is also involved in multiple 
signalling procedures. The flow of the CSF is involved in directing the migration of 
newly proliferated cells from the adult subventricular zone (SVZ) (Sawamoto et al., 
2006).The constituents of the CSF also have signalling roles for example insulin-like 
growth factor (IGF-2) levels stimulate stem cell production in development and 
glioblastomas (Lehtinen et al., 2011). These indicate that the CSF fulfils a range of 
roles and is involved in signalling with the CNS cells by a multiple methods.  
1.2.2 CSFcCs 
1.2.2.1 Distribution and structure of CSFcCs 
CSFcCs represent a population of cells which have been identified in a range of 
species from marine chordates such as lancelets to mammals including humans 
(Bruni and Reddy, 1987; Lamotte, 1987; Bjugn et al., 1988; Vigh et al., 2004) and are 
present along the length of the ventricular system and the central canal.  
These cells sit in the ependymal cell layer or subependymally and send a dendritic 
process into the internal CSF. These processes bear a number of stereocilia, with the 
number of the stereocilia varying between species. Many of these cells also possess 
axons extending away from the central canal and making contact with the external 
cerebrospinal fluid in the subarachnoid space (Lamotte, 1987; Stoeckel et al., 2003). 
The number of CSFcCs is not consistent between species, with far lower numbers in 
mammals compared to fish or amphibians (Vigh and Vigh‐Teichmann, 1998; Vigh et 
al., 2004). Non-mammalian vertebrate CSFcCs bear a cilium in addition to the 
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stereocilia, however mammalian CSFcCs do not possess this (Vigh et al., 1977). Cilia 
are supported by a cytoskeletal structure called the axoneme which is composed of 
microtubules. The formation of the axoneme differs between different types of cilia. 
The cilia typically have a circle of 9 doublets (9x2) or triplets (9x3) microtubules with 
motile cilia also having a pair of central microtubules (9x2+2). The type of cilium 
present changes between ventricular CSFcCs and medullo-spinal CSFcCs. While 
ventricular CSFcCs have a 9x2+0 cilium which is characteristic of chemosensory 
cells, medullo-spinal CSFcCs express a 9x2+2 kinocilium which is typical of 
mechanosensory cells such as those in the inner ear and the lateral line organ of fish. 
This kinocilium has been seen to be associated with Reissner’s fibre in the carp, 
which is the fibre from the subcommissural organ that runs through the ventricular 
system and suggests a role in detection of movement of the spinal cord (Vigh et al., 
2004). Whilst the lack of kinocillia in the mammalian system makes this role for 
CSFcCs less likely, there are a number of other factors suggesting a range of roles 
involved in detection of the internal CSF and intercellular solution.  
1.2.2.2 CSFcC expression profile 
CSFcCs express immature neuronal markers and markers of plasticity 
CSFcCs do not have the characteristics of fully mature neurons, instead maintaining 
expression of immature neural markers, doublecortin (Dcx), a neuronal migration 
protein, and neuronal RNA-binding proteins HuC/D into adulthood (Marichal et al., 
2009). Dcx expression is typical of migrating neuroblasts (Kuhn and Peterson, 2008), 
with expression of Dcx ceasing as they become electrophysiologically mature 
neurons and become positive for the mature neuronal marker NeuN (Neuronal 
Nuclei)(Mullen et al., 1992). Hu proteins are expressed in the very early stages in 
newborn neurons (Marusich et al., 1994). CSFcCs do not express NeuN (Marichal et 
al., 2009), and whilst NeuN is not a definitive marker for mature neuronal cells with 
cell types including cerebellar Purkinje and Golgi cells of the cerebellum (Mullen et 
al., 1992; Tulke et al., 2016) devoid of NeuN in maturity, this supports the conclusion 
of an immature neuronal profile suggested by the expression Dcx and HuC/D by 
CSFcCs. In addition to expression during immaturity, many of these markers are also 
expressed during times of neuronal plasticity and remodelling. Hu proteins (Okano 
and Darnell, 1997; Deschênes‐Furry et al., 2006) and Dcx (Nacher et al., 2001; 
Brown et al., 2003) are expressed in mature neurons during neuronal remodelling 
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and sprouting as shown in neurons of the piriform cortex (Nacher et al., 2004). Other 
markers associated with neuronal plasticity and neural development which CSFcCs 
express include Polysialylated Neural Cell Adhesion Molecule (PSA-NCAM) and 
Growth Associated Protein 43 (GAP-43; a protein expressed in high levels in 
neuronal growth cones during development and during axonal regeneration and 
plasticity) (Theodosis et al., 1994; Benowitz and Routtenberg, 1997; Cremer et al., 
2000; Stoeckel et al., 2003; Studeny et al., 2005; Marichal et al., 2009; Reali et al., 
2011). The polysialylated form of NCAM is more commonly found in immature 
neurons (Seki and Arai, 1993), with expression maintained into adulthood within 
proliferative areas such as the subventricular zone (SVZ) (Bonfanti and Theodosis, 
1994) and where cells are undergoing plasticity. However CSFcCs are not 
proliferative past embryological periods. They do not express proliferating cell nuclear 
antigen, an endogenous cell cycle protein expressed in all stages of the cell cycle of 
proliferating cells (Marichal et al., 2009). Additionally, when a marker for proliferating 
cells, EdU or BrdU (thymidine analogues that are incorporated into any DNA 
undergoing DNA replication) was applied between P0 and P5 no CSFcCs were 
labelled, with all CSFcCs being labelled when the thymidine analogue was applied 
before E17 (Marichal et al., 2009; Petracca et al., 2016). This indicates that all 
CSFcCs are born embryologically and the expression of these molecules above 
suggests that they are either still undergoing development into adulthood, or are in a 
state of dormant plasticity.  
Subcellular components and synaptic equipment 
The process of CSFcCs which passes through the ependymal cell layer ends in a 
globular expansion containing numerous vesicles of varying size and shape and 
many mitochondria (Alfaro‐Cervello et al., 2012). They were distinguishable from the 
surrounding ependymal cells by their less electron-dense cytoplasm, lack of 
intermediate filaments and a wealth of rough endoplasmic reticulum and ribosomes. 
CSFcCs were shown to receive axosomatic synaptic contacts (Alfaro‐Cervello et al., 
2012) and have axons that lead away from the central canal (Stoeckel et al., 2003). 
These axons are present in CSFcCs caudal to mid thoracic levels and are very small 
and unmyelinated (Stoeckel et al., 2003). These axons run around and through the 
ependymal cell layer to the ventral end of the central canal and form axon bundles 
which run ventrally from the central canal and through the corticospinal tract and then 
along the sides of the ventral median fissure. The presence of visible bundles only in 
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the more caudal regions of the spinal cord suggests that they may also run caudally 
down the spinal cord but this has not been confirmed. These axons are 
immunoreactive for GAP-43, which is involved in neurite outgrowth by regulating 
cytoskeletal organisation (Benowitz and Routtenberg, 1997).  
Whilst the CSFcC axons express a number of synapse-associated proteins in 
mammals, these are not arranged in discrete synapses in the mammalian spinal cord 
(Stoeckel et al., 2003). The axonal tracts were strongly labelled with synaptotagmin 
and more lightly labelled with both synaptophysin and cysteine string protein (CSP). 
Diffuse labelling of synaptic proteins has been observed in neurons undergoing 
differentiation or preceding synapse establishment (Rene et al., 1996). However in 
non-mammalian species functional synapses are observed. In Xenopus spinal cord, 
CSFcC axons form endings with dense-cored vesicles and small, clear vesicles, 
usually into the external CSF (Vigh et al., 1977). The axons in the non-mammalian 
CSFcCs also run ventrally, terminating on the ventrolateral surface between glial 
endfeet. These terminals contain synaptic and granular vesicles and attach by 
hemidesmosone-like structures to the basal lamina surrounding the spinal cord. 
Hemidesmosomes are an integrin-based structure that functions to attach cells to 
basal membranes. Vesicle-containing endfeet were observed in a range of non-
mammalian species including fish, reptiles and birds (Vigh et al., 1977). These 
findings again suggest an immature or plastic nature to mammalian CSFcCs and 
greater indications for settled roles for CSFcCs in the non-mammalian spinal cord. 
However findings by Lamotte (1987) suggest that there is considerable variation 
amongst mammalian species, as well as between mammalian and non-mammalian 
CSFcCs. Lamotte (1987) looked at CSFcCs positive for the peptide hormone 
vasoactive intestinal polypeptide (VIP; discussed in detail below) and observed that 
from the basal end of CSFcCs within the thoracic region of the cat spinal cord there 
were many long dendrites and thin varicose axons running for long distances parallel 
to the central canal but also running ventrally and ventralaterally to reach the pial 
surface of the spinal cord. The varicosities on the CSFcC axons in the cat contained 
small round clear vesicles and dense core vesicles. In rat spinal cord, no varicosities 
were observed on the CSFcC axons which were positive for P2X2, GAD and GAP-43 
(Stoeckel et al., 2003) suggesting different functions of the CSFcC axons in these 
species or investigation of different types of CSFcC with other non-investigated 
CSFcCs showing parallel structures.  
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Expression of neurotransmitter-related molecules 
Whilst the contents of these synaptic and granular vesicles have not been identified 
in the mammalian spinal cord, there are a number of neurotransmitter-related 
proteins that have been observed in spinal cord CSFcCs. One neurotransmitter that 
has been shown to produce responses in CSFcCs indicating the presence of 
functionally active receptors is γ-aminobutyric acid (GABA). GABAergic terminals 
have been identified in close apposition to the cell bodies of CSFcCs, identified by 
their apical process projecting into the central canal (McLaughlin et al., 1975) and the 
CSFcCs are themselves immunoreactive for glutamic acid decarboxylase (GAD; the 
enzyme which synthesises GABA) (Barber et al., 1982; Stoeckel et al., 2003). The 
expression of GAD in CSFcCs is a conserved characteristic of these cells, with 
expression demonstrated in the lancelet (Cephalochordata) spinal cord where they 
constitute a large portion of the GABAergic neurons (Anadón et al., 1998). In rat 
spinal cord, the highest numbers of GABAergic CSFcCs were observed in caudal to 
mid thoracic regions, similar to the distribution of CSFcC axons (Stoeckel et al., 
2003). 
Application of GABA has been shown to produce a response in CSFcCs as 
demonstrated in perforated patch and whole cell patch clamp electrophysiological 
recordings (Marichal et al., 2009; Corns, 2012), mediated by GABAA receptors as 
indicated by the sensitivity of the response to the selective GABAA receptor 
antagonist gabazine. However CSFcCs in the rat spinal cord have also been shown 
to be immunoreactive for the GABAB receptor (Margeta‐Mitrovic et al., 1999). The 
actions of the metabotropic GABAB receptor on K+ channels result in a much more 
hyperpolarised reversal potential than that of ionotropic GABAA receptors, which are 
caused by an increase Cl- conductance (Kuriyama et al., 1993). GABAB is thought to 
act as an autoreceptor as well as having post-synaptic actions, to inhibit further 
release of GABA from a cell (Waldmeier et al., 1993). The presence of functional 
GABAergic signalling in the mammalian CSFcCs suggests that they are integrated 
into to ependymal circuitry and possibly the wider spinal cord circuitry.  
However not all receptors identified in non-mammalian CSFcCs have been shown to 
be present in mammalian CSFcCs.  A role for catecholaminergic signalling has been 
shown in CSFcCs in Xenopus spinal cords as the CSFcCs were shown to be 
immunoreactive for tyrosine hydroxylase (TH), a protein involved in the production of 
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catecholamines by the conversion of tyrosine to L-DOPA (Heathcote and Chen, 
1994). In the fish spinal cord (eel and trout), a population of CSFcCs was 
immunoreactive for both TH and dopamine (DA) and was distinct from the population 
of CSFcCs shown to express GABA by immunohistochemical methods (expressed as 
GABA-positive henceforth) (Roberts et al., 1995). Neither population of CSFcCs was 
immunoreactive for choline acetyltransferase (ChAT; the enzyme responsible for 
producing acetylcholine). These two populations of CSFcCs in the fish occupied 
different locations around the central canal (Roberts et al., 1995). The dopaminergic 
CSFcCs were located predominantly on the ventral aspect of the central canal, 
usually close to the midline, while the GABAergic CSFcCs were more likely to be 
located laterally. The GABAergic CSFcCs were also more numerous than the 
dopaminergic CSFcCs. In mammalian spinal cord, no catecholaminergic 
immunoreactivity has been detected, unlike in the fish and amphibian spinal cord, 
CSFcCs do not express TH (Stoeckel et al., 2003). Mammalian CSFcCs (rat and 
mice) do not express several other monoamines or related proteins including DA, 
serotonin and phenylethanolamine N-methyltransferase (PNMT; an enzyme which 
converts norepinephrine to epinephrine) (Jaeger et al., 1983; Nagatsu et al., 1988). 
However, despite the lack of expression of any catecholamines, rat and mice spinal 
cord CSFcCs do express the enzyme aromatic L-amino acid decarboxylase (AADC) 
(Jaeger et al., 1983; Nagatsu et al., 1988). This enzyme acts in a number of 
decarboxylation reactions, including the production of dopamine from L-DOPA, of 
serotonin (5-hydroxytryptamine) from 5-hydroxytryptophan, the production of 
histamine from L-histadine, and in the production of a number of trace amine 
neuromodulators such as tryptamine and phenylethylamine. It could be possible that 
this enzyme functions to produce one of these trace amine neuromodulators, 
although this hasn’t been reported, or it could be that AADC expression is a remnant 
of a functioning catecholamine production system previously expressed in these cells 
further back in the evolutionary timeline.  
There are several species differences in the proteins expressed by CSFcCs. One 
protein that has been observed expressed in CSFcCs of the cat and monkey is 
vasoactive intestinal polypeptide (VIP) (Lamotte, 1987). VIP is a peptide hormone 
that also acts as a signalling molecule between cells in certain brain regions such as 
within the suprachiasmatic nuclei where VIP release plays a critical role in circadian 
cycle regulation (Fan et al., 2015). In the subrachiasmatic nucleus the VIP-positive 
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neurons have been shown to co-release GABA and VIP (Castel and Morris, 2000). 
Methionine-Enkephalin-Arg6-Gly7-Leu8 has also been shown to be expressed by 
CSFcCs of the rat (Shimosegawa et al., 1986) with the number of Met-Enk-Arg-Gly-
Leu-positive CSFcCs varying along the rostrocaudal extent of spinal cord. The 
highest numbers of Met-Enk-Arg-Gly-Leu-positive CSFcCs was in thoracic regions, 
with slightly lower numbers in the cervical and lumbar regions and no Met-Enk-Arg-
Gly-Leu-positive CSFcCs in the brainstem. This indicates that there are expression 
differences between medullary and spinal CSFcCs. The expression of these proteins 
gives indications as to the roles played by CSFcCs with spatial and species 
differences suggesting possible differences in these functions.  
Expression of receptors affected by changes in pH 
Mammalian CSFcCs do express 2 functional receptors that share in common a 
response to changes in pH. The first of these is polycystic kidney disease 2-like 1 
protein (PKD2L1) which is expressed by CSFcCs in mouse spinal cord (Huang et al., 
2006; Petracca et al., 2016) and the macaque and zebrafish spinal cords (Djenoune 
et al., 2014). PKD2L1 is a member of the transient receptor potential (TRP) family 
(Delmas, 2005). It is a non-selective cation channel that can be activated by small 
decreases in extracellular pH (Huang et al., 2006), a property that has been identified 
in CSFcCs (Marichal et al., 2009; Petracca et al., 2016). While PKD2L1 is also 
involved in the detection of pH (sour tastes) in the taste receptor cells, where typical 
pH levels being detected are <pH 5, CSFcCs are able to respond to a much smaller 
change in pH levels. A reduction from the control pH of 7.4 to pH 6.9 produced a 
significant increase in action potential frequency, and more so at pH 6.5 (Huang et 
al., 2006). However, from their work on CSFcCs in the mouse brainstem Orts-
Del'Immagine et al. (2016) argued that PKD2L1 could be more effectively activated 
by alkalinisation (pH 8.8) than by extreme acidification (pH 2.8) and that P2K2L1 was 
more involved in the OFF response upon release of acidification with alkalinisation 
able to generate depolarisations large enough to trigger action potentials. There were 
considerable differences in the age of the animals, the CNS region from which the 
CSFcCs were being assessed and the pH level of the acidification. However in all 
these experiments, PKD2L1-expressing CSFcCs were sensitive to changes in 
extracellular pH and therefore may have a sensory role in regulation of the pH of the 
intercellular solution or CSF.  
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In mouse CSFcCs PKD2L1 is expressed with PKD1L2, a complementary protein 
thought to act in a regulatory manner for PKD2L1 (Petracca et al., 2016). In 
zebrafish, all PKD2L1-positive CSFcCs were GABAergic (Djenoune et al., 2014), 
however in mice only 80% of PKD2L1-positive CSFcCs were immunoreactive for 
GAD (Petracca et al., 2016). The PKD2L1 staining did not colocalize with either the 
glial marker glial fibrillary acidic protein (GFAP) or the ependymal cell marker 
vimentin (an intermediate filament) (Petracca et al., 2016) showing that the 
expression of PKD2L1 was confined to CSFcCs but was robustly expressed by the 
entire CSFcC population and well conserved throughout species.  
Another protein expressed by mammalian CSFcCs is P2X2, which although not 
directly stimulated by changes in pH, does have its response to its agonist modulated 
by changes in pH (Stoeckel et al., 2003). P2X2 is a purinergic non-selective cation 
channel that opens in response to extracellular Adenosine Triphosphate (ATP). Both 
the cell bodies of CSFcCs and the axons have been shown to be immunoreactive for 
P2X2 in the rat spinal cord. P2X2 labelling in both the cell body and axons is of a 
punctate nature and around the cell body is often observed to be membranous 
staining (Stoeckel et al., 2003). P2X2 staining was also observed in the apical 
process with the same punctate distribution. Electron microscopy revealed that the 
CSFcCs displayed finger-like projections at the basal end of the cell body, 
intermingling with the synapses between the CSFcCs and the surrounding neuropil. 
These finger-like projections were particularly dense in P2X2 labelling (Stoeckel et al., 
2003). Unlike other P2X receptors, the response of P2X2 receptors to ATP can be 
potentiated by lower pH levels where the affinity of the channel for ATP was 
increased up to 5 fold with the maximum response at pH 6.5 (King et al., 1997; Stoop 
et al., 1997; Ding and Sachs, 1999). P2X2, in addition to other purinergic receptors, 
will be examined in detail further on in this introduction.  
It may well be that as Orts-Del'Immagine et al. (2016) hypothesised for CSFcCs in 
the brainstem, an alternative mechanism, perhaps through P2X2 receptors, is capable 
of detecting small changes in levels of acidification and PKD2L1 detects release of 
acidification. While P2X2 is predominantly responds to levels of extracellular ATP, the 
fact that the amplitude of the response to ATP is modulated by pH suggests that both 
P2X2 and PKD2L1 may respond to pH changes in CSFcCs, with P2X2 possibly 
playing a significant role in times of high extracellular ATP concentration. 
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1.2.2.2 Variation in CSFcCs 
From a range of measures and multiple different factors, spinal cord CSFcCs are a 
non-homogenous cell population, even within the same species. In lamprey spinal 
cord, 2 types of CSFcC with different shapes, expression patterns and 
electrophysiological characteristics have been identified (Jalalvand et al., 2014), 
which they labelled as type 1 and type 2. Type 1 CSFcCs were positioned close to 
the central canal and had a very short apical process ending with a large spherical 
bulb. These cells had active neuronal properties, displaying spontaneous action 
potential firing, excitatory postsynaptic potentials (EPSPs) and inhibitory postsynaptic 
potentials (IPSPs). They depolarised to application of GABA and glutamate and were 
immunoreactive for GABA and somatostatin. The type 2 CSFcCs identified in the 
lamprey spinal cord had a longer, thinner apical process and were located further 
away from the central canal. They did not display any active neuronal properties and 
were not immunoreactive for GABA or somatostatin but did show immunoreactivity for 
taurine. Jalalvand et al. (2014) suggest that the type 2 CSFcCs in lamprey spinal cord 
may be a type of glial cell, indicating some of the difficulties in defining the CSFcC 
population. Despite some of the uncertainty as to the CSFcC nature of these cells, 
other findings show significant differences between clearly defined CSFcC 
populations.  
In mammalian spinal cord Barber et al. (1982) also noted differences in the shape of 
CSFcCs. They observed that the GAD-positive CSFcCs around the central canal 
could be categorised into two groups based on the shape of the cell body. One group 
had spherical cell bodies, measuring 10-12 μm in diameter and were found on the 
outer edge of the ependymal cell layer, while the other group had a cell body that was 
a fusiform shape and were longer than the other group, measuring 20 μm by 5-8 μm. 
CSFcCs of the second type were observed in many different positions through the 
ependymal cell layer. When Golgi’s silver staining method was used to stain CSFcCs, 
it stained CSFcCs that had a similar shape and location to the second type of 
CSFcCs observed with GAD staining, which were found throughout the ependymal 
cell layer. CSFcCs bearing the spherical shape were not observed using this method 
(Barber et al., 1982). This may suggest that there may be another CSF-contacting 
cell population which are not neuronal and as such do not take up the neuronal Golgi 
silver stain. It is for this reason that CSF-contacting cells are here referred as such 
rather than CSF-contacting neurons (CSFcNs) as is done in the majority of work.  
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As was mentioned above, Roberts et al. (1995) detected two populations of CSFcCs 
within the fish spinal cord, one of which was GABAergic and the other dopaminergic. 
The GABAergic CSFcCs made up the larger population of CSFcCs and were 
predominantly located laterally, although some were located ventrally. The 
dopaminergic population of CSFcCs was lower in number and restricted to the ventral 
end of the central canal.  
A strikingly similar pattern was observed in mammalian spinal cord where it was 
found that in spinal cord that there were two distinct populations of PKD2L1-positive 
CSFcCs  coming from different embryonic origins (Petracca et al., 2016). This was 
investigated by detection of the transcription factors Gata2 and Gata3 in the 
population of PKD2L1-expressing CSFcCs in the mouse spinal cord. All of these 
CSFcCs were shown to be born between E14.5 and E16.5, an embryological period 
associated with the production of astrocytes and oligodendrocytes. Embryological 
neurogenesis occurs earlier, with some of the latest interneurons differentiating 
between E10 and E12 (Zhou et al., 2000; Francius et al., 2013). Of the CSFcCs, the 
vast majority (90 %) were found to derive from the late-p2 domain and the dorsal half 
of the oligodendrogenic (pOL) domain. These CSFcCs were termed CSFcN’ and 
were found predominantly laterally. The second population was termed CSFcN’’ and 
made up only 10 % of PKD2L1+ CSFcCs. This CSFcN’’ population was derived from 
precursors in the proximity of the embryological floor plate and occupied an 
exclusively ventral position around the central canal at E15.5. There were also 
differences observed between these two populations in the electrophysiological 
profiles. Amongst the CSFcN’ population, the majority of the cells were able to fire 
multiple spikes (80 %) but none of the CSFcN’’ population could produce multiple 
spikes (approximately 50 mV in amplitude), instead only producing a single spike of 
similar amplitude in response to a 10 pA depolarising current step.  
Whilst the lack of catecholaminergic immunoreactivity in mammalian CSFcCs 
suggests that there may only be the GABAergic CSFcCs conserved into mammalian 
spinal cords, this connection between the two populations and numerical distribution 
and locations suggests that they may be the same two populations in mammalian 
spinal cord as in non-mammalian spinal cord but in the mammalian spinal cord the 
two populations bear more similarity than they do in the non-mammalian spinal cord.  
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In addition to the multiple spiking and single spiking CSFcCs observed by Petracca et 
al. (2016) in mouse spinal cord, a non-spiking population of CSFcCs has also been 
previously observed in the rat spinal cord (Marichal et al., 2009; Corns, 2012). Both of 
these studies described spiking behaviour in CSFcCs as a fast event with a 
depolarising and repolarising event. In comparison to action potentials, these spikes 
have smaller amplitude (amplitude of spikes was 38-56 mV (Marichal et al., 2009)) 
and longer half-amplitude duration (3.8-6 ms (Marichal et al., 2009)). This work will 
use the same definition of spikes to facilitate discussion of events that do not satisfy 
the criteria for action potentials.  
Marichal et al. (2009) described three populations of CSFcC. The first of these 
produced a slow regenerative potential (a reduction in the extent of depolarisation 
caused by a positive current pulse over the duration of its application) upon 
application of depolarising current pulses, which was abolished when in the 
presences of 3 mM Mn2+ indicating that this response to current injection was a Ca2+ 
conductance. The majority of the activity in these cells was insensitive to the Na+ 
channel blocker tetrodotoxin (TTX) indicating that Na+ conductances did not cause 
the depolarisation. However there was an initial element to the response that was 
sensitive to TTX showing a small level of involvement of voltage-gated Na+ channels. 
These cells also showed a small rebound spike upon release of hyperpolarising 
current that was sensitive to the T-type Ca2+ channel blocker 300 μM Ni2+. 
The second type of CSFcC identified by (Marichal et al., 2009) had smaller input 
resistances than the first and produced a single spike with a mean amplitude of 38 
mV and a half-amplitude duration of 6 ms in response to a depolarising current pulse. 
For an event to be considered an action potential it must fulfil a number of commonly-
accepted criteria. These include having a rapid depolarising then a rapid repolarising 
phase usually followed by an after-hyperpolarisation, a duration as measured by the 
half-amplitude duration of < 3 ms and a peak amplitude of over 60 mV at resting 
membrane potential. The term spike is used when the event has rapid depolarising 
then hyperpolarising phases but does not fulfil one or multiple of the other criteria.   
Some of these cells had a slow depolarising potential similar to those observed 
without the spike, whilst others had a rapid repolarising phase but none of these cells 
displayed a slow after-hyperpolarisation. These spikes were all sensitive to TTX 
indicating that they were produced by opening of voltage-gated Na+ channels. 
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Amongst this group of CSFcCs there was considerable variation in the shape of the 
cell body and the complexity and reach of basal processes. 
The third group of CSFcCs in this study was able to produce a train of spikes and in 
some cases spikes that would be considered action potentials (Marichal et al., 2009). 
The spikes produced by these CSFcCs had larger amplitude (56 mV) and shorter 
half-amplitude duration (4 ms), than those of the single spiking cells. Some of the 
CSFcCs that could produce multiple spikes displayed increasing half-amplitude 
duration in the later spikes. Others were able to fire more robustly, with smaller 
differences from spike to spike. In these robustly firing cells there was a defined slow 
after-hyperpolarisation. As with the single-spiking cells, the spikes in the multiple-
spiking cells were sensitive to TTX. Only in a small proportion of the cells was there a 
TTX-resistance depolarisation indicating that the more robust the spiking, the less the 
contribution of calcium conductances present in that cell.  These multiple-spiking 
CSFcCs were observed to have greater complexity of basal processes than the 
single-spiking CSFcCs displayed but still did not express NeuN (Marichal et al., 
2009).  
Previous work from our group (Corns, 2012) has seen the same variation as has 
been previously reported. Additionally, they observed a population of CSFcCs within 
the rat spinal cord that showed passive, glial-like electrophysiological responses to 
current injection reminiscent of the glial-like type 2 CSFcCs observed in lamprey 
spinal cord (Jalalvand et al., 2014). Few of the non-spiking CSFcCs with slow Ca2+-
mediated depolarisations were observed (Corns, 2012), although cells producing a 
slow depolarisation after a single spike were more frequently observed. This work 
defined subtype 1 cells (CSFcC 1s) as the CSFcCs with glial-like non-spiking 
characteristics, subtype 2 cells (CSFcC 2s) as those that could produce a single 
spike and subtype 3 cells (CSFcC 3s) as those that could produce > 1 spike. The 
work presented in this thesis will use this classification of CSFcCs throughout.  
1.2.2.3 Functions of CSFcC 
There is little consensus on the primary function of CSFcCs with inter-species 
differences and within species differences suggesting that CSFcCs may fulfil a range 
of functions. There are multiple aspects of CSFcC structure that indicate that in many 
cases, they are likely to fulfil sensory roles; however these sensory roles are not 
always sensing the same physiological aspect.  
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The first physiological aspect that may be being detected by CSFcCs is movement of 
the spinal cord or flow of the CSF.  In many non-mammalian species, the 
CSF-contacting bouton of CSFcCs displays a 9x2+2 cilium that is characteristic of 
kinocilia (Vigh and Vigh‐Teichmann, 1998; Vigh et al., 2004). This differs from 
ventricular CSFcCs which show are more likely to have a 9x0+2 cilia (Vigh-
Teichmann and Vigh, 1983). These kinocilia have been observed in contact with 
Reissner’s fibre in the lancelet (a marine chordate) (Vigh-Teichmann and Vigh, 1983). 
This has been suggested to be able to detect movement of the spinal cord. Whilst 
mechanically sensitive neurons, called edge cells, have been identified in the lamprey 
spinal cord (Grillner et al., 1984), these cells were not comparable to CSFcCs.  
CSFcC have also been shown to be mechanosensitive via a mechanism that is 
dependent on the expression of the PKD2L1 channel (Bohm et al., 2016). In 5 day 
old zebrafish, genetic ablation of CSFcCs (named Kolmer-Agduhr cells in this study) 
reduced spontaneous forward swimming (Wyart et al., 2009). Further investigation 
showed that the CSFcCs modulate components of the central pattern generator 
(CPG) by synapsing on glutamatergic interneurons (Fidelin et al., 2015). The 
response of CSFcCs to active and passive movement of the spinal cord was absent 
in the PKD2L1-knockout mutant zebrafish (Bohm et al., 2016). Although there are 
many similarities between the CSFcCs in the zebrafish and in mammalian systems, 
expressing PKD2L1, GABA and the olig2 transcription factor, differences in cilia 
structure and axonal characteristics mean that this functioning is not necessarily 
conserved into mammals.  
The CSFcCs have variable numbers of stereocilia from the bouton on the apical CSF-
contacting process (Vigh et al., 2004). These stereocilia are similar to those found in 
the inner ear, where they sense the flow of the endolymph fluid (Zetes and Steele, 
1997). Both mammalian and non-mammalian spinal CSFcCs have stereocilia on the 
ends of their apical process, although there are few on mammalian CSFcCs (Vigh-
Teichmann and Vigh, 1983). This leaves open the possibility that one role for 
CSFcCs conserved between species is detection of CSF flow. Whilst it has not been 
demonstrated that CSFcCs possess this role, maintaining the flow of CSF is very 
important, particularly in the spinal cord, where it is more prone to stasis (Whedon 
and Glassey, 2009). CSF stasis is associated with hydrocephalus and intracranial 
hypertension and thus detection is likely to be important.  
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As mentioned above, another aspect of CSF and the local environment around the 
CSFcCs that they are well equipped to detect is changes to pH. Expression of both 
PKD2L1 and P2X2 receptors (via modulation of the response to ATP) enables 
CSFcCs to detect changes to pH levels and whilst P2X2 has not been as widely 
identified, PKD2L1 appears to be one of the more conserved aspects of the CSFcC 
expression profile (Stoeckel et al., 2003; Studeny et al., 2005; Huang et al., 2006; 
Marichal et al., 2009; Djenoune et al., 2014). This could be detection of the pH of 
either the intercellular fluid or the CSF as the receptors identified which can sense pH 
are present throughout the cell and CSF-contacting process.  
The CSFcCs could also be sensing signals released from nearby cells. CSFcCs 
receive synaptic inputs in the form of PSPs recorded from single cells abolished by 
TTX (Russo et al., 2004; Marichal et al., 2009) and respond to a number of 
neurotransmitters. CSFcCs from rat and turtle spinal cord have been shown to 
respond to GABA via GABAA receptors. This produced either a depolarisation or a 
hyperpolarisation, which has been suggested to be due to differences in expression 
of chloride transporters amongst CSFcCs (Reali et al., 2011; Chamma et al., 2012). 
Mammalian  CSFcCs also respond to cholinergic signalling occurring through 
nicotinic acetylcholine receptors (Corns et al., 2015). The ionotropic purinergic 
receptor P2X2 is also expressed in CSFcCs from P2 to adulthood in mammalian 
spinal cord as mentioned above (Stoeckel et al., 2003; Studeny et al., 2005). P2X2 
receptors primarily respond to levels of extracellular ATP. Purinergic signalling is 
involved in a range of functions including interactions between neuronal and glial 
cells (Fields and Burnstock, 2006; Lohr et al., 2014), and roles in stem cell signalling 
and development (Ulrich et al., 2012; Jiang et al., 2016). It may therefore be that the 
presence of P2X2 receptors on CSFcCs enables purinergic signalling as part of the 
wider spinal cord circuitry.   
The next point to consider is outcome of the detection of any of the above factors. 
CSFcCs are connected to the neuropil surrounding the central canal via the multitude 
of basal processes. There are many axons and neuronal cell bodies that run near the 
central canal, particularly at the ventral end (Bruni and Reddy, 1987). Synapses have 
been observed between CSFcCs and these neuronal cells (Stoeckel et al., 2003). 
This indicates that any information detected by the CSFcCs could therefore be 
transferred to these neighbouring cells by these connections.  
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Alternatively, in CSFcCs where the CSFcC axons are present, is transmission of the 
information to cells near the pial surface. However in most species such as in the rat 
spinal cord the synaptic proteins are diffusely dispersed throughout the axons and not 
concentrated at synapses (Stoeckel et al., 2003). This suggests that information 
release is not the primary function of these axons as this diffuse labelling of synaptic 
proteins is more normally associated with neurons during development before the 
attainment of functional synapses (Rene et al., 1996). In other species such as the 
Xenopus spinal cord there do appear to be functional vesicles but these do not 
appear to be functioning as synapses, releasing instead into the external CSF, rather 
than onto cells so they could therefore be acting as a hormonal signalling mechanism 
for the substances to act on a wide range of cells.   
This release into the external CSF could function as a communication system, but it 
could also function as a trafficking system. The fact that the CSFcCs in Xenopus 
spinal cords are in contact with both the internal and the external CSF make them 
uniquely placed to modulate the compositions of both of these solutions.  
There is some evidence for each of these suggested functions however the 
differences between species and the frequent variation within species make it unlikely 
that any one function is undertaken by all CSFcCs. It is likely that CSFcC are involved 
in a range of functions and may also have features of other roles that they no longer 
perform.  
1.2.3 Ependymal cells 
1.2.3.1 Distribution and expression of ependymal cells  
Ependymal cells around the central canal are predominantly pseudostratified 
cuboidal ependymal cells forming the lining of the channel through which the 
cerebrospinal fluid flows (Bruni and Reddy, 1987)(Figure 1.2). This layer of 
ependymal cells is only a single cell thick in the majority of the rat spinal cord, 
however in some places it is thickened such that it contains multiple layers of 
ependymal cells. The cells in the single layer of ependymal cells are consistent in 
shape and orientation, with slight differences at the dorsal and ventral poles of the 
ependymal cells where the cells are more elongated in shape (Bruni and Reddy, 
1987). The ependymal cells of the mammalian spinal cord are surrounded by 
collagens I and III and fibronectin which act as a basement membrane (Azzi et al., 
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1990). Under electron microscopy ependymal cells have large nuclei and electron 
dense cytoplasm rich in intermediate filaments (Bruni and Reddy, 1987; Alfaro‐
Cervello et al., 2012). They also have numerous mitochondria, lipid droplets towards 
the apical membrane and Golgi apparatus in a horse-shoe shape (Alfaro‐Cervello et 
al., 2012).  
In studies of the mouse spinal cord, ependymal cells usually have 2 motile (9+2) cilia 
which were approximately 8 µm long and were invaginated at their ends (Alfaro‐
Cervello et al., 2012). The cilia of the ependymal cells were associated with electron-
dense basal bodies that differed from those associated with cilia in any of the ciliated 
ventricular ependymal cells. The basal bodies were also not associated with a 
daughter centriole as has been observed with one type of ventricular cell (Doetsch et 
al., 2002; Mirzadeh et al., 2008; Alfaro‐Cervello et al., 2012). A small percentage of 
cells (<7 %) had only one cilium but the type and basal body were similar to those 
with 2 cilia (Alfaro‐Cervello et al., 2012). Similarly small populations of ependymal 
cells had 3 or 4 cilia and those with 4 cilia were larger and possessed 2 nuclei (Alfaro‐
Cervello et al., 2012). There were no large differences in cilia presentation of 
ependymal cells along the rostro-caudal axis of the spinal cord. The motility of the 
cilia has been demonstrated by the deposition of fluorescent microbeads which 
became attached to the cilia and revealed their back and forth motion (Alfaro‐Cervello 
et al., 2012). Some ependymal cells had basal processes leading away from the 
central canal. These cells have predominantly been identified at the dorsal and 
ventral poles of the central canal with the processes leading along the dorsal-ventral 
axis (Bruni and Reddy, 1987; Alfaro‐Cervello et al., 2012).  
Ependymal cells are connected to neighbouring ependymal cells via a number of 
connections. Long zonulae adherens junctions run along the lateral sides of the 
ependymal cells (Alfaro‐Cervello et al., 2012). These junctions are formed of 
cadherins (Ferreri and Vincent, 2008) and are linked to the actin cytoskeleton (Guo et 
al., 2007). 
The second type of junctional connection through which the ependymal cells are 
connected is gap junctions. Expression of connexin 43 (Belliveau and Naus, 1995; 
Ochalski et al., 1996; Marichal et al., 2009), connexin 45 (Chapman et al., 2013) and 
connexin 50 (Rodriguez-Jimenez et al., 2016) has been observed in ependymal cells 
in the mammalian spinal cord. Additionally connexion 30 has been identified in 
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ventricular ependymal cells (Kunzelmann et al., 1999) but this is thought not to be 
expressed in spinal cord as Cx30-Cre recombinase reporter mice did not label any 
ependymal cells, only astrocytes within the grey and white matter (Barnabé-Heider et 
al., 2010). The expression of these connexins has been shown to produce 
functionally active gap junctions between the cells as demonstrated during 
electrophysiological experiments by the increase in input resistance upon application 
of gap junction blockers (Corns, 2012; Corns et al., 2013). Application of gap junction 
blockers also increased the voltage change seen in response to agonist application 
(Corns et al., 2013) indicating that this could be a way ependymal cells modulate their 
responses to signalling.  
The expression profile of ependymal cells  
Ependymal cells in the mammalian spinal cord express a number of markers 
associated with stem cells. Sox2, a transcription factor essential for the maintenance 
of pluripotency in undifferentiated stem cells and a related protein, Sox9, are widely 
expressed in ependymal cells around the central canal (Hamilton et al., 2009; 
Barnabé-Heider et al., 2010). Sox2 expression has been observed in a range of 
species including rat (Hamilton et al., 2009), mouse (Meletis et al., 2008) and human 
spinal cord (Dromard et al., 2008). Nestin is expressed in a subset of ependymal 
cells, predominantly found dorsal to the central canal and usually those with long 
basal processes leading dorsally away from the central canal, occasionally they are 
also seen ventrally or laterally (Hamilton et al., 2009; Alfaro‐Cervello et al., 2012). 
Nestin is an intermediate filament found in developing cells and cells after injury, 
further suggesting that the ependymal cells around the central canal may act as stem 
cells within the spinal cord. 
The majority of ependymal cells contain vimentin, an intermediate filament associated 
with mesenchymal cells, and the calcium binding protein S100β which is 
predominantly found in astrocytes (Hamilton et al., 2009). Further, ependymal cells 
express CD24, a glycoprotein expressed by mature ependymal cells (Mirzadeh et al., 
2008; Alfaro‐Cervello et al., 2012) and CD133 (Alfaro‐Cervello et al., 2012) which is 
observed in ependymal cells and astrocytes. Ependymal cells can also be identified 
by their expression of the transcription factor FoxJ1 which acts as a marker for 
ciliated epithelia and cells of ependymal lineage (Huang et al., 2003; Meletis et al., 
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2008; Alfaro‐Cervello et al., 2012). There are further proteins expressed in a subset 
of ependymal cells which will be discussed below. 
1.2.3.2 Proliferative abilities of ependymal cells 
Spinal cord ependymal cells show proliferative properties that can be modulated by a 
number of factors. Under physiological control situations ependymal cells replicate at 
a low rate and self-duplicate to maintain ependymal cell numbers with minimal 
differences between different regions along the rostro-caudal axis of the spinal cord 
(Horner et al., 2000; Alfaro‐Cervello et al., 2012). Whilst this proliferation occurs in all 
aspects of the central canal, a largest proportion of the newly-proliferated cells have 
been observed dorsally and dorsolaterally with the lowest proportion laterally and 
intermediate levels in ventral regions (Alfaro‐Cervello et al., 2012). The cells 
produced were almost all ependymal cells as they still expressed CD24 (96%) and 
were ciliated (Alfaro‐Cervello et al., 2012). In young mice there was a higher rate of 
proliferation of ependymal cells which correlated with growth of the spinal cord 
(Alfaro‐Cervello et al., 2012) resulting in a low rate of self-duplication that was 
maintained into adulthood in mice (Barnabé-Heider et al., 2010) and rats (Horner et 
al., 2000). These newly proliferated cells were observed to stay in the location of the 
central canal.  
There are physiological and pathological factors that can modulate central canal 
proliferation. Enhanced physical activity by use of a running wheel, increased the 
level of proliferation around the central canal in rat spinal cord by 2.1-2.6 fold after 4 
days (Cizkova et al., 2009) but this difference decreased to closer to the control levels 
by 14 days suggesting that it is a short-lived response and not on-going. Cizkova et 
al. (2009) also observed re-expression of nestin in previously nestin-negative 
ependymal cells with increased physical activity.  
A range of spinal cord insults including contusion and incision insults (Cizkova et al., 
2009; Barnabé-Heider et al., 2010; Lacroix et al., 2014) also produced a considerable 
increase in proliferation rate of ependymal cells. This response was not seen when 
the functioning of the spinal cord including locomotion was damaged by 
demyelinating lesions. Neither chemically induced demyelination nor autoimmune-
related demyelination produced any change in the rate of ependymal cell proliferation 
(Lacroix et al., 2014). This is very different from injured spinal cord, where the 
increased rate of proliferation peaked at 3 days after injury in the adult mouse spinal 
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cord, followed by a wave of proliferation moving rostrally up the spinal cord such that 
the segment rostral to the injury had peak proliferation 14 days after injury and 
cervical segments showed peak proliferation after 21 days (Lacroix et al., 2014). In 
the rat spinal cord, proliferation was observed to increase 2.6 fold, compared to 
control levels (Cizkova et al., 2009).  
Increases in proliferation rate could also be triggered by growth factors, which when 
infused into the 4th ventricle, increased the number of newly proliferated cells within 
the 4th ventricle and around the central canal in the spinal cord (Martens et al., 2002). 
The increase in proliferation around the central canal was seen with the triple infusion 
of epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2) and heparin. This 
caused approximately a 33-fold increase in the numbers of newly-proliferated cells 
around the central canal. The newly-proliferated cells produced by this treatment 
were predominantly around the central canal. Martens et al. (2002) suggested that 
the proliferating cells may not be ependymal cells as the thymidine analogue marker 
for newly-proliferated cells (BrdU) did not co-localise with S100β, which is known to 
be expressed by ependymal cells (Hamilton et al., 2009). This lack of co-localisation 
between the marker for newly-proliferated cells and S100β was also observed under 
physiological conditions (Horner et al., 2000) however neither study used any other 
ependymal cell markers to confirm this finding and ensure that proliferating 
ependymal cells express S100β. S100β is a calcium binding protein expressed in 
mature ependymal cells and there may be changes to expression during proliferation. 
Alternatively there could be multiple proliferating cell types around the central canal, 
however S100β is also expressed by astrocytes so reducing the pool of potential 
other dividing cell types. In a similar study with rat spinal cord (Kojima and Tator, 
2000), EGF and FGF2 increase the rate of proliferation in cells that were described 
as likely to be ependymal cells due to their location clearly within the ependymal cell 
layer and their lack of expression of GFAP, an astrocytic marker not widely expressed 
in ependymal cells (Bruni et al., 1985).  
Using electrophysiological experiments, ependymal cells were shown to respond to 
acetylcholine (ACh) application and modulation of cholinergic signalling potentiated 
the electrophysiological response of ependymal cells to ACh and increased the 
numbers of newly-proliferated cells around the central canal in an organotypic slice 
culture model using mouse spinal cord and in vivo (Corns et al., 2015). In this study 
the newly-proliferated cells marked with an alternative thymidine analogue (EdU) co-
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localised with two markers for spinal cord ependymal cells, namely the Na-K-ATPase 
α1 subunit (NKAα1) and CD24, as well as being positive for the stem-cell marker 
Sox2. This indicates that in the case of cholinergic enhancement of proliferation 
around the central canal, ependymal cells are the proliferating cell. In the non-
mammalian spinal cord dopamine has a neurogenic role. During spinal cord 
regeneration in the adult zebrafish endogenous dopamine signalling plays an 
important role in the production of motor neurons similarly to the pro-motor 
neurogenic role dopamine signalling plays during development (Reimer et al., 2013). 
Despite demyelinating disorders not triggering increases in proliferation nicotine 
signalling increases ependymal cell proliferation (Gao et al., 2015). Experimental 
autoimmune encephalomyelitis (EAE) decreases the level of proliferation of 
ependymal cells even lower than is seen in uninjured spinal cord, accompanied by an 
increase in nestin production. Application of nicotine reduced both of these effects of 
EAE, reducing the increase in nestin expression and the decrease in proliferation, 
and also acted to increase the number of oligodendrocytes present and decrease the 
presence of inflammatory microglia and leukocytes (Gao et al., 2015).   
1.2.3.3 Characteristics of newly-proliferated ependymal cells 
For ependymal cells to be classified as stem cells rather than progenitor cells, they 
must fulfil a number of criteria. The first of these is that they are unspecialised. The 
morphology of ependymal cells is simple cuboidal with relatively few specialisations. 
The second is that the cells are capable of self-renewal. Self-renewal of stem cells is 
associated with asymmetric division, which is indicated by a plane of cleavage 
parallel to the luminal surface of the cell. In ependymal cells after spinal cord injury, in 
83% of newly-proliferated ependymal cells with a detectable plane of cleave the 
plane was parallel to the luminal cell surface (Johansson et al., 1999). The third 
criterion is that the progeny they produce are specialised cells. This has been 
demonstrated by (Barnabé-Heider et al., 2010), as discussed below.  
Barnabé-Heider et al. (2010) showed that it is not only the ependymal cells that 
increase their proliferation after spinal cord injury. There were two other cell 
populations which proliferate in the intact spinal cord and respond to spinal cord 
injury by increasing their proliferation rate. In the intact spinal cord oligodendrocyte 
precursors were observed to self-renew and produce mature oligodendrocytes. 
Ependymal cells were observed just to self-replicate and produce more ependymal 
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cells in the intact spinal cord, as has been previously observed (Alfaro‐Cervello et al., 
2012). Similarly, in the intact spinal cord, astrocytes also self-duplicated, producing 
more astrocytes. Genetic fate mapping was used with FoxJ1-Cre recombinase mice 
to track ependymal cells, Connexin30-Cre mice to track astrocytes and Olig2-Cre 
recombinase mice to track cells of oligodendrocyte lineage. In the intact cord the 
number of newly proliferated ependymal cells was much lower than of astrocytes and 
oligodendrocytes, but after an incision was made to the dorsal funiculus, the biggest 
increase in the rate of proliferation was seen in the ependymal cells. After injury, 
ependymal cell proliferation increases by 4-5 fold, while the proliferation of the other 
two cell populations increases approximately 2-fold (Barnabé-Heider et al., 2010). 
These increases in proliferation were not observed in segments adjacent to the injury, 
where the levels were the same as in intact spinal cords, indicating that the response 
to the injury was local and not throughout the spinal cord.  
The use of genetic fate mapping in this experiment also showed differential 
localisation of these newly-proliferated cells after incision of the dorsal funiculus 
(Barnabé-Heider et al., 2010). Unlike in the intact condition, where ependymal cells 
are found exclusively within the central canal region, after injury the newly-expressed 
ependymal cells were predominantly found in the centre of the lesion site, in the scar-
forming tissue, which in these experiments was in the dorsal funiculus. They 
accounted for over half the cells within the glial scar. Astrocytic progeny also 
accumulated near the injury site but unlike ependymal cells which were found at the 
centre, newly-proliferated astrocytic cells were found on the perimeter of the injury 
site. Oligodendrocytic progeny were also observed to be more numerous after injury 
and there were some present within and near the injury site but similar distribution to 
that observed in the grey matter and other white matter regions. This migration of 
ependymal cells to the site of injury has also been observed in other studies 
(Johansson et al., 1999; Meletis et al., 2008) as well as in minimal injury models, 
where there was insufficient injury to draw the ependymal cells fully to the site of 
injury, but there was a 8-fold increase in proliferation and migration of ependymal 
cells in dorsal and ventral directions (Mothe and Tator, 2005). 
A further difference observed by Barnabé-Heider et al. (2010) between intact and 
injured spinal cord was in the phenotype of the newly-proliferated cells. This type of 
injury produced considerable cell death of neurons and no BrdU labelled cells 
expressed NeuN (a neuronal marker) indicating that no new neurons were produced. 
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Of the newly-proliferated cells, those of oligodendrocyte lineage developed as in 
intact spinal cords to produce oligodendrocyte precursors and mature 
oligodendrocytes. The cells of astrocytic lineage also predominantly maintained 
astrocytic features as was seen in intact spinal cords, however there were 
morphological changes. After injury the newly-proliferated astrocytic cells displayed a 
more elongated and less ramified shape. In both intact and injured spinal cords, a 
small number of cells of astrocytic lineage expressed a marker for oligodendrocyte 
precursors (Olig2), with a lower percentage displaying Olig2 expression after spinal 
cord injury. Cells of ependymal lineage showed considerable differences in the 
phenotype after spinal cord injury compared with those in the intact condition. In the 
intact spinal cord, all newly-proliferated cells of ependymal lineage showed 
ependymal cell markers (FoxJ1 and Sox9) and were localised to the central canal 
region. After spinal cord injury <30 % displayed FoxJ1 expression and over 20 % 
displayed GFAP positivity, where none was observed in the intact cords. Additionally 
a small percentage of ependymal progeny displayed expression of the 
oligodendrocyte precursor marker, Olig2. This indicates that after spinal cord injury, 
ependymal cells are able to differentiate into astrocytes and oligodendrocyte 
precursors as well as the ependymal cells they produce in the intact spinal cord.  
The formation of the glia scar by cells of ependymal lineage has been shown to be 
beneficial (Sabelström et al., 2013), and not purely detrimental as has been 
suggested due to its action as a barrier to axonal regrowth (Burda and Sofroniew, 
2014). Sabelström et al. (2013) used a mouse model with selective inducible 
knockout of all Ras genes within the FoxJ1-expressing ependymal cells (as used in 
Barnabé-Heider et al. (2010)) to assess the outcomes of removing ependymal 
contribution to the glial scar. Ras genes enable the ependymal cells to proliferate, 
thus knock out of these genes prior to injury removal of the involvement of ependymal 
progeny in the response to the injury without disruption of the non-proliferative 
functions of ependymal cells. In the mice without ependymal contribution there was a 
higher fibrous component contributed by pericytes, and also a higher contribution to 
the glial scar by resident astrocytes. After 14 weeks, the mice without scar forming 
contribution by ependymal cells had far larger and deeper lesions, with thinner 
remaining spinal cord at the level of the lesion, compared to controls (Sabelström et 
al., 2013). Blocking the pericytes response didn’t have the same effect of deepening 
the lesions site compared to controls, suggesting that ependymal cell contribution is 
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particularly important for minimising lesion depth. A secondary factor likely to have 
contributed to the increased lesion depth in the mice with no ependymal cell 
contribution is the fact that the ependymal cell progeny acted as a rich source of 
neurotrophic factors without which there was increased neuronal death (Sabelström 
et al., 2013). The consequence of this deepened lesion in this experiment using a 
lesion to the dorsal funiculus was that damage to the corticospinal tract was more 
frequently observed indicating a protective role for glial scar-forming ependymal cells.  
While Barnabé-Heider et al. (2010) showed the progeny of ependymal cells did not 
include any mature neuronal cells, as no BrdU was observed to co-localise with 
NeuN, they did observe expression of some markers associated with neural stem 
cells. Cells of ependymal lineage and astrocytic lineage but only a few of 
oligodendritic lineage expressed Sox2 while both CD133 expression and nestin 
second intron enhancer activity were only seen in cells of ependymal lineage. 
Additionally various in vitro and transplantation studies have provided evidence for 
this capability in spinal cord ependymal cells (Weiss et al., 1996; Shihabuddin et al., 
1997; Johansson et al., 1999). Cells from all regions along the rostro-caudal axis of 
the spinal cord of a 3 month old rat, once cultured in a fibroblast growth factor 2 
(FGF-2) produced some passagable neurospheres expressing the neuron-specific 
microtubule-associated protein 5 (MAP-5) (Shihabuddin et al., 1997). Neurospheres 
are free-floating spherical expansions of cells that express nestin, which is found in 
stem cells and neural progenitors (Gage, 2000). Weiss et al. (1996) also observed 
that both primary culture and secondary expanded clones from all spinal cord regions 
produced spheres of undifferentiated cells that could be induced to differentiate into 
either neurons, astrocytes and oligodendrocytes as determined by expression of 
neurofilament M, GFAP and O4 respectively. However Weiss et al. (1996) found that 
the greatest yield of multipotent cells was obtained from cells collected from the 
lumbar/sacral region of the spinal cord. All three lineages, astrocytes, 
oligodendrocytes and neurons could be produced from cultures from a single founder 
cell, indicating the multipotency of spinal cord ependymal cells and the process of 
serial passaging and recloning indicated that in vitro they are self-renewing 
(Shihabuddin et al., 2000).  
With respect to the type of neurons produced by these cultures of ependymal cell-
derived progenitors, Hamilton et al. (2009) induced neurospheres to differentiate into 
neurons expressing βIII tubulin and GAD-65. Moreno-Manzano et al. (2009) 
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demonstrated differentiation of the neurospheres into functional spinal motor neurons 
as demonstrated by electrophsiological recording of the cells produced and 
expression of the motor neuron-specific transcription factor HB9 and axons and 
dendrites labelled with MAP-2. These could represent the same population of 
GABAergic motor neurons or the differences in culture protocol and culture medium 
could have induced the stem cells to differentiate into different types of neuron.  
It has been shown that these neurospheres and spheres of undifferentiated cells 
originate from the ependymal cells and not any astrocytes or oligodendrocyte 
precursors by use of genetic fate mapping in cultured cells (Barnabé-Heider et al., 
2010). This showed that astrocyte and oligodendrocyte precursors were not 
responsible for the production of neurospheres in the culture of spinal cord cells. 
Instead approximately 80 % of neurospheres were labelled by recombination of 
FoxJ1-Cre. This was the same proportion of ependymal cells labelled by this method, 
suggesting that they were all likely to be derived from cells of ependymal lineage.  
These in vitro experiments demonstrate the multipotency and neurogenic potential of 
ependymal cells, however not all this potential is seen in vivo. Shihabuddin et al. 
(2000) cultured ependymal cells in vitro and expanded a clonal population of these 
cells that were transplanted into various CNS regions. When these cultured 
ependymal stem cells were transplanted back into the spinal cord, they did not 
produce any cells of neuronal lineage shown by no co-localisation of the marker for 
the cloned cells and NeuN. Instead mainly astrocytes (GFAP expression) and glial 
precursors (NG2 expression) were produced, with a few oligodendrocytes (Rip or 
adenomatous polyposis coli expression without GFAP expression). The cells were 
also transplanted into the hippocampus. When they were located in the neurogenic 
regions of the hippocampus, the majority of the cells expressed NeuN and almost all 
of them also expressed calbindin-D28k and some showed morphology of mature 
hippocampal granule neurons. Many of the remainder of the cells expressed markers 
of glial progenitors. The cultured cells transplanted into the non-neurogenic region of 
the hippocampus did not display any co-localisation of the transplanted cell marker 
and NeuN indicating that none of the transplanted cells differentiated into neurons in 
this region. Instead the cells displayed markers of glial progenitors, astrocytes and 
oligodendrocytes with the proportion of these cells reasonably similar to what was 
observed in the from endogenous ependymal cell populations in the spinal cord but 
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with fewer GFAP-positive astrocytes (Shihabuddin et al., 2000). This suggests that 
the spinal cord is a particularly gliogenic environment.  
The idea that the spinal cord is a gliogenic environment is supported by a study which 
showed that transplantation of ependymal-derived cultured stem cells which had 
been transduced to express the neurogenesis-promoting protein neurogenin-2, still 
produced very few neurons upon transplantation into the spinal cord (Hofstetter et al., 
2005). The neurogenin-2 expression did act to shift the differentiation of the 
transplanted cells towards an oligodendrocyte phenotype and away from an 
astrocytic one. This had multiple effects compared to transplantation of non-
neurogenin-2 cultured stem cells. Transduction of neuogenin-2 expression increased 
the positive effects of stem cell transduction after injury, with increased amounts of 
myelin in the injured area and recovery of hindlimb functioning and sensory 
responses. Neurogenin-2 expression in the transplanted stem cells also reduced the 
allodynia observed with transplantation of non-neurogenin-2-treated stem cells 
(Hofstetter et al., 2005). This indicates that multiple aspects of the potential 
responses of ependymal cells to spinal cord injury could be beneficial although it may 
need directed to produce the maximal result.  
The capabilities of ependymal cells after spinal cord injury was expanded on by 
Moreno-Manzano et al. (2009) who cultured ependymal cells in a similar way to the 
studies mentioned above but with some of the initial cells coming from animals with 
spinal cord injury. The ependymal stem/progenitor cells from injury (epSPCis) 
proliferated 10 times faster than those from non-injured spinal cord (epSPCs) and 
while both epSPCs and epSPCis produced functional, HB9-expressing spinal motor 
neurons, a better yield was produced by neurospheres formed by epSPCi culture. 
Acute transplantation of undifferentiated epSPCis or resulting oligodendrocyte 
precursors into rat model of severe spinal cord contusion injury improved motor 
functioning 1 week after injury. The transplanted cells migrated a considerable 
distance (2 mm) from the transplantation site to the injury site. When the outcome of 
the transplantation of epSPCis or oligodendrocyte precursor cells (OPC) on the motor 
functioning (assessed by Basso, Beattie, and Bresnahan (BBB) scoring) was 
compared, it showed that the animals with OPC transplantation performed better than 
those with epSPCi transplantation. This suggests that whilst the formation of the glial 
scar is important (Sabelström et al., 2013), additional benefits are gained by more 
oligodendrocytes and oligodendrocyte precursors.  
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Infusion of growth factors also improves functional recovery from spinal cord injury 
(Kojima and Tator, 2002), and as this has been shown to increase ependymal cell 
proliferation greatly (30-fold) (Kojima and Tator, 2000), this further hints at a 
beneficial role for ependymal cells and a great importance for understanding their 
signalling as a potential method to improve outcome from spinal cord injury by 
utilising the endogenous stem cell capabilities of the spinal cord. 
1.2.3.4 Variation of ependymal cells and their role in the neurogenic niche 
Ependymal cells have widely been recognised as a heterogeneous group and there 
are many aspects in which there is variation between ependymal cells. One way in 
which ciliated ependymal cells expressing FoxJ1 (a protein which identifies cells with 
motile cilia (Meletis et al., 2008)) differ is the number of the cilia they possess. Most 
ependymal cells had 2 cilia but ependymal cells with 1, 3 and 4 were also observed 
(Alfaro‐Cervello et al., 2012). The ependymal cells with 4 cilia were noted to be 
binucleated.  
Another structural way that ependymal cells vary is between the cuboidal cells with 
and without basal processes. Sabourin et al. (2009) used GFAP-GFP mice to show 
that GFAP was expressed in radial ependymal cells predominantly in the dorsal 
region of the central canal although a few were observed laterally and ventrally. 
These cells were observed either within the ependymal cell layer or subependymally 
with a process into the central canal. These cells were observed to have radial 
processes leading away from their basal end and towards the pial surface of the 
spinal cord. As well as expressing GFAP, these cells express the epithelial-
mesenchymal-transition zinc finger E-box-binding protein 1 (ZEB1) and a subset also 
expressed brain lipid-binding protein (BLBP) (Sabourin et al., 2009), a protein 
proposed to be involved in the establishment of radial fibres (Feng et al., 1994).  
The vast majority of neurospheres produced by culturing of central canal cells from 
the GFAP-GFP mice showed expression of GFP, with those that were GFP negative 
ascribed to the incomplete expression of GFP in GFAP expressing cells in this 
transgenic model (Sabourin et al., 2009). This was supported by the fact that all 
neurospheres expressed BLBP with no BLBP observed in non-GFAP expressing 
cells (Sabourin et al., 2009). Additionally, use of a transgenic line expressing an 
inactive form of ZEB1 almost eliminated the production of neurospheres and 
dramatically increased the amount of cell death, indication that expression of ZEB1 
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was essential for the survival of neural stem cell functioning in vitro (Sabourin et al., 
2009). They noted that GFAP expression was only seen with polyclonal antibodies 
and was not seen with monoclonal antibodies. This may explain some differences in 
observed level of GFAP expression within the ependymal cell layer and in resultant 
cell cultures.  
Sabourin et al. (2009) observed that a proportion of the GFAP-positive stem cells 
were located subependymally and put a process into the central canal, accessing the 
CSF. This morphology is reminiscent of CSFcCs and has also been described in 
GFAP-positive cells (Alfaro‐Cervello et al., 2012), where they were defined as 
astrocytes. In this experiment the GFAP-positive subependymal astrocytes were not 
observed to proliferate in vivo. This suggests that there may be different populations 
of stem cells within the spinal cord. It may be that the neurogenic population is not 
the primary proliferative population that produces the majority of astrocytes and 
oligodendrocytes. Sabourin et al. (2009) also showed that CD15 was expressed 
around the central canal and was co-localised with both GFAP and BLBP. CD15 is a 
stem cell marker (Zhang et al., 2013; Li et al., 2016). Dromard et al. (2008) observed 
CD15 expression around the central canal in the human spinal cord, with CD15 
expressed predominantly dorsal to the central canal and very little in ventral regions. 
They drew connections between the expression of GFAP, CD15, nestin and Sox2 at 
the dorsal end of the central canal with the neural stem cells in the subventricular 
zone (SVZ; an adult neurogenic niche within the brain). The SVZ neural stem cells 
express Sox2 (Ferri et al., 2004), GFAP and CD15 (Capela and Temple, 2002; 
Doetsch, 2003). 
The studies above have looked at the ability of the GFAP-positive radial cells to form 
neurospheres in the culture situation however there is evidence that they may also be 
important in the proliferation seen in vivo, in situations such as spinal cord injury. 
GFAP, nestin and CD15 expression have all been observed predominantly around 
the dorsal aspect of the central canal, with minimal expression laterally and ventrally. 
This correlates with where the majority of the proliferation has been observed in vivo, 
where the highest rates are from dorsal regions of the central canal (Hamilton et al., 
2009; Sabourin et al., 2009).  
It could be that it is just GFAP-positive radial ependymal cells that are stem cells and 
not cuboidal ependymal cells but it may also not be that clear cut. Antigenic 
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differences between cuboidal ependymal cells, radial ependymal cells and tanycytes 
(discussed below), which are also sometimes considered a subclass of ependymal 
cell, have not been clearly defined and intermediate phenotypes have also been 
observed, suggesting that perhaps the cells represent a spectrum of ependymal cells 
(Meletis et al., 2008). There may also be a range of capabilities of the cells, perhaps 
with only a subpopulation that has neurogenic potential in vitro. Mothe and Tator 
(2005) used DiI labelling to track the ependymal cells as they migrated away from the 
central canal in response to injury. No co-localisation was seen between DiI and 
GFAP until 14 days after injury, however after that point the majority of DiI labelled 
cells also expressed GFAP. This fits with the fact that ependymal cells produce 
predominantly astrocytes after injury but would suggest that it is a non-GFAP 
expressing cell population within the ependymal cells that is responsible for the 
proliferation after injury. Whilst Sabourin et al. (2009) noted difficulties visualising 
GFAP, other cells are shown to be GFAP positive as are some ependymal cells after 
14 days suggesting that this was not an issue. There may be species differences as 
the cultured GFAP positive ependymal cells were from the mouse spinal cord where 
the migratory ependymal cells in situ experiments were done in the rat. However it is 
also possible that there are multiple types of stem cell within the heterogeneous 
ependymal cell population with different activators and differentiation capabilities.  
1.2.4 Tanycytes  
The other population of cells in this area are the tanycytes, which are also sometimes 
referred to as radial ependymal cells (Figure 1.2). These cells provide a link between 
the internal CSF and the vasculature, as they sit within the ependymal cell layer and 
contact the CSF via microvillia and a single cilium at their apical end (Rafols and 
Goshgarian, 1985; Meletis et al., 2008) and from their basal end, they have a process 
of which terminates on a blood vessel (Rafols and Goshgarian, 1985). Tanycytes 
have been observed along the length of the spinal cord (Bruni and Reddy, 1987) at 
an average frequency of 1-3 cells per 0.5 μm section, although the numbers were 
higher in the lumbar and sacral regions than in cervical and thoracic levels. In 
addition to the basal process that terminates on blood vessels subjacent, the 
tanycytic processes also contact neurons (Bruni and Reddy, 1987). Ependymal cells 
and tanycytes and CSFcCs show immunoreactivity for vasoactive intestinal 
polypeptide (VIP) (Basbaum and Glazer, 1983; Lamotte, 1987; Chung and Lee, 
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1988), a hypertensive and vasodilatory peptide found in the CSF (Fahrenkrug et al., 
1977; Sharpless et al., 1984).  
This section of the introduction has discussed the stem cell niche around the central 
canal of the spinal cord and the neurogenic potential of the spinal cord ependymal 
cells. The central canal region is not the only stem cell niche in the adult central 
nervous system; there are two stem cell niches within the brain which have proven 
neurogenic potential. These are discussed and contrasted with the central canal 
region below. 
 
1.3 Adult CNS stem cell niches 
 
Although the vast majority of neurogenesis is completed in embryological 
development there are two stem cell niches within the adult mammalian brain that 
maintain neurogenic activity into adulthood. The adult brain neurogenic niche that is 
best characterised is the subventricular zone (SVZ) of the forebrain (Chojnacki et al., 
2009) with the other being the dentate gyrus of the hippocampus (Zhao et al., 2008). 
Within the SVZ the neural stem cells are of astrocytic type (Hamilton et al., 2009) and 
sit subependymally. Also subependymally, the SVZ has transit-amplifying 
progenitors, neuroblasts, tanycytes, microglia and blood vessels all sitting outside the 
quiescent ependymal cells which line the lateral ventricles and are post-mitotic 
(Mirzadeh et al., 2008; Hamilton et al., 2009). The astrocytic stem cells (the stem 
cells are the B1 cell group (Spassky et al., 2005)) generate the transit-amplifying 
progenitors, that then produce neuroblasts. These neuroblasts migrate to the 
olfactory bulb and produce new interneurons (Morshead et al., 1994; Doetsch et al., 
1999). The morphology of the SVZ astrocytes is such that they have an apical 
process which contacts the CSF in the lateral ventricle despite their subependymal 
location, and also a basal process terminating on blood vessels (Mirzadeh et al., 
2008; Tavazoie et al., 2008). Under normal physiological conditions, the stem cells of 
the SVZ replicate at a steady rate producing the progenitors which move along the 
developmental pathway to become new neurons and also produce oligodendrocyte 
precursors which mature into oligodendrocytes. This differs from the stem cells in the 
spinal cord which do not function to produce any other cell types under intact 
physiological conditions. Spinal cord stem cells then increase their proliferation 
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dramatically in the injured situation and the SVZ astrocytic stem cells also respond to 
external situations. When the cells in the SVZ were experimentally depleted, there 
was a corresponding increase in the proliferation of the stem cells to replace the lost 
cells (Morshead et al., 1994; Doetsch et al., 1999).  
Despite also being an adult CNS stem cell niche, there are multiple differences 
between the SVZ and the spinal cord ependymal cells. In the spinal cord there is no 
clear subependymal region, with a few cells positioned subependymally but often of 
the same cell type as found ependymally (Sabourin et al., 2009). Significantly the cell 
type acting as the stem cell in these regions differs, despite the expression of GFAP 
in the spinal cord stem cell (Sabourin et al., 2009) it is widely agreed that ependymal 
cells are the stem cell in the spinal cord (Meletis et al., 2008), unlike the astrocytic 
stem cells in the SVZ.  
A further difference is the role of PSA-NCAM- and Dcx-containing cells within these 
stem cell niches. In the spinal cord stem cell niche the Dcx-containing cells are the 
CSFcCs which have not been observed to proliferate in the adult spinal cord 
(Marichal et al., 2009), whereas, in the SVZ, Dcx is expressed by the neuroblasts in 
the SVZ and as they migrate towards the olfactory bulb (Kuhn and Peterson, 2008). 
These neuroblasts go on to produce new neurons and start expressing the marker for 
mature neurons, NeuN (van Praag et al., 2002).  
Despite the fact that astrocytic SVZ stem cells could repopulate a portion of the SVZ 
subependymal cells, generally experimental insults to the ventricular ependyma are 
not reversible and the functioning of the stem cells in this area does not appear to be 
focussed on response to injury (Garfia et al., 1979). Instead the role of the SVZ stem 
cells is to produce cells including neurons which integrate into a range of circuits and 
are involved in pattern separation, olfactory discrimination and memory (Gengatharan 
et al., 2016; Migaud et al., 2016).  
The other brain region that produces new neurons in adulthood is the dentate gyrus 
of the hippocampus, where the adult-born dentate granule cells integrate into the 
local hippocampal circuitry (Parent, 2007). The neurogenic ability of the dentate gyrus 
is important for several learning processes and for dentate gyrus plasticity (Saxe et 
al., 2006; Winocur et al., 2006; Dupret et al., 2008). Unlike in the subventricular zone 
where the proliferating cells are multi-potent stem cells, the proliferating cells within 
the dentate gyrus are progenitor cells (Seaberg and van der Kooy, 2002). Culture of 
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the proliferative cells from the dentate gyrus in vitro showed that there are separate 
neural and glial progenitors within this region. Despite the fact that the dentate gyrus 
does not contain stem cells, one similarity between the dentate gyrus and the central 
canal region is that exercise also increases the rate of cell production in the dentate 
gyrus (Fabel and Kempermann, 2008). This increase in neurogenesis in the dentate 
gyrus is also seen with factors such as enrichment of the environment (Van Praag et 
al., 2000). There are more similarities between the central canal region and the SVZ 
than with the dentate due to the dentate gyrus not having a location next to the CSF 
and therefore no ependymal cells.  
Despite the fact that the SVZ has ependymal cells, the ependymal cells in the brain 
do not display the same level of proliferative ability as those in the central canal 
region. This is highlighted by the proportion of gliomas that ependymomas account 
for in the two regions. Ependymomas constitute only 4-6 % of intracranial gliomas but 
63 % of medullary and spinal gliomas (Rubenstein, 1989). 
 
1.4 Response of the central canal region to damage – Spinal Cord Injury 
 
The responses of ependymal cells to injury to the spinal cord have been discussed 
above in terms of their proliferation rate, migration and the lineages of cells produced. 
It is important to put into context the other factors occurring during the injury states 
where the increase in ependymal proliferation is seen. The predominant way that the 
increased proliferative abilities of ependymal cells could be activated is by spinal cord 
injury (SCI). SCI occurs at a worldwide annual incidence rate of between 10 and 40 
cases per million people mainly due to vehicle accidents, falls, sports injuries, work 
related injuries and violence (Lee et al., 2014a). Spinal cord injury affects a range of 
people but disproportionally affects males and shows a bimodal distribution for age, 
affecting young adults and the elderly at the highest rates (Furlan et al., 2009).  
In mammals, spinal cord injury leads to irreversible loss of function distal to the lesion 
site. This loss of damage is mediated through several factors including damage to the 
axons passing through the lesion site, demyelination and death of cells involved in 
the healthy functioning of the spinal cord such as oligodendrocytes, astrocytes and 
neurons (Grossman et al., 2001; Hulsebosch, 2002).  There are multiple stages of 
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spinal cord injury which contribute to this damage to axons, death of cells and loss of 
functioning. The primary mechanical trauma disrupts cells and axons and initiates a 
cascade of further events, many of which contribute to the damage. Loss of 
microcirculation around the damage site contributes to local ischemia (Tator and 
Fehlings, 1991) and together with other factors, expands the injury site.  The cavity 
formed by the rapid necrosis of cells becomes filled by a cyst containing many 
microglia, fibroblasts and astrocytes and leads to the formation of a glial scar (Iyer et 
al., 2017). All of these factors play a number of roles which may be both beneficial 
and detrimental at different times and in different circumstances.  
It is therefore likely that a number of therapeutic treatments will be needed to fulfil 
these varying requirements. One possible therapeutic option under consideration for 
a role in the response to spinal cord injury is utilisation or modulation of the properties 
of ependymal cells or epSPCs (Parr et al., 2008; Moreno-Manzano et al., 2009). Both 
cultured ependymal cells derived from injured and non-injured spinal cords have 
been shown to have beneficial effects on the functional outcome after spinal cord 
injury in rats.  
Spinal cord-derived neural stem/progenitor cells (NSPCs; likely to be analogous to 
epSPCs as cultured from the ependymal regions of the rat spinal cord) implanted 9 
days after a spinal cord injury was shown to produce an improved functional outcome 
(Parr et al., 2008). Implantation of bone marrow-derived mesenchymal stromal cells 
(BMSCs) has previously been shown to be beneficial when implanted after SCI 
(Chopp et al., 2000; Syková and Jendelová, 2005) however Parr et al. (2008) showed 
no functional benefit of either BMSCs alone nor when BMSCs and NSPCs were 
applied, despite showing a reduction in cavity size, with only application of NSPCs 
alone improving the BBB score of locomotor functioning. These differences in the 
effectiveness of BMSC transplantation may have been due to timing of 
transplantations and possibly also the strain and culturing methods of BMSCs. 
However the implantation of NSPCs alone was able to improve functional recovery as 
shown by a significantly better performance in both the ladder-walk and open-field 
tests compared to both control and BMSC treated animal (Parr et al., 2008). 
Transplanted NSPCs produced a high number of cells expressing APC 
(adenomatous polyposis coli), a marker for oligodendrocytes (Lang et al., 2013). 
Additionally, their transplantation was shown to help preserve or promote 
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regeneration of the descending axons as shown by retrograde labelling to brain 
regions such as motor nuclei (Parr et al., 2008).  
Ependymal-derived stem/progenitors for injury (epSPCis) were shown to proliferate 
10 times faster in vitro than epSPCs and were shown to aid functional recovery when 
transplanted into injured rat spinal cords 1 week after the SCI (Moreno-Manzano et 
al., 2009). The implanted cells showed good survival rates and migrated to the site of 
injury. Unlike with implantation of epSPCs/NSPCs (Parr et al., 2008), implantation of 
epSPCis was shown to reduce the size of cysts/cavities around the injury site. 
Transplantation of epSPCis improved the open-field BBB scores compared to control 
animals despite minimal differentiation of the transplanted cells being seen (Moreno-
Manzano et al., 2009). This lack of differentiation of the transplanted cells suggests 
that either the transplanted cells are providing an environment that is more conducive 
to the optimal functioning of endogenous cells or that the transplanted cells can 
provide positive effects in their undifferentiated state.  
1.4.1 Possible methods of detection of damage by ependymal cells 
While it is known that spinal cord injury affects the functioning of ependymal cells, it is 
not known which aspect of the spinal cord injury is being detected by the ependymal 
cells or if other cells are detecting the damage and signalling to the ependymal cells. 
One theory is that their response is triggered by the raised levels of extracellular ATP 
and other nucleotides that are observed after spinal cord injury (Wang et al., 2004), 
mechanical brain injury (Franke et al., 2006) and even ischemia (Melani et al., 2005). 
ATP is used as a damage signalling mechanism in other regions of the body such as 
in the cochlea (Paemeleire and Leybaert, 2000; Lahne and Gale, 2010). In spinal 
cord injury levels of extracellular ATP have been shown to play important roles in the 
local response mechanisms, where in addition to the injury site, ATP was shown to 
be released by the peritraumatic zones for multiple hours after injury (Wang et al., 
2004). This raised level of extracellular ATP was a factor in the death of neurons and 
oligodendrocytes. ATP and several analogues were also shown to be sufficient to 
cause cell death (10 μM in 2 μL aliquots), with the P2X7 receptor implicated due to 
similar levels of cell death with the P2X7-specific agonist BzATP (Wang et al., 2004). 
In addition to the cell death, this raised level of extracellular ATP is likely to affect a 
range of cells as purinergic receptors are expressed on many cells. ATP is frequently 
used as an intercellular signalling molecule including in neuron-glia interactions 
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(Fields and Burnstock, 2006; Lohr et al., 2014). Purinergic signalling is also used by 
astrocytes which release ATP in order to propagate waves of calcium. These are a 
response to stimuli such as synaptic activity and traumatic injury (Arcuino et al., 2002; 
Fields and Stevens-Graham, 2002).  
This increase in extracellular ATP levels is implicated in multiple aspects of the 
response to spinal cord injury such as activation of microglia (Wang et al., 2004; 
Davalos et al., 2005) and the proliferation of astrocytes (Franke et al., 2001). The 
modulation of the purinergic signalling may also affect the response of ependymal 
cells to spinal cord injury. Intrathecal infusion of broad spectrum purinergic 
antagonists PPADS and suramin after spinal cord injury was shown to decrease the 
numbers of GFAP positive cells in the injury site (Rodríguez-Zayas et al., 2012). This 
reduction in GFAP-positive cells after treatment with purinergic antagonists may have 
been due to reduced proliferation of ependymal cells, reduced differentiation into 
GFAP-expressing cells, as was seen by Mothe and Tator (2005), or it could have 
been an impact on the astrocytes which infiltrate the injury site but are not those 
derived from ependymal cells. The reduction in GFAP+ cells within the injury site was 
accompanied by a decrease in the amount of spared tissue. However this difference 
in the tissue spared from the injury did not affect the functional outcome of the injury, 
with open-field testing showing no difference between the conditions. This work and 
the expression of purinergic receptors around the central canal of the spinal cord 
(discussed below) indicate a potential role for purinergic signalling in these cells, 
particularly after spinal cord injury.  
1.4.2 Regenerative potential in non-mammalian species 
Unlike in mammals, considerable regeneration is seen in lower vertebrates after 
injury to the spinal cord (Bruni and Reddy, 1987). Spinal cord regeneration in lower 
species is seen both through axonogenesis which is able to bridge the gap but not 
faithfully replicate the structures that were there before injury and through 
neurogenesis, which together with axonogenesis can produce a more comparable 
spinal cord structure (Tanaka and Ferretti, 2009). The central canal region plays an 
early role in the reconnection of the cord after transection in the eel spinal cord 
(Dervan and Roberts, 2003). This occurs by the central canal cells forming a new 
canal by producing flat plates that serve as templates for the formation of the lateral 
and dorsal walls with ependymal cells displaying a modified phenotype which is 
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thought to have trophic effects on the regenerating axons. In the salamander, the 
ependymal tube that gives rise to the regenerated spinal cord following tail 
amputation bears considerable similarity to the early structure of the neural tube in 
development (Tanaka and Ferretti, 2009). The proliferating cells within these species 
with regenerative spinal cord capabilities have stem cells that show features of radial 
glia and are more similar to those seen during development and it is suggested that 
this presence of functional radial glia that also retain stem cell potential is an 
essential difference between non-regenerative and regenerative species (Tanaka and 
Ferretti, 2009). This suggestion that the retention of features associated with 
development is supported by the high levels of regeneration seen after injury in 
embryonic mammalian spinal cord (Nicholls and Saunders, 1996), however there 
may be other factors such as the spinal cord environment adding to the differential 
regenerative abilities of different species.  
 
1.5 Purinergic signalling  
 
 
Figure 1.3 ATP and its derivatives act as agonists on pre-synaptic and post-
synaptic purinergic receptors. 
Schematic showing the extracellular metabolism of ATP to ADP, then AMP and then 
Adenosine and the actions of these products on purinergic receptors in pre- and post-
synaptic neurons. ATP is shown to act on ionotropic P2X receptors, ADP on P2X and 




As well as acting as an intracellular energy store (Hultman and Greenhaff, 1991), 
ATP and other purine nucleotides and nucleosides also act as neurotransmitters and 
are often involved in sensory and autonomic systems via actions on a range of pre-
synaptic and post-synaptic receptors (Figure 1.3) (Lohr et al., 2014; Shatarat et al., 
2014; Adriaensen et al., 2015). The processing pathway of purine nucleotides and 
individual receptors are discussed in detail below. Purinergic signalling is involved in 
a wide range of systems throughout the body and is particularly highly used during 
development from some of the first stages of development in the fertilised egg (Kupitz 
and Atlas, 1993). Many embryos respond to ATP signalling, including mammalian 
embryos. This was shown by electrophysiological recordings of mouse mesodermal 
stem cell line cells which showed an initial increase in internal Ca2+ after ATP 
application, followed by a hyperpolarisation of the cell mediated by Ca2+-activated K+ 
conductances (Kubo, 1991). Purinergic signalling is utilised by many cell types during 
development to trigger particular processes and delay others. Modulation can 
therefore lead to significant changes in outcomes of this development. Application of 
ATP to dendrites of embryonic hippocampal neurons produced changes in dendritic 
morphology in vitro (Khakh et al., 2001) and acts as a trophic factor on grown axons 
during development, with an increase in hippocampal connectivity seen after 
application of purinergic agonists and a reduction with antagonists (Heine et al., 
2006). These suggest a role for ATP in the correct development of these processes. 
During development, purinergic signalling interacts with many other factors such as in 
the inner ear where brain-derived neurotrophic factor (BDNF)-mediated development 
of spinal ganglion neurons was inhibited by purinergic signalling in the neonatal rat 
cochlea (Greenwood et al., 2007). Another way in which purinergic signalling impacts 
development other than direct action upon the neurons is through actions on the glial 
cells which play important roles during development. Purinergic signalling is 
frequently used by  radial glial cells to communicate over long distances with other 
glia or neurons by propagation of calcium waves (Weissman et al., 2004). These 
ATP-elicited calcium waves act to modulate proliferation in the developing neocortex, 
with reduced calcium waves decreasing proliferation in the ventricular zone during 
the peak period of neurogenesis. Myelinating glial cells, Schwann cells in the 
periphery and oligodendrocytes in the central nervous system, are also affected by 
purinergic signalling during development (Lecca et al., 2012). ATP release 
non-synaptically from electrically stimulated axons activates receptors on nearby 
oligodendrocytes and triggers myelination (Fields and Stevens, 2000). A further role 
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of purinergic signalling on oligodendrocyte development has been shown via indirect 
signalling upon astrocytes which release a cytokine, leukaemia inhibitory factor, that 
then acts on the oligodendrocytes to promote myelination (Ishibashi et al., 2006). 
Myelination is not the only process that purinergic signalling has been shown to elicit 
in oligodendrocyte lineage cells. In oligodendrocyte precursor cells (OPs), application 
of ATP or ADP but not UTP was shown to stimulate OP migration and differentiation  
(Agresti et al., 2005b). These various roles indicate the importance of purinergic 
signalling during development on multiple different cell types. There is therefore the 
question of whether there are similar roles for purinergic signalling in postnatal 
development and adult niches that retain stem cell features.  
Adult post-natal neurogenic niches in the mammalian brain also retain multiple 
features of purinergic signalling with both B cells of the subventricular zone (SVZ) and 
of the radial glial cells in the dentate gyrus of the hippocampus expressing nucleoside 
triphosphate diphosphohydrolase 2 (NTPDase2) (Braun et al., 2003). NTPDase2 is 
an ecto-ATPase, a protein which hydrolyses extracellular nucleoside triphosphate to 
the respective diphosphates e.g. ATP to ADP, and therefore acts to control levels of 
extracellular nucleotide triphosphates, such as ATP, and thus modulate levels of ATP 
signalling (Langer et al., 2007). Additionally, the radial glia in the dentate gyrus and 
the B cells of the SVZ express functional purinergic receptors (Shukla et al., 2005; 
Mishra et al., 2006; Messemer et al., 2013), with SVZ cells expressing another type of 
purinergic receptor when they mature into immature neurons and migrate to the 
olfactory bulb. This suggests that the expression of the particular purinergic receptors 
(metabotropic P1 and P2Y receptors, expanded upon below) is important for the 
functioning of these regions as stem cell niches. Evidence to support this comes from 
the responses of SVZ-derived cultured neurospheres to purinergic signalling, where 
application of agonists increased the rate of proliferation while application of 
antagonists or knockout of the metabotropic purinergic receptor P2Y1, discussed 
below, reduced the proliferation rate (Mishra et al., 2006). This increase in the rate of 
proliferation in SVZ cells with increased purinergic signalling has also been observed 
in vivo. Infusion of ATP into the lateral ventricles increased the numbers of newly-
proliferated cells and was decreased by application of a specific antagonist for P2Y1 
or P2Y1 knock out (Suyama et al., 2012).  
The fact that purinergic signalling has been shown to be involved in a range of 
processes including development, adult-stem cell niches and responses of multiple 
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cell types after spinal cord injury makes it a viable candidate for a significant role in 
central canal functioning. The following section will detail the receptors involved in 
purinergic signalling and look at their expression around the central canal of the 
spinal cord.  
1.5.1 Extracellular nucleotide metabolism 
Adenosine triphosphate (ATP) is composed of adenosine and three phosphate 
groups. ATP can be dephosphorylated by ecto-nucleotide triphosphate 
diphosphydrolase (ecto-NTDPase) (Doleski et al., 2016). This produces adenosine 
diphosphate (ADP), which can be further dephosphorylated by the same enzymes to 
adenosine monophosphate (AMP) (Figure 1.3). This can then be completely 
dephosphorylated to adenosine by ecto-5’-nucleotidase enzymes (Street et al., 
2013). There are other enzymes which dephosphorylate ATP directly to AMP. 
Collectively enzymes that are involved in the extracellular metabolism of nucleotides 
are known as ecto-nucleotidases or ecto-ATPases if they are specific for ATP. 
Ecto-ATPases are bound to the membranes of many cells and act to metabolise 
external nucleotides meaning that the levels of extracellular ATP and other 
nucleotides such as UTP are controlled by multiple factors including release, uptake 
and metabolism (Zimmermann et al., 2012).  
Many of these molecules are able to act as agonists on some purinergic receptors. 
ATP acts on P2X receptors and a subset of P2Y receptors, ADP acts on a subset on 
P2Y receptors, as does UTP and UDP-glucose while adenosine acts on P1 (or A1) 
receptors. The structure and function of these will be expanded upon below.  
1.5.2 Structure of purinergic receptors 
1.5.2.1 P2X receptors 
Ionotropic P2X receptors are ligand-gated ion channels which are bound to the 
plasma membrane. Individual subunits have 2 transmembrane domains with 
intracellular N- and C-termini and form trimeric channels. There are 7 subunits 
(P2X1-7) which can form heteromeric and homomeric assemblies. Heteromeric 
assemblies of P2X receptors that have been identified include P2X2/3, P2X4/6, P2X1/5, 
P2X2/6, P2X1/4 and P2X1/2. All subunits form homomeric assemblies except P2X6 
(Abbracchio et al., 2009). All 7 P2X subunits are expressed in neural tissue with P2X3 
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and P2X2/3 expressed in sensory and autonomic peripheral neurons (Abbracchio et 
al., 2009). All of these assemblies are sensitive to ATP, although with different 
potencies. Specifically homomeric P2X7 has a lower sensitivity to ATP than the other 
receptors; whilst the other receptors have an EC50 of 1-10 μM (Abbracchio et al., 
2009), P2X7 has an EC50 of 100 μM for ATP (Donnelly-Roberts et al., 2009), but is 
more sensitive to BzATP for which the EC50 is 26 μM (Zhang et al., 2005). They also 
all form non-specific cation channels through which Na+, K+ and Ca2+ ions can flow 
once 3 molecules of ATP are bound (Burnstock, 2006), however the permeability of 
each channel to calcium varies slightly depending on the subtypes which form the 
channels (North, 2002).  
Despite these similarities, there are multiple differences between ion channels with 
made up of different P2X subunits. One difference is that some subtypes 
demonstrate an increase in the size of the pore after prolonged exposure to ATP 
which allows passage of larger ions such as NMDG+ and the dye YO-PRO-1 (Khakh 
et al., 1999; Virginio et al., 1999). P2X2, P2X2/3, P2X4 and P2X7 all show this biphasic 
response which is activated by ATP application for longer than 10 seconds. The size 
of the initial pore opened with application of ATP is about 8-20 Å with the larger pore 
formed after prolonged application at least 3 Å larger than the initial pore (Eickhorst et 
al., 2002). This increased pore size changes the permeability of NMDG from 5 % of 
that of Na2+ to 50 % of the permeability of Na2+ (North, 2002). This biphasic response 
allows cells expressing these purinergic receptors to produce 2 different currents, one 
elicited initially upon detection of ATP, the second after prolonged exposure and it 
has been suggested that this property may be involved in synaptic plasticity (Khakh 
et al., 1999).  
The desensitisation times of the receptors also vary between receptors made up of 
different subtypes for example P2X1 and P2X3 homomeric receptors have a fast 
desensitisation compared to P2X2 homomeric receptors which sustain currents for 
multiple seconds with sustained application (North, 2016), while heteromeric P2X2/3 
receptors and homomeric P2X4 receptors showing intermediate desensitisation 
characteristics (Mackenzie et al., 1999).  
The heteromeric channels display a range of characteristics maintaining some 
characteristics of each of the homomeric channels of the constituent subtypes. For 
example P2X2/3 heteromer channels resemble P2X3 receptors with respect to factors 
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such as sensitivity to Ap5A (1 μM for P2X3 and P2X2/3, and inactive in P2X2 
receptors) and lack of effect of high zinc levels (100 μM) on the response size to 
ATP. Zinc significantly potentiates the response in P2X2 receptors but not in P2X3 or 
P2X2/3 (Liu et al., 2001). Conversely, P2X2/3 receptors resemble P2X2 receptors in 
respect to the desensitisation times (North, 2002). In other characteristics, the 
heteromeric P2X2/3 receptor displays an intermediated profile. P2X2 receptors have 
their response to ATP potentiated by a decreased pH while acidification has a slight 
inhibitory effect on P2X3 receptors. In this respect, P2X2/3 receptors show a small 
potentiation of response when the pH is decreased from 7.4 to 6.5 (Liu et al., 2001).  
There are some characteristics that are specific to one particular subtype 
arrangement of P2X receptor. The functioning of the P2X3 receptor is modulated by 
temperature (Khmyz et al., 2008). Under normal temperatures the P2X3 receptor 
desensitises rapidly and is slow to return to the non-desensitised state slowly but 
when the temperature is increased to 40 °C the rate of desensitisation did not change 
but the rate of recovery increases significantly. Knock out experiments of the P2X3 
subunit demonstrated a role for this receptor subtype in non-noxious temperature 
sensing (Egan et al., 2006).  
1.5.2.2 P2Y receptors 
Metabotropic P2Y receptors are seven-transmembrane domain G-protein coupled 
receptors which respond to a range of nucleotides. There are 8 P2Y subtypes, 
named P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14, with the non-
consecutive numbering due to naming of putative new subtypes that were later 
shown not to be true P2Y receptors e.g. P2Y5 (Pasternack et al., 2008). As with P2X 
receptors, P2Y receptors are found in a wide range of tissues throughout the body. 
Whilst the receptors tend to respond to different nucleotide agonists with a range of 
sensitivities, they can all be classified according to which one or two nucleotides act 
as their primary agonists. P2Y1, P2Y12 and P2Y13 all have the highest sensitivity for 
adenosine diphosphate (ADP). P2Y6 has the highest sensitivity for UTP, P2Y14 for 
UTP-glucose and P2Y11 for ATP. P2Y2 and P2Y4 both respond with high levels of 
sensitivity to both ATP and UTP (von Kügelgen and Hoffmann, 2016).  
There is variation amongst the P2Y receptor population regarding the G proteins 
coupled to the receptors, with the receptors split into two main groups. The first group 
contains P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 which couple to the Gq/11 pathway while 
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the second group, made up of P2Y12, P2Y13 and P2Y14, couples to the Gi/o pathway 
(Abbracchio et al., 2009). However P2Y receptors have been observed coupling to 
multiple pathways, sometimes in response to activation by different agonists such as 
in P2Y11 where activation by ATP mobilises inositol triphosphate (IP3) to produce an 
increase in intracellular Ca2+ concentration, while UTP application raised intracellular 
Ca2+ levels without mobilisation of IP3 suggesting an agonist-dependent difference in 
intracellular signalling pathways (White et al., 2003).  
Despite P2Y receptors primarily acting as monomers, some P2Y receptors form 
dimers, sometimes with other P2Y receptors and sometimes with other receptors. 
P2Y1 has been shown to dimerise with the adenosine receptor A1 upon activation of 
both receptors (Yoshioka et al., 2001, 2002) with the resultant dimer demonstrating 
combined properties of the monomers of the two constituent channels. The P2Y1-A1 
receptor responded to ADPβS, a feature of P2Y1 receptors, but this response was 
sensitive to the A1-specific antagonist DPCPX. This indicates the potential complexity 
in purinergic signalling via P2Y receptors.  
1.5.2.3 Adenosine receptors 
ATP is dephosphorylated and produces adenosine and this is the primary production 
route for adenosine. Where the dephosphorylation of ATP is intracellular, the 
adenosine is more often released by transporters rather than vesicular release (Sheth 
et al., 2014).  
There are also purinergic receptors that respond selectively to adenosine. There are 
four adenosine receptors (P1 receptors), the A1, A2A, A2B and A3 receptors. They are 
all G-protein coupled receptors. A1 and A3 are coupled to Gi/o inhibitory intracellular 
signalling proteins which inhibit adenylyl-cylase to reduce the levels of cyclic AMP 
and therefore the concentration of intracellular calcium. A2A and A2B receptors are 
coupled to Gs intracellular signalling proteins which act in an excitatory manner by 
increasing intracellular calcium levels (Jacobson et al., 2012; Sheth et al., 2014). 
Adenosine receptors are involved in a range of functions including modulation of 
neurotransmitter release (Sebastião and Ribeiro, 2000) and neuroprotection (Ferreira 
and Paes-de-Carvalho, 2001). In addition to the activation of adenosine receptors by 
release of adenosine, the presence of ecto-ATPases means that where adenosine 
receptors are present, there could be activation of adenosine receptors when levels 




1.5.3 Purinergic signalling in the central canal region 
1.5.3.1 Purinergic signalling in CSFcCs 
A range of purinergic receptors has been identified in the ependymal cells and 
CSFcCs of the mammalian spinal cord both under intact physiological conditions and 
in conditions of spinal cord injury or in vitro culturing of epSPCs or epSPCis. 
Within CSFcCs, P2X2 expression has been shown at all stages of development 
(Stoeckel et al., 2003). The expression of P2X2 within CSFcCs appears strong within 
a large proportion of CSFcCs. When this expression is assessed via electron 
microscopy, it was shown that P2X2 intensely expressed along the inner membrane 
of the cell with the strongest concentration in discrete regions. This pattern of P2X2 
expression was similar along the apical process and the bouton that sits within the 
central canal. However P2X2 was particularly intensely expressed in small finger-like 
projections which intrude into the surrounding neuropil. Within these projections P2X2 
expression is in regions which were closely opposed to synaptic boutons outside the 
cell (Stoeckel et al., 2003). P2X2 expression is also present in the axons leading 
away from the CSFcCs in ventral then ventrolateral directions. These P2X2 receptors 
were shown to be functionally active in that they produce a rapid inward current which 
then shows strong rectification of the current (Marichal et al., 2009). Inward 
rectification of a channel is when current passes more readily in the inward direction 
than in the outward direction and is a feature of P2X2 receptors (Zhou and Hume, 
1998). CSFcCs also respond to changes in pH (Marichal et al., 2009). This is 
significant because P2X2 receptors have their responses to ATP potentiated by 
acidification (King et al., 1997; Stoop et al., 1997; Ding and Sachs, 1999). This may 
not be the cause of the response in the electrophysiological recordings by Marichal et 
al. (2009) as another pH sensitive molecule, PKD2L1, has been identified in CSFcCs 
(Huang et al., 2006; Petracca et al., 2016), however the P2X2 receptors present in 
CSFcCs could also be playing these roles.  
1.5.3.2 Purinergic signalling in radial glia 
P2X7 receptors have also been identified around the central canal (Marichal et al., 
2016). The first cell type that P2X7 has been identified in is CC-contacting radial glia 
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which could be activated by either ATP or BzATP, with the response inhibited by 
Brilliant Blue G (BBG). This expression of P2X7 is along both the apical and basal 
processes and upon activation of the basal endfoot of the radial glia a wave of Ca2+ is 
propagated along the process towards the cell body and then along the apical 
process (Marichal et al., 2016).  
1.5.3.3 Purinergic signalling in ependymal cells 
The other cell type around the central canal that express P2X7 receptors is the 
ependymal cell (Marichal et al., 2016). Similarly to the responses seen in radial glia, 
application of either BzATP or ATP produces an inward current in ependymal cells. 
An increase in intracellular calcium levels was also seen although it did not propagate 
in a wave as ependymal cells do not display the same processes as radial glial cells. 
As P2X7 receptors do not show very high sensitivity for ATP, these responses were 
only seen with a long pulse (>1s) of a relatively high concentration of ATP (1 mM).  
Another receptor that has been observed in native ependymal cells is the P2Y-like 
protein GPR17 (Ceruti et al., 2009). The GPR17 is activated by both uracil 
nucleotides (UDG-glucose) and also cysteinyl-leukotrienes, such as Leukotriene D4 
(LTD4) and Leukotriene C4 (LTC4). The GPR17 receptor plays a role in the response 
of the ependymal cells to injury. GPR17 is upregulated in cells undergoing apoptotic 
cell death due to an ischemic infarct in the brain and inhibition of GPR17 increases 
the amount of cell death but at later times GPR17 activation is important in the 
remodelling and repair responses (Lecca et al., 2008). An effect in spinal cord injury 
has also been showing using animals with the GPR17 receptor knocked down by use 
of a specific antisense oligonucleotide. After spinal cord injury, the animals with 
GPR17 knock down showed both morphological and functional differences. Knock 
down of GPR17 acted in a neuroprotective manner in spinal cord injury causing a 
reduced disruption of the myelin structure and higher locomotor function score 7 days 
after spinal cord injury (Ceruti et al., 2009). A similar role for GPR17 in increasing the 
sensitivity of cells to nucleotide-mediated cell death has been observed in 
oligodendrocyte precursor cells (Ceruti et al., 2011). These indicate that GPR17 
signalling is involved in multiple aspects of the response to injury including roles in 
mediating cell death and also in the secondary repair responses to the injury, one or 




1.5.3.4 Purinergic signalling after spinal cord injury 
In addition to roles in the response to spinal cord injury, the expression levels of 
some purinergic receptors have been shown to be modulated by spinal cord injury. 
Much of this work has looked at epSPCs and epSPCis. Within epSPCs both 
ionotropic P2X and metabotropic P2Y receptors were identified. Activation by ATP 
produces increases in intracellular calcium concentration via P2X4 and P2X7 and 
P2Y1 and P2Y4 (Gómez-Villafuertes et al., 2015). Analysis of P2X RNA found in 
epSPCs showed presence of P2X2, P2X4, P2X5, P2X6 and P2X7 but with P2X4 and 
P2X7 observed at the highest quantities and expression of these was confirmed by 
western blot. The contribution of P2X7 was demonstrated by the high levels of 
activation by the P2X7 specific agonist BzATP. In addition to P2Y1 and P2Y4, a band 
corresponding to P2Y2 was also identified but was not seen in Western blot analysis. 
P2Y1 is activated by ADP and P2Y2 and P2Y4 are activated by UTP. Both ADP and 
UTP highly activate epSPCs. Additionally, UDP and two diadenosine polyphosphates 
(Ap4A and Ap5A) produce a small response (Gómez-Villafuertes et al., 2015). The 
expression of the purinergic receptors in epSPCis differs from those in epSPCs with a 
downregulation of P2Y1 (Gómez-Villafuertes et al., 2015). When the responses of 
epSPCis were compared to those of epSPCs to various nucleotide agonists, the 
majority showed very similar pharmacological properties however the response in 
intracellular calcium levels to ADP application was significantly smaller and the 
response to Ap5A was slightly larger.  
In vivo assessment of P2X4 and P2X7 levels at the site of spinal cord injury has 
shown that there is an accumulation of P2X4-positive and P2X7-positive cells within 
the injury site and peaking at 7 days after injury (Schwab et al., 2005). These cells 
were predominantly microglia and surviving neurons (Schwab et al., 2005; Gómez-
Villafuertes et al., 2015). Transplantation of epSPCis to the injury site reduced the 
injury-induced increases in both P2X4 and P2X7 expression around the central canal 
which correlated with the increased functional locomotor scores seen with epSPCi 
transplantation (Gómez-Villafuertes et al., 2015).  
Another purinergic receptor which is found at higher concentrations in the grey and 
white matter after spinal cord injury is P2Y2 (Rodríguez-Zayas et al., 2010). P2Y2 
expression is seen in neurons in the ventral horn in uninjured animals and in the 
white matter P2Y2 is expressed at low levels in glial cells. 14 days after a 
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compression spinal cord injury, rat spinal cord displayed increased levels of P2Y2 
expression as shown by RT-PCR studies. This was largely due to an increase in 
numbers of P2Y2 expressing cells within the white matter with significantly more P2Y2 
positive processes. The cell types expressing P2Y2 after spinal cord injury were 
shown to be astrocytes, macrophages, oligodendrocytes, neurons and neuronal 
axons as demonstrated by co-localisation with GFAP, MAB 328, CD68: Biotin, NeuN 
and NF-H respectively (Rodríguez-Zayas et al., 2010). It is not known whether these 
P2Y2 expressing cells are derived from ependymal cells or if the P2Y2 expression is 
due to proliferation of another cell type, infiltration of P2Y2-positive cells or increased 
P2Y2 expression from cells already present. 
Purinergic signalling has also been implicated in other aspects of the response to 
spinal cord injury via P2X7 and P2X4 receptors which are highly expressed in neurons 
and immune cells (de Rivero Vaccari et al., 2012). P2X7 has been suggested to have 
a role in causing cell death. Application of P2X7 antagonists have been shown to 
have neuroprotective effects including a reduction in neuroinflammation, resulting in 
an improvement in motor function (Peng et al., 2009) and (Wang et al., 2004) . A 
similar reduction in neuronal cell death with application of P2X4 modulators has been 
seen in a model of amytrophic lateral sclerosis (Andries et al., 2007). P2X4 has a 
critical role in the development of neuropathic pain following spinal cord injury (de 
Rivero Vaccari et al., 2012) . P2X4 is upregulated after by 24 hours post injury (Tsuda 
et al., 2013) and application of the histone deacetylase inhibitor valproic acid had an 
inhibitory effect on the expression of P2X4 in microglia and helped preserve neuronal 
fibres after spinal cord injury.  
These findings detailed above demonstrate the complexity of the spinal cord stem 
cell niche and the processes it is involved in, particularly in response to injury to the 
spinal cord tissue. There is also a breadth of evidence to suggest multiple roles of 
purinergic signalling via a range of purinergic receptors within the cell types around 




1.6 Hypotheses and aims 
 
The cells of the central canal region of the spinal cord are involved in the responses 
of the spinal cord to injury. Purinergic signalling is hypothesised to play a role in the 
detection of this injury and the responses to it due to the increases of extracellular 
nucleotide levels after spinal cord injury and the presence of purinergic receptors and 
ecto-nucleotidases in the cell types in this area. There is currently little understanding 
of the electrophysiological behaviour of ependymal cells and CSFcCs in response to 
application of nucleotides and purinergic agonists, particularly in spinal cord slices as 
opposed to cultured epSPCs. This study will investigate the role of purinergic 




This study has 2 specific hypotheses: 
1. Activation of purinergic receptors by application of nucleotides and purinergic 
agonists will produce changes to membrane potential of the ependymal cells and 
CSFcCs of the central canal region of the mammalian spinal cord.  
 
2. Modulation of purinergic signalling will affect the behaviour of cells within 
organotypic spinal cord slices in culture.  
These hypotheses can be summarised in the overall hypothesis:  
Cells within the central canal region of the mammalian spinal cord can respond to 
application of nucleotides and purinergic agonists via ionotropic and metabotropic 







This study uses whole cell patch-clamp electrophysiological recordings and EdU-
labelling of proliferative cells in organotypic slice cultures to: 
1. Better understand the electrophysiological responses of ependymal cells to a 
range of nucleotides and purinergic agonists.  
 
2. Determine any variation in the responses of CSFcCs to application of ATP and if 
this variation correlates with the CSFcC subtypes previously identified. 
 
3. Determine the effect of modulation of purinergic signalling on the behaviour of 
cells of the central canal region in organotypic slice cultures, behaviour which is 












Chapter 2 - General Methods 
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All experiments were carried out as detailed in the Animals Scientific Act (1986) and 
the ethical standards prescribed by the University of Leeds Ethical Review Committee 
by Home Office-approved individuals. At all times, efforts were made to reduce the 
number of animals used and minimise any suffering they experienced.  
2.1 Animals 
Two species of animal were used for the following experiments. For the 
electrophysiological experiments, wild-type Wistar rats (p 7-13) were used. For the 
culture and proliferation experiments wild-type C57bl6 mice (p 12-21) were used. The 
immunohistochemical analysis was carried out on wild-type Wistar rats both pre-
weaner (p7-13) and adult (aged approximately 3 months), and on wild-type C57bl6 
mice, pre-weaner (p 12-21) and adult (aged approximately 3 months). All C57bl6 
mice were obtained from the in-house breeding facility at the Central Biomedical 
Services at the University of Leeds. The majority of the Wistar rats were similarly 
obtained from the in-house breeding facility at the Central Biomedical Services. A 
small proportion of the Wistar rats were obtained from Charles River Laboratories, 
UK, through the Central Biomedical Services at the University of Leeds.  
2.2 Spinal cord slice preparation 
7-13 day old rats as detailed above were anaesthetised by intraperitoneal (I.P.) 
administration of either pentabarbitone (Euthatal – Merial Animal Health Ltd, UK) or 
urethane (Sigma-Aldrich, UK) made up in aCSF at doses of 60 mg/kg and 2g/kg of 
body weight respectively. Minimal acceptable level of anaesthesia was such that the 
pedal withdrawal reflex in response to a foot pinch was abolished. 
After necessary level of anaesthesia was achieved, spring scissors were then used to 
do a transverse laparotomy. The diaphragm was perforated and vertical incisions 
made to the clavicle and the ventral rib cage removed. The right atrium was then 
perforated and 20 ml of ice cold sucrose artificial cerebrospinal fluid (sucrose aCSF; 
see table 2.1 for constituents) transcardially perfused by injection into the left 
ventricle. Ice cold sucrose aCSF was used for the preparation of the slices to cool the 
spinal cord and to reduce the levels of extracellular sodium ions (sucrose takes the 
place of the sodium ions, see Table 2.1) to minimise cell death by excitotoxicity. The 
sucrose aCSF was oxygenated by continual bubbling with 95% O2:5% CO2 until the 
time of perfusion. Appropriate level of perfusion was determined by blanching of the 
liver and limb extremities. Decapitation was then performed using blunt scissors.  
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A dorsal laminectomy was used to expose the spinal cord. This involved the use of 
blunt scissors to remove the skin and fatty tissue from over the spinal column. Spring 
scissors were then used to make incisions on the lateral edges of the vertebrae such 
that the dorsal portion of the vertebrae could be removed. The nerve rootlets 
attached to the spinal cord were severed using spring scissors. This allowed the 
spinal cord to be lifted from the vertebral column and placed into a petri dish. Using a 
dissecting microscope (SM2 2B, Nikon, Japan) for visualisation, fine forceps were 
used to remove the dura and pia mater. A segment of the thoracic and upper lumbar 
regions, approximately 1 cm in length was then selected for sectioning. This segment 
was set into warm agar (Sigma Aldrich, UK, made at 3% in aCSF; see table 2.1 for 
aCSF constituents) for stability during sectioning. Once cooled, this agar block was 
set in front of a larger 4% agar block for further support and superglued in place. This 
was then placed in a bath of ice cold sucrose aCSF which was oxygenated (95% 
O2:5% CO2) throughout the sectioning process. Transverse slices were cut at 300 μm 
thickness, using settings of 108 Hz, 0.8 mm amplitude and 0.5 mm/s advance speed 
(Leica VT1200s, Leica Microsystems, UK with stainless steel blades or Integraslice 
7550 PSDS, Campden Instruments, UK with ceramic blades). Slices were placed in a 
holding chamber containing oxygenated aCSF (for composition see Table 2.1) at 
room temperature; they were left for 60 minutes to equilibrate.  
Table 2.1 Composition of extracellular solutions for electrophysiological 
experiments 
Component Sucrose aCSF (mM) aCSF (mM) 
Sucrose 217  
NaCl  124 
NaHCO3 26 26 
KCl 3 3 
MgSO4.7H2O 2 2 
NaH2PO4 2.5 2.5 
Glucose 10 10 
CaCl2 1 2 
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2.4 Whole cell patch clamp electrophysiology 
2.4.1 Experimental set up 
Recordings were made after the 60 minute equilibration time. The slice was first 
transferred to the recording chamber and the border of 3% agar remaining from the 
sectioning was pinned under a taught thread to immobilise the slice. Oxygenated 
(95% O2; 5% CO2) aCSF flowed at a rate of approximately 4-6 ml/minute through the 
recording chamber, gravity fed from a flask above. The pH of the aCSF was 7.83 
prior to being bubbled with gas and 7.54 after bubbling.  Outflow from the recording 
chamber used a suction system and was not recycled. Recordings were done at 
room temperature (16-24°C). 
The glass electrode was pulled using a Sutter P97 micropipette puller (Sutter 
Instruments, USA), from borosilicate glass capillary tubes (inside diameter 0.94 mm, 
and outside diameter 1.2 mm; Warner Instruments, USA). The pulled electrodes had 
resistance of 5-8 MΩ and a tip diameter of approximately 1-3 μM.  
The bath contained a silver chloride pellet connected to a silver wire; this acted as the 
reference electrode. The recording electrode consisted of a silver wire which sat 
within a glass electrode containing intracellular solution composed of in (mM): K 
gluconate (110), EGTA (11), MgCl2 (2), CaCl2 (0.1), HEPES (10), Na2ATP (2), 
Na2GTP (0.3) and additionally 0.5% Neurobiotin (Vector Laboratories, USA) and 
0.02% dextran tetramethylrhodamine (rhodamine; Invitrogen, USA). The electrode 
was filled about a 1/3 of the way with the intracellular solution, such that it just 
contacted the silver wire and thus electrically connected the electrode tip to the silver 
wire of the electrode holder (QSW A12P, Warner Instruments, USA). 
The electrode holder and the reference electrode, which was placed in the aCSF 
within the recording chamber, were attached to a headstage (CV-4 1/100U from Axon 
Instruments, USA). This completed the electrical circuit from inside the cell, measured 
with the recording electrode, to outside the cell, measured using the bath reference 
electrode. The electrode holder had a side tube for pressure application. The 
headstage also acted to preamplify the signal from the recording electrode. The 
signal was then filtered by a Bessel low pass filter set at 2-5 kHz and passed through 
the Axopatch 1D amplifier (Axon Instruments, USA). The mains noise was filtered out 
using a HumBug (Quest Scientific, via Digitimer, UK). The signals were then 
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converted from analogue signals that leave the amplifier to digital signals by the 
Digidata 1322A analogue to digital converter (Axon Instruments, USA). These digital 
signals were then captured by the pClamp 9 software. The acquisition frequencies 
varied between the recording modes discussed below (2.5), with a frequency of 20 
kHz for the sweep mode characterisation recordings and 5 kHz for the continuous 
mode experimental recordings.  
Adjustment of the timing and duration of the current and voltage applied to the cell (in 
voltage-clamp and current-clamp modes respectively) was provided by the Master-8 
stimulator (A.M.P.I., Israel) which connects to the Axopatch 1D amplifier. The 
amplitude and polarity of the current and voltage steps were set according to the 




Figure 2.1 Experimental set up for whole cell patch clamp electrophysiology 
recordings 




2.4.3 Whole cell patch clamp recordings 
The recording chamber that the slices were held in was positioned under an upright 
microscope (Olympus BX50W1). The x10 magnification lens was used to position the 
central canal in the centre of the field. The central canal was re-identified at x 60 
magnification. The visualisation was then switched over to differential interference 
contrast (DIC) imaging using a camera (QImaging Rolera-XR, QImaging, Canada) 
attached to the microscope, which transmitted the images to the QCapture Pro 
software to enable the individual cells to be seen.  
2.5.1 Cell identification 
DIC imaging was used to identify healthy cells by their even grey tone and visible but 
not overly distinct or large outline. In many cases cell types could be identified. Prior 
to recording ependymal cells were often distinguishable by their presence within the 
ependymal cell layer, their more cuboidal shape and their less distinct cell outline. 
CSFcCs differed from ependymal cells in that they tended to be slightly larger and 
were more likely to have a subependymal location. After recording, further 
morphological characteristics could be viewed due to the inclusion of 0.02 % dextran 
tetramethylrhodamine (rhodamine; see section 2.4.1) in the intracellular solution. 
Excitation of the rhodamine by a wavelength of 550 nm allowed visualisation of the 
recorded cell and was used, in conjunction with the electrophysiological 
characterisation, to identify the cell type. Presence of a process into the central canal 
and/or spiking responses to depolarisation or repolarisation indicated that the cell 
being recorded from was a CSFcC. Ependymal cells were identified by passive, non-
spiking profile and an absence of processes into the central canal. Neuronal cells 
could be identified by the production of action potentials and the presence of many 





Figure 2.2 Configuration of electrodes for patch-clamp electrophysiology 
Illustration of the electrode placement during the electrophysiology recordings. 
Recording electrode (filled with intracellular solution shown in orange) was attached 
to and recording from either a CSFcC (a) or an ependymal cell (b). The pressure 
ejection electrode containing drug to be pressure ejected (shown in green) was 
positioned near the cell being recorded from but not directly pointing towards it to 
minimise movement of the cell.  
 
Once a cell of interest was selected, the recording electrode (and drug ejection 
electrode if used) was brought down to a level slightly above the slice by first using 
the x10 magnification, then the x60, and positioned over the cell using the 
micromanipulator. Before being introduced to the aCSF in the recording chamber, a 
small amount of positive pressure was applied to the recording electrode to reduce 
the likelihood of blockages. Once in the solution and a small distance above the slice, 
in current-clamp mode, the offset and resistance of the electrode due to a -250 pA 
current pulse, were compensated for using the amplifier’s offset and the series 
resistance dials respectively. This brought the baseline voltage reading to 0 mV. The 
amplifier was then switched to voltage-clamp and track modes with a voltage pulse of 
-25 mV. The electrode was then brought down towards the cell until a dimple was 
visible on the cell surface, caused by the positive pressure in the electrode. At this 
point, the positive pressure was released, and a small amount of negative pressure 
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was applied if necessary, to form a seal where the resistance was ≥3 GΩ. The 
amplifier was then switched back to current-clamp and the current pulse reduced to -
50 pA. A small amount of additional holding current was also applied to the cells to 
help stabilise their membrane potentials. The membrane within the tip of the 
electrode was interrupted by a strong, quick period of negative pressure, to produce a 
whole cell patch clamp recording. The configuration of electrodes is illustrated in 
figure 2.2, with the recording electrode represented in position a) if recording from a 
CSFcC or position b) if recording from an ependymal cell.  
Details of the constituents of the pressure ejection and recording electrodes are listed 
above in table 2.2 and section 2.4.1 respectively.  
2.4.4 Electrophysiological cell characterisation 
For the characterisation of the electrophysiological behaviour of the recorded cell, 1 s 
current pulses were applied to the cell with the resulting voltage responses measured 
and analysed. Positive current pulses (+10 to +50 pA) were used to determine if there 
was any spiking or action potentials produced in response to the depolarisation 
created by the current pulse. Negative current pulses (-10 to -50 pA) produced 
hyperpolarisations. These were then used to calculate the input resistance (IR) of the 
cell by using Ohm’s law (input resistance = voltage response / current injected). 
2.4.2 Application of drugs 
All drugs apart from ATP and UTP were applied in the bath solution. This was 
achieved with separate smaller flasks, also oxygenated, containing a dilution of the 
drug in aCSF, flow of which was controlled via three-way taps.  
ATP and UTP were applied in a more focal and rapid way, via local pressure ejection 
through a glass electrode (resistance 3-5 MΩ, tip diameter 3-4 μm) attached to a 
PV800 pneumatic pico pump (World Precision Instruments, UK) that was connected 
to a pressurised gas cylinder. Positioning of the pressure ejection electrode was 
controlled by another micromanipulator (PatchStar, Scientifica, UK). The PV800 was 
also connected to the pClamp9 program via the Digidata 1322A, and thus allowed the 
program to record the timing of the pressure ejection of the drug. The two drug 
application methods were used in conjunction to apply ATP or UTP via puff ejection 
before, during and after bath application of antagonist. A list of drugs applied during 
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the electrophysiological experiments can be found below (table 2.2) with details of the 
concentrations they were used at, their known functions and the supplier. All drugs 
for application in the bath solution were stored at -20 °C in stock solutions at x103 
their working concentrations. ATP and UTP were stored in the same concentrations 
that would be used to fill the ejection electrode. All drugs were dissolved in aCSF 




Table 2.2 Drugs for electrophysiological experiments 











P2X and P2Y2, 4, 6, 11 and 13 
agonist 
Puff applied at 
300 μM  
Previously used 
effectively (Gómez-
Villafuertes et al., 2015) 
Sigma-
Aldrich, UK 





P2Y2, 4, 6, 11 and 14 agonist 
Puff applied at 
300 μM  
Slight increase1 in 
concentration previously 
used effectively (Gómez-




Adenosine diphosphate, ADP 
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-
3,4-dihydroxyoxolan-2-yl]methyl 
phosphono hydrogen phosphate 
P2Y1, 12 and 13 agonist 
Puff applied at 
300 μM  
Slight increase1 in 
concentration previously 
used effectively (Gómez-
Villafuertes et al., 2015) 
Sigma-
Aldrich, UK 
                                               
 
 







P2X and P2Y antagonist 50 μM  
Previously used 










P2X3 and P2X2/3 antagonist 1 μM  
Previously used 







P2X antagonist 10 μM  
Previously used 
effectively (Flores-Soto 




2-Aminoethoxydiphenyl borate,  
2-APB  
2-Diphenylboranyloxyethanamine 
TRP channel (1, 3, 5, 6, V6, 
M3, M7, M8 and P2) 
antagonist, and IP3 and 
SOC channel antagonist 
100 μM 
dissolved in 
50 % ethanol 
Previously used 





Apamin Amino acid sequence: 
CNCKAPETALCARRCQQH 
SK channel antagonist 100 nM  
Previously used 




Dipropylcyclopentylxanthine, DPCPX  
8-Cyclopentyl-1,3-dipropylxanthine 














antagonist (and nAChr 
antagonist with IC50 = 60 
μM; (Blanchet and Dulon, 
2001) 
500 μM  
Previously used 







Chloride channel antagonist 







Robles et al., 2013) 
Sigma-
Aldrich, UK 
18β-glycyrrhetinic acid  
3β-Hydroxy-11-oxo-18β,20β-olean-12-
en-29-oic acid  
Gap junction inhibitor 
100 μM 
dissolved in 
50 % ethanol  
Previously used 
effectively (Momose-
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2.5 Cell identification  
2.5.1 Post fixative identification of cells using Neurobiotin  
Neurobiotin was also included in the intracellular solution. It acted to fill the cell in a 
similar way to rhodamine, however it was visualised after fixation of the slice with 
0.1 M phosphate buffer (PB) containing 4 % paraformaldehyde (PFA) and 0.2 % 
glutaraldehyde for approximately 18 hours at 4°C. Unlike rhodamine (Heyman and 
Burt, 2008), neurobiotin is able to pass through gap junctions into the coupled cells 
(Hou et al., 2013; Ponce et al., 2014). The process for visualisation of the neurobiotin 
filled cells utilised 3, 3’-diaminobenzidine (DAB).  Slices were removed from the PFA 
solution and washed 3 times for 10 minutes in 0.1 M PB. The 3 % agar border was 
then removed. The membranes were then permeabilised using 50 % ethanol for 30 
minutes and the sections were then washed in 0.1 M phosphate buffered saline 
(PBS; 3 x 10 minutes). Sections were then incubated in extravidin peroxidase (EAP; 
Sigma-Aldrich, UK; 1:250 in 0.1 M PBS with 0.2 % Triton) for approximately 72 hours 
at 4 °C to detect the neurobiotin. Following this, they were washed in 0.1 M PBS (2 x 
10 minutes) to remove excess EAP. The EAP was then detected using a DAB 
substrate kit (Vector Laboratories, UK). The slices were then incubated in distilled 
water (dH2O) containing Buffer Stock Solution (16.8 μl/ml of dH2O), DAB Stock 
Solution (20 μl/ml) and Hydrogen Peroxide Solution (20 μl/ml) for between 2 and 18 
minutes. The progress of the reaction was monitored at 2 minute intervals to 
determine the point at which the EAP marking the recorded cell was identified but 
before the endogenous peroxidase had also reacted making the slice too dark to 
identify the recorded cell. The slices were then rinsed in dH2O to stop the DAB 
reaction.  
2.5.2 Enhanced clarity of visualisation with ClearT 
The clarity of the visualisation of the recorded cell and its processes was occasionally 
enhanced using the ClearT method (Kuwajima et al., 2013) to clear the tissue within 
the slice. This method uses successive, increasing concentrations of formamide (see 
table 2.3).  
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Table 2.3 ClearT method for sections (20-1000 μm) 
Solution  Incubation time (minutes) 
20% formamide 5 
40% formamide 5 
80% formamide 5 
95% formamide 5 
95% formamide 15 
 
After being removed from the second incubation in 95% formamide, slices were 
mounted temporarily onto slides under glass coverslips. They were then imaged on a 
microscope (Nikon Eclipse E600 microscope, Nikon, Japan) with the images captured 
on the AcQuis image capture software (Digital Imaging Systems, UK) via a 
microscope-mounted camera (Micropublisher 5.0 RTV; QImaging, Canada).  
2.6 Data analysis 
2.6.1 Data collection 
Electrophysiological data were collected on the Clampex program of the pClamp 
software (Molecular Devices, USA). The data were then analysed on the Clampfit 
program. Averages for a particular group were calculated and expressed as the mean 
± standard error of the mean (S.E.). For drugs applied in the bath solution, 
comparisons were made before application, at the last point of application, and after 
10 minutes of drug wash-out. The measurements made were of amplitude of voltage 
response (MP; measured as a change in membrane potential) and input resistance 
(IR; as calculated from the current steps using Ohm’s law). For drugs applied via 
focal pressure ejection, current steps could not be maintained during the pressure 
ejection as the time period of response was too short and would have been lost within 
a current pulse such that the changes in MP and IR could not be separated. 
Therefore the current pulses were switched off shortly before each pressure ejection. 
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The measurements made of the responses to pressure ejected drugs were amplitude 
of response (MP), onset to start of response (ms) and duration of response (s).  
Due to the lack of change in the composition of the intracellular and bath solutions 
and therefore the consistent influence of the junction potential across experiments, 
this was not compensated for except in experiments where reversal potentials were 
calculated. The junction potential for these solutions was calculated using the 
Clampex junction potential calculator as 13.9 mV. Therefore for reversal potential 
calculations, the membrane potential was calculated using the following equation: 
Vm = Vr - 13.9 mV where Vr is the voltage recorded.  
2.6.2 Statistical analysis of electrophysiological experiments 
Data were tested to determine whether or not they were normally distributed. Those 
that were not normally distributed but were log-normal distributions were treated as 
such. The analyses utilised both parametric and non-parametric test according to the 
distributions of the data being analysed. The tests were selected as laid out in table 
2.4 below.  
Table 2.4 Statistical tests used in the analysis of the data produced by this 
study 
Testing the difference 
between: 
Parametric test  
(test statistic) 
Non-parametric test  
(test statistic) 
2 groups or 
subgroups 
Independent samples t 
test (t) 
Mann-Whitney U Test (U) 
>2 groups or 
subgroups 












Parametric tests were performed if the data in each groups being compared all fitted 
into either normal or log-normal distributions. If any of the groups of data could not be 
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normalised or if the groups did not fit into the same distribution (i.e. normal or log-
normal) then the corresponding non-parametric test was chosen. 
2.7 Proliferation experiments  
2.7.1 Experimental set up for 1 day proliferation preparation 
The slices for the 1 day proliferation preparation were taken from the spinal cords of 
wild-type C57bl6 mice, pre-weaner (p12-21). The animals were anaesthetised and 
perfused and the spinal cords removed and sectioned as for the electrophysiological 
experiments, detailed in 2.2 above. The slices were removed from the agar border as 
they were being sectioned and were then moved to custom built holding chambers. 
The slices rested on a mesh membrane, submerged within the beaker of aCSF, such 
that both surfaces of the slice are in contact with the aCSF. The aCSF was bubbled 
throughout the procedure with 95 % CO2: 5 % O2. The holding chamber was then 
placed within a water bath, heated to 37 °C; (Figure 2.3).  
The slices were kept in the holding chamber within the water bath for the remainder 
of the experimental period. For the first 60 minutes, the slices were left to acclimatise 
in a similar way to those used in the electrophysiological experiments. At this point 
EdU (5-ethynyl-2’-deoxyuridine) made up in medium C (see table 2.5) was added 
directly to the aCSF in the chamber. The concentration of EdU in the chamber was 10 
μM as has been previously shown to maximally label proliferative cells, without 
inducing toxicity (Chehrehasa et al., 2009). 
In the drug conditions, either 50 μM ARL 67156 (ecto-ATPase inhibitor, made up in 
aCSF; Sigma-Aldrich, UK) or 200 μM suramin (purinergic antagonist, see table 2.2, 
made up in aCSF; Tocris Bioscience, UK) was added to the aCSF, in addition to EdU. 
In the control condition, only EdU was added to the aCSF.  
EdU is a thymidine analogue which is incorporated into the DNA of dividing cells 
during S-phase (Taupin, 2007) and therefore acts as a marker of cells that have 
newly-proliferated during the experimental period (period of EdU application). The 
method of detection of proliferation traditionally usually used is BrdU (5-bromo-2'-
deoxyuridine) (Cavanagh et al., 2011). This is another thymidine analogue and 
incorporates similar way as EdU to the DNA during S-phase. However, unlike the 
incorporation method, the detection methods differ, with EdU being detected by click 
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chemistry (Buck et al., 2008) and BrdU being detected by antibody recognition 
(Gratzner, 1982). Detection of BrdU must, therefore, involve denaturation of the DNA, 
either by heat or acid treatment, which degrades the tissue. EdU detection uses the 
click chemical reaction that covalently bonds an azide-conjugated fluorescent probe 
to the alkene incorporated into the DNA as part of the EdU. This reaction works on 
the double-stranded DNA and does not therefore require denaturation. This confers a 
significant advantage in the use of EdU over BrdU and motivates the decision to use 
EdU as the proliferation marker in these experiments.  
In the drug conditions either 50 μM ARL 67156 (ecto-ATPase inhibitor, made up in 
aCSF; Sigma-Aldrich, UK) or 200 μM suramin (purinergic antagonist, see table 2.2, 
made up in aCSF; Tocris Bioscience, UK) was added to the aCSF, in addition to EdU, 
after the slices had acclimatised for 60 minutes. In the control condition, only EdU 
was added to the aCSF.  
The slices were then bubbled in the aCSF at 37 °C containing EdU and drugs for a 
further 4 hours; no further EdU or drugs were added during this period. After this 
point, the slices were removed from the aCSF and fixed in 0.1 M phosphate buffer 
(PB) containing 4% paraformaldehyde (PFA) at 4°C for 1 hour. After 1 hour, they 




Figure 2.3 Experimental set up for 1 day proliferation preparation 
Slices in 1 day proliferation preparation experiments were held inside a plastic tube 
with a mesh membrane base, suspended within a glass tube containing artificial 
cerebral spinal fluid (aCSF) and bubbled with a gas mixture of 95% oxygen (O2) and 
5% carbon dioxide (CO2). Glass tubes were placed in a water bath maintained at 
37°C.  
2.7.2 EdU detection of proliferation preparations 
The fixed slices were washed in 0.1 M phosphate buffered saline (PBS) with 0.2 % 
Triton for 12 minutes to permeabilise the cell membranes. They were then washed in 
TBS (2 x 10 minutes; 50 mM Tris, 150 mM NaCl, pH 7.6). The slices were then 
incubated in a solution of 320 μl distilled water, 25 μl Tris (2 M), 50 μl Cu(II)SO4 (10 
mM), 5 μl biotinylated azide (1 mM) and 100 μl ascorbic acid (0.5 M) for 30 minutes 
and protected from light from this point onwards. They were then washed again in 
TBS (2 x 10 minutes) and then a third wash in 0.1 M PBS with 0.2% Triton (1 x 10 
minutes). The slices were then incubated with streptavidin555 (1:1000 in 0.1 M PBS) 
for 1 hour before a final set of washes in 0.1 M PBS with 0.2% Triton (3 x 10 
minutes). They were then mounted onto slides using VectaMount mounting medium 
with DAPI (Vector Laboratories, UK) and covered with a cover slip, which was 
secured in place using nail polish.  
The slices were then imaged on a fluorescence microscope (Nikon Eclipse E600 
microscope, Nikon, Japan) with the images captured on the AcQuis image capture 
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software (Digital Imaging Systems, UK) via a microscope-mounted camera 
(Micropublisher 5.0 RTV; QImaging, Canada).  
EdU-positive cells were manually marked onto a schematic representation of the 
spinal cord and then counted by spinal cord region. The data produced by these 
counts were statistically analysed according to table 2.4.  
2.8 Organotypic slice culture preparation experiments 
2.8.1 Experimental set up for organotypic slice culture preparations 
Organotypic slice culturing is a method which allows extension of the viability period 
of neuronal tissue slices from up to 9 hours (Hatton et al., 1980) to maintenance of 
the electrophysiological and morphological characteristics for over 3 weeks (Davids et 
al., 2002). The method of organotypic slice culturing used in this experiment was the 
interface method (Stoppini et al., 1991) whereby slices are held at the interface 
between medium and air by the fact that they are placed on a semi-porous mesh. 
This culture method offers the physiological heterogeneity of cell types and 
cyto-architecture of the spinal cord that is available in in vivo experiments, but retains 
the drug accessibility of cell culture methods. It has therefore become widely used for 
injury modelling (Labombarda et al., 2013; Llorente et al., 2015) and exploration of 
cellular development (Heine et al., 2015). This technique also has the advantage that, 
as the slices could be prepared in a similar way to those used for the 
electrophysiological and proliferation preparations, there could be greater comparison 
between the results.  
As mentioned above, the slices were prepared as in section 2.2. The animals used 
for these experiments were wild-type C57bl6 mice (p12-21). As with the proliferation 
preparations, the slices were removed from their agar border at the time of 
sectioning. They were then transferred to a sterile Falcon tube containing sterile 
medium A (see table 2.5 for details of composition of all media used for organotypic 
slice culture experiments). They were then moved into a laminar flow hood and 
transferred onto Millicell organotypic filter inserts (Merck Millipore, Germany), with 3-6 
slices per filter. They were transferred by means of suction into a widened, sterile tip 
of a P1000 pipette, and ejection onto the filter insert. The filter inserts sat on medium 
B such that the medium was in contact with the underside of the filter insert. The 
medium had been pre-heated to 37 °C. This medium contained foetal bovine serum 
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as this aids neuronal survival and recovery from trauma (Takeshima et al., 1994). 
After plating of the slices, the plate was transferred to a sterile incubator at 37 °C with 
100 % humidity, 95 % air and 5 % CO2-enriched environment.  
2.8.2 Maintenance and experimental period of 5 day organotypic slice cultures 
After 24 hours in the incubator, the culture plate was transferred back to the laminar 
flow hood, where the medium under the filters was changed for medium C. The 
removal of serum from the medium, ensured more exact knowledge of the 
constituents of the medium as animal sera are undefined and have variable 
composition (van der Valk et al., 2010). Foetal bovine serum (FBS) contains a large 
and complex mixture of growth factors, vitamins, hormones, proteins and trace 
elements. Medium C contains a B27 supplement (Brewer et al., 1993) as this has 
been shown as effective for CNS slice culture and avoids problems with other defined 
(serum-free) media of fibroblast or astrocyte overgrowth (van der Valk et al., 2010). 
This protocol whereby a medium containing serum is used for the initial period of 
culturing, which is then replaced with a defined (serum-free) medium shortly before 
and during the experimental period (Noraberg et al., 1999) has been found to work 
well for organotypic CNS cultures.  
After 48 hours in culture, the medium in the plate was exchanged for medium C 
containing 10 μM EdU (made up in medium C). In addition to the EdU, the 
experimental drugs were also added at this time. The experimental drugs for the 
organotypic slice culture experiments were the same as for the proliferation 
preparation experiments above (section 2.6.1), namely 50 μM ARL 67156 
(ecto-ATPase inhibitor; Sigma-Aldrich, UK) or 200 μM suramin (purinergic antagonist, 
see table 2.2; Tocris Bioscience, UK). These were then returned to the incubator for a 
further 42 hours.  
After 42 hours, the filter medium under the filter was removed and replaced with 
0.1 M phosphate buffer (PB) containing 4% paraformaldehyde (PFA). Further PFA 
was then added to the top of the filter to ensure complete fixation of both sides of the 
spinal cord slices. The slices were fixed in PFA for 6 hours at 4 °C. They were then 
removed from the filter using a fine paint brush and placed in 0.1 M phosphate 
buffered saline (PBS). 
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Table 2.5 Composition of media for culture experiments 
Medium A – dissecting 
medium 
Medium B – serum medium 
Medium C – serum-free 
medium 
Dulbecco’s modified 
eagles medium (DMEM; 
Sigma-Aldrich, UK) 
Neurobasal A medium 
(Invitrogen, USA) 











1 % L-Glutamine  
(Sigma-Aldrich, UK) 
1 % L-Glutamine  
(Sigma-Aldrich, UK) 
 
10 % foetal bovine serum 
(Sigma-Aldrich, UK) 
2 % B27 supplement 
(Invitrogen, USA) 
 
2.8.3 EdU detection of 5 day organotypic slice cultures 
Detection of EdU on fixed slices from the organotypic slice culture experiments was 
carried out as per section 2.6.2 for the fixed slices from the proliferation preparation 
experiments.  
2.8.4 Analysis of EdU labelling in 5 day organotypic slice cultures 
EdU labelling was too expansive and overlapping for a counting procedure to be 
reliable. Therefore a fluorescence analysis was carried out to give a reading of the 
distribution of EdU positive cells within the slice. This involved imaging the fixed and 
processed slices (as in section 2.6.2) using the AcQuis image capture program 
(Digital Imaging Systems, UK) on the computer, which captured the images through 
the camera (Micropublisher 5.0 RTV; QImaging, Canada) mounted onto the 
microscope (Nikon Eclipse E600 microscope, Nikon, Japan). The images were taken 
at x 4 and x 20 magnification, with the fluorescence analysis applied to the x 4 
images.  
Images were then opened in ImageJ image processing software (National Institutes 
of Health, USA). Within this program, images were adjusted manually to maximise 
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EdU positive cell fluorescence and minimise background fluorescence. The analysis 
measured the light intensity of the image over a lateral half of the spinal cord slice, 
from the midpoint of the central canal across the half width of the spinal cord slice to 
the lateral edge (see figure 2.4). The midpoint of the central canal was selected using 
the DAPI nucleic stain to identify the central canal. The half of the slice to be 
analysed was chosen for completeness of the slice section and lower levels of 
background fluorescence. Data were expressed as amount of light intensity (in 
arbitrary units) for each vertical column of pixels in a 300 pixel height strip extending 
from the midpoint of the central canal to the edge of the slice. These data were then 
combined to create a simple moving average (15 pixel period) for each of the 3 
conditions. The output (over 5 pixels) of this was averaged to create a weighted 
moving average (over a total period of 19 pixels). This was plotted as light intensity as 
a function of distance from the central canal, which was then normalised by area 
under the curve. This allowed comparison of particular pixel distances corresponding 
to areas of interest between drug and control conditions (statistically analysed as 
detailed above in table 2.4) as well as comparison of location and spread of light 




Figure 2.4  Illustrative example of fluorescence analysis for organotypic slice 
cultures 
A transverse section of the spinal cord demonstrating the procedures used for 
analysis of location of EdU-containing cells. EdU-positive cells are shown in red with 
the box indicating the area of the spinal cord analysed. The left hand side of the box 
was positioned on the midpoint of the central canal, the right hand side is outside the 
limits of the slice. The height of the box was 300 pixels (256 μm) with the central 
canal at the midpoint of the box height. An example trace is shown after use of 
weighted moving averages to reduce the spikes corresponding to individual cells.  
2.8.5 Maintenance and experimental period of time-point organotypic slice 
cultures 
Similarly to the 5 day cultures, the maintenance of which is detailed above in 2.7.2, 
the medium was changed after 24 hours, from medium B to medium C. 45 hours after 
the slices were first prepared the EdU (made up in medium C) was added to the 
medium C in the wells with an in-well concentration of 10 μM. The slices in the drug 
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condition also had ARL 67156 added to the well at a final concentration of 50 μM. 
The slices remained in the presence of EdU for 4 hours. At this point all slices were 
removed from the EdU containing medium. For this experiment there were two time-
point conditions (1 and 3), with a control well and a drug condition well at each time 
point. After 8 hours in EdU containing medium, the wells in the time-point 1 condition 
were fixed above and below the filter with 0.1 M phosphate buffer (PB) containing 4% 
paraformaldehyde (PFA) at 4°C for 1 hour. At this time, the wells in time-point 3 had 
the medium under the filter exchanged for fresh medium C, to which ARL 67156 was 
again added to the drug condition wells. The wells in the time-point 3 condition were 
fixed in 4% PFA as above after 48 hours in non-EdU containing medium.  
2.8.6 EdU detection of time-point organotypic slice cultures 
The EdU was detected using the same click-chemistry protocol that was used above 
in both the proliferation preparation experiments, and the 5-day organotypic slice 
culture experiments, see section 2.6.2 above.  
2.8.7 Analysis of EdU labelling in time-point organotypic slice cultures 
The EdU was only taken up by the cells that underwent S-phase during the 8 hour 
period in which the slices were in EdU-containing medium. This meant that unlike the 
slices in the 5 day organotypic slice culture experiments, the number of EdU-positive 
cells was low enough to be counted using an automated counting program, ImageJ, 
NIH, US. Therefore the analysis was carried out as was done in the proliferation 
preparation experiments (section 2.6.2). Slices were viewed on the microscope 
(Nikon Eclipse E600 microscope, Nikon, Japan) with any images captured using the  
AcQuis image capture program (Digital Imaging Systems, UK) on the computer, 
through the microscope-mounted camera (Micropublisher 5.0 RTV; QImaging, 
Canada).   
EdU-positive cells were then manually marked onto the spinal-cord schematic 
representation and manually counted by spinal cord region. Data from these counts 






2.9.1 P2X3 immunohistochemistry on fixed slices 
Immunohistochemistry was carried out by Lucy Peers. 
Tissue for immunohistochemical analysis of P2X3 expression was prepared by 
perfusion with 0.1 M phosphate buffer (PB) containing 4 % paraformaldehyde (PFA). 
After spinal cord dissection, the spinal cord was post-fixed in the same PFA solution. 
Slices were sectioned at 50 μM on a Leica VT100 S vibratome (UK). After 3 x washes 
in PBS, slices were incubated in rabbit anti-P2X3 antibody (Alomone Labs, 
Jerusalem, Israel) in PBS with 0.1 % triton (PBST) overnight, then washed with PBS 
a further 3 times. The secondary antibody, donkey anti-rabbit IgG Alexa Fluor 488 
(Invitrogen, US), was applied at 1 in 1000 in PBS for 2 hours and then washed 3 x 
with PBS. They were then mounted using VectaMount mounting medium with DAPI 











Chapter 3 - CSFcCs respond to purinergic activation with 





Previous work on the electrophysiological properties of CSFcC suggests that there is 
considerable variation within the CSFcC population. Cells previously identified 
include cells which passively responded to current injections and showed no 
spontaneous activity, through cells which exhibited some spontaneous activity and 
were able to produce a single spike or action potential in response to depolarising 
current pulses, and cells which fired a train of action potentials or spikes in response 
to current injection (Corns et al., 2015). These were labelled CSFcC 1, CSFcC 2 and 
CSFcC 3 respectively and this nomenclature was continued in this work.  
Several differences have been observed in CSFcCs showing different 
electrophysiological profiles. The ionic contribution to their responses to depolarising 
current pulses differs, with cells producing slow regenerative potentials or small 
amplitude, long half-amplitude duration spikes being largely mediated by Ca2+ 
(Marichal et al., 2009). This was demonstrated by their sustained occurrence in the 
presence of the specific voltage-gated sodium blocker TTX and blockage in the 
presence of 3 mM manganese (Mn2+), which is a potent calcium channel blocker. 
There was however a small component of the response blocked by TTX suggesting a 
small contribution of voltage-gated Na2+ channels to otherwise Ca2+ mediated 
currents. These cells also demonstrated a small low threshold spike (LTS) as a 
rebound response from a hyperpolarising current pulse. Application of 300 μM nickel 
(Ni2+) blocked this rebound response indicating that it was via T-type Ca2+ channels.  
Unlike in the non-spiking or minimally spiking CSFcCs, in CSFcCs that could larger 
spike or action potential, the fast spike was inhibited by TTX indicating that, in these 
cells, the depolarisation was due to voltage-gated Na+ channels (Marichal et al., 
2009). The CSFcCs that produced only a single spike did not show the slow after-
hyperpolarisation (AHP) typically observed in spinal neurons (Russo and 
Hounsgaard, 1999; Marichal et al., 2009). However the CSFcCs that were able to 
produce a train of spikes or action potentials, particularly those with the most robust 
firing pattern, did display AHPs. The spikes or action potentials in these multi-spiking 
cells tended to have larger amplitude and shorter half-amplitude duration than single 
spiking cells. As with the single-spiking cells, no activity was seen in the multi-spiking 




No correlation between the electrophysiological phenotype and the age of the animal 
was observed (Marichal et al., 2009). There was also no link between the phenotype 
of the CSFcCs and the embryological period in which they are born. All CSFcCs are 
born in a late embryological period (E14.5-16.5 in mice)(Petracca et al., 2016), 
alongside astrocytes and oligodendrocytes. In addition to determining the embryonic 
age of CSFcCs, Petracca et al. (2016) also showed that CSFcCs are produced from 
2 distinct dorso-ventral regions of the spinal cord. Most CSFcCs (90 %) were derived 
from progenitors in the late-p2 and the oligodendrogenic (pOL) domains, while a 
subset (10 %) arose from progenitors near the floor plate. In these experiments they 
used Gata2GFP tissue to identify CSFcCs which expressed the transcription factor 
Gata2. All of the cells identified in this way produced either a single spike or a train of 
spikes in response to depolarising current pulses, and they termed these cells 
CSFcNs. This method allowed targeting of Gata2-positive, PKD2L1-positive cells, 
which may not represent the entire range of CSFcCs recorded in other studies.  
As the cells from the two separate embryonic regions differentially used Pax6 as an 
embryonic transcription factor, the cells could be traced to show that they adopt 
separate locations around the central canal (at E18.5) and show different 
electrophysiological profiles or subtypes (at P1-2) (Petracca et al., 2016). At these 
times, the subset of cells derived from the floor plate were located ventrally and 
showed only single spiking, whilst of CSFcCs derived from p2/pOL, 80 % could 
produce a train of spikes in response to current injection and most were located 
laterally. These studies show the breadth of electrophysiological profiles of CSFcCs 
and demonstrate some of the causes of those differences. Whilst the study by 
Petracca et al. (2016) is in very young and embryonic animals, previous work has 
demonstrated similar levels of variation amongst the CSFcC population at different 
ages (Corns, 2012), suggesting this variation is not a temporary feature.  
As well as differences in ionic contributions and embryonic origins between CSFcC 
subtypes, there are also differences in their responses to neurotransmitters. GABA 
produces a range of responses in CSFcCs via GABAA receptors (Marichal et al., 
2009; Corns, 2012). Both hyperpolarisations and depolarisations are produced, with a 
range of reversal potentials from -80 mV to -43 mV in gramicidin-perforated patch 
clamp experiment, which could be due to differences in internal Cl- levels due to K-Cl 
co-transporter (KCC2)/ N-K-Cl co-transporter (NKCC1) expression (Marichal et al., 
2009; Kaila et al., 2014), however both hyperpolarisations and depolarisations have 
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been observed in whole cell patch clamp experiments (Corns, 2012). In whole cell 
patch clamp experiments, the internal Cl- concentration should be set by the 
composition of the intracellular solution in the electrode. There are also differences in 
the responses of CSFcCs to acetylcholine (ACh) (Corns et al., 2015). Whilst all 
CSFcCs depolarised to ACh, a different composition of receptors was responsible for 
the effects. Both non-α7* nicotinic ACh receptors and α7* nAChrs were shown (by 
use of selective antagonists) to contribute to the response but to varying extents in 
different subtypes. Non-spiking CSFcC 1s mainly responded to ACh via α7* nAChrs 
but with contribution from non-α7* nAChrs, whilst CSFcC 2s predominantly, and 
CSFcC 3s almost exclusively, responded via non-α7* nAChrs (Corns et al., 2015). 
This indicates differential receptor make-up between CSFcC subtypes.  
It has been shown that CSFcCs express P2X2 receptors and that they can respond to 
extracellular ATP and produce a depolarisation (Marichal et al., 2009). It is not yet 
know if the differences in receptor composition, ion balance and electrophysiological 
profiles of CSFcCs will produce significant differences in their responses to ATP.  
3.1.1 Hypothesis  
The hypotheses of this chapter are that CSFcCs around the central canal of the 
spinal cord would: 
1. Fall into subtypes which would be distinguishable by their level of activity in the 
voltage response to current pulses or other changes in membrane potential 
2. Acutely respond to ATP application with a depolarisation 
3. That ATP would produce the response by acting via the ionotropic P2X receptor, 
P2X2.  
3.1.2 Aims 
This chapter uses patch-clamp electrophysiology in addition to fluorescence and 
post-fixation DAB imaging following intracellular dye-loading to: 
1. Identify and categorise the CSFcCs in the area surrounding the central canal of 
the spinal cord 
2. Investigate whether there is an acute response to ATP in the CSFcCs and look 
for differences between subtypes 




The data in this chapter come from recordings made using spinal cord slices from 
Wistar rats, aged 7-13 days.  
3.2.1 CSFcCs have varied phenotypes which can be sub-classified 
Electrophysiological experiments revealed CSFcCs to display considerable variation 
in phenotype. This extended from a passive phenotype which was indistinguishable 
from that of ependymal cells to a profile which produced multiple spikes and bore 
closer similarity to the behaviour of some neurones. As used by Marichal et al. 
(2009), the term spike is used to refer to a fast event with depolarising and 
repolarising phases, but one which does not fulfil the criteria to be classified as an 
action potential. Spikes have lower amplitude than action potentials, not going above 
0 mV. Spikes also have larger half-amplitude duration than would be expected for 
action potentials. There was a continuum of responses of CSFcCs to depolarising 
current pulses between those with a passive phenotype which are unable to produce 
any spontaneous or evoked electrical activity and those that could fire repetitively.  
Due to this range of responses to the depolarising current pulses, these could not be 
used to confidently identify CSFcCs from the recordings from ependymal cells. 
Therefore visualisation of the cell, either by post-recording fluorescent imaging or 
post-fixation DAB imaging, was used for this purpose. Specifically, the phenotypic 
feature that was used to identify CSFcCs was the presence of a process (closed 
arrowheads, Figure 3.1 Aiii, Biii and Ciii) which extended towards the lumen of the 
central canal, the direction and boundaries of which were identified by infrared DiC 
imaging (Figure 3.1 Aii, Bii and Cii).  
Despite the continuum of responses, CSFcCs were categorised into 3 subtypes 
dependent on their voltage response to the depolarising current pulses applied during 
the characterisation of the cell. These subtypes enabled analysis of the different 
responses to the drugs and allowed correlation between response size or type and 
extent of spontaneous or evoked electrical activity. The subtypes used for this 
analysis have been applied previously (Corns et al., 2015).  
The CSFcC 1 subtype was comprised of cells which showed a passive 
electrophysiological profile and were unable to produce any spikes or action 
potentials when depolarised with a positive current pulse (Figure 3.1 Ai). These cells 
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also displayed no spontaneous activity. CSFcC 1s had a relatively low input 
resistance compared with the other subtypes of CSFcC (194.19 ± 34.35 MΩ; n = 37; 
N = 32) but the resistances appeared to have a bimodal distribution (Figure 3.3 A). 
Type 1 CSFcCs had a resting membrane potential (RMP) of -64.23 ± 4.01 mV (n = 
39; N = 39). CSFcC 1 was the most common subtype in the recorded CSFcCs (48.2 
% of CSFcCs (39 of 81); Figure 3.2 C). 
CSFcCs were classified as CSFcC 2s if they were able to produce a single spike in 
response to a depolarising current pulse (Figure 3.1 Bi). CSFcC 2 had a larger IR 
than CSFcC 1 (891.88 ± 101.98 MΩ; n = 25; N = 21) and a less hyperpolarised RMP 
(-36.3 ± 2.80 mV; n = 31; N = 28). CSFcC 2s were less frequently observed than 
CSFcC 1s (38.3 % of recorded CSFcCs (31 of 81)).  
CSFcC 3s were capable of producing a train of spikes or action potentials in 
response to a depolarising current pulse (Figure 3.1 Ci). CSFcC 3s are less common 
than CSFcC 1 and 2s, comprising only 13.6 % of CSFcCs (11 of 81) in the recorded 
population. In terms of RMP and IR, CSFcC 3s had an RMP of -58.22 ± 9.77 mV 
(n = 11; N = 10) and an IR of 995.20 ± 344.13 MΩ (n = 7; N = 6). 
For both IR and RMP, the data for all CSFcC subtypes were not normally distributed 
as assessed by the Shapiro-Wilk test. Therefore comparisons used the 
Kruskal-Wallis test and indicated that there were significant differences between the 
CSFcC subtypes for both characteristics (RMP: P < 0.001, Figure 3.2 A; IR: P < 
0.001, Figure 3.2 B).  
Bonferroni post-hoc analysis showed that CSFcC 1s have a significantly more 
negative RMP than CSFcC 2s (P < 0.001), however neither group were significantly 
different to CSFcC 3s (P = 0.889 for CSFcC 1s; P = 0.674 for CSFcC 2s). In similar 
analysis of IR, CSFcC 1s had a significantly lower IR than both CSFcC 2s (P < 0.001) 
and CSFcC 3s (P = 0.002) while the IRs of these subtypes were not significantly 
different from one another (P = 1.000). 
There was an uneven distribution of cells of each CSFcC subtype around the central 
canal (Figure 3.2 D), with a higher proportion of CSFcC 3s around the ventral end of 
the spinal cord compared to the other regions of the ependymal zone. CSFcC 1s and 




Figure 3.1 Characteristics of CSFcC 1s, CSFcC 2s and CSFcC 3s 
Ai, Bi and Ci) Whole cell patch clamp traces in current clamp of a CSFcC 1, CSFcC 2 and CSFcC 3 respectively, responding to a 
negative and positive current pulse. Aii, Bii and Cii) The DIC image of the recorded cell showing location around the CC. Aiii, Biii and 
Ciii) Post recording excitation of rhodamine produces shows fluorescent image of recorded cell, closed arrowheads show the CSFcC 




Figure 3.2 Comparisons of CSFcC subtypes 
A-B) Comparison of the mean resting membrane potential (RMP) ± S.E. (A) and the 
mean input resistance (IR) ± S.E. (B) for the 3 CSFcC subtypes by Kruskal-Wallis test 
as data previously determined not to be normally distributed by Shapiro-Wilks tests. 
** = p < 0.01. *** = p < 0.001. C) Proportion of recorded CSFcCs by subtype. D) 






Despite having a significantly lower mean IR than that for CSFcC 2s and CSFcC 3s, 
the IRs of some CSFcC 1s overlap with some of those of the spiking subtypes. This 
can be seen when the data points are plotted on a frequency histogram. A combined 
histogram for CSFcC 2 and CSFcC 3 IR resembles a typical right skewed distribution 
as would be expected when the mean is closer to 0 MΩ than the extent of the spread 
of the distribution (Figure 3.3 B). However, a histogram for CSFcC 1 IR data did not fit 
a similar distribution and instead looked like it may be a bimodal distribution (Figure 
3.3 B). Within this distribution, there is a population of IR measurements that is in line 
with the distribution of the IR for the CSFcC 2s and CSFcC 3s, although increasing 
the skewedness of the distribution. The other modal peak of the CSFcC 1 IR 
distribution is considerably lower than any of the recordings for IR from the other 
CSFcC subtypes.  
One explanation for this is the difference within the CSFcC-identified population, 
particularly within the CSFcC 1 population, in levels of gap junction coupling. Most 
CSFcCs, including all spiking CSFcCs, do not show any gap junction coupling. During 
electrophysiological recording, the cell is filled with Neurobiotin, which is included in 
the intracellular solution in the electrode. Neurobiotin can travel through gap junctions 
and allows for gap junction connectivity to be viewed post-fixation and staining of the 
Neurobiotin with DAB staining. Most CSFcCs appear as a single cell with a visible 
process (Figure 3.3 C). However some CSFcC 1s are gap junction coupled. 
Therefore these appear as a spread of dye throughout part of the ependymal cell 
layer (Figure 3.3 D). Some processes heading dorsally and ventrally can also be 
observed in the post-fix images. The cell exemplified could clearly be identified as 
CSFcC by the rhodamine-enabled fluorescent imaging.  
The reason why the differential levels of gap junctions in some CSFcC 1s could 
account for the separate population in terms of IR distribution is that the higher gap 
junction coupled a cell is the lower the input resistance. The IR of a cell is lower in 
cells with more open ion channels and/or with more gap junctions. This has been 
demonstrated in other cells types by use of gap junction blockers to increase IR 







A) Frequency histogram for input resistances for CSFcC 1s showed a bimodal 
distribution. B) Frequency histogram for the input resistances of the combined 
population of spiking CSFcCs (CSFcC 2 and CSFcC 3). C and D) Visualisation of a 
CSFcC that is not gap junction-coupled (C) and a CSFcC that is gap-junction coupled 
(D) with irDIC image showing location of the cell around the central canal (Ci and Di), 
the process demonstrated by fluorescence imaging (Cii and Dii) and post-fix DAB 
staining with dye-coupling indicating gap junction coupling if present (Ciii and Diii). 
Scale bar = 20 μm (Ciii) and 50 μm (Diii).  
 
Figure 3.3 There are two populations of CSFcC 1s based on input resistance 
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3.2.2 Some CSFcCs show loss of spiking throughout recordings 
Cells were classified into subtypes during the initial characterisation period of the 
recording. In the vast majority of recordings, the cell may have drifted somewhat in its 
membrane potential, which was corrected for by adjusting the holding potential, 
however they stayed within the classification criteria for the same CSFcC subtype. A 
proportion of the cells with clearly defined spikes held for > 20 minutes displayed 
changes in phenotype with a reduction or loss of spikes (n = 8 of 15). These changes 
were more often a change from a cell with high levels of spiking (CSFcC 3) to a cell 
with less spiking (CSFcC 2) (Figure 3.4). They were frequently accompanied by a 
change in membrane potential, however even when corrected for by adjustment of 
holding potential, the initial responses could not be resurrected (data not shown).  
Figure 3.4 CSFcC 3s can lose spontaneous spiking and become CSFcC 2s 
Whole cell patch clamp continuous recording of a CSFcC changing from a subtype 3 
phenotype (A) to a subtype 2 phenotype (B) as shown by the shape of the voltage 
responses to hyperpolarising current pulses (-50 pA). 
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3.2.3 A population of CSFcCs responded to ATP with a depolarising response 
This study applied 300 μM ATP locally, using pressure ejection, to CSFcCs. All 
CSFcCs recorded showed a response to the pressure ejection of ATP. One 
population of CSFcCs responded with a depolarisation. Depolarising responses were 
observed in CSFcCs from subtypes 1, 2 and 3 (Figure 3.5 Ai, Bi, Ci respectively) with 
the range of subtypes demonstrated by the voltage responses to depolarising and 
hyperpolarising current pulses (Figure 3.5 Aii, Bii and Cii) in addition to the 
visualisation of the process (Figure 3.5 Aiv, Biv and Civ) through the ependymal cell 
layer (Figure 3.5 Aiii, Biii and Ciii). The proportion of cells within each subtype that 
showed the depolarising response to local application of ATP was not consistent. 
Amongst CSFcC 1s, the majority of cells did not show a depolarising response (2 of 
28 cells depolarised; 7.14 %) (Figure 3.5 D). Approximately half of CSFcC 2s 
responded to ATP with a depolarisation (12 of 23 CSFcC 2s; 47.8 %) and the majority 
of CSFcC type 3s responded to local application of ATP with a depolarising response 
(9 of 11 CSFcC 3s depolarised; 81.8 %). There was a correlation between the 
response to ATP (as measured by the amplitude change upon application of ATP) 
and the CSFcC subtype (Pearson correlation value 0.314, P = 0.005). CSFcC 2s 
produced significantly larger depolarisations than CSFcC 1s to ATP, however there 
was no significant difference between the amplitude of depolarisations of CSFcC 3s 
and those of any either of the other subtypes (Figure 3.5 E). The average size of 
depolarisation to ATP was 5.30 ± 2.04 mV for CSFcC 1 (n = 2; N = 2), 26.08 ± 9.80 
mV for CSFcC 2 (n = 10; N = 10) and 15.81 ± 1.51 mV for CSFcC 3 (n = 2; N = 2). 
The size of a voltage change is affected by the input resistance of the cell, therefore 
the data was then analysed as voltage change (mV)/ input resistance (MΩ). The data 
analysed in this format did not show any significant differences between the 








Figure 3.5 Subpopulations of all CSFcC subtypes respond to local application of ATP with a depolarisation 
Ai, Bi, Ci) Example of whole cell patch clamp recordings of a CSFcC 1 (Ai), CSFcC 2 (Bi) and CSFcC 3 (Ci) depolarising to a 
200 ms pressure ejection puff of 300 μM ATP (black bar). Aii, Bii and Cii) corresponding recordings of the cells exemplified 
in Ai, Bi and Ci of the responses to positive and negative current pulses, indicating CSFcC subtype. Aiii, Biii, Ciii) DIC 
images of the cells recorded from in i and ii, showing location around the CC. Aiv, Biv and Civ) Rhodamine-excited 
fluorescent images showing CSFcC processes. D) Proportion of cells in each subtype which responded to 300 μM ATP 
responding with a depolarisation, with the remainder responding with a hyperpolarisation. E) Comparison of amplitude of 










3.2.4 Depolarisations to ATP were mediated by P2X receptors 
 
The depolarising response to 300 μM ATP in CSFcCs of all subtypes was partially 
antagonised by 50 μM suramin from a depolarisation magnitude of 29.95 ± 2.20 mV 
(n = 31; N = 24) in response to ATP prior to antagonist application, to 10.70 ± 3.18 
mV (n = 14; N = 12) depolarisation to ATP in the presence of suramin (Figure 3.6 C). 
There was a partial return to control levels after antagonist washout, with amplitudes 
to ATP application increasing to 18.91 ± 4.24 mV (n = 4; N = 4). The amplitude of the 
depolarising response to ATP with suramin was significantly different from the 
response sizes before and after suramin application (P = 0.003), whilst there was no 
significant difference between the amplitudes of response after washout and control 
values (P = 0.06). This antagonism by suramin was seen in CSFcCs of different 
subtypes, including CSFcC 1s (Figure 3.6 Ai) which were shown to be CSFcCs by 
DIC and fluorescent imaging (Figure 3.6 Aii and Aiii, respectively) and spiking 





Figure 3.6 CSFcC depolarisations to local application of ATP were inhibited by 
bath application of suramin 
Ai and B) Whole cell patch clamp recording of a CSFcC 1 (A) and a CSFcC 2 (B) 
depolarisation to 300 μM ATP (black bars), before (black traces), during (red traces), 
and after (grey traces) application of 50 μM suramin; CSFcC 1 imaged by DIC (ii) and 
fluorescent imaging (iii) showing process into the central canal. C) Bar chart showing 
average responses to 300 μM ATP in the presence of 50 μM suramin and after 
suramin washout. * = p < 0.05. 
 
 
Amplitudes of depolarisations to ATP were measured in CSFcCs at a range of 
holding membrane potentials to allow reversal potential to be estimated for this 
response. As the membrane potential was raised manually by applying depolarising 
current, the amplitude of the response to ATP decreased (Figure 3.7 A). The 
amplitude of the depolarisation was plotted against the holding membrane potential 
allowing the reversal potential to be estimated (Figure 3.7 B). The reversal potentials 
were estimated by extrapolation of the line of best fit producing an estimate of -51.44 





Figure 3.7 Reversal potentials of the depolarising response to ATP in CSFcCs 
A) Whole cell patch clamp continuous recording of a CSFcC responding to 
application of 300 μM ATP (black bars) with depolarisations at 3 membrane potentials 
(-63 mV, -48 mV and -80 mV); membrane potentials changed manually. B) Lines of 
best fit on chart of amplitude of depolarisation to ATP against membrane potential 
extrapolated to estimate reversal potential of response and adjusted for the liquid 
junction potential. 
3.2.5 A population of CSFcCs responded to ATP with a hyperpolarising 
response 
As shown by Figure 3.4 D, a proportion of CSFcC 1s (26 out of 28 cells), CSFcC 2s 
(11 out of 23 cells) and CSFcC 3s (2 out of 11 cells) showed hyperpolarising 
responses to local application of ATP. The hyperpolarising response to ATP was 
seen in both non-spiking (Figure 3.8 A) and spiking CSFcCs (Figure 3.8 B). The 
hyperpolarising responses in CSFcC 3s were of large amplitude (-26.4 mV and -33.8 
mV) similar to those seen in CSFcC 2s, however the responses of CSFcCs are not 
analysed further as there were only 2 examples recorded with a large difference in 
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their amplitudes. The data from the responses in CSFcC 1s and CSFcC 2s were 
analysed to determine if there were any differences in the characteristics of the 
response between the cell subtypes (n = 22; N = 22 for CSFcC 1 and n = 11; N = 10 
for CSFcC 2). The onset of response was not significantly different between the 
subtypes (36.50 ± 4.64 ms for CSFcC 1 and 39.91 ± 4.85 ms for CSFcC 2; P = 0.475; 
Figure 3.8 C). The duration of the response was also not significantly different 
(2.33 ± 0.25 s for CSFcC 1 and 2.23 ± 0.35 s for CSFcC 2; P = 0.827; Figure 3.8 D). 
When analysed in terms of amplitude of response, there was a significant difference 
between CSFcC 1 and CSFcC 2 (-6.71 ± 1.26 mV and -25.30 ± 3.90 mV respectively; 
P < 0.001; Figure 3.8 E). However magnitude of a voltage response is affected by the 
input resistance of a cell and my data have shown that there is a significant difference 
in the IRs of CSFcC 1 and CSFcC 2s. Therefore, further analyses were done on the 
amplitude of change (mV)/ IR (MΩ) and this showed no significant difference between 
CSFcC 1 and CSFcC 2s (-0.084 ± 0.024 mV/MΩ for CSFcC 1 and -0.053 ± 0.012 
mV/MΩ for CSFcC 2, P = 0.593; Figure 3.8 F).  
The results were analysed to assess whether there was any correlation between the 
responses to ATP recorded from different cells but on the same day. The number of 
days 2 or more CSFcC 2s or 3s were recorded from on the same day was counted 
and the numbers of days the same or different responses observed were compared 
to the expected likelihood of receiving those outcomes. The likelihood of getting 2 
CSFcC 2s or 3s that produced the same response to ATP was higher than would 
have been expected if there was no correlation of the response type of cells recorded 
on the same day (6 days rather than the 3.56 days predicted by chance alone), with 
fewer than expected with 1 hyperpolarising and 1 depolarising response (1 day 






Ai and Bi) Whole cell patch clamp recordings of CSFcC 1 (Ai) and CSFcC 2 (Bi) which hyperpolarised to 300 μM ATP (black 
bars). Aii and Bii) Voltage responses to negative and positive current pulses indicating CSFcC subtype. Aiii-iv and Biii-iv) 
DIC and fluorescent images showing the location of the recorded cells and their processes. C-E) Comparison of the 
hyperpolarisations of CSFcC 1 and CSFcC 2 in terms of onset (C), duration (D), amplitude (E) and amplitude/IR (E). *** = p 
< 0.001; comparisons used Mann-Whitney U test as data not normally distributed 
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Unlike the depolarising response to ATP, the hyperpolarising response was not 
antagonised by 50 μM suramin. This lack of antagonism by suramin was seen in all 
CSFcC subtypes, including CSFcC 1s (Figure 3.9 Ai) which constitute the majority of 
the hyperpolarising responses (cell identification demonstrated by the voltage 
responses to current pulses (Figure 3.9 Aii) and the visualisation of the process 
(Figure 3.9 Aiii)). There was no significant difference between the amplitudes of the 
hyperpolarisation to ATP, before, during or post-suramin application (pre-suramin: -
4.91 ± 1.29 mV (n = 8; N = 8), with suramin application: -5.64 ± 1.98 mV (n = 8; 
N = 8), P = 0.459; Figure 3.8 B).  
CSFcC 2s produce either depolarising or hyperpolarising responses to ATP 
application in reasonably similar proportions (Figure 3.5 D), and as such, this is a 
good population to examine any relationship between cell characteristics and type of 
response. CSFcC 2s that depolarised to ATP were compared with those that 
hyperpolarised in terms of RMP and IR (Figure 3.9 C and D respectively). In both of 
these comparisons, there were no significant differences between the depolarising 
and hyperpolarising CSFcC 2 groups. The depolarising group had a RMP which was 
-37.16 ± 4.51 mV (n = 12; N = 11), whilst that for the hyperpolarising group was -
34.85 ± 3.75 mV (n = 11; N = 9; P = 0.702). The IR for the depolarising CSFcC 2 was 
1169.39 ± 256.18 MΩ (n = 12; N = 11), and 712.13 ± 110.42 MΩ (n = 11; N = 9) for 




Figure 3.9 The hyperpolarisations of CSFcCs to ATP were not antagonised by suramin 
Ai) Hyperpolarisations recorded in whole cell patch clamp recordings in response to application of 300 μM ATP (black bar) 
before 50 μM suramin application (black trace) and during suramin application (red trace). Aii) Voltage responses to positive 
and negative current pulses indicated the recorded cell was CSFcC 1. Aiii) Rhodamine-excited fluorescent image shows 
CSFcC process. B) Amplitude of hyperpolarisations not reduced by application of 50 μM suramin as determined by paired 
t-test. C-D) Comparison of CSFcC 2 that depolarise to ATP to those that hyperpolarise to ATP in terms of RMP (C), and IR 
(D) with comparisons by independent-samples t-test.
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3.2.6 A population of cells that initially depolarised to ATP, later showed 
hyperpolarisations. 
Similarly to how there were CSFcCs which were observed to be changing from 
subtype 3 to subtype 2 (Figure 3.2), there were also cells which changed their 
response type to ATP (n = 5; N = 5). This was sometimes in line with changes in 
subtype (n = 3; N = 3). For example, one CSFcC changed from a CSFcC 3 which 
depolarised to local application of ATP (Figure 3.10 Ai), to a CSFcC 2 which 
hyperpolarised to ATP (Figure 3.10 Aii). These changes were accompanied by a 
reduction in IR and a decrease in spontaneous spiking. The change that was observ-
ed in membrane potential was not necessary for the change in response to ATP. This 
is demonstrated by an alternative recording which was accompanied by a 
hyperpolarisation of membrane potential (Figure 3.10 B), and also shows that when 
the holding membrane potential was raised back up to the starting membrane 




Figure 3.10 Changes in spiking can be associated with a change in response 
to ATP 
A) Whole cell patch clamp continuous recording showing a CSFcC changing both 
response type to 300 μM ATP (black bars) and subtype phenotype over time with 
phenotype demonstrated by voltage responses to hyperpolarising current pulses. At 
Ai) the cell shows a CSFcC 3 phenotype and depolarises to ATP, at Aii) a CSFcC 2 
phenotype and robust hyperpolarisations are displayed. B) Whole cell patch clamp 
recording showing a cell changing from a depolarising to a hyperpolarising response 
to 300 μM ATP (black bars) accompanied by a hyperpolarisation of membrane 





In addition to changes in response type to ATP over a period of minutes, there were 
also sometimes changes in response over a matter of seconds. These recordings 
indicated a desensitisation of the depolarising response to application of ATP (Figure 
3.11). In some cases this desensitisation reduced the amplitude of the depolarising 
response to ATP (Figure 3.11 A), whilst in others the depolarising response to ATP 
gave way to a hyperpolarising response (Figure 3.11 B). Additionally there were 
examples where there were elements of both a depolarising and hyperpolarising 
response to ATP, with the hyperpolarisation occurring first (Figure 3.11 C). In these 
cases the depolarising response reduced in amplitude, as the hyperpolarising 
response increased. To minimise the impact of this desensitisation on the statistical 
analyses, measurements were taken from the first response from a group of 3, with 
an interval of >2 minutes between the sets of ATP pulses as the response size had 




Figure 3.11 Depolarising responses to ATP show desensitisation 
A, B and C) Whole cell patch clamp recording of CSFcCs responding to 300 μM ATP (black bars) showing desensitisation of 
the depolarising response to repeated application of ATP. 
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3.2.7 P2X3 is involved in the depolarising response to ATP in a subset of 
CSFcCs  
A subset of CSFcCs that responded to application of ATP with a depolarisation 
showed either reduction in magnitude or complete elimination of the depolarisation 
with the P2X3/P2X 2/3 specific antagonist A-317491 (1 μM; Figure 3.12 A). These cells 
were located predominantly in the ventral aspect of the central canal region. Cells 
that were located dorsal, dorsolateral or lateral (n = 5; N = 4) were not affected by 
application of A-317491 (25.96 ± 3.17 mV versus 22.08 ± 2.52 mV with A-317491, 
P = 0.366, Figure 3.12 B). However cells that were located either ventral or 
ventrolateral (n = 11; N = 10) had the amplitude of the depolarisation to ATP 
significantly reduced in the presence of A-317491 (34.02 ± 4.32 mV to 21.42 ± 6.26 
mV with A-317491, P = 0.005).  
The responses to ATP of the CSFcCs were then divided by presence or absence of 
P2X3-involvement as assessed by whether or not their response to ATP was 
antagonised by A-317491. When comparing the responses to ATP which were 
elicited in part or full by P2X3-containing receptors to those without P2X3 involvement, 
there was no significant difference between the amplitudes of the depolarisations to 
ATP prior to antagonist application (P = 0.25). The A-317491 responders (n = 9 of 19) 
had a significantly shorter onset in their depolarising response to ATP than the A-
317491 non-responders (0.052 ± 0.018 ms compared to 0.260 ± 0.052 ms; p = 0.020; 
Figure 3.12 D). There was, however, no significant difference in the duration of the 
response to ATP between the A-317491 responders and the A-317491 non-
responders (1.48 ± 0.50 s for responders and 1.45 ± 0.14 s for non-responders; p = 
0.70; Figure 3.12 E).  
The presence of the P2X3 receptor subunit around the ventral extent of the central 
canal region was demonstrated using immunohistochemistry with an antibody raised 
against the P2X3 subunit (Figure 3.11 C). The P2X3 subunit appeared not to be 
expressed strongly in cells, instead with the most intense staining being in small, 
circular points at the ventral end of the central canal. This staining suggested that the 
P2X3 was possibly present in fibres sitting between, and immediately ventral of, the 





Figure 3.12 Involvement of P2X3 in the depolarising response to ATP 
 
A) Whole cell patch clamp recordings of CSFcCs depolarising to 300 μM ATP (black 
bar) before (black trace) and during application of 1 μM A-317491 (purple trace) with 
a graphical representation of the location of each cell around the central canal. B) 
Comparison of the effects of A-317491 on depolarisation amplitude to ATP with cells 
group by location around central canal. ** = p < 0.01; data assessed by paired or 
independent-samples t-tests as appropriate. C) Immunohistochemistry for the P2X3 
subunit (green) around the CC. Scale bar = 50 μm. Immunohistochemistry completed 
by Lucy Peers. D and E) Bar charts showing averages of the onset (D) and duration 









This chapter has characterised the basic characteristics of CSFcCs. These 
electrophysiological characteristics were then used to subcategorise CSFcCs into 
subtypes albeit with a continuum between subtypes and occasional changes of 
subtype-defining characteristics within a recording. The subtypes were defined by the 
ability of the cells to produce spikes in response to depolarising current pulses, with 
type 1 unable to produce spikes, type 2 able to produce a single spike and type 3 
producing a train of spikes. CSFcCs were shown to respond to locally applied ATP 
with either a depolarisation or a hyperpolarisation. There was involvement of P2X3 
receptors in a spatially-dependent subset of depolarising responses to ATP.  
3.3.1 CSFcC subtypes may represent temporary sub-states  
The differences observed in electrophysiological characteristics of CSFcCs cover a 
considerable range. This range is continuous between the spiking behaviours, with 
no discrete boundaries between electrophysiological profiles of CSFcC 2 and CSFcC 
3s. All cells that could be confirmed to be CSFcC by visualisation of the process were 
assigned a subtype, however there was no definite boundary about what constituted 
a spike and particularly, or what constituted multiple spikes after the first as there are 
often membrane potential oscillations. The assessment was done on what behaviour 
the cell typically showed to a +50 pA current pulse with spikes taken to be 
depolarisations with a rapid repolarisation. Previously, CSFcC type 2 and 3 have 
been described (Marichal et al., 2009) with some research suggesting non-spiking 
CSFcCs are a different classification of cells.  
The distribution of the input resistances of CSFcC 1s suggests that there may be a 
long-term difference between subgroups of CSFcC (subtypes rather than sub-states). 
CSFcC 2 and 3s have a typical right skewed distribution, which would be what would 
be expected of a population with a mean relatively close to zero, a large standard 
deviation and no negative values. However the histogram for CSFcC 1s less clearly 
resembles this distribution and looks to be bimodal. This is supported by previous 
data which shows that one subpopulation of CSFcC 1s, but none of the spiking 
CSFcCs, have gap junction connections similarly to ependymal cells and therefore 
would be likely to have a much lower IR (Corns, 2012). As gap junctions are unlikely 
to change readily, this fits with the fact that the changes in subtype observed were 
109 
 
from a CSFcC 3 profile with high levels of spontaneous and evoked activity, to a 
CSFcC 2 profile with far lower frequency and amplitude of spiking, but did not change 
to a CSFcC 1 profile. Additionally to this, the different electrophysiological 
phenotypes have been shown to correlate with cell markers in turtle spinal cord 
(Russo et al., 2004). Cells which passively responded to current pulses and 
correlated with CSFcC 1s, expressed S100, as did cells with delayed rectifying 
currents, however spiking cells did not express S100, but did express HuC/D.  
Despite there being many similarities in the CSFcC subtype data between that found 
in this study and previous research, there were differences in the proportions of each 
CSFcC subtype recorded. Previous research observed a far higher proportion of 
CSFcCs recorded to be CSFcC 3s, 27 % (Corns et al., 2015) compared to 13.6 % in 
this study. As the spatial distribution of CSFcC 3s was not equal around the central 
canal, this difference in the observed proportion of CSFcC subtypes could have been 
due to differences in the rate at which the different locations around the central canal 
were targeted for cell recording. It has been reported that PKD2L1-positive CSFcCs 
are derived from 2 distinct developmental locations, with one smaller population 
derived from the ventral pole of the neural tube, which produced the majority of the 
ventral CSFcCs, and the other the larger population originated from the late-P2 and 
pOL domains, being more widely spread throughout the central canal region 
(Petracca et al., 2016). Petracca et al. (2016) also observed spatial differences in the 
spiking behaviours however this was opposite to what was observed presented here. 
They reported that cells derived from the floor plate sat ventrally and showed single 
spiking profiles, while cells from the late-P2 and pOL domains were found laterally 
and the majority could produce trains of spikes, whereas our findings show a greater 
proportion of multiple spiking CSFcC 3s ventrally. There are a number of 
explanations for these differences. Firstly Petracca et al. (2016) used considerably 
younger mice (P1-2) compared to the P11 rats used here. Another difference could 
be the population of CSFcCs examined, as their pool was limited to those expressing 
PKD2L1.  
There is very little synchrony in central canal literature as to the cell types found with 
almost no consensus on names for cells. One possibility is that CSFcC 1s represent 
2 distinct groups of cells as differentiated by the presence and absence of gap 
junction coupling, which therefore caused differences in input resistance. It could be 
that the low IR CSFcC 1s represent the glial fibrillary acidic protein (GFAP) positive 
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central canal-contacting astrocytes identified by Alfaro‐Cervello et al. (2012). They 
used electron microscopy to identify central canal contacting astrocytes with a 
process through the ependymal cell layer with a single primary cilium, while central 
canal contacting neurons (which correspond to CSFcCs) had a process that ended 
with a mitochondria-rich globular expansion, with multiple other ultrastructural 
differences. 
Connexin gap junctions have been observed between astrocytic processes and 
ependymal cells and also between ependymal cells and unidentified inter-digitating 
processes (Ochalski et al., 1996). Whist zonulae adherens have been observed 
between CSFcCs and ependymal cells, no gap junctions have been observed in 
electromagnetic imaging studies (Stoeckel et al., 2003). The fact gap junctions have 
been observed between cells identified as CSFcCs both in this study and by previous 
work in our lab (Corns, 2012) suggests that these cells may not be the same as the 
CSF-contacting neurons identified in other studies.  
The fact that hyperpolarising and depolarising responses are seen in both non 
spiking and spiking CSFcCs, although to differing degrees, would suggest that 
although there may be considerable differences between the cells sampled, these 
differences don’t align with a split in cells identified as CSFcC 1 and with a 
homogenous sample of spiking CSFcCs. It is however possible that within a 
population of CSFcC-identified cells with a range of responses, there is a population 
of astrocytes that happen to respond in the same manner as one subpopulation of 
CSFcCs. Whilst there was no significant difference between the IRs of CSFcC 1s 
located dorsal or dorsolateral (D/DL) and those located ventral or ventrolateral (V/VL) 
the former group had 71% with IR in the first peak (<100 MΩ) whilst the second group 
had only 33%. This has significance because astrocytes have been reported 
predominantly dorsal to the central canal (Sabourin et al., 2009) and proliferation also 
occurs predominantly in the dorsal region (Hamilton et al., 2009).  
Marichal et al. (2009) did not observe CSFcCs with no spontaneous or evoked 
activity in turtle spinal cord. Furthermore all GFP-positive cells in a Gata2GFP mouse 
model produced either a train of spikes or a single spike (Petracca et al., 2016). The 
transcription factor Gata2 colocalised with PKD2L1, which is known to be expressed 
in CSFcCs (Djenoune et al., 2014), does not appear to be a transcription factor in 
CSFcC 1s. Therefore, it could be that all CSFcC 1s are actually GFAP-positive 
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astrocytes, with separate populations of gap-junction coupled and non-gap junction 
coupled astrocytes. However the fact that 2 CSFcC 1s were observed to respond to 
ATP with a depolarisation, similarly to CSFcC 2 and 3 would require these astrocytes 
to express the same purinergic receptors. Whilst similarity of purinergic receptor 
expression makes the possibility of all CSFcC 1s being central canal-contacting 
astrocytes less likely, it has been reported that ATP can cause proliferation and 
gliosis in cultured astrocytes via P2X2 receptors (Neary et al., 2003) suggesting the 
presence of P2X2 receptors on astrocytes could occur in some cases. 
Immunohistochemistry for GFAP on a slice with a Neurobiotin filled-CSFcC 1 could 
check for co-localisation to confirm this possibility. This could provide greater insight 
into the characteristics and identity of CSFcC 1s, particularly those with gap junction 
coupling.  
There is also debate as to whether the astrocytes in this area are capable of stem cell 
behaviour and the extent of any contribution to the increase in proliferation seen with 
spinal cord injury (Kriegstein and Alvarez-Buylla, 2009; Moore and Oglesbee, 2015; 
Zhou et al., 2015). This is largely due to the fact that astrocytes are regularly 
identified by the expression of GFAP or the intermediate filament protein, vimentin. 
However subpopulations of ependymal cells express one or both of these molecules. 
GFAP and vimentin positive cells have been identified in the central canal region as 
having multi-potency (Moore and Oglesbee, 2015) whilst others report the stem cells 
to be GFAP negative (Meletis et al., 2008), and some report some level of stem 
activity in both populations (Sabourin et al., 2009). Further evidence suggests that the 
GFAP positive cells are the stem cells as GFAP has been shown to co-localised with 
the carbohydrate adhesion molecule (CD15) and brain lipid-binding protein (BLBP) 
(Sabourin et al., 2009), which are both stem cell markers (Keilani and Sugaya, 2008; 
Abranches et al., 2009; Lukenda et al., 2016). In humans, CD15 staining has been 
shown to be present in ependymal cells except for those at the ventral aspect of the 
central canal (Dromard et al., 2008).  BLBP is, however, only expressed in a subset 
of ependymal cells (Sabourin et al., 2009). Additionally, it seems unlikely that 
astrocytes play a key stem cell role in the central canal region, since while astrocytes 
have been positively reported in this area, they have been observed not to be 
proliferating under normal circumstances (Alfaro‐Cervello et al., 2012).  
It may be that some of the cells represented here as CSFcCs are in fact astrocytes, 
as suggested by the similarities in observed morphology (Figure 3.12), however the 
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current research would suggest that they are not the main stem cell in this area. The 
techniques utilised here do not always allow for conclusive identification as the most 
significant differences are ultrastructural (Alfaro‐Cervello et al., 2012). As the 
responses to purinergic signalling presented here do not show a pattern matching to 
the bimodal pattern seen in gap junction coupling or CSFcC subtype, these 
hyperpolarising and depolarising response groups have not been split according to 
any of these other factors.  
3.3.2 Understanding the different responses within the CSFcC population  
Even aside for the possible inclusion of astrocytes within the CSFcC-identified 
population, there is a range of responses produced to local application of 300 μM 
ATP. There are several possibilities as to the cause of these different responses.  
There could be differences in the cellular mechanisms or molecular expression profile 
of the cells. There is a correlation between the response type to ATP application and 
the spiking behaviour suggesting that some cellular differences that cause the 
differential spiking behaviour could be linked to the different ATP responses. 
However, there were CSFcC 1s that depolarised to ATP despite showing no spiking 
activity, meaning that the ATP-response differences cannot be solely due to the same 
molecular or expression differences that cause the spiking behaviour in some 
CSFcCs. There could be an impact of differential expression of purinergic receptors, 
as whilst P2X2 has been shown to be expressed in CSFcCs, there was a 
subpopulation which did not show P2X2 immunofluorescence (Stoeckel et al., 2003). 
It is therefore possible that the hyperpolarising responses come from this P2X2-
negative subpopulation. However, there was a correlation between the ATP response 
and CSFcC subtype and both of these were observed changing, sometimes in 
parallel.  
The cause of the expression differences of purinergic receptors (Stoeckel et al., 
2003) and channels involved in spiking is not known. It has been shown that the 
likelihood of cells producing spikes or multiple spikes is not correlated with the age of 
the cell, with CSFcCs born at E14.5 (Marichal et al., 2009; Petracca et al., 2016). An 
alternative could be differences in the age of the animals, perhaps with 
hyperpolarising responses being immature responses; however both depolarising 
and hyperpolarising responses were recorded from animals ages P7 to P13. This 
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covers the extent of the age range used for these experiments indicating that neither 
response type was restricted to either extent of the age range. 
There could have instead been a difference in the experimental set up that caused 
the differences in response type. This could have been involvement of factors such 
as the pH of the aCSF, the pH of the intracellular solution, the temperature of the 
recordings, the position of the electrode or the flow rate. With most of these factors 
we would expect some correlation between recordings made on the same day. When 
analysis was done to investigate if the responses recorded from different cells on the 
same day were independent of each other, the data showed that there was a higher 
chance of observing 2 CSFcC 2s or 3s producing the same response on the same 
day than would be expected by chance alone. This would suggest that there may be 
a factor which increases the chance of recording the same response in a day, but as 
different responses were recorded in a day, it is not absolute. In one case, the first 
cell of the day depolarised to ATP, the next hyperpolarised and the third depolarised, 
whilst other cells changed their response to ATP within the course of a recording. 
Additionally, desensitisation was observed frequently within the recordings, in some 
cases changing the response type from depolarisation to hyperpolarisation. This 
desensitisation could occur via different cellular mechanisms than the longer time-
period changes. However, the same factor that causes the desensitisation could also 
be involved in the longer term changes and also the initial response type. A possible 
factor in this situation could be ion balance; however the intracellular ion 
concentrations should have been set by their concentration in the intracellular 
solution.  
One factor of experimental set up that differed between cells is the relative location of 
the puff electrode with respect to the cell being recorded from, as both the distance 
between release of drugs and the cell and the composition of the tissue in between 
the two is likely to affect the distribution of the drug. This is unlikely to affect the type 
of response but is likely to affect the time course and concentration of drug delivery. 
The distance between the cell body and puff electrode was kept consistent 
throughout the electrophysiological experiments to minimise the differences in drug 
delivery, however proximity of processes and composition of tissue in between could 
not be controlled and may contribute to some of the differences in response size and 
shape to agonist application.  
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Another factor that could be involved in differences in the responses of CSFcCs to 
ATP could be changes in permeability of the channel to those ions. Whilst 
permeability of an ion channel protein to its namesake ion is a typically stable 
property of membrane proteins, P2X2 is thought to initially open a small pore which 
only allows small ions such as Na+, K+ and Ca2+ with prolonged activation further 
dilating the pore (Li et al., 2015). The larger pore allows through larger cations such 
as NMDG+ and Yo-Pro (Virginio et al., 1999). This is a feature that only occurs with 
high expression levels of P2X2 (Fujiwara and Kubo, 2004; Li et al., 2015) so could 
have differential levels of effects in cells with different P2X2 expression levels. Rate of 
dilation is dependent on the time and concentration of ATP application (Virginio et al., 
1999), which is not easy to assess with local puff application as the concentration is 
not constant, but with the concentration threshold for induction of permeability 
increases being 10-20 μM (Virginio et al., 1999), it is likely that the puff applications 
passed that threshold, particularly as there may be some baseline level of 
extracellular ATP due to the damage caused to the slice during the sectioning. This 
however is unlikely to account for the hyperpolarisations seen in CSFcCs as P2X 
receptors are non-selective cation channels and due to the hyperpolarised membrane 
potential of the cells, the net flow of cations, of any size is from outside to inside, 
acting to depolarise the cell. 
This damage to cells on the top and bottom of the slices is likely to have caused 
release of multiple factors of damage (Paemeleire and Leybaert, 2000; Lahne and 
Gale, 2010). While these factors released may have been washed away by the 
constant flow of aCSF through the bath in which the slices are held, there may be 
some remaining and perhaps depth into the slice or proximity of the cell to the top or 
bottom of the slice could affect the presence of these factors. In addition to ATP, 
these damage-related factors present in the spinal cord slices may include growth 
factors (PDGF, VEGF) (Khallaf et al., 2016) and cytokines (IL-1β, IL-6) (Coronel et 
al., 2016) which are also released at higher concentrations after spinal cord injury. 
These could have caused changes to the CSFcCs, potentially in receptor expression. 
Variations in levels of these factors could cause variation in CSFcCs which might 
account for the variation in the responses of CSFcCs to ATP. However the link 
between response type to ATP and CSFcC subtype mean that these changes in 
response to spinal cord injury factors would have to be very broad, making this 
explanation less likely.  
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Another possible characteristic of P2X2 receptors which may be involved in the 
responses of the ependymal cells to extracellular ATP is the coupling of P2X2 
receptors and GABAA receptors (Boué-Grabot et al., 2004b). This coupling leads to 
cross-inhibition dependent on GABAA subunit composition (Boué-Grabot et al., 
2004a). There is also inhibitory cross-talk and physical clustering of 5-HT3 and P2X2 
receptors (Boué-Grabot et al., 2003) and of 5-HT3 and P2X2 and/or P2X3 receptors in 
pelvic afferent neurons (Ma et al., 2006). These indicate that P2X2 receptors can 
interact with multiple other neurotransmitter-gated channels, producing current 
modulation and plasticity that could be involved in the range of responses seen in 
CSFcCs in response to local application of ATP.  
3.3.4 The role of P2X3 subunits in the depolarising response to ATP 
The selective involvement of P2X3-containing receptors is of significance because 
these receptors have different characteristics compared to P2X2-containing receptors. 
It is not known if the P2X3 containing receptors were in the form of homomeric or 
heteromeric assemblies, so the implications of both will be considered. The 
homomeric P2X3 receptor has a far more rapid desensitisation than the P2X2 receptor 
(North, 2002). The desensitisation of the response of P2X3 –receptors is seen 
predominantly at higher concentrations of ATP, whilst at lower concentrations of ATP 
(<300 nM), the response is sustained for much longer. As mentioned previously, it is 
not possible to know exactly what concentration of ATP is in the extracellular space 
around the cell with puff application of ATP, but as we are applying 300 μM ATP, it is 
likely that the concentration around the cell at peak concentration is well above 
300 nM. P2X2 receptors do exhibit calcium-independent desensitisation however this 
desensitisation opposes a dilation of the pore, allowing larger cations to flow through, 
meaning desensitisation is not necessarily observable (Khadra et al., 2012). This fits 
with the fact that the majority of cells did not show desensitisations in the 
depolarisations in response to ATP in this study.  
Once the P2X3  receptor has desensitised, its recovery to a closed state takes a long 
time, with gaps of 15 minutes necessary to produce similar, non-desensitised 
responses, however high calcium can reduce this time considerably (Cook et al., 
1998). The heteromeric P2X2/3 receptors have desensitisation properties similar to 
homomeric P2X2 receptors (North, 2002). As the duration of response to ATP in cells 
that had showed a reduction in amplitude of response to ATP with A-317491 was not 
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different from those unaffected by A-317491 application, this would suggest that 
either the desensitisation was not taking effect until after the ATP had diffused away 
or that the P2X3 receptors exist in P2X2/3 heteromers. 
P2X2 and P2X3 receptors and the heteromeric P2X2/3 receptor are permeable to 
calcium, although P2X2 receptors are more permeable than both P2X3-containing 
receptors (Virginio et al., 1998). P2X2 receptors are also known to be strongly 
inhibited as the levels of external calcium approach 10 mM (Evans et al., 1996). 
Homomeric P2X3 receptors were relatively insensitive to this calcium-induced ATP 
response blockade, with P2X2/3, displaying an intermediary profile with a slight 
blockade at very high extracellular calcium levels (>20 mM Ca2+; (Virginio et al., 
1998)). As the extracellular calcium concentration in this study was 2 mM (North, 
2002), there is unlikely to be a significant effect of this on our data, however it could 
provide some insight on the differential functioning of the CSFcCs with different 
purinergic receptor subtypes in physiological situations.  
These spatial differences in the receptor type and involved in producing the response 
to ATP could have implications in spinal cord injury. P2X3-containing receptors have 
been implicated in multiple forms of pain (de Oliveira et al., 2010; Hansen et al., 
2012; Xu et al., 2012; Li et al., 2013). One difference between P2X2 receptors and 
P2X3-containing receptors is the differential response to calcium. Whist P2X2 
receptors are inhibited by high levels of external calcium (Evans et al., 1996), whilst 
P2X3-containing receptors have their desensitisation of response attenuated by 
increased calcium (Cook et al., 1998). This means that the functioning of these 
receptors will alter over time after spinal cord injury as the levels of extracellular 
calcium vary. Initially, extracellular calcium levels fall, the levels then rose such that 
by after 2 hours calcium levels had risen significantly higher than sham-operated 
control levels and also significantly higher than neighbouring spinal cord segments 
(Moriya et al., 1994). The implications of this are that the P2X2 receptors have a 
larger response immediately after spinal cord injury, then during the following couple 
of hours P2X3 receptors have a less desensitised response to the still increased 
levels of extracellular ATP (Wang et al., 2004). 
Unlike staining observed with P2X2 antibodies (Studeny et al., 2005), the P2X3 
expression does not appear to be intense within the CSFcCs themselves, rather in 
fibres running up rostro-caudally along the ventral aspect of the ependymal region. 
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These fibres are contacted by processes from the cells in the ependymal layer (Bruni 
and Reddy, 1987). It could be that these processes come from CSFcCs and are the 
means by which receptors on the fibres are able to cause a response within the 
CSFcCs. Many of the fibres in this area are axons of autonomic visceral afferents 
(Morgan et al., 1981; Neuhuber, 1982) and observed penetrating between the 
ependymal cells (Neuhuber, 1982). Significantly, synapses have been reported on 
these longitudinally-running sympathetic afferents at the ventral end of the central 
canal (Neuhuber, 1982). Fibres in this location have also express substance P 
(Gibson et al., 1981; Probert and Hanley, 1987). The presence of Substance P 
degrading enzyme in ependymal cells (Probert and Hanley, 1987), suggests that 
these fibres may interact with ependymal cells as well as CSFcCs. It is also worth 
noting that P2X2 staining has also been observed in transversely sectioned axons, 
predominantly at the ventral end but also at the dorsal end of the central canal 
(Stoeckel et al., 2003). However the onset for responses in CSFcCs sensitive to A-
317 (and therefore with P2X3 involvement) had a quicker onset than those that were 
non-sensitive to A-317491, therefore making it less likely for the response to be 
mediated by multiple steps. This indicates that there may be faint P2X3 staining on 
the CSFcCs made hard to distinguish by that in the fibres but nevertheless, the 
receptors in the fibres will respond to the ATP applied and may well have secondary 
effects on the ependymal region.  
3.3.5 Conclusions 
There is considerable diversity in the responses of the CSFcCs to ATP, as well as in 
the CSFcCs themselves. CSFcCs can be differentiated by their level of spontaneous 
and evoked activity, with CSFcC 1s not showing any spontaneous or evoked activity 
in response to depolarising current pulses, and CSFcC 2s and 3s showing a single 
spike and a train of spikes respectively, with a continuum of responses between the 
two. The CSFcCs could also be divided by the presence or absence of gap-junction 
coupling. Whilst the majority, including all the spiking CSFcCs had no gap-junction 
coupling, a subset of CSFcC 1s displayed gap-junction coupling to the surrounding 
CSFcCs, as shown by lower input resistances and dye-coupling due to movement of 
Neurobiotin through the gap junctions. The third variation in the CSFcC population 
was their response to ATP. A proportion of predominantly spiking CSFcCs showed a 
suramin-sensitive depolarisation to ATP, whilst the remaining CSFcCs produced a 
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suramin-insensitive hyperpolarisation. Of the depolarising responses, the majority of 
these were likely to have been mediated by the P2X2 receptors that have been shown 
to be strongly expressed in CSFcCs (Marichal et al., 2009). In a ventral subset of 
CSFcCs, the depolarising responses to ATP were sensitive to the P2X3, 2/3-specific 
antagonist A-317491 indicating P2X3 involvement in these responses. The fact that 
the depolarising responses with P2X2 and P2X3 involvement but not the 
hyperpolarisations were sensitive to suramin will allow further investigations using 
suramin as the antagonist to look at the effect of the depolarising responses in 
CSFcCs. The range of CSFcC responses to ATP and the variety of receptors 
involved in mediating these responses suggest that it is likely that spinal cord 









Chapter 4 - Purinergic activation produces hyperpolarisations 




While originally proposed as passive cuboidal ependymal cells (Bjugn et al., 1988), 
ependymal cells have been shown to respond to a number of neurotransmitters, and 
in some of these cases, similarly to some CSFcCs. Ependymal cells respond to 
GABA predominantly via GABAA receptors (Corns et al., 2013), which may be 
released from GABAergic terminals on varicosities near the central canal (Magoul et 
al., 1987). Ependymal cells also depolarise in response to acetylcholine, with a 
receptor composition that is similar to that seen in the non-spiking CSFcC 1s (Corns 
et al., 2015). Both these cell types, unlike spiking CSFcC 2 and 3s, have 
depolarisations that are mediated by α7-containing nicotinic ACh receptors 
(α7*nAChrs) and non-α7*nAChrs in similar proportions, while CSFcC 2s and 3s have 
only a very small or negligible proportion of their responses to ACh mediated by 
α7*nAChrs. This indicates that there are some aspects in which ependymal cells 
behave similarly to CSFcCs, particularly CSFcC 1s.  
Ependymal cells differ from CSFcCs in the presence and extent of gap junction 
coupling in ependymal cells (Ochalski et al., 1996; Corns et al., 2013; Rodriguez-
Jimenez et al., 2016) as demonstrated by the presence of lack of dye-coupling seen 
with cells filled with Neurobiotin during patch clamp recordings (in this work and 
previously (Corns et al., 2015). Whilst a subset of CSFcCs have been observed to 
show gap junction coupling (Corns, 2012), this was only present in a small number 
and was not observed in any of the spiking CSFcCs. In contrast all ependymal cells 
show gap junction coupling. Gap junctions can be modulated by a number of 
neurotransmitters in other cell types such as retinal ganglion cells where permeability 
modulation occurs via dopamine signalling (Bu et al., 2014), and in photoreceptors, 
where levels of phosphorylation are modulated by adenosine (Li et al., 2014). Within 
the spinal cord, ependymal cells have downregulated connexin-50 (Cx-50) after 
severe contusion spinal cord injury in rats as shown by western blotting of epSPCis 
compared to epSPCs (Rodriguez-Jimenez et al., 2015). This downregulation of the 
Cx-50 resulted in a change in the fate of the newly-proliferated cells after spinal cord 
injury away from a glial fate. This was shown by upregulation of Cx-50 which resulted 
in more GFAP+ cells (an astrocytic marker) and few Tuj1+ cells (a neuronal 
marker)(Rodriguez-Jimenez et al., 2015). This means that ependymal cells modulate 
their expression of ion channels, in addition to a range of other proteins such as Sox2 
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(Lee et al., 2013), in response to detection of damage. It is possible that the raised 
levels of ATP after spinal cord injury are part of the signals that trigger this 
upregulation and therefore that purinergic signalling may affect the gap junctions 
present in the ependymal cells. 
P2X2 staining has been hypothesised to be expressed in a subpopulation of 
ependymal cells based on the expression of P2X2 around the central canal (Studeny 
et al., 2005), however other studies show co-localisation of P2X2  with known markers 
for CSFcCs (Stoeckel et al., 2003). P2X7 has been shown to be expressed in 
ependymal cells lining the ventricles (Yu et al., 2008) and around the central canal in 
the spinal cord (Genzen et al., 2009; Marichal et al., 2016), with P2X7 functionally 
active as shown by electrophysiological responses to the agonist BzATP, which is far 
more potent at P2X7 receptors than ATP. The responses caused by P2X7 receptors 
can be differentiated from responses caused by other P2X receptors by the fact that 
P2X7 receptors have low affinity towards ATP (EC50 > 100 μM) (Surprenant et al., 
1996). This was demonstrated in puff application experiments with ependymal cells 
around the central canal by Marichal et al. (2016) who saw no current when 50 ms of 
1 μM ATP was applied and almost none when 500 ms was applied, only seeing a 
significant response when 1 s of 1 μM ATP was applied. Whilst it is known that ATP 
levels are raised after spinal cord injury (Wang et al., 2004), the concentrations of 
ATP in different regions of the spinal cord and at different time points after injury are 
not known. Therefore it is important to understand what the responses of the cells in 
the central canal area are to lower levels of extracellular ATP, as these levels are 
likely to occur at a larger distance from the injury and be sustained for longer than the 
high levels of ATP necessary to activate P2X7 receptors.  
4.1.1 Hypothesis 
The hypotheses of this chapter are the ependymal cells around the central canal of 
the mammalian spinal cord: 
1. Have passive electrophysiological profiles which do not distinguish them into 
subcategories 





The aims of this chapter were to utilise patch clamp electrophysiology and 
intracellular dye loading to investigate: 
1. The differences and similarities between ependymal cells and CSFcCs around 
the central canal 
2. The presence of any effect of local application of ATP on the ependymal cells 
3. The mechanisms involved in any response to ATP seen 
4. The effect of local application of other nucleotides. 
 
4.2 Results 
Data for this chapter came from experiments using P7-13 Wistar rats. 
4.2.1 Ependymal cells show passive electrophysiological characteristics 
Electrophysiological characterisation showed that ependymal cells show passive 
recordings, where the cells do not show any spiking activity. This was shown by a 
complete absence of spikes or action potentials in response to depolarising current 
pulses (Figure 4.1 Ai). In terms of visualisation, ependymal cells were positioned 
within the ependymal cell layer, with a less distinct cell outline when viewed with irDIC 
microscopy (Figure 4.1 Aii), particularly when compared to CSFcCs or neurones. At 
post-recording visualisation via rhodamine-enabled fluorescence, ependymal cells 
are small and display no apical process into the central canal (Figure 4.1 Aiii). The 
cilia are not visible on any visualisation methods used in this study. Some cells with 
positioning within the ependymal cell layer and ependymal cell-like 
electrophysiological properties display a single thin basal process. These cells have 
been described as tanycytes (Rafols and Goshgarian, 1985; Meletis et al., 2008) and 
are detailed in the section 4.2.4. Due to similarities in responses shown in section 
4.2.4, tanycytes will be treated as a subset of ependymal cells and included in 
ependymal cell data unless otherwise specified. Ependymal cells had a 
hyperpolarised resting membrane potentials (RMP = -75.38 ± 6.23 mV), which was 
significantly more negative than CSFcC 2s (P < 0.001) and CSFcC 3s (P = 0.019), 
but not significantly different from CSFcC 1s (P = 0.121) (Figure 4.1 B). Ependymal 
cells had a low input resistance (IR = 74.11 ± 17.24 MΩ), which was significantly 
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lower than that of both CSFcC 2s and CSFcC 3s (P < 0.001 and P = 0.001 
respectively), however not significantly different from CSFcC 1s (P = 1.000; Figure 
4.1 C). These low input resistance values are likely to be due to the high levels of gap 
junction coupling, as indicated by the post-fixation DAB visualisation of dye-coupled 
cells (Figure 4.1 Aiv). Ependymal cells do not show a significantly different IR to 
CSFcC 1s, likely due to a subpopulation of the latter also show gap junction coupling. 
Due to the similarities of this passive electrophysiological profile to that of CSFcC 1s 
the visualisations were used for cell identification, with an absence of visible 
processes used to identify ependymal cells.  
 
 
Ai) Whole-cell patch clamp recording of an ependymal cell showing passive voltage 
responses to depolarising and hyperpolarising current pulses. Aii-iv) The DiC (ii), 
fluorescence visualisation of recorded cell (arrow) filled with rhodamine (iii) and dye 
coupling of the neurobiotin-filled ependymal cell detected by post-fixation DAB 
images, indicating gap junction coupling (scale bars: 20 μm for Aiv). B-C) 
Comparison of the resting membrane potential (RMP; B) and input resistance (IR; C) 
of ependymal cells with the subtypes of CSFcCs assessed by Kruskal-Wallis test as 
prior Shapiro-Wilk determined the data to be not normally distributed.  
Figure 4.1 The characteristics of ependymal cells 
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4.2.2 Characterisation of ependymal hyperpolarising responses to ATP 
All ependymal cells responded to local application of ATP with a hyperpolarisation 
(n=9/9; Figure 4.2 Ai). This response was similar to those seen CSFcC 
sub-population which produced a hyperpolarising in response to ATP application, 
composed of mainly CSFcC 1s with lower numbers of CSFcC 2s and 3s (Figure 4.2 
Bi). When these responses of ependymal cells were compared those of 
hyperpolarising CSFcCs, there were multiple similarities between the characteristics 
of the responses. There was no significant difference between either the onset of 
response or the duration of the response (Figures 4.2 F and 4.2 G respectively). The 
onset of the ependymal response (38.80 ± 12.53 ms) did not differ from that of 
CSFcCs (39.20 ± 3.25 ms) (p = 0.473). Similarly, there was no significant difference 
between the duration of ependymal cell responses (2.64 ± 0.47 s; n = 9; N = 9) and 
the duration of CSFcC responses (2.27 ± 0.18 s; n = 49; N = 42) (p = 0.975).  
Ependymal cells and CSFcCs were also compared with respect to the amplitude of 
the hyperpolarising response to locally applied ATP. In this characteristic of the 
response, there was a significant difference between the cell types. Ependymal cells 
had significantly smaller amplitude of response (-3.69 ± 0.68 mV voltage change) 
compared to CSFcCs (-12.45 ± 1.56 mV voltage change; p = 0.04). However the 
extent of voltage change is affected by the input resistances and as there are CSFcC 
2s and 3s included in the hyperpolarising CSFcC group, there is a difference in IR 
levels between the groups (p = 0.049). Therefore the responses were analysed as 
amplitude of response (mV) / IR (MΩ). When these differences in IR were controlled 
for, there was no significant difference between the amplitudes of the responses for 
ependymal cells (-0.0746 ± 0.0214 mV/MΩ) and CSFcCs (-0.0834 ± 0.0169 mV/MΩ; 
p = 0.834). This suggests that the differences in amplitude were due to the 
differences in input resistance.  
When a greater amount of ATP was applied, by a longer pulse (1 s compared to 
300 ms) of higher concentration (1 mM as opposed to 300 μM), ependymal cells 
produced a depolarisation (Figure 4.2H). This depolarisation was not seen when 





Ai and Bi) Example whole-cell patch clamp traces of hyperpolarisations in response to 
local application of 300 μM ATP (black bar) in an ependymal cell and a CSFcC 
respectively. D-G) Comparisons of the ATP-induced hyperpolarisations in ependymal 
cells to those produced by all hyperpolarising CSFcCs in terms of amplitude (D), 
amplitude/IR (E), onset (F) and duration (G). D-E) Significance assessed by Mann-
Whitney test as data not normally distributed as determined by Shapiro-Wilks test (** 
= p < 0.01. F-G) Data normally distributed so significance determined by independent 
samples t-test. Hi) 1s pulse of 1 mM ATP elicits a depolarising response when applied 
to ependymal cells.  
Figure 4.2 Ependymal cells hyperpolarise to 300 μM ATP and depolarise to 




4.2.3 Large variation in estimated reversal potential of hyperpolarisations 
The amplitude of the hyperpolarisations decreased as the holding membrane 
potential depolarised. This was seen for all hyperpolarising responses in ependymal 
cells and CSFcCs. In some examples, the response was seen to pass the reversal 
potential for that cell and show a depolarisation (Figure 4.3 Cell 8). However, unlike 
with the depolarising responses there was little correlation between the reversal 
potentials for the different cells (Figure 4.3), with reversal potentials ranging from -
78.9 mV to + 106.3 mV. This value does represent reversal potentials of 
hyperpolarising responses from all cell types which hyperpolarise to ATP, however 
there was no observable correlation between the cell type producing the 




Figure 4.3 Reversal potential of hyperpolarising response to ATP 
Reversal potential for a number of cells including ependymal cells adjusted for the 
liquid junction potential (cell 6), CSFcCs (cells 2 and 7) and tanycytes (cells 4, 5 and 
8) and cells that couldn’t be identified (cells 1 and 3) are estimated based on the 
amplitude of the hyperpolarisation to 300 μM ATP (black bars) at a range of holding 
membrane potentials. Beneath 2 example traces are shown with responses reducing 
in amplitude as the membrane potential of the cells is depolarised and in the second 
example, this passes the reversal potential and a hyperpolarisation is produced in 
response to ATP application. 
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4.2.4 Responses of Tanycyte-like cells to ATP  
A population of cells (n = 3) were identified which bore similarity to cells previously 
described as tanycytes (Rafols and Goshgarian, 1985; Meletis et al., 2008), generally 
regarded as a subpopulation of ependymal cells (Bruni and Reddy, 1987). These 
cells had ependymal cell-like electrophysiological profiles but possessed a basal 
process leading away from the central canal (Figure 4.4 A, B and C). These 
processes were clearly visible in the fluorescent imaging of the rhodamine filled cells 
(Figures 4.4 Aii, Bii and Cii), whilst no apical processes were visible. Tanycyte-like 
cells responded to local application of ATP with a hyperpolarisation, similar to those 
seen in both ependymal cells and hyperpolarising CSFcCs. The hyperpolarisations of 
ependymal cells and tanycyte-like cells were compared to examine if the responses 
to ATP were likely to be caused by the same mechanisms. The amplitude of 
responses for tanycyte-like cells was -2.84 ± 0.43 mV compared to -4.23 ± 0.91 mV 
for ependymal cells (p = 0.493; Figure 4.4 D) and was not significantly different. 
Neither was the duration of the response different (3.43 ± 0.39 s for tanycyte-like cells 
compared to 2.65 ± 0.51 s for ependymal cells; p = 0.262; Figure 4.4 E) nor the onset 
of the response to ATP (69.0 ± 31 ms for tanycyte-like cells and 31.0 ± 5.9 ms for 




Figure 4.4 Characteristics and responses to ATP of tanycyte-like cells 
Ai, ii-Ci, ii) Examples of the visualisations and fluorescent imaging showing processes 
leading away from the central canal but an absence of processes leading into the 
central canal and a location within the ependymal cell layer. Aiii-Ciii) Whole cell patch 
clamp recordings showing passive voltage responses to depolarising and 
hyperpolarising current pulses. Aiv-Civ) Responses of tanycyte-like cells to local 
application of 300 μM ATP (black bars). D-F) Comparisons of responses to ATP 
application between tanycyte-like cells and ependymal cells in terms of amplitude (D), 
duration (E) and onset (F) (amplitude data were not normally distributed as determined 
by Shapiro-Wilk test, so Mann-Whitney test was used to determine significance of 
difference, data for duration and onset were normally distributed so an independent 
measures t-test was used for these parameters). 
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4.2.3 Hyperpolarisations not affected by a range of antagonists 
The similarities in characteristics of the hyperpolarising responses to ATP have been 
demonstrated between ependymal cells (including tanycyte-like cells) and CSFcCs 
(see section 4.2.2). Due to this similarity, the hyperpolarising responses have been 
considered as a similar population for the purposes of antagonist assessment. No 
significant effect was observed with any of the antagonists applied to the 
hyperpolarising responses (Figure 4.5 A). To ensure that there was no effect limited 
to the responses of one cell type which might be masked in statistical analysis by 
examples from the other cell types, individual recordings were examined for a 
reduction of hyperpolarisation amplitude followed by a recovery of response 
amplitude, however none of these responses were seen in any of the cell types with 
any of the antagonists used.  
Suramin (Figure 4.5 B), the P2X3 and P2X2/3 antagonist A-317491 (Figure 4.5 C), 
apamin (Figure 4.5 D), 2-APB (Figure 4.5 E), PPADS (Figure 4.5 F), DPCPX (Figure 
4.5 G), TEA (Figure 4.5 H), bicuculline (Figure 4.5 I), niflumic acid (Figure 4.5 J), the 
gap junction blocker, 18β-glycyrrhetinic acid (Figure 4.5 K) all did not have any 
significant effect on the amplitude of the hyperpolarisations to ATP seen in 

















Suramin 50 μM  
Broad spectrum antagonist of P2X and 
P2Y receptors at different potencies 
(North and Jarvis, 2013) 
-0.79 ± 2.71 -2.87 ± 2.49 15 15 0.842 
A-317491 1 μM  Selective P2X3  and P2X2/3 antagonist -5.21 ± 2.14 -4.68 ± 2.19 23 20 0.131 
Apamin 100 nM 
Ca2+-activated K+ channel (SK channel) 
blocker   
-6.45 ± 1.78 -7.11 ± 1.82 16 16 0.605 
2-APB 100 μM  
TRP channel antagonist at TRP 
1,3,5,6,V6,M3,M7,M8 and P2 and SOC 
antagonist 
-3.58 ± 0.83 -4.47 ± 1.09 10 10 0.799 
PPADS 10 μM  P2X antagonist -5.80 ± 2.42 -6.39 ± 2.77 5 4 0.500 
DPCPX 500 nM  Adenosine A1 antagonist -4.61 ± 0.89 -4.23 ± 0.85 15 11 0.088 
TEA 500 μM  
K+ channel blocker (and nAChr 
antagonist) 
-6.94 ± 1.93 -7.28 ± 2.00 13 12 0.157 
Bicuculline 50 μM  
GABAA antagonist (and Ca2+-activated K+ 
channel blocker) 
-6.15 ± 2.44 -5.94 ± 2.44 5 4 0.345 
Niflumic Acid 100 μM  
Chloride channel antagonist, COX 2 
antagonist and TRPA1 activator 




100 μM  Gap junction inhibiter  -15.98 ± 4.01 -12.34 ± 3.62 15 12 0.280 
Table 4.1 Antagonists applied to hyperpolarising responses elicited by 300 μM ATP; further information regarding source 







Figure 4.5 Antagonists applied to hyperpolarisations to ATP did not reduce the amplitude of the response 
A) Bar chart showing the average amplitude of hyperpolarisations to 300 μM ATP in ependymal cells and hyperpolarising 
CSFcCs after application of antagonists compared to the amplitude of hyperpolarisation prior to antagonist application. B-K) 
50 μM suramin (B), 1 μM A-317491 (C), 100 nM apamin (D), 100 μM 2-ABP (E), 10 μM PPADS (F), 500 μM DPCPX (G), 
500 μM TEA (H), 50 μM bicuculline (I), 100 μM niflumic acid (J) and 100 μM 18β-glycyrrhetinic acid were bath applied (K) 
were applied to hyperpolarisations induced by 300 μM ATP (black bars); control trace (black), trace with antagonist (red), 








4.2.4 UTP application, but not ADP or aCSF produces similar 
hyperpolarisations 
To determine whether the hyperpolarisations are due to just flow of the solution from 
the electrode, rather than activation of a specific receptor, the solution used to 
dissolve the drugs, artificial cerebrospinal fluid (aCSF), was locally applied using the 
same Picopump apparatus and settings as those used when the ATP had been 
applied previously. This produced no clear and consistent response in ependymal 
cells or CSFcC 1s or 2s (-0.0817 ± 0.833 mV; n = 6; N = 5) (Figure 4.6 A). Other 
nucleotides, UTP and ADP were also applied using the Picopump apparatus. UTP, 
but not ADP, was able to replicate the hyperpolarisations seen with ATP. 300 μM 
ADP did not produce any clear response in ependymal cells and CSFcC 1s 
(-0.503 ± 0.633 mV; n = 4; N = 2) (Figure 4.6 B).  
Conversely, UTP was able to produce a replicable hyperpolarisation in all the cells 
types that ATP is frequently able to produce a hyperpolarisation, namely, CSFcC 1s 
(Figure 4.6 C), ependymal cells (Figure 4.6 D) and tanycyte-like cells (Figure 4.6 E). 
However when UTP was applied to spiking CSFcCs which are likely to depolarise to 
ATP, UTP did not produce a response (Figure 4.6 F). The proportion of cells of each 
cell type that hyperpolarised to UTP is similar to the proportions of cells that 
hyperpolarise to ATP, particularly in that a smaller proportion of CSFcCs 
hyperpolarise to UTP than the proportion of ependymal cells that hyperpolarise to 
UTP (Figure 4.7 E). This was a similar pattern to that seen with ATP 
hyperpolarisations, however unlike with ATP application, no depolarisation was seen 
in the cells that did not hyperpolarise to UTP (Figure 4.6 F).  
The characteristics of the hyperpolarisations caused by local application of UTP were 
compared with those of hyperpolarisations caused by ATP across all the cell types 
that show hyperpolarisations to these agonists. With respect to the onset of 
response, there was no significant difference between those caused by UTP and 
those caused by ATP (25.6 ± 4.27 ms (n = 8; N = 5) and 36.1 ± 4.71 ms (n = 38; 
N = 36) respectively; p = 0.183; Figure 4.7 A). Similarly with duration, there was no 
significant difference between the responses (2.21 ± 0.24 s for UTP and 2.32 ± 0.21 
for ATP; p = 0.483; Figure 4.7 B). There was however a difference in the amplitude of 
the response, with the hyperpolarisations to local application of UTP having a 
significantly smaller amplitude compared to those caused by local application of UTP 
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(-1.88 ± 0.37 mV for UTP and -6.43 ± 0.94 mV for ATP; p = 0.004; Figure 4.7 C). 
Unlike with the difference in hyperpolarisation amplitude between CSFcCs and 
ependymal cells, the difference between hyperpolarisations caused by ATP and 
those caused by UTP did not disappear when amplitudes were considered as 
amplitude/IR (-0.022 ± 0.007 mV/MΩ for UTP and -0.091 ± 0.018 mV/MΩ for 






Figure 4.6 UTP but not ADP or aCSF produces hyperpolarisations in 
ependymal cells and CSFcCs 
Ai - Fi) Cells characterised by voltage responses to current injection of +50 and -
50 pA. Aii) Local puff application of aCSF (black bar) did not produce a 
hyperpolarisation, shown in an ependymal cell. Bii) 300 μM ADP (black bar) did not 
produce any change in membrane potential exemplified in a CSFcC 1. Cii, Dii, Eii) 
300 μM UTP (black bars) produced hyperpolarisations in some CSFcCs (C), 
ependymal cells (D) and tanycyte-like cells (E). Fii) 300 μM UTP (black bar) did not 




Figure 4.7 Comparison of the hyperpolarisations produced by ATP and UTP 
 
A-D) Comparisons of the hyperpolarisations produced by UTP to those produced by 
ATP in terms of onset (A), duration (B), amplitude (C), and amplitude/IR (D). Duration 
data were normally distributed (as determined by Shapiro-Wilk test) so were 
assessed by independent samples t-test, all other data were not normally distributed 
so were assessed by Mann-Whitney tests; ** = p < 0.01, * = p < 0.05. E) Proportion of 
each cell type which responded to local application of either ATP (darker bars) or 





4.2.5 Ap4A produces depolarisations in cells that hyperpolarise to ATP 
In addition to local application of ATP, a stable analogue of ATP was also applied 
Ap4A could be applied in the bath solution as it was not as readily broken down by 
ecto-ATPases present in the extracellular solution. This allowed Ap4A to be applied 
to the same cells to which ATP was applied. Ap4A (100 μM) produced a small 
depolarisation in ependymal cells, tanycyte-like cells and CSFcCs (2.012 ± 0.47 mV; 
n = 15; N = 11) (Figures 4.8 A, B and C respectively). These cells which depolarised 
to Ap4A responded to local application of ATP with a hyperpolarisation. Although the 
depolarisation to Ap4A is small in magnitude it is a significant depolarisation which 
returns to baseline levels after washout of Ap4A (Figure 4.8 D; p < 0.001). The 
depolarisation caused by Ap4A application is eliminated by the application of 50 μM 
suramin, even with longer Ap4A application used to ensure that a longer application 




Figure 4.8 Bath applied Ap4A produced small depolarisations in cells that hyperpolarised to local application of 
ATP 
A-C) 100 μM Ap4A produced small depolarisations in ependymal cells (A), tanycyte-like cells (B; tanycytic process indicated 
by the arrow) and CSFcCs (C) which produced a hyperpolarisation in response to local application of 300 μM ATP 
(unlabelled black bars). D) This depolarisation was small but was a significant as assessed by repeated measures ANOVA; 




4.3.1 The response of ependymal cells to local application of ATP 
ATP produces hyperpolarising responses in ependymal cells, which are similar to 
those produced by a subset of CSFcCs with respect to onset, duration and also 
amplitude once the differences in IR are accounted for. The CSFcCs that are more 
likely to produce a similar response to ATP as ependymal cells are the non-spiking 
CSFcC 1s. This is not the only case where the response to neurotransmitters of 
CSFcC 1s bears more similarity to those of ependymal cells than those of spiking 
CSFcCs. In the response of these cell groups to acetylcholine, CSFcC 1s bear more 
similarity to ependymal cells than to CSFcC 2s and 3s. CSFcC 1s and ependymal 
cells have considerable contribution from α7*nAChRs while CSFcC 2s and 3s have 
very minimal α7*nAChRs contribution (Corns et al., 2015).  
 The hyperpolarisations caused by ATP in ependymal cells and the hyperpolarising 
population of CSFcCs were not affected by a range of antagonists. The fact that they 
were not antagonised by either suramin or PPADS makes it unlikely that the ATP is 
acting on P2X receptors as although these antagonists are variably potent on 
different receptor subtypes, only the P2X4 receptor is not strongly antagonised by at 
least one of these antagonists (Charlton et al., 1996; Lambrecht, 2000; Kennedy, 
2005). P2X4 receptors have been observed in the progeny of spinal cord ependymal 
cells (Gómez-Villafuertes et al., 2015), although expression in vivo has not been 
determined. After spinal cord injury P2X4 is present in microglia but not in sham-
operated animals (Lu et al., 2013) and has a role in the development of tactile 
allodynia (Tsuda et al., 2003). Whilst it is not possible to rule out involvement of P2X4 
in the production of hyperpolarising responses to ATP it is an unlikely channel to 
cause hyperpolarisations as, similar to P2X2 receptors, P2X4 is a non-selective cation 
channel (Shieh et al., 2006) and is therefore most likely to cause a depolarisation. 
The other P2X receptor that has been identified and been shown to be functionally 
active in ependymal cells is P2X7 (Marichal et al., 2016). It is unlikely that P2X7 are 
the receptors responsible for the hyperpolarisations seen in ependymal cells with 
application of ATP for two reasons. Firstly P2X7 is a non-selective cation channel 
(Rassendren et al., 1997; Chessell et al., 1998) similar to the other P2X receptors 
and is therefore most likely to cause a depolarisation upon channel opening. 
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Secondly, the P2X7 receptor has relatively low affinity for ATP compared to the other 
P2X receptors (Bartlett et al., 2014), such that previous experiments which puff 
applied ATP used 1s applications of 1 mM ATP to activate P2X7 receptors (Marichal 
et al., 2016). These indications that the hyperpolarisations were independent of P2X7 
were supported by the fact that the depolarising responses mediated by P2X7 
observed previously could be replicated by used of the same puffing parameters 
used in that study.  
ATP is readily broken down by ecto-ATPases, which dephosphorylate ATP to ADP to 
AMP and then to adenosine (Fuentes and Palomo, 2015). It is therefore a possibility 
that the responses seen with application of ATP did not actually use ATP as the 
agonist and instead, ATP was dephosphorylated and one of the products of this 
acted as the agonist. However, the rapid onset of response and time to peak 
response of the hyperpolarisations make this an unlikely method of action. 
Additionally, when ADP was applied no hyperpolarisations were seen. As ADP is a 
step on the dephosphorylation pathway of ATP, the lack of response with ADP 
indicates that neither ADP nor any of the downstream produces, namely AMP or 
adenosine, were the mediators of the hyperpolarising response. This was supported 
by the lack of effect of the adenosine A1 receptor antagonist DPCPX on the 
hyperpolarisations elicited by ATP.  
Another possible cause of the hyperpolarisations to local application of ATP could be 
the pressure wave used to release the ATP locally, rather than the ATP itself. There 
are a number of pressure and stretch sensitive channels which respond to changes in 
flow and pressure within a tissue or fluid such as the CSF. One such channel is 
TMEM16A/anoctamin 1. This is a calcium-activated chloride channel which, whilst it 
has not been identified around the central canal, has been shown to detect stretch 
within the cerebral arteries (Bulley et al., 2012). However, the response produced by 
this stimulation is a depolarisation that is sensitive to 2-APB (Viitanen et al., 2013; 
Zhu et al., 2015), making it unlikely to be the cause of the 2-APB-insensitive 
hyperpolarisations seen with ATP. This conclusion is supported by lack of response 
when aCSF was locally applied in the same manner to ATP to replicate the pressure 
wave without any changes to the composition of the solution around the cells.  
2-APB is also an antagonist of the intracellular signalling molecule IP3, which triggers 
release of calcium from intracellular stores (Saleem et al., 2014). IP3 is a second 
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messenger in the Gq/11 signalling pathway via the Gα protein. The lack of inhibition of 
the hyperpolarisations with 2-APB indicates that IP3 and therefore the Gαq/11 is not 
involved in this response. It is worth noting that the Gq/11 signalling  pathway could still 
be involved, via the Gβγ proteins, which are often play a role in interactions with ion 
channels and other intracellular proteins (Kahanovitch et al., 2014; Shymanets et al., 
2015).  
Other antagonists that did not affect the amplitude of the hyperpolarisations to ATP 
include the non-selective potassium channel blocker TEA (Liu et al., 2014), which 
also acts as a competitive inhibitor at nicotinic acetylcholine receptors (Akk and 
Steinbach, 2003). The GABAA antagonist bicuculline (Braden et al., 2015) and 
blocker of calcium-activated potassium channel (Khawaled et al., 1999) also did not 
affect the hyperpolarisations. Similarly, the calcium-activated chloride channel blocker 
niflumic acid (Criddle et al., 1996) did not antagonise the receptors responsible for 
the hyperpolarising response to ATP. Niflumic acid also acts as a blocker of GABAA 
receptors (Sinkkonen et al., 2003), NMDA channels (Lerma and Martín del Río, 1992) 
and T-type calcium channels (Balderas et al., 2012). These results suggest that none 
of these channels are involved in the production of the hyperpolarising response to 
ATP by ependymal cells and CSFcCs. Furthermore, the lack of change in the 
amplitude of the hyperpolarisations with application of the gap junction blocker 18β-
glycyrrhetinic acid indicates that the hyperpolarisation is not reliant on the gap 
junction-coupling of the ependymal cells. This is also supported by the fact that 
hyperpolarisations are also seen in some CSFcC 2s and 3s, whereas no gap 
junction-coupling is observed in these cell types (see chapter 3 for discussion of this).  
4.3.2 The response of ependymal cells to local application of UTP 
The signalling of UTP in addition to ATP has been investigated for a number of 
reasons. The first is that UTP has been hypothesised to be released at sites of injury 
in a similar way to that which ATP is released (Wang et al., 2004; Ceruti et al., 2009). 
The second reason is that metabotropic P2Y receptors have been identified on 
ependymal cells, some of which respond to UTP. The progeny of ependymal cells 
which have been grown in culture are termed ependymal spinal cord-derived 
stem/progenitor cells (epSPCs). Within these cells, metabotropic P2Y receptors have 
been identified, in addition to ionotropic P2X receptors (Gómez-Villafuertes et al., 
2015). Both P2Y1 and P2Y4 have been identified in epSPCs and they are differentially 
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affected by spinal cord injury, with epSPCs from an injured animal (epSPCis) showing 
a downregulation of P2Y1 receptors and P2Y4 receptors. Whilst some P2Y receptors 
are coupled to inhibitory Gαi proteins, both P2Y1 and P2Y4 usually couple to Gq/11 
proteins which release calcium from internal stores and would therefore depolarise 
the cell (Gómez-Villafuertes et al., 2015).  
Local application of UTP produced hyperpolarisations in ependymal cells and 
CSFcCs that were similar to those produced by application of ATP, except with lower 
amplitude of response. Despite the presence of ectonucleoside-diphosphokinases on 
some cells which can act to convert dinucleotides to trinucleotides (Harden et al., 
1998), the application of ADP did not produce any response. The short time course of 
the local application puff of ADP was likely to have helped ensure that there was not 
significant phosphorylation of ADP.  
P2X receptors are not activated by UTP or ADP (Puchałowicz et al., 2014; Jacobson 
and Müller, 2016), further suggesting that P2X receptors are not responsible for the 
hyperpolarisations in response to either ATP or UTP. Unlike P2X receptors, 
metabotropic P2Y receptors are activated by a wider range of native agonists 
including ATP, ADP, UTP, UDP, and UDP-glucose (Jacobson and Müller, 2016). 
Whilst not all P2Y receptors respond to all of these native agonists, P2Y2 and P2Y4 
respond to both ATP and UTP (Wildman et al., 2003; Lechner and Boehm, 2004).  
P2Y2 and P2Y4 mainly couple to pertussis toxin resistant Gq/11 proteins (Köles et al., 
2008; von Kügelgen and Hoffmann, 2016) but there are reports of individual 
receptors also coupling to pertussis toxin resistant  Gi/o proteins (Erb et al., 2006; 
Rossi et al., 2007). However in none of these examples does the combined coupling 
produce a hyperpolarisation, instead using the Go protein to increase intracellular 
calcium levels (Mosbacher et al., 1998; Bagchi et al., 2005).  
P2Y receptors interact with a number of intracellular proteins including the 
MAPK/extracellular signal-regulated kinase pathway (Soltoff et al., 1998; Sellers et 
al., 2001), integrins in platelets (Erb et al., 2001; Hollopeter et al., 2001; Bagchi et al., 
2005) and tyrosine kinases (Liu et al., 2004; Seye et al., 2004). However the results 
from this study indicated that the latency to onset was shorter for the hyperpolarising 
response than it was for the depolarising responses. This makes it unlikely that 
interactions with these or other cellular macromolecules are responsible for the rapid 
hyperpolarisations seen in ependymal cells and predominantly non-spiking CSFcCs.  
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P2Y receptors can also interact with ion channels. They have been observed to 
interact with voltage-sensitive sodium channels (Baker, 2005), voltage-activated 
calcium channels (Filippov et al., 2003) and glutamate receptors (Wirkner et al., 
2007). Most significantly for the data reported here, P2Y2 and P2Y4 have been 
reported to interact with potassium channels (Lechner and Boehm, 2004; Köles et al., 
2008). Specifically, both ATP (Lee et al., 2014b) and UTP (Lee et al., 2015) have 
been shown to produce outward currents and hyperpolarisation in PDGFRα-positive 
interstitial cells due to the activation of small-conductance Ca2+-activated K+ channels 
via P2Y2 or P2Y4 receptors. In contrast to the hyperpolarisations presented in this 
study, the hyperpolarisations in PDGFRα-positive cells were inhibited by the SK2 
channel blocker apamin (300 nM) and the broad-spectrum purinergic antagonist 
suramin (30 μM). A lower concentration of apamin (100 nM) but a comparable 
concentration of suramin (50 μM) failed to reduce the amplitude of the 
hyperpolarisations seen in ependymal cells and CSFcCs. However, it is worth noting 
that P2Y4 is the only P2Y receptor not antagonised by suramin (Köles et al., 2008), 
which would suggest that the channels activated in the PDGFRα-positive interstitial 
cells were P2Y2 channels. The inward currents induced in PDGFRα-positive cells 
reversed at approximately 0 mV, which is within, the large range of reversal potentials 
estimated for the hyperpolarising responses of cells around the central canal. It is 
therefore a possibility that the hyperpolarisations seen in ependymal cells and 
CSFcCs with application of ATP or UTP are mediated through P2Y4 receptors, using 
similar intracellular mechanisms as observed with P2Y2 in PDGFRα-positive 
interstitial cells, potentially via SK1 channels, although as SK channels are 
responsible for the slow after-hyperpolarisation a slower onset to response might be 
expected.  
There are other UTP-sensitive receptors within the spinal cord ependymal cells, such 
as GPR17 (Ceruti et al., 2009). GPR17 is an orphan receptor highly expressed in 
organs during periods of ischemic damage (Köles et al., 2008). It is Gi/o coupled 
(Simon et al., 2016) but has not been shown to respond to ATP so is unlikely to be 
responsible for the hyperpolarisations seen in response to local application of ATP. 
Due to the complexity of P2Y channels the exact conformation and identity would 
need further investigation, however the sensitivity to ATP and UTP and insensitivity to 





4.3.3 The response of ependymal cells to bath application of Ap4A 
Ependymal cells and CSFcCs that hyperpolarised in response to local application of 
ATP were shown to produce a small depolarisation in response to bath application of 
Ap4A. Diadenosine polyphosphates, such as Ap4A, are naturally occurring 
nucleotidic compounds that are linked to the proliferative state of the cell (Rapaport 
and Zamecnik, 1976; Pintor et al., 2000) as it is synthesised in response to DNA 
damage and blocks further DNA replication (Marriott et al., 2015). Ap4A is able to be 
bath applied as it is not broken down by extracellular nucleotidase enzymes and 
there are fewer, more localised enzymes that do degrade it (Andersson, 1989). 
However Ap4A does not act on all purinergic receptors with the same potency as 
ATP. Ap4A can activate P2Y1 (Schachter et al., 1996), P2Y2 (Lazarowski et al., 
1995), P2Y4 (Communi et al., 1996) and P2X1 (Wildman et al., 1999), P2X2 (Pintor et 
al., 1996), P2X3 (Wildman et al., 1999), P2X4 (Wildman et al., 1999). Of interest is the 
fact that at the P2Y4 receptor, Ap4A has an EC50 value of ~5 μM but the maximal 
response size is 25 % of the maximal response size to UTP activation (Communi et 
al., 1996). Despite both ATP and Ap4A producing responses in ependymal cells, the 
responses they produce are very different. ATP produces a rapid hyperpolarisation, 
whilst Ap4A produces a slow onset depolarisation. It may be that these agonists are 
activating different receptors, or it could be that they are activating the same receptor, 
possibly P2Y4, but activating different mechanisms internal mechanisms: outwards 
currents via potassium channels for the ATP and UTP responses and release of 
calcium from intracellular stores for the Ap4A response.  
4.3.4 Tanycyte-like cells 
In this study, tanycyte-like cells were differentiated on the basis of basal processes 
leading away from the cell and presumed to be terminating on blood vessels as 
previously reported (Rafols and Goshgarian, 1985). The reporting of tanycyte-like 
cells in studies of this area is very variable, suggesting that they may be identified as 
other cell types in some studies. While some papers looking at rat spinal cord tissue 
discuss ependymal cells and tanycyte-like cells (Mothe and Tator, 2005), other 
studies in murine spinal cord, discuss cuboidal ependymal cells, with no processes, 
radial ependymal cells, which are described as having a long basal process and 
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reside in the dorsal and ventral poles, and tanycyte-like cells, which were 
differentiated by their darker cytoplasm (Meletis et al., 2008). Radial ependymal cells 
had intermediary characteristics between ependymal cells and tanycyte-like cells in 
aspects such as the shape of the nucleus under electron microscopy. In other studies 
of murine spinal cord, astrocytes and some ependymal cells were identified to have 
processes, without separation of ependymal subgroups on the basis of processes 
(Hamilton et al., 2009), and in other studies GFAP-positive cells with radial processes 
have been identified as radial glia (Sabourin et al., 2009). It has also been suggested 
that GFAP-positive dorsal cells with basal processes which have previously been 
identified as astrocytes (Alfaro‐Cervello et al., 2012) may be a subtype of tanycyte 
(Hugnot and Franzen, 2011). In this study, there were no differences in the 
responses to ATP, UTP or Ap4A of ependymal cells without any basal processes, 
and cells with basal processes and ependymal electrophysiological characteristics 
(identified as tanycyte-like cells). Therefore they were grouped as ependymal cells for 
comparisons between ependymal cells and CSFcCs and this lack of differences 
suggests that tanycyte-like cells may be a subtype of ependymal cells.  
4.3.4 Conclusions 
Ependymal cells and tanycyte-like cells were identified by their lack of apical 
processes and square, passive voltage responses to current injection. These cells, 
collectively referred to as ependymal cells, responded to 300 μM ATP in a similar way 
to the hyperpolarising population of CSFcCs, however with smaller amplitude due to 
their smaller input resistance. Once this difference in IR was accounted for, the 
responses to 300 μM ATP were identical. This response was separate from the P2X7-
mediated response elicited by higher concentration ATP application for a longer time 
period, as observed previously (Marichal et al., 2016). The hyperpolarisations to ATP 
could be replicated by application of UTP, but not ADP or aCSF, indicating that they 
may be mediated by a P2Y receptor sensitive to both ATP and UTP, but are unlikely 
to be mediated by a dephosphorylation product of ATP or the pressure wave of 
application. Ap4A produces a small depolarisation in the cells that produce a 
hyperpolarisation to ATP and UTP, either via alternative receptors or via the same 














In a physiological state, the ependymal stem cells show very low levels of 
proliferation, predominantly self-renewing to produce more ependymal cells 
(Barnabé-Heider et al., 2010). Traumatic spinal cord injuries, but not demyelinating 
lesions, dramatically increase their proliferation rate (Cizkova et al., 2009; Moreno-
Manzano et al., 2009; Lacroix et al., 2014). The proliferation seen after SCI is 
predominantly asymmetric division as shown by the plane of cleavage relative to the 
luminal surface of the cell (Johansson et al., 1999). The proliferation rate of 
ependymal cells can also be increased by stimulation with growth factors such as 
epidermal growth factor (EGF) + fibroblast growth factor 2 (FGF2) (Kojima and Tator, 
2000) and EGF+FGF2+heparin, even when injected into the 4th ventricle (Martens et 
al., 2002). Levels of proliferation can also be affected by altering neurotransmitter 
signalling, with potentiation of cholinergic signalling increasing cell proliferation with 
both in organotypic slice culture and in vivo (Corns et al., 2015). This increase in 
proliferation with increased cholinergic signalling was seen in the central canal 
region, where ependymal cells were the dividing cells, and in the rest of the grey and 
white matter, where the cells replicating expressed markers for oligodendrocyte 
precursors. The increase in proliferation is accompanied by a number of other 
changes after spinal cord injury, including an increase in nestin expression in the 
ependymal cells with processes leading dorsal and away from the cc, and later 
predominantly in the white matter, where it was accompanied by GFAP staining 
(Shibuya et al., 2002; Mothe and Tator, 2005).  
Once the cells in the ependymal region have proliferated, they then migrate out away 
from the central canal. By 3 days after a minimal spinal cord injury, the newly-
proliferated cells from the central canal region have migrated 70 μm away from the 
central canal (Mothe and Tator, 2005). These cells migrate in dorsal and ventral 
directions, showing internalisation of the ATF3 protein into the nucleus during 
migration (Mladinic et al., 2014), and migrate to the site of injury (Johansson et al., 
1999; Meletis et al., 2008). Despite increases in proliferation in astrocytes and 
oligodendrocyte precursors, oligodendrocyte precursors do not migrate to the injury 
site, whilst astrocytes migrate to the periphery of the injury, and ependymal cells 
migrate to the centre of the injury site (Barnabé-Heider et al., 2010). This migration to 
the injury site was not seen when a minimal injury model was used (Mothe and Tator, 
2005). In the minimal injury model, very limited cell death was observed from the 
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injury site, with only a few apoptotic cells in the white matter. It may be that not 
enough of the attractant chemicals were released for the cells to migrate towards.  
After spinal cord injury, ATP is released initially by the cells undergoing cell death and 
then by perilesional cells extending the raised extracellular ATP levels for over 6 h 
(Wang et al., 2004). It is therefore hypothesised that the increased levels of 
purinergic signalling induced by this increased levels of extracellular ATP could play a 
role in the modulation of ependymal cell proliferation or the directional migration of 
newly-proliferated ependymal cells following spinal cord injury. 
5.1.1 Hypothesis 
The hypotheses tested in this chapter are that: 
1. Modulation of purinergic signalling will have an effect on proliferation 
2. Modulation of purinergic signalling will have an effect on the migration of newly 
proliferated cells. 
5.1.2 Aims 
The aims of this chapter are to determine the longer term effects of purinergic 
signalling. This will involve the use of proliferation preparations and culture 
preparations to investigate the effects of modulation of purinergic signalling on the 






5.2.1 Modulation of purinergic signalling does not alter number of newly-
proliferated cells within each slice 
The effect of modulation of purinergic signalling on proliferation rate was assessed 
using a preparation where slices were held in aCSF in the presence of EdU for 4 
hours. After fixation and immunohistochemistry for EdU, the slices were visualised 
and schematic representations made of each slice as the EdU positive cells were on 
a number of visual planes within the 300 μm slices. As such, the slices couldn’t be 
imaged in a way that either captured all the EdU positive cells in one image or in a 
way that took multiple images without capturing the same cell multiple times. An 
image taken at one plane of depth missed many cells which could be accurately 
marked on the corresponding schematic representation (Figure 5.1 A). There were 
quite variable numbers of EdU positive cells between the slices, with EdU positive 
cells present throughout the slice (Figure 5.1 B-D). Despite the widespread nature of 
the newly proliferating cells, there were several trends observed. There were 
relatively high levels of newly proliferated cells within the white matter in all 
experimental conditions. There were also many examples of paired cells where they 
were positioned very close to each other and sometimes distant from other cells 





A) Example of image from which the schematic representation adjacent was 
produced; scale bar 300 μm. B-D) Example schematic representations of the EdU+ 
cells within a slice, from each of the three conditions: control condition where EdU 
alone was applied (C), condition where 50 μM ARL 67125 (ecto-ATPase inhibitor) 
was applied with EdU (B) and the condition with 200 μM suramin (purinergic 










The number of EdU positive cells within each region of the spinal cord were then 
manually counted using the schematic representations. When the whole slice was 
counted, there was no significant difference between the control condition (n = 36; 
N = 6) and either the condition where purinergic signalling was increased by 
increasing the amount of extracellular ATP (by inhibition of its breakdown using ARL 
67125; n = 21; N = 5) or where the levels of purinergic signalling were decreased by 
use of the antagonist suramin (n = 26; N = 6) (ARL: 176.2 ± 25.0 cells, control: 176.0 
± 16.2 cells, suramin: 177.4 ± 19.0 cells; p = 0.999; Figure 5.2 A). This was the same 
when the grey matter including lamina X and the central canal region was counted 
(ARL: 53.3 ± 8.9 cells, control: 56.1 ± 6.0 cells, suramin: 54.3 ± 6.7 cells; p = 0.863; 
Figure 5.2 B). The numbers of newly-proliferated cells in the central canal region and 
lamina X were counted and again there was no significant difference between the 
conditions (ARL: 2.95 ± 0.51 cells, control: 2.58 ± 0.39 cells, suramin: 3.96 ± 0.71 
cells; p = 0.161; Figure 5.2 C). However, when only cells within the central canal 
region were counted, the number of cells in the suramin condition was significantly 
higher than in the control and the ARL condition (ARL: 0.76 ± 0.2 cells, control: 0.53 ± 
0.13 cells, suramin: 1.54 ± 0.33 cells; p = 0.07; Figure 5.2 D). When the EdU positive 
cells in the white matter alone were counted, there was once again no effect of 
purinergic modulation (ARL: 66.7 ± 7.0 cells, control: 61.22 ± 4.3 cells, suramin: 64.8 




Aii-Eii) Comparison of numbers of proliferated cells as determined by detection of 
EdU-incorporation into the DNA between the control condition and the conditions with 
altered purinergic signalling. Ai-Ei) Comparisons split by spinal cord region counted, 
with counted regions indicated by shading on schematic representation of the spinal 
cord. Areas counted were the whole slice (A), the grey matter including lamina X and 
CC (B), lamina X and CC (C), CC (D) and the white matter (E). For all spinal cord  
regions, counts were not normally distributed (as determined by Shapiro-Wilk) so 
comparisons used Kurskal-Wallis test to determine significance of difference.  
Figure 5.2 Suramin affects number of EdU+ cells near CC 
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5.2.2 Application of suramin or ARL 67125 affects the location of the newly-
proliferated cells 
To further investigate the difference seen in number of newly proliferated cells around 
the central canal with decreased purinergic signalling, the next experiment used 5 
day organotypic spinal cord slice cultures, with the same modulators of purinergic 
signalling. In these experiments, the EdU positive cells could not be counted, as there 
were considerably more EdU positive cells due to the fact that the slices were in the 
presence of EdU for 3 days. This higher amount of EdU+ cells meant that there was 
frequent overlap between cells (Figure 5.4 B), especially around the central canal, 
making counting particularly difficult, either by hand or using image analysis 
packages. Therefore, the slices were imaged and the images processed to remove 
background fluorescence (Figure 5.3 Ai, Bi and Ci). The images were then analysed 
as a function of fluorescence intensity (in arbitrary units (A.U.)) laterally from the 
midpoint of the central canal out to the edge of the slice, for a 300 pixel (256 μm) strip 
at the level of the central canal (Figure 5.3 Aii, Bii and Cii). The value of the 
fluorescence intensity was taken as a representation of the number of EdU+ cells at 
that position in the slice. Within each condition, the data for each distance point away 
from the midpoint of the central canal was averaged, normalised to total to the same 
overall fluorescence (as equal levels of proliferation were demonstrated in both the 
proliferation preparation (section 5.2.1) and in culture experiments (section 5.2.3)) 
and then used to produce a running average (Figure 5.3 D). This showed that when 
the level of purinergic signalling was reduced by use of the purinergic antagonist 
suramin (n = 26; N = 10), there was a higher level of fluorescence intensity, and 
therefore likely more EdU+ cells, closer to the central canal relative to the rest of the 
slice, compared with control (n = 26; N = 11;Figure 5.4 B and C). This was a similar 
pattern to that observed with suramin in the proliferation experiments (see section 
5.2.1), with more cells in the central canal area. Additionally, the running averages 
indicate that the opposite occurred with the ecto-ATPase ARL 67156 (n = 23; N = 7), 
where there were fewer cells in the central canal, relative to the rest of the slice, 
compared to both the control condition and the suramin condition (Figure 5.4 A).  
One pattern in the locations of the newly proliferated cells that was observed often in 
the ARL and control conditions was a star shape pattern around the central canal 
(n = 5), with cells appearing to be placed on radial lines coming away from the central 
canal (Figure 5.4 D). Along these radial lines cells were elongated along the axis of 
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each radial line. This pattern was not seen in suramin conditions, where the central 
canal was often quite clearly defined, with a large proportion of cells contained within 
the CC (Figure 5.4 C). Another pattern occasionally observed in every condition was 





Ai, Bi and Ci) Example images of cultures slices from each of the 3 conditions, ARL 
(A), control (B) and suramin (C) with the area analysed in Aii, Bii and Cii represented 
by the coloured box; EdU in red; scale bars = 200 μm. Aii, Bii and Cii) Fluorescence 
intensity as a function of lateral distance away from the midpoint of the central canal 
with dashed line representing the average edge of the central canal ependymal cell 
layer (40.85 ± 2.56 μm). D) Normalised running average for each of the conditions.  
Figure 5.3 Application of suramin or ARL 67125 location of newly proliferated cells 
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Figure 5.4 Patterns observed in 5 day culture experiments 
A-C) Location of EdU+ cells around the central canal in ARL 67156 condition (incubated with 50 μM ARL 67156) (A), control 
condition (B) and suramin condition (incubated with 200 μM suramin) (C). D) A star-shaped pattern of EdU+ cells observed 
in a slice incubated with 50 μM ARL 67156 (arrows indicate prongs of starring). E) EdU+ cells concentrated along the 
midline of the spinal cord. Scale bars: 30 μm in A, B, C and Dii; 200 μm in Di and E.  
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5.2.3 Newly-proliferated cells migrate away from the central canal 
Organotypic slice cultures fixed at different time points after EdU application were 
used to assess movement of the newly proliferated cells. After a 4 hour incubation 
with EdU on day 3 of culturing, one set of control and ARL slices were fixed 
(Control (3) (n = 24; N = 5) and ARL (3) (n = 22; N = 4) respectively) with the other 
set returned to EdU-free media, for a further 2 days to be fixed on day 5 (Control (5) 
(n = 34; N = 7) and ARL (5) (n = 43; N = 7); Figure 5.5). After fixation the EdU 
containing cells were visualised using immunofluorescence and imaged (Figure 5.5 
Ai, Bi, Ci and Di). As with the previous experiment, fluorescence intensity images 
were produced for a 300 pixel (256 μm) strip (Figure 5.5 Aii, Bii, Cii and Dii).  
These data were then used to produce normalised running averages as done 
previously for the 5 day culture experiments (Figure 5.6 Ai). When the section of the 
data nearest the central canal was analysed (Figure 5.6 Aii), the relative location of 
the peaks of fluorescence intensity indicating the EdU-positive cells for each 
condition could be identified. Both conditions fixed on day 3 (Control (3) and ARL (3)) 
showed a higher proportion of the fluorescence intensity near the central canal than 
in conditions fixed on day 5 (Control (5) and ARL (5)). When the ARL conditions were 
compared to the corresponding control condition, of those fixed in day 3, immediately 
after EdU incubation, the slices also incubated in 50 μM ARL 67156 had a higher 
proportion of fluorescence intensity in the central canal region compared to the 
control condition. However, after the slices had been returned to an non-EdU-
containing medium for a further 2 days and fixed on day 5, the ARL (5) condition had 
a lower proportion of the fluorescence intensity and indicating a lower proportion of 
EdU-positive cells in the central canal region, compared to the control (5) condition.  
The numbers of cells were also counted for the lateral half of slice on the side of 
which the fluorescence analysis was done but the entire half slice not a strip as was 
used for the fluorescence analysis. This showed that there were significantly more 
cells in both the 5 day conditions, compared to the 3 day conditions (p = 0.03 for ARL 
(3) and ARL (5); and p = 0.17 for Control (3) and Control (5); Figure 5.6 B), but that 
there was no significant difference between either of the ARL conditions and their 
corresponding control condition (p = 0.524 for ARL (3) and Control (3); and p = 0.559 
for ARL (5) and Control (5). 
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Schematic protocol for the migration experiments and examples from each conditions 
of the experiment: Control 3 (A), ARL 3 (B), Control 5 (C) and ARL 5 (D). Ai, Bi, Ci 
and Di) Example images from each of the 4 conditions indicating the area assessed 
in the fluorescence analysis; red fluorescence indicates EdU; scale bars = 200 μm. 
Aii, Bii, Cii and Dii) Fluorescence intensity (in arbitrary units (A.U.) as a function of the 
distance from the midpoint of the central canal for the 300 pixel strip of the image 
exemplified in Ai, Bi, Ci and Di.  
 
Figure 5.5 Example fluorescence intensity traces from control and ARL 67156 








Ai) Normalised running averages for each of the 4 conditions exemplified in Figure 5.4 A-D of the fluorescence intensity over 
a 300 pixel strip as a function of the distance from the midpoint of the central canal. Aii) A zoomed in version of the 
innermost 30 μm of Ai. B) Average counts of EdU positive cells in a lateral half of a slice for each of the conditions; 
** = p < 0.01; * = p < 0.05; n.s. = p > 0.05. 
 
Figure 5.6 Time point culture studies showed that application of ARL 67125 facilitates migration of EdU+ cells 








In the experiments presented in this chapter suramin has been used for its action as 
a broad-spectrum purinergic antagonist and ARL 67125 used for its action as 
ecto-ATPase inhibitor, to increase the concentration of extracellular ATP. Whilst 
suramin is known to have actions outside the antagonistic effects on purinergic 
receptors, including effects on cell migration via growth factor binding (Takano et al., 
1994), the functions of ARL 67125 are less varied. As the effects seen with suramin 
are opposed by the effects seen with ARL 67125, this provides support for the 
function of suramin as a purinergic antagonist been significant in these responses. 
The results presented above are discussed below based on this argument for the role 
of purinergic signalling in these responses.  
5.3.1 Purinergic signalling did not affect proliferation rate of stem cells but 
does affect the location of the newly proliferated cells 
The effect of modulation of purinergic signalling on proliferation was measured over a 
relatively short period such that the extent of cell death on the number of EdU-
positive cells was minimised. This method did not replicate the conditions of non-
injured, intact spinal cord as the numbers of newly proliferated cells after 4 hours in 
EdU were far higher than in previous research where EdU has been injected 
intraperitoneally daily for 4 days prior to fixation (Corns et al., 2015). Given that 
damage to the spinal cord increases the amount of cell proliferation (Barnabé-Heider 
et al., 2010), this suggests this slice preparation model causes some outcomes of 
damage to be present in the tissue, likely to be due to the sectioning process, which 
then causes the higher levels of proliferation seen.  
The results from the proliferation preparation indicated that there is no effect of 
suramin-sensitive purinergic signalling on the proliferation rate of the cells of the 
spinal cord. An important point to consider is that all the proliferation and culture 
experiments used suramin as the antagonist. This is significant because of the two 
response types observed in ependymal cells and CSFcCs, only the depolarising 
response in CSFcCs was sensitive to suramin, with the hyperpolarising response to 
ATP seen in ependymal cells and some CSFcCs insensitive to suramin. However the 
compound used to increase purinergic signalling was an ecto-ATPase inhibitor, the 
effect of which was to reduce the breakdown of ATP, thereby increasing the amount 
of extracellular ATP and therefore the amount of purinergic signalling. It is also worth 
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noting that this will have the impact of reducing the amount of the dephosphorylation 
products of ATP such as ADP, AMP and adenosine. The differing nature of the drugs 
applied allowed differentiation of the cause of any effects observed. Any differences 
seen with suramin will be due to suramin-sensitive signalling, including the 
depolarising responses of CSFcCs, whereas, any differences seen just with ARL 
could be due to a wider range of purinergic signalling pathways.  
Whilst EdU (ethynyldeoxyuridine) and another commonly used thymidine analogue 
BrdU (bromodeoxyuridine) are frequently used as proliferation assays (Taupin, 2007; 
Mead and Lefebvre, 2014), they work by replacing the thymidine nucleoside during 
DNA replication. In addition to DNA replication, nucleosides have also been shown to 
be incorporated into DNA during DNA repair (Kao et al., 2001; Lee et al., 2011). BrdU 
has been shown to be incorporated into DNA during DNA repair (Yoshii et al., 2016) 
as shown by comparison with phospho-histone H3, a marker of cell mitosis. This 
research has looked at BrdU but it is highly likely that these mechanisms occur with 
EdU too as the differences between EdU and BrdU are in the detection methods, 
rather than the incorporation methods (Mead and Lefebvre, 2014). However, the 
assessment of EdU labelling in this study did not quantify total EdU, instead it looked 
at the cells in which it was expressed. It is unlikely that the amount of EdU 
incorporated for DNA repair would come close to the amount incorporated during 
DNA replication, so EdU incorporated due to DNA is likely to appear much fainter 
than that for replication. As only clear cells were counted, it is unlikely to have 
affected the counts significantly. In the fluorescence analysis, it could have some 
effect as faint cells were not ruled out, however most cells appeared brightly stained, 
and thus will have had a far larger effect on the overall analysis. It is also worth noting 
that EdU has been observed to decrease cell survival and increase cell volume of 
surviving cells in transplanted myogenic precursor cells (Andersen et al., 2013). This 
is an effect that must be considered, although, as all conditions included EdU 
application, this should not create any confounding effects for between condition 
comparisons.  
For these experiments all tissue used was taken from thoracic or lumbar levels. This 
was due to requirements to balance consistency of results and to maximise the use of 
animal tissue and the numbers of slices needed to populate the conditions. The 
proliferation under physiological levels is not the same along the rostro-caudal axis of 
the spinal cord (Blasko et al., 2012). Under physiological, non-injured conditions, 
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proliferation is very low within the ependymal region with sacral/coccygeal regions 
showing the highest levels of proliferation and cervical showing the lowest. Thoracic 
and lumbar regions have comparable levels of proliferation and it is for these reasons 
that these levels were used for these experiments. Also significant for these 
experiments was the numbers of CSFcCs along the rostro-caudal axis of the spinal 
cord. Unpublished work from our group has shown that there are higher levels of 
CSFcCs in the thoracic and lumbar regions compared to the cervical and sacral 
regions, and that the levels are not different between the thoracic and lumbar regions 
(Daniel, 2015).  
Paired cells were frequently observed in all conditions, which could be indicative of 
recent division. Immunohistochemistry for other markers could give indication if 
symmetric or asymmetric division is occurring but it is highly likely that some of these 
occurrences of cells near each other is merely co-incidence and as such, the type of 
division happening could not be stated with certainty using these experimental 
protocols.  
Despite there being no difference in the total number of newly proliferated cells in the 
slices between the conditions when the entire slices were counted, there was a 
difference when only the central canal region was counted. The slices where the 
suramin-sensitive currents had been inhibited by application of suramin had 
significantly more cells in the central canal region than in the control and ARL 
condition where the level of extracellular ATP had been raised.  
This pattern of greater numbers of cells in the central canal region relative to the rest 
of the slice in slices with inhibited suramin-sensitive currents was also seen in the 
organotypic slices culture experiments where the slices were in the presence of EdU 
and purinergic modulators for 3 days. In this experiment the converse was also seen, 
with fewer EdU-positive cells around the central canal, and more in the grey and 
white matter in the ARL condition. In this experiment EdU-positive cells were not 
counted as there were too many to distinguish, however the proliferation experiment 
demonstrated that there was not a difference in number of newly proliferated cells 
between the three conditions and this same lack of difference was shown between 
control and ARL conditions in 3 and 5 day cultures. This still leaves the question of 
whether these longer culture experiments were differentially affected by cell death. In 
the time-point experiments, EdU-positive cells were counted and there was no 
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significant difference between the numbers of EdU-positive cells in control or ARL 
conditions either immediately after EdU application or when kept for the same 
duration of time as for these culture experiments (note there was no suramin 
condition in these time-point experiments). This suggests that the changes in relative 
proportion of cells in certain slice regions with purinergic modulation were not due 
differential rates of cell survival of the newly-proliferated cells.  
It is important to note that ependymal cells are not the only cells proliferating in these 
slices. There are also astrocytes and oligodendrocyte precursors that proliferate both 
under intact and injured conditions (Barnabé-Heider et al., 2010). Of the three cell 
types, ependymal cells undergo the lowest rate of proliferation in uninjured tissue, but 
as shown by the higher rate of proliferation in the slices from these experiments 
compared to in vivo experiments, this experimental model involves injury to the cells 
and produces a response in line with the increases in proliferation rate seen after 
injury. Despite there being increases in the proliferation rate of all these cell types 
with a transverse cut in the dorsal funiculus at the injured segment compared to the 
adjacent segment, the greatest increase was in the ependymal cells as determined 
by genetic fate mapping (Barnabé-Heider et al., 2010).  
There are two different possibilities for the differences in location of newly proliferated 
cells within the 5 day cultured slices with different levels of purinergic signalling. The 
first is that increased purinergic signalling is increasing the proliferation rate of one of 
the cell types dispersed around the spinal cord slice and decreasing the proliferation 
rate of the ependymal cells within the central canal region by an equal amount 
(working on the assumption of equal levels of proliferation as demonstrated by the 
proliferation experiment). The second is that the increased purinergic signalling is not 
altering the proliferation rate of any of the cell types but is halting the migration of the 
ependymal cells away from the central canal region. The relation of these findings to 
previous research is discussed in the following section.  
5.3.2 Location of cells following spinal cord injury 
Ependymal cells have been shown to be located exclusively within the central canal 
region in non-injured animals, however after spinal cord injury, the majority of the 
newly-proliferated progeny of ependymal cells were found to be in the core of the 
scar tissue within the injury site, in this case the dorsal funiculus (Barnabé-Heider et 
168 
 
al., 2010). Some ependymal cell progeny have also been identified dispersed around 
the grey and white matter (Meletis et al., 2008). However cells of ependymal lineage 
were not the only cell type of the newly-proliferated cells to change the location. 
Newly-proliferated cells from astrocytic lineage were also observed to be located in 
the region of the injury, however in their case they appeared to be located on the 
perimeter of the scar tissue (Meletis et al., 2008; Barnabé-Heider et al., 2010).  
Other studies have used time-points to observe migration of the ependymal cells 
away from the central canal towards the site of a minimal needle injury (Mothe and 
Tator, 2005). This study utilised DiI labelling to trace only the cells originating from the 
central canal region, as DiI is a lipophilic tracer that is irreversibly incorporated into 
the cell membrane. They showed that with a minimal injury, GFAP negative 
ependymal cells migrated away from the central canal by about 70 μm between 3 and 
14 days post injury. In this minimal injury model, no ependymal progeny were 
observed in the injury site but given the data above, it is likely that the stimulus from 
the minimal injury wasn’t large enough.  
The data from the time-point organotypic slice culture experiment supports these 
findings that the ependymal cells are migrating away from the central canal region 
and provides evidence that purinergic signalling is involved in the facilitation of this 
migration. Other studies have reported ependymal cells migrating towards the site of 
the injury, however in the preparation used for these culture experiments, there is no 
specific injury site, with the injury factors most likely being released from the 
damaged layer of cells from the top and bottom of the slice. For this reason, despite 
the fact that purinergic signalling was not increased by adding ATP but by inhibiting 
the breakdown wherever the extracellular ATP was in the slice, migration towards any 
damage mediators would likely be towards the surfaces of the entire slice. This could 
be assessed in future experiments by use of confocal imaging at different z levels.  
The time-point experiments showed that immediately after incubation with ATP there 
is a greater proportion of the newly proliferated cells within the centre of the slice, 
near the central canal region, however after a further 2 days in a non-EdU-containing 
medium, a greater proportion of the newly proliferated cells was located further out 
into the grey and white matter of the slice. There were significantly more cells in the 
condition where the slices had a further 2 days in non-EdU-containing medium 
indicating that further divisions occurred between EdU containing cells, marking both 
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progeny of those divisions, however the numbers of EdU containing cells did not 
even double, suggesting that most did not proliferate more times after that period.  
This study also looked at the 2 time points in slices incubated with ARL to increase 
purinergic signalling. At the first time point, it appears that there is a greater 
proportion of cells in the central canal area in the ARL condition, compared to the 
control condition. The hypothesis for this experiment was that the cells would migrate 
away from the central canal at the later time point and that increased purinergic 
signalling by ARL would enhance this migration. It would have been expected that the 
ARL would have minimal effect at the first time point as there had not been time for 
much migration of newly-proliferated ependymal cells to occur. It must be 
remembered that by the time that the EdU and ARL is applied, there are already 
ependymal cells, unlabelled by EdU, that are differentiating and migrating away from 
the central canal as there is already endogenous ATP released by the damage 
caused by slicing. It is also likely that the ARL has a lower effect earlier in the 
experiment, when there is likely to be more extracellular ATP anyway such that there 
would still be purinergic signalling occurring even without inhibition of the ATPase 
enzymes. When the later time point ARL condition was compared to the later time 
point control condition, there was a smaller proportion of ependymal cells in the 
central canal area compared to the entire slice, similar to what was seen in the 
previous culture experiments. These experiments don’t tag the cells, so we cannot 
prove that the greater proportion of cells away from the central canal region originate 
from the ependymal cell layer but there are factors which when considered with the 
previous research that has tagged the cells, support this conclusion.  
5.3.3 The migration of spinal cord ependymal cells 
One factor supporting the role for purinergic signalling in the migration of ependymal 
cells away from the central canal is the position of the cells around the central canal 
in the slice culture experiments. In some of the ARL cultured slices, groups of 
ependymal cells appear to be placed along strands with cells on these strands having 
an elongated shape, the long axis of which is perpendicular to the ependymal cell 
layer. This pattern was not observed in slices incubated in suramin, where there was 
sometimes a very clear outline of the central canal region, with a large proportion of 
the EdU-positive cells contained within this region.  
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It is likely that these patterns around the central canal and further out into the spinal 
cord are similar to the patterns of nestin expression. Nestin is an intermediate 
filament protein which is expressed during development in immature CNS cells and in 
multiple glioma cell lines (Tohyama et al., 1992). The expression during development 
is not maintained and by P6 there is no immunoreactivity for nestin around the central 
canal (Hockfield and McKay (1985) where nestin was identified by Rat-401). However 
nestin is expressed in stem cells within the subventricular zone (Morshead et al., 
1994) and is re-expressed in the ependymal cells around the central canal after 
spinal cord injury (Frisén et al., 1995; Shibuya et al., 2002; Mothe and Tator, 2005). 
After spinal cord injury nestin expression is present in processes extending away 
from the ependymal cell layer, at the injury site and is also found in the white matter 
of the spinal cord, with processes extending into the grey matter (Shibuya et al., 
2002). The nestin expression at the white matter was co-localised with GFAP 
suggesting that it was due to precursor sub-pial astrocytes. In injury models the 
patterns of newly-proliferated cells from the central canal (as traced by DiI labelling) 
mimic the patterns of nestin labelling as well as the cells themselves being nestin 
positive (Johansson et al., 1999; Mothe and Tator, 2005). This matched the pattern of 
EdU-positive cells seen in the culture experiments presented here where the greatest 
concentration of EdU-positive cells was around the central canal and in the white 
matter. In another neural stem cell, population nestin was shown to be necessary for 
the migration of the neural stem cells (Yan et al., 2016). It would be of interest for 
future experiments to investigate the effect of inhibition of suramin-sensitive 
purinergic signalling on nestin expression to investigate if purinergic signalling is 
involved in the re-expression of nestin fibres or the ability of cells to migrate along 
these fibres.  
Another protein that is involved in migration of ependymal cells that may be affected 
by purinergic signalling is the transcription factor ATF3 which co-localises with nestin 
following spinal cord injury (Mladinic et al., 2014). These also co-localise with 
vimentin and Sox2. Nestin and AFT3 staining was observed around the central canal 
and in processes extending away from the central canal, in the white matter and also 
along the ventral and dorsal midline away from the central canal. This is of interest as 
in some of the slices from the 5 day culture experiments, a concentration of EdU 
positive cells was observed along this midline. There appear to be species 
differences in ATF3 expression with this matched expression with nestin being seen 
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in rats, but while nestin expression is present in mice (Krityakiarana et al., 2016), 
ATF3 expression was not observed (Mladinic et al., 2014). This suggests that nestin 
expression may be more significant in the culture experiments as the slices used 
were from mouse spinal cord.  
Another factor involved in the migration of ependymal cells is the chemotactic 
cytokine CXCL12 (or SDF1), which has effects on a range of cell types (Jaerve et al., 
2012). Levels of CXCL12 were increased for 2-42 days after moderate and severe 
spinal cord injury (Friederike Knerlich-Lukoschus et al., 2011). The raised levels of 
CXCL12 promote migration of oligodendrocyte precursors (Dziembowska et al., 
2005), CXCR4-positive macrophages and activated microglia (Tysseling et al., 2011) 
and transplanted neural stem cells (Takeuchi et al., 2007) towards the site of injury. 
Ependymal cells have been shown to express CXCR4 (Tysseling et al., 2011) levels 
of which are also elevated after spinal cord injury, peaking after 7 days (Bai et al., 
2016) and are therefore also likely to migrate towards concentrations of CXCL12. 
Other responses to increased levels of CXCL12 include stimulation of axonal 
sprouting (Jaerve et al., 2011) and recruitment pericytes for revascularisation 
(Graumann et al., 2010).  
Purinergic signalling via both P2X and P2Y receptors has been shown to interact with 
chemokine-based chemotaxis in a range of cell types. In human mesenchymal stem 
cells (hMSCs), there has been a connection shown between purinergic signalling and 
the chemotactic response to CXCL12 (Ferrari et al., 2011). Application of ATP, UTP, 
ADP, UDP and BzATP were all able to elicit increases in internal Ca2+ concentration 
which were reduced in magnitude when the extracellular solution was depleted of 
Ca2+ indicating a significant role for ionotropic P2X receptors in the intracellular Ca2+ 
increases seen. Pre-incubation with ATP to hMSCs pushed the cells from a 
proliferative state to a state sensitive to CXCL12-triggered chemotaxis as shown by 
an upregulation of genes involved with migration. While application of ATP alone did 
not increase migration in these cells, application of ATP but not UTP significantly 
increased the chemotactic response to the chemokine attractant CXCL12 (Ferrari et 
al., 2011).  
In other cell types there is involvement of P2Y receptors in the chemotactic response 
to cytokines. In THP-1 cells (a human monocyte cell line) and human peripheral 
mononuclear cells (PBMCs) the Ca2+ response to application of the cytokine CCL2 is 
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modulated by the levels of extracellular nucleotides (Campwala et al., 2014). 
Scavenging of extracellular nucleotides by apyrase reduced the Ca2+ response to 
CCL2 by up to 80% and strongly reduced the chemotactic response of THP-1 cells to 
CCL2, while intracellular Ca2+ levels increased further upon CCL2 application when 
nucleotide levels had been increased by application of ARL 67156. Unlike in hMSCs 
where P2X receptors where suspected to mediate the response, P2Y6 receptors have 
been implicated in this interaction as application of a specific P2Y6 antagonist 
reduced both the Ca2+ response and the chemotactic response to CCL2 application 
(Campwala et al., 2014).  
Additionally, purinergic signalling was shown to be involved in the chemotactic 
response to other chemotactic peptides. The chemotactic response to application of 
fMLP was also inhibited by apyrase, as was the Ca2+ response but in this case, the 
P2Y6-selective antagonist had no effect indicating a different purinergic signalling 
receptor was involved in the response to fMLP (Campwala et al., 2014).  
A similar involvement of purinergic signalling in chemokine-mediated migratory 
responses has been seen in hematopoietic stem cells which migrate towards 
CXCL12 (Rossi et al., 2007). This response is sensitive to pertussis toxin, indicating 
the receptors involved are P2Y receptors coupled to the Gαi intracellular proteins. 
Expression analysis of these hematopoietic stem cells confirms that the response is 
elicited by P2Y2 receptors as supported by the fact that ATP produced a similar 
response. As with THP-1 cells, increased levels of extracellular nucleotides, achieved 
by UTP application, increased the Ca2+ response to chemokine (CXCL12) application 
(Rossi et al., 2007). These studies show a tendency for involvement of purinergic 
signalling and concentration of extracellular nucleotides in increasing the migratory 
response towards other chemotactic factors. 
Whilst it cannot be said for certain which cells and which receptors are responsible for 
eliciting the differences in levels of migration in newly-proliferated cells from the 
ependymal layer in the culture experiments detailed in this chapter, we can exclude 
certain receptors. Despite the hyperpolarisations being consistently shown in 
ependymal cells in response to local application of ATP, they were not sensitive to 
suramin, and suramin application produced a clear effect in the culture experiments. 
It has previously been suggested that the P2X7 receptors expressed by ependymal 
cells could act to detect damage such as spinal cord injury (Marichal et al., 2016) as 
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its low affinity to ATP and increased permeability with sustained application of ATP 
could be useful characteristics. However P2X7 is relatively insensitive to suramin, 
requiring at least 500 μM (Kennedy, 2005), which is significantly higher than the 
slices in these culture experiments received, suggesting that these responses here 
are not mediated by P2X7. We cannot rule out involvement of other cell types not 
recorded from in the patch clamp experiments as some spinal neurons also express 
P2X receptors (Hugel and Schlichter, 2000; Aoyama et al., 2010). Although there are 
likely be other cells which detect the rise in ATP due to injury and extended by 
application of ARL, the proximity of the CSFcCs to the ependymal cells and their 
features suggesting sensory roles make them a viable candidate for involvement in 
the response of ependymal cells to extracellular ATP and to spinal cord injury.  
5.3.4 Conclusions 
The results presented in this chapter indicate that modulation of purinergic signalling 
has no effect on the proliferation rate of cells of the spinal cord in an organotypic slice 
model with features of spinal cord injury. There is also indication that it doesn’t affect 
the survival rate of the newly-proliferated cells. However, the data does support a role 
for purinergic signalling, via the increases in extracellular ATP seen in spinal cord 
injury (Wang et al., 2004), in the migration of the newly-proliferated cells away from 
the central canal region.  
This is not the first cellular system in which purinergic signalling has been implicated 
in migration. As mentioned above, ATP, UTP and nucleotide diphosphates have been 
implicated in roles promoting migration either acting directly or by enhancement of the 
action of other chemotactic factors. Extracellular ATP, but not UTP, was shown to 
induce migration in human mesenchymal stem cells, hypothesised to be via a P2X 
receptor (Ferrari et al., 2011). In hematopoietic stem cells UTP acts to enhance the 
migration of the cells to the chemoattractant CXCL12 in the bone marrow, via 
activation of P2Y2 receptors (Rossi et al., 2007). Conversely in rat oligodendrocyte 
precursor cells, P2Y1 receptors are responsible for the stimulation of migration and 
differentiation by either extracellular ATP or ADP (Agresti et al., 2005a). These 
indicate that purinergic signalling is frequently involved in the promotion of migration, 
often towards a concentration of CXCL12 or other chemotactic factors and that these 
responses are mediated by a range of purinergic receptors. The fact that the 
migratory effects were sensitive to suramin provide support for the suggestion that 
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currents due to P2X2 and P2X3-containing receptors in CSFcCs could act on 
ependymal cells and be responsible for the migratory response, however further 










Chapter 6 - General Discussion  
176 
 
6.1 Impact of this study 
This study has demonstrated the complexity of the responses of ependymal cells and 
CSFcCs around the central canal to purinergic signalling and has demonstrated a 
role for this signalling in the migratory responses in an organotypic slice culture model 
that has characteristics of an injury situation. There are multiple aspects to consider 
with respect to these findings and the directions in which future studies could build on 
this work. Whilst levels of extracellular ATP will be affected by multiple factors both in 
the healthy and injured or diseased spinal cord, the discussion below focuses on the 
situations where ependymal cell proliferation and differentiation has been previously 
shown to be activated. The pathological conditions discussed are spinal cord injury, 
Amytrophic Lateral Sclerosis and Multiple Sclerosis, particularly spinal cord injury as 
ATP release has been demonstrated to occur and have functional effects (Wang et 
al., 2007).  
6.1.1 Applicability of these findings to spinal cord injury 
A role for ependymal cells in spinal cord injury 
It is difficult to dissect specifically the role of ependymal cells in spinal cord injury and 
the effects of their modulation due to the multitude of responses of other cell types in 
SCI. Some studies have made use of animal strains with selective deletion of Ras 
genes involved in mitosis in only FoxJ1 expressing cells (ependymal cells) upon 
application of tamoxifen (Sabelström et al., 2013). This method allowed investigation 
of the effect of removing the proliferative abilities of ependymal cells but without 
affecting them during development. The removal of ependymal cell proliferation 
reduced the glial scar and increased the injury depth over the following 9 weeks, 
whereas the group with normally proliferating ependymal cells showed reduction in 
injury depth over this time period. This deeper injury site was caused by increased 
cell death, likely due to reduced release of various survival-promoting factors by 
ependymal cells due to their reduced numbers. This study indicates that ependymal 
cells play an important role in the response to spinal cord injury and that loss of them 
has negative effects on the survival of neurons.  
The converse has also been demonstrated with enhancement of the numbers of 
ependymal cells via transplantation of ependymal-derived stem/progenitor cells 
(epSPCs), cultured from ependymal cells in vitro, correlating with increased recovery 
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from spinal cord injury. Transplantation into the injured spinal cord of cultured 
ependymal cells from intact spinal cord (epSPCs) and from injured spinal cord 
(epSPCis) have both been shown to be beneficial (Parr et al., 2008; Moreno-
Manzano et al., 2009). There were differences in the proliferation rate and rate of 
formation of differentiated cells between epSPCs and epSPCis in vitro but these 
differences did not render either epSPCs or epSPCis ineffective after transplantation. 
It may be that the differences between epSPCs and epSPCis are reduced after 
transplantation into injured cord where the injury-induced activation that occurred to 
epSPCis prior to culturing happens to epSPCs after transplantation into the injured 
cord. While the culture process may have changed the capabilities of the cells, the 
fact that the cultured epSPCs still had the capability to respond to spinal cord injury 
might suggest that the effect of culturing does not change the cells significantly. This 
would indicate that the beneficial results seen with transplantation of epSPCs or 
epSPCis is due to increased presence and action of ependymal cells rather than a 
unique quality of the cultured cells. The neurogenic potential of epSPCs and 
particularly epSPCis is not maintained in vivo, with the majority of transplanted 
epSPCs maintaining an undifferentiated state (Moreno-Manzano et al., 2009). This 
suggests that the positive results from transplantation of epSPCs/epSPCis are largely 
due to the increased numbers of ependymal cells responding to the spinal cord injury, 
rather than extra capabilities due to the culturing process. These studies that have 
reduced and increased the number of ependymal cells in spinal cord injury models 
have provide support for the idea that despite the increases in potential cell fates of 
ependymal progeny, a significant part of their role in the response to spinal cord 
injury is a structural and supporting role, stabilising surviving tissue and minimising 
the damage caused by the secondary injury of spinal cord injury. 
Applicability of organotypic slice cultures to spinal cord injury 
The study presented here did not use a spinal cord injury model but there is evidence 
to indicate that this organotypic slice culture protocol retains some of the features of 
damage caused by the slicing procedure. One way that this is demonstrated is the far 
higher rate of proliferation both in the central canal region and more generally across 
the white and grey matter of the spinal cord in slices where EdU was applied during 
organotypic slice culture experiments compared to spinal cord slices with EdU 
applied in vivo. Previous work from our group has used the same animal strain and 
the same EdU detection technique to look at rate of proliferation both in vivo and in 
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organotypic slice cultures (Corns et al., 2015). This work is particularly relevant to 
consider as the organotypic slice cultures followed the same protocol as those used 
in this study, allowing the conclusions regarding the effects of that method protocol to 
be applied to the data presented here. In 50 μm sections from the in vivo application 
of EdU (daily injections for 4 days of 0.1 mL of 10 mM EdU) Corns et al. (2015) saw 
1.2 ± 0.3 EdU positive cells in the central canal region. However, in 300 μm 
organotypic cultured slices which had received a single application of 1 μM EdU left 
on for 16 hours 76 ± 5 EdU positive cells were observed around the central canal 
region. These experiments cannot be directly correlated as different concentrations 
and timings of EdU were applied but given that EdU was applied 4 times in vivo it is 
unlikely that the in vivo tissue received less EdU than the cultured tissue. Therefore 
as there are far higher numbers in the cultured experiments, even after accounting for 
the difference in slice thickness, that would suggest that this is due to a higher 
proliferation rate. Within the in vivo spinal cord, a higher proliferation rate is 
associated with spinal cord injury (Cizkova et al., 2009; Barnabé-Heider et al., 2010; 
Lacroix et al., 2014), suggesting that the organotypic slice cultures retain some 
features of the injured state.  
Supporting this is the cell fates observed in organotypic slice cultures which show 
more similarity to the cell fates observed in spinal cord injury than those that are 
observed in the intact spinal cord injury. Again, previous work from our group 
provides a good system to compare the fates of cells in organotypic slice cultures and 
intact in vivo, as, since the ependymal cells are not tagged, only the cells around the 
central canal could be assessed and use of the same study ensures the area 
assessed was consistent. In slices from intact spinal cords with in vivo EdU 
application, there was no co-localisation between EdU and the astrocytic marker 
GFAP, the oligodendrocytic marker PanQKI nor the neuronal marker NeuN around 
the central canal (Daniel, 2015). However when the same markers were assessed for 
co-localisation in the organotypic slice cultures around the central canal region there 
was some co-localisation seen with both GFAP and PanQKI but not NeuN. 
Approximately 2.5 % of EdU+ cells expressed the astrocytic marker GFAP and 7.3 % 
of EdU+ cells expressed the oligodendrocytic marker PanQKI. While we cannot draw 
exact connections between these percentages and those observed in spinal cord 
injury due to those results not presenting co-localisations specifically within the 
central canal region and using different markers for each cell type, there were 
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considerable similarities. After spinal cord injury, approximately 25 % of cells labelled 
by the FoxJ1 transcription factor, the marker for the ependymal cells, expressed 
GFAP and approximately 4 % express the oligodendrocyte marker Olig2 (Barnabé-
Heider et al., 2010). These proportions, while not identical, are reasonably similar 
considering the different populations of cells assessed, especially as FoxJ1-positive 
GFAP-positive cells were found mainly in the core of the injury site (Barnabé-Heider 
et al., 2010), explaining the far higher rate of GFAP expression in all ependymal cells 
(in the SCI experiment), compared to those just around the central canal (in the 
cultured slices).  
Whilst this does not indicate that organotypic slice cultures produce the exact same 
response as spinal cord injury, it clearly indicates that in multiple respects the 
behaviour of ependymal cells in organotypic slice cultures bears more similarity to 
ependymal cells after spinal cord injury than ependymal cells in the intact spinal cord.  
It is likely that the injury aspect comes from the damage to the top and bottom of the 
slice caused by the slicing procedure. Studies that have looked at the location of the 
newly-proliferated cells and particularly those from the ependymal cells after spinal 
cord injury used a dorsal funiculus incision (Barnabé-Heider et al., 2010). In this 
study, cells of ependymal lineage are found in the centre of the lesion site and 
therefore must have migrated from the ependymal layer around the central canal to 
the injury site. In the organotypic slice cultures presented in this work the cells were 
observed migrating away from the central canal in all directions and due to the nature 
of the protocol, it is likely that the damage done to the spinal cord tissue during the 
slicing procedure is the damage being sensed by the cells of the spinal cord.  
It is important to recognise that results from organotypic slice cultures will not 
necessarily translate to spinal cord injury studies. This may be due to the retention of 
some factors but not others, as there is inevitably washout of some damage related 
factors and inability of influx of cells from other regions of the spinal cord or from 
outside the spinal cord. Any lack of translation of results to spinal cord injury could 
also be due to considerable differences in the effect of different spinal cord injury 
models on the central canal region. While partial transection models do not injure the 
central canal region, compression and contusion models frequently used for their 
consistency and relevancy to the types of spinal cord injury seen most frequently in 
humans include damage to the central canal (Cheriyan et al., 2014). The study by 
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Wang et al. (2004) imaged ATP release after a contusion spinal cord injury, it is not 
known how this may differ in the dorsal funiculus incision protocol that is often used 
for cell migration experiments (Stenudd et al., 2015). Additionally the cells within the 
central canal region will likely be differently affected factors in contusion injury 
compared to incisions by a range of other such as hypoxia, change in pressures and 
other factors released after spinal cord injury.  
Applicability of the work to adulthood 
Another important point to consider when discussing the translatability of this work is 
the fact that this work was all done on immature spinal cord tissue. Both the 
electrophysiological recordings and the organotypic slice cultures used spinal cord 
slices from animals under 3 weeks of age, which is well before the spinal cord has 
reached its full adult length. In the mouse spinal cord the number of dividing cells 
around the central canal is affected by the age of the animal (Alfaro‐Cervello et al., 
2012), with the highest proliferation rate around the central canal observed at 1 week 
of age. The proliferation rate is slightly lower at 2 and 4 weeks and considerably 
lower by 13 weeks (Alfaro‐Cervello et al., 2012). This very low baseline level is 
maintained through adulthood but is increased upon spinal cord injury or exercise 
(Cizkova et al., 2009; Barnabé-Heider et al., 2010; Lacroix et al., 2014). This means 
that these experiments were done at ages with higher baseline levels of proliferation 
in the ependymal cells, but the fact that the responses under study had aspects of 
injury situation means this is less significant, because the responses to injury are 
maintained in adulthood. There may however still be differential responses to 
different signalling pathways and factors so the exact responses in adulthood would 
have to be fully investigated to draw conclusive conclusions as to the effect of 
purinergic signalling in the adult spinal cord. Importantly, however, the maintenance 
of the response to injury in adult mammals suggests similar responses that are not 
altered by the fact that the spinal cord has finished its growth.  
6.1.2 Applicability of these findings to humans 
The human spinal cord central canal area and ependymal cells 
Multiple studies have reported that the patency of the central canal in the adult 
human spinal cord is not as consistent as that of adult rat and mouse spinal cords 
most commonly used for investigations into the central canal region and spinal cord 
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injury. Autopsy investigations have suggested that there is closure or partial closure 
of the central canal in human spinal cord at increasing incidence rates with age 
(Milhorat et al., 1994; Yasui et al., 1999). These findings showed that there was at 
least partial closure in the majority of individuals by adolescence (13 – 29 years). This 
autopsy data has been supported by MRI scans showing a similar lack of patency of 
the central canal region of the adult humans spinal cord (Garcia-Ovejero et al., 2015). 
This study also looked at the morphology of the ependymal regions where the central 
canal displayed closure and saw a dense accumulation of cells without any clear 
lumen or ependymal layer. The ependymal region displayed considerable presence 
of glial cells as shown by expression of GFAP-positive processes spreading through 
this region. There were groups of vimentin-positive cells identified as ependymocytes 
which possessed intercellular junctions, cilia and expressed CD15, features of 
ependymal cells (Sabourin et al., 2009; Garcia-Ovejero et al., 2013). There were 
some ependymocytes observed surrounding pseudo-canals but also sometimes 
observed surrounding blood vessels, called perivascular pseudo-rosettes (Garcia-
Ovejero et al., 2015). This latter feature was deemed of significance due to its 
presence in ependymomas (Wippold and Perry, 2006), although no Ki67-positive 
cells were observed indicating no proliferation was taking place in these samples.  
Garcia-Ovejero et al. (2015) investigated the expression profile of cells in adult 
human central canal area and suggest that there should be caution in considering the 
transferability of therapeutic options developed animal models because of the 
ependymoma-like properties of the human ependyma. While the effect of the partial 
or complete closure of the central canal on response to spinal cord injury is not 
known, the link to ependymomas based on the expression profile is not convincing. 
This experiment looked at expression of 117 genes designated ependymoma-related 
and compared the number of these expressed in the human ependymal region to the 
number of the ependymoma-related genes expressed in the ventral horn. They 
observed 43 ependymoma-related genes expressed in the ventral horn and 
ependymal region, and a further 53 ependymoma-related genes expressed in the 
ependymal region. This does not look at the expression of ependymoma-related 
genes in either younger humans nor in animals of any age so does not provide any 
insight into the translatability of therapeutics effective in animal models. Additionally, 
the finding that there is greater gene expression in common between an area high in 
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ependymal cells and ependymomas compared to a neuron rich area with no 
ependymal cells and ependymomas is a rather unsurprising conclusion.  
This study also looked at the expression of neurogenic niche-genes and concluded 
that their low expression also reduced the chances of translatability from animal 
models (Garcia-Ovejero et al., 2015). Again there are multiple points that do not 
support this conclusion. The set of genes assessed contains a mixture of genes 
related to neurogenesis (e.g. BMI1), immature neurons (e.g. Dcx) and stem-cells (e.g. 
sox2 and S100β). The ventral horn was similarly used as the control in this 
experiment and was shown to express 47 of the 93 neurogenic-niche related genes, 
a high proportion considering the non-neurogenic nature of the ventral horn. Cells of 
the ependymal region were shown to express a further 14 neurogenic-niche related 
gene additional to those expressed in the ventral horn. This relatively low number of 
additional neurogenic-niche related genes compared to the ventral horn was also 
suggested to indicate the lack of transferability from animal studies. However these 
gene have not all been shown to be expressed in high levels in rodent spinal cords, 
and crucially, are unlikely to be expressed at high levels in the uninjured spinal cord, 
where no stem cell or neurogenic activity is thought to occur in any mammalian 
species during adulthood.  
While the impact of the reduced flow of CSF that is likely to occur with the closure or 
partial closure of the central canal in the adult human spinal cord has not been 
assessed and may alter the response of this area to spinal cord injury, the ependymal 
cells have been shown to express Sox2 and have similar neurosphere-forming 
capabilities in vitro as rodent ependymal cells (Dromard et al., 2008; Mothe et al., 
2011). Sections of human ependymal cells were enzymatically dissociated and the 
cells cultured and showed that they share with non-human ependymal cells the ability 
to form passagable neurospheres (Dromard et al., 2008). The rate of neurosphere 
formation was lower for the human ependymal cells compared to mouse ependymal 
cells. Despite this lower rate of neurosphere formation, the differentiated cells from 
the neurospheres produced astrocytes and NeuN positive neurons. The 
oligodendrocytes that are observed produced by neurospheres from rodent epSPCs 
(Moreno-Manzano et al., 2009) were not observed with the human ependymal cell 
cultures, although some of these experiments used specialised oligodendrocyte 
differentiation protocols and Dromard et al. (2008) used a neuronal culture medium. A 
subset of neurons produced by the human ependymal-derived neurospheres showed 
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K+-currents and TTX-sensitive Na+-currents indicative of functional neurons. This 
indicates that despite the frequent closure of the central canal (Dromard et al. (2008) 
observed a lack of clear central canal in over half the samples used for their imaging 
experiment) the ependymal cells still show the in vitro stem cell and neurogenic 
potential of non-human ependymal cells.  
The human spinal cord after spinal cord injury 
The most significant difference identified between the human ependymal region and 
the rodent ependymal region is the degree of patency of the central canal. Therefore 
when considering the translatability of findings in animal models of spinal cord injury, 
both the effect of spinal cord injury on the patency and the effect of the lower patency 
on the response to the injury need to be considered. No effect of spinal cord injury on 
patency was observed (Garcia-Ovejero et al., 2015).  
The effect of the differences in patency and any expression differences on the 
response to spinal cord injury cannot be investigated in as much depth. However 
there are a number of factors in which human ependymal cells have been observed 
to behave in a similar manner to in non-human mammalian spinal cords. Human 
ependymal cells have been shown to increase the expression of nestin after spinal 
cord injury  (Cawsey et al., 2015) as in rat ependymal cells (Liu et al., 2002; Mao et 
al., 2016) and significantly there was a correlation between the percentage of 
ependymal cells expressing nestin and the survival time after injury. Another 
interesting point is that nestin levels were observed increased at multiple levels of the 
spinal cord as well as the level of the injury site (Cawsey et al., 2015). This 
communication of injury could have occurred via non-canal mediated factors, but if 
the CSF-flow through the canal is significant, this would indicate that there is still 
sufficient flow of factors despite the reduced patency in the human spinal cord.  
Many current treatments are looking at promoting axonal sprouting to attempt to 
re-connect the severed axons.  One aspect of this that must be considered before 
being transferred into human spinal cord injury is that a symptom suffered by a larger 
proportion of spinal cord injured patients is chronic neuropathic pain and is a key 
factor in reducing their quality of life (Siddall and Loeser, 2001). Transplantation of 
spinal cord-derived neural stem cells into an animal model of spinal cord injury 
improved motor outcome but also produced allodynia as shown by decreased 
withdrawal reflex (Hofstetter et al., 2005). They were able to reduce the sprouting of 
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sensory fibres associated with this development of allodynia by transduction of the 
neural stem cells to express neurogenin-2, which had the effect of reducing the 
amount of astrocytic differentiation of the neural stem cells, increasing the 
oligodendritic differentiation and enabling a small amount of neural differentiation.  
6.1.3 Applicability of these findings to other pathological conditions 
While in healthy spinal cords, ependymal cells do not migrate away from the central 
canal or differentiate into astrocytes of oligodendrocytes, there are pathological 
conditions other than spinal cord injury, which cause ependymal cells to demonstrate 
these behaviours. In a SOD1 transgenic mouse model of amytrophic lateral sclerosis 
(ALS), a nestin positive subset of ependymal cells increased their proliferation and 
migrated first to the dorsal horns and then to the ventral horns where the 
degeneration of motor neurons was occurring (Chi et al., 2006). The increase in 
proliferation of the nestin-positive ependymal cells was seen even before the disease 
symptoms were apparent. The SOD1-mutant mice had higher CXCR4 expression in 
the nestin-positive ependymal cells compared to the control animals, suggesting that 
CXCL12 may be involved in the migration of ependymal cells in this SOD1 MS mouse 
model, in a similar manner to its probable involvement in spinal cord injury. 
Interestingly, whilst application of CXCL12 improves locomotor recovery from spinal 
cord injury by promoting cell survival, increasing the numbers of microglia and 
astrocytes and the amount of cell proliferation (Zendedel et al., 2012), the same 
positive effect is not seen in ALS. In a SOD1-mutant mouse model of ALS, 
application of the CXCR4 antagonist AMD3100 reduced the levels of expression of 
microglial inflammatory markers, increased motor neuron survival, improved motor 
functioning and extended animal survival (Rabinovich-Nikitin et al., 2016). 
Rabinovich-Nikitin et al. (2016) suggested that this effect may be due to a reduction 
in the glutamate excitotoxicity caused by glutamate release from glial cells. It may be 
that enhancing the migratory response of ependymal cells in a manner that doesn’t 
elicit the glutamate excitotoxicity can provide a beneficial outcome in ALS. 
Another degenerating condition that activates ependymal cells is multiple sclerosis 
(MS), which triggers increases of proliferation and expression of the radial glial 
marker, RC1 (Talbott et al., 2005; Danilov et al., 2006). Many treatments have looked 
at promoting remyelination of the demyelinated axons and thereby inhibiting their 
degradation. Ependymal cells have been shown in vitro and in vivo to produce a 
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limited number of oligodendrocyte progenitors (Shihabuddin et al., 2000; Barnabé-
Heider et al., 2010). It has previously been shown that ependymal cells can be 
modulated to produce a higher proportion of cells immunoreactive for the 
oligodendritic marker PanQKI by modulation of cholinergic signalling (Corns et al., 
2015). In an experimental autoimmune encephalomyelitis (EAE) model of MS nicotine 
application increased the proliferation of ependymal cells and increased the numbers 
of mature oligodendrocytes present although these may not have derived from the 
ependymal cells (Gao et al., 2015). However multiple studies have indicated that 
astrocytic involvement is of great importance in supporting the remyelination (Talbott 
et al., 2005), and thus the astrocyte-forming capabilities may be useful in promoting 
the remyelination of axons in multiple sclerosis. Greater understanding of the roles of 
ependymal cells in these demyelinating disorders and the signalling in the spinal cord 
that elicits these roles could help maximise the beneficial potential of ependymal 
cells.  
 
6.2 Future work  
There are many interesting facets of this research that would benefit from further 
research to elucidate the roles that purinergic signalling plays in the stem cell niche of 
the spinal cord. Two potential avenues for continuation of the work are detailed 
below. 
6.2.1 Elucidation of the roles of purinergic signalling on the cell fate of 
ependymal progeny 
The processes of cell proliferation, migration and differentiation are often interlinked 
such that changes in one cause a corresponding decrease in another.  
Studies in human mesenchymal stem cells (hMSCs) demonstrate one aspect of 
these linked changes caused by ATP signalling (Ferrari et al., 2011). In this cell 
population, application of ATP and UTP induced increases in intracellular calcium 
concentration. In cultured cells, the ATP, but not UTP application, was associated 
with a decrease in proliferation rate. This decrease in proliferation rate was 
accompanied by an increase in migration in vitro. ATP application caused an 
increase in the spontaneous migration of hMSCs and also enhanced the directional 
migration of hMSCs towards CXCL12, a chemokine they migrate towards at a lower 
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rate without ATP application (Ferrari et al., 2011). Significantly, the migration 
triggered directly by ATP was shown not to be directional migration but rather an 
increase in cell motility (chemokinesis) as the increase in migration was only seen 
when ATP was in the same chamber of the transwells to the hMSCs; when ATP was 
added to a different chamber to the cells, no effect was seen, suggesting that 
perhaps the concentration was not high enough to elicit spontaneous migration. 
However this concentration was enough to significantly enhance the directional 
migration (chemotaxis) of hMSCs towards CXCL12. UTP did not promote any 
migration either directly or by potentiating the chemotactic effect of CXCL12. This 
suggests that in hMSCs, ATP signalling may increase migration via two mechanisms, 
chemokinesis and chemotaxis. Pre-incubation with ATP increased the migration of 
transplanted hMSCs in vivo. This effect of pre-incubation of ATP was likely due to the 
changes in gene expression elicited by ATP. ATP signalling affects expression of 
genes in hMSCs, downregulating genes involved in proliferation and upregulating 
genes involved in migration (Ferrari et al., 2011).  
Purinergic signalling also acts on oligodendrocyte progenitors (OPs) (Agresti et al., 
2005a). ATP and ADP but not UTP promote additional directional migration of OPs in 
vitro towards the ATP or ADP concentration gradient over the amount of migration 
seen in OPs without purine application (Agresti et al., 2005b). This response was 
eliminated by application of the P2Y1 antagonist MRS2179. Agresti et al. (2005b) also 
saw a small increase in migration of OPs in vitro with application of adenosine or the 
A1-specific agonist CPA, however Othman et al. (2003) observed a larger effect on 
migration with CPA application, perhaps due to the longer incubation time in this 
study. ATP and ADP were also shown to have a minor effect increasing the rate of 
proliferation in OPs (by 10-15 %) however they had a more considerable effect in the 
opposite direction when applied to OPs treated with the growth factor platelet-derived 
growth factor (PDGF) (Agresti et al., 2005b). ATP and ADP reduced the pro-
proliferative effect of PDGF by half with this reduction in proliferation inhibited by the 
P2Y1 antagonist MRS2179. In the PDGF-treated OPs, the anti-proliferative effect of 
ATP and ADP was accompanied by an increase by about 80 % in the percentage of 
cells expressing O1, a marker for differentiated oligodendrocytes. This indicates that 
in the PDGF-treated OPs, purinergic signalling switches cells from a proliferating to a 




Modulation of cell fate within ependymal cells 
Within ependymal cells, the results presented here suggest that modulation of 
purinergic signalling affects migration but does not affect the proliferation rate. It is 
not known if purinergic signalling is involved in the differentiation of the cells from 
stem cells to differentiated cells or if it favours any fates over others. As the 
ependymal cells migrate after spinal cord injury, they change their phenotype. They 
cease expressing an ependymal phenotype, for example through Sox2 expression 
and use of the FoxJ1 promoter, and begin expressing Sox9 and GFAP (Mothe and 
Tator, 2005; Meletis et al., 2008). After 4 months post-injury, there was also a 
population of mature oligodendrocytes descended from central canal ependymal 
cells, showing that ependymal cells increase their range of cell fates after spinal cord 
injury (Barnabé-Heider et al., 2010), compared to in uninjured spinal cords.  
Signalling with neurotransmitters can modulate events in ependymal cells affecting 
both the rate of proliferation and the proportions of cells expressing markers of 
differentiated cells. Modulation of cholinergic signalling via application of PNU 120596 
(a selective α7*nAChR potentiator) increases the amount of proliferation in 
ependymal cells in organotypic slice cultures (Corns et al., 2015). Application of PNU 
120596 also increases the percentage of newly-proliferated cells labelled with the 
oligodendrocyte progenitor and oligodendrocyte marker PanQKI. This again shows 
duel effects on proliferation and differentiation, in this case increasing both 
proliferation and differentiation; while ependymal cells differentiate into multiple cell 
types no reduction in expression of other markers of other post-differentiated cell 
types was observed (Corns et al., 2015). This modulator was also applied to the 
intact spinal cord in vivo and whilst the increase in proliferation was still seen (Corns 
et al., 2015), there was no increase in proportion labelled with PanQKI . This is likely 
due to the fact that in vivo in an uninjured cord, no differentiation into 
oligodendrocytes (or astrocytes) is seen as ependymal cells just replace themselves 
in the intact cord. Therefore there was no oligodendrocytic differentiation pathway 
open for PNU 120596 signalling to upregulate, suggesting that these drugs do not 
push ependymal cells into differentiation pathways without prior activation by spinal 
cord injury. This may occur by altering expression of some of the cell fate 
determinants that have been identified as upregulated after spinal cord injury, such 
as Notch1, Numb, Pax6, BMP4, Shh and Msx2 (Yamamoto et al., 2001; Chen et al., 
2005) once the situation of spinal cord injury has enabled their expression. Once the 
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full effects of modulation of ependymal signalling have been understood, it may well 
be that different signalling modulators need to be applied at different times to produce 
the most beneficial effect for recovery from spinal cord injury. 
For purinergic signalling, this could be investigated using the organotypic slice culture 
protocol as the results with modulation of cholinergic signalling (Corns et al., 2015) 
have demonstrated that this protocol provides enough activation seen in spinal cord 
injury to produce differentiation responses into astrocytes and oligodendrocytes, 
similar to that seen in vivo after spinal cord injury.  
6.2.2 Investigation of the functional implications of spatial differences in P2X 
receptors in CSFcCs 
One particular unexpected result was the involvement of the P2X3 subunit in 
mediating the responses to ATP of a spatially-determined subset of CSFcCs. 
P2X3-containing receptors have very different properties to P2X2 receptors and as 
such are likely to function differently in a range of situations, including producing 
different responses in raised concentrations of calcium and with variations in pH 
levels (North, 2002), both of which are altered in many situations including spinal cord 
injury (Moriya et al., 1994; Wang et al., 2004). Therefore understanding the ways that 
alteration of these factors affects the responses of CSFcCs to ATP could shed light 
on the impact of this spatial variation of P2X receptors in CSFcCs.  
P2X3 subunit-containing receptors, are highly expressed within a subset of primary 
nociceptive afferents (Chen et al., 1995; Adriaensen et al., 2015) and are involved in 
peripheral pain mechanisms (Burnstock, 2001; North, 2004). Understanding the roles 
of P2X3-containing receptors in pain signalling can provide insight into how 
characteristics such as desensitisation and response to calcium levels provide 
reliable signalling without excessive or inappropriate signalling. Homomeric P2X3 
receptors show a number of characteristics that are different from other P2X 
receptors, particularly from P2X2 receptors, with the heteromeric P2X2/3 receptors 
resembling P2X2 receptors in some aspects, P2X3 in other aspects and showing 
intermediate characteristics in the others (see section 3.3.4 for further information on 
these differences and features). These features of P2X3-containing receptors are 
significant in the functions they perform. A key feature of P2X3 receptors is that they 
show both fast and slow desensitisation and a desensitisation that can be mediated 
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even by concentrations of ATP which are unable to elicit a detectable change in 
membrane potential (Sokolova et al., 2004; Pratt et al., 2005). This is a process 
called high affinity desensitisation. It may be that the desensitisation and high affinity 
desensitisation shown by P2X3 play a role in reducing inappropriate excitation of 
nociceptive fibres against physiological releases of ATP such as those seen after 
exercise (Mortensen et al., 2011), preventing nociception due to ATP released from 
causes related to non-noxious stimuli. The desensitisation of P2X3 receptors means 
that only large bursts of ATP release can overcome the desensitisation with 
alterations to the desensitisation properties playing a role in the development of 
chronic pain (Burnstock, 2001). Modulation of the desensitisation could contribute to 
the development of chronic pain and particularly inflammatory pain (North, 2004; 
Giniatullin and Nistri, 2013). One way in which this desensitisation could be reduced 
is by reconfiguration of the receptors from the homomeric P2X3 receptors which show 
the high affinity desensitisation to the heteromeric P2X2/3 receptors which do not.  
It could be that some of these characteristics that enable successful functioning of 
P2X3-containing receptors in nociceptive afferent neurons also play a role in the 
functioning of P2X3-containing receptors in CSFcCs. The impact of the response to 
ATP being mediated by P2X3-containing receptors in a subset of CSFcCs compared 
to the P2X2-mediated response in the majority of CSFcCs could be of value to help 
elucidate the importance of the two receptor types. To investigate how modulation of 
the external environment differentially affects these two CSFcC populations further 
electrophysiological experiments could be done under different conditions. 
Modulation of the pH of the extracellular solution and of the concentration of 
extracellular calcium could be examined as both of these characteristics have been 
shown to differentially affect P2X2 and P2X3-containing receptors. This could provide 
insight as to how the two groups of cells function in the changes of conditions seen in 
spinal cord injury.  
Another aspect of the P2X3-containing receptor involvement in CSFcC functioning 
that deserves further investigation is the location of the P2X3 subunit expression. 
Immunohistochemistry did not show strong expression within the CSFcCs, instead 
the strong expression appeared to be within a bundle of fibres just ventral to the 
central canal. Clarification of whether the depolarisation to ATP was mediated directly 
by P2X3 located post synaptically, could be achieved by blocking synaptic signalling 
using a combination of Na+ channel blockers, excitatory and inhibitory amino acid 
190 
 
receptor antagonists for example TTX, DNQX, AP-5, bicuculline and strychnine (as 
has been used previously in Deuchars et al. (2001)). A lack of response under these 
conditions would indicate that the P2X3-containing receptors were located 
pre-synaptically while continued presence of the response would suggest a post-
synaptic expression on the CSFcCs. 
Another important part to investigate would be the role of the P2X3-mediated 
responses in CSFcCs in the responses to spinal cord injury. This is particularly 
pertinent due to the fact that the Ca2+ levels rise after spinal cord injury (Moriya et al., 
1994) which affect P2X2 receptors and P2X3-containing receptors in very different 
ways. Increased levels of extracellular Ca2+ inhibit the responses of P2X2 to ATP 
(Evans et al., 1996), while the raised levels of Ca2+ have the effect of attenuating the 
desensitisation of P2X3-containing receptors (Cook et al., 1998). This could be 
investigated using the organotypic slice culture model using the selective P2X3/P2X2/3 
antagonist ARL 67156. In addition to examining the behaviour of cells around the 
central canal in this experiment, it would also be worth determining if there were any 
differences along the ventral midline and on the ventromedial edge of the slice as 
P2X2 is expressed in the axons of the CSFcCs (Stoeckel et al., 2003), with the 
expression of P2X3 not having been previously investigated.  
 
6.4 Conclusions 
This study has provided an in-depth characterisation of the role of purinergic 
signalling around the central canal of the adult spinal cord. The responses of both 
ependymal cells and CSFcCs to application of nucleotide triphosphates indicate the 
importance of these as intercellular signalling molecules and the results from the 
organotypic slice cultures show the role of this signalling in “injury” situations. Within 
this situation purinergic signalling, via suramin-sensitive channels, facilitates the 
migration of the ependymal cells away from the central canal. This could occur via 
enhancement of chemokine chemotaxis as is seen in other migratory cell types. The 
value of proliferation and differentiation in ependymal cells in spinal cord injury has 
been demonstrated so the effect of purinergic signalling on the migration of 
ependymal cells warrants further study. Better understanding of the factors that 
control the proliferation, migration and differentiation of ependymal cells in spinal cord 
injury and spinal cord pathologies such as multiple sclerosis and ependymomas will 
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allow optimisation of response of ependymal cells to produce the best functional 
outcome. These findings provide greater understanding of the complexity of 
electrophysiological responses of cells around the central canal to purinergic 
signalling and demonstrate a novel role for this signalling in an experimental model 





Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H (2009) Purinergic 
signalling in the nervous system: an overview. Trends in Neurosciences 
32:19-29. 
Abranches E, Silva M, Pradier L, Schulz H, Hummel O, Henrique D, Bekman E 
(2009) Neural differentiation of embryonic stem cells in vitro: a road map to 
neurogenesis in the embryo. PLoS ONE 4:e6286. 
Adriaensen D, Brouns I, Timmermans J-P (2015) Sensory input to the central 
nervous system from the lungs and airways: A prominent role for purinergic 
signalling via P2X2/3 receptors. Autonomic Neuroscience 191:39-47. 
Agresti C, Meomartini ME, Amadio S, Ambrosini E, Volonté C, Aloisi F, Visentin S 
(2005a) ATP regulates oligodendrocyte progenitor migration, proliferation, and 
differentiation: involvement of metabotropic P2 receptors. Brain Research 
Reviews 48:157-165. 
Agresti C, Meomartini ME, Amadio S, Ambrosini E, Serafini B, Franchini L, Volonté C, 
Aloisi F, Visentin S (2005b) Metabotropic P2 receptor activation regulates 
oligodendrocyte progenitor migration and development. Glia 50:132-144. 
Akk G, Steinbach JH (2003) Activation and block of mouse muscle-type nicotinic 
receptors by tetraethylammonium. The Journal of Physiology 551:155-168. 
Akpinar A, Uğuz AC, Nazıroğlu M (2014) Agomelatine and Duloxetine Synergistically 
Modulates Apoptotic Pathway by Inhibiting Oxidative Stress Triggered 
Intracellular Calcium Entry in Neuronal PC12 Cells: Role of TRPM2 and 
Voltage-Gated Calcium Channels. The Journal of Membrane Biology 247:451-
459. 
Alfaro‐Cervello C, Soriano‐Navarro M, Mirzadeh Z, Alvarez‐Buylla A, Garcia‐Verdugo 
JM (2012) Biciliated ependymal cell proliferation contributes to spinal cord 
growth. The Journal of Comparative Neurology 520:3528-3552. 
Anadón R, Adrio F, Rodríguez-moldes I (1998) Distribution of GABA immunoreactivity 
in the central and peripheral nervous system of amphioxus (Branchiostoma 
lanceolatum pallas). The Journal of Comparative Neurology 401:293-307. 
Andersen DC, Skovrind I, Christensen ML, Jensen CH, Sheikh SP (2013) Stem cell 
survival is severely compromised by the thymidineanalog EdU (5-ethynyl-2′-
deoxyuridine), an alternative to BrdU for proliferation assays and stem cell 
tracing. Analytical and Bioanalytical Chemistry 405:9585-9591. 
Andersson M (1989) Diadenosine tetraphosphate (Ap4A): Its presence and functions 
in biological systems. International Journal of Biochemistry 21:707-714. 
Andries M, Van Damme P, Robberecht W, Van Den Bosch L (2007) Ivermectin 
inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and 
extends the life span of a transgenic mouse model of amyotrophic lateral 
sclerosis. Neurobiology of disease 25:8-16. 
Aoyama T, Koga S, Nakatsuka T, Fujita T, Goto M, Kumamoto E (2010) Excitation of 
rat spinal ventral horn neurons by purinergic P2X and P2Y receptor activation. 
Brain Research 1340:10-17. 
Arcuino G, Lin JH-C, Takano T, Liu C, Jiang L, Gao Q, Kang J, Nedergaard M (2002) 
Intercellular calcium signaling mediated by point-source burst release of ATP. 
Proceedings of the National Academy of Sciences 99:9840-9845. 
Azzi G, Jouis V, Godeau G, Groult N, Robert AM (1990) Immunolocalisation of 
extracellular matrix macromolecules in the rat spinal cord. Matrix 9:479-485. 
193 
 
Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA, Erb L (2005) The 
P2Y2 Nucleotide Receptor Interacts with αv Integrins to Activate Go and 
Induce Cell Migration. Journal of Biological Chemistry 280:39050-39057. 
Bai L, Wang X, Li Z, Kong C, Zhao Y, Qian J-L, Kan Q, Zhang W, Xu J-T (2016) 
Upregulation of Chemokine CXCL12 in the Dorsal Root Ganglia and Spinal 
Cord Contributes to the Development and Maintenance of Neuropathic Pain 
Following Spared Nerve Injury in Rats. Neuroscience Bulletin 32:27-40. 
Baker MD (2005) Protein kinase C mediates up-regulation of tetrodotoxin-resistant, 
persistent Na+ current in rat and mouse sensory neurones. The Journal of 
Physiology 567:851-867. 
Balderas E, Ateaga-Tlecuitl R, Rivera M, Gomora JC, Darszon A (2012) Niflumic acid 
blocks native and recombinant T-type channels. Journal of Cellular Physiology 
227:2542-2555. 
Barber RP, Vaughn JE, Roberts E (1982) The cytoarchitecture of gabaergic neurons 
in rat spinal cord. Brain Research 238:305-328. 
Barnabé-Heider F, Göritz C, Sabelström H, Takebayashi H, Pfrieger FW, Meletis K, 
Frisén J (2010) Origin of New Glial Cells in Intact and Injured Adult Spinal 
Cord. Cell Stem Cell 7:470. 
Bartlett R, Stokes L, Sluyter R (2014) The P2X7 Receptor Channel: Recent 
Developments and the Use of P2X7 Antagonists in Models of Disease. 
Pharmacological Reviews 66:638-675. 
Basbaum AI, Glazer EJ (1983) Immunoreactive vasoactive intestinal polypeptide is 
concentrated in the sacral spinal cord: a possible marker for pelvic visceral 
afferent fibers. Somatosensory Research 1:69-82. 
Belliveau D, Naus C (1995) Cellular Localization of Gap Junction mRNAs in 
Developing Rat Brain (Part 1 of 2). Developmental Neuroscience 17:81-89. 
Benowitz LI, Routtenberg A (1997) GAP-43: an intrinsic determinant of neuronal 
development and plasticity. Trends in Neurosciences 20:84-91. 
Bjugn R, Haugland HK, Flood PR (1988) Ultrastructure of the mouse spinal cord 
ependyma. Journal of Anatomy 160:117-125. 
Blanchet C, Dulon D (2001) Tetraethylammonium ions block the nicotinic cholinergic 
receptors of cochlear outer hair cells. Brain Research 915:11-17. 
Blasko J, Martoncikova M, Lievajova K, Saganova K, Korimova A, Racekova E 
(2012) Regional differences of proliferation activity in the spinal cord 
ependyma of adult rats. Open Life Sciences 7:397-403. 
Bohm UL, Prendergast A, Djenoune L, Nunes Figueiredo S, Gomez J, Stokes C, 
Kaiser S, Suster M, Kawakami K, Charpentier M, Concordet J-P, Rio J-P, Del 
Bene F, Wyart C (2016) CSF-contacting neurons regulate locomotion by 
relaying mechanical stimuli to spinal circuits. Nature Communications 7. 
Bonfanti L, Theodosis D (1994) Expression of polysialylated neural cell adhesion 
molecule by proliferating cells in the subependymal layer of the adult rat, in its 
rostral extension and in the olfactory bulb. Neuroscience 62:291-305. 
Boué-Grabot É, Toulmé E, Émerit MB, Garret M (2004a) Subunit-specific Coupling 
between γ-Aminobutyric Acid Type A and P2X2 Receptor Channels. Journal 
of Biological Chemistry 279:52517-52525. 
Boué-Grabot É, Émerit MB, Toulmé E, Séguéla P, Garret M (2004b) Cross-talk and 
Co-trafficking between ρ1/GABA Receptors and ATP-gated Channels. Journal 
of Biological Chemistry 279:6967-6975. 
Boué-Grabot É, Barajas-López C, Chakfe Y, Blais D, Bélanger D, Émerit MB, 
Séguéla P (2003) Intracellular cross talk and physical interaction between two 




Braden BB, Kingston ML, Koenig EN, Lavery CN, Tsang CWS, Bimonte-Nelson HA 
(2015) The GABAA antagonist bicuculline attenuates progesterone-induced 
memory impairments in middle-aged ovariectomized rats. Frontiers in Aging 
Neuroscience 7. 
Braun N, Sévigny J, Mishra SK, Robson SC, Barth SW, Gerstberger R, Hammer K, 
Zimmermann H (2003) Expression of the ecto-ATPase NTPDase2 in the 
germinal zones of the developing and adult rat brain. European Journal of 
Neuroscience 17:1355-1364. 
Brewer GJ, Torricelli JR, Evege EK, Price PJ (1993) Optimized survival of 
hippocampal neurons in B27-supplemented neurobasal™, a new serum-free 
medium combination. Journal of Neuroscience Research 35:567-576. 
Brown JP, Couillard‐Després S, Cooper‐Kuhn CM, Winkler J, Aigner L, Kuhn HG 
(2003) Transient expression of doublecortin during adult neurogenesis. 
Journal of Comparative Neurology 467:1-10. 
Bruni J, Del Bigio M, Clattenburg R (1985) Ependyma: normal and pathological. A 
review of the literature. Brain Research Reviews 9:1-19. 
Bruni JE, Reddy K (1987) Ependyma of the central canal of the rat spinal cord: a light 
and transmission electron microscopic study. Journal of Anatomy 152:55-70. 
Bu J-Y, Li H, Gong H-Q, Liang P-J, Zhang P-M (2014) Gap junction permeability 
modulated by dopamine exerts effects on spatial and temporal correlation of 
retinal ganglion cells’ firing activities. Journal of Computational Neuroscience 
36:67-79. 
Buck SB, Bradford J, Gee KR, Agnew BJ, Clarke ST, Salic A (2008) Detection of S-
phase cell cycle progression using 5-ethynyl-2'-deoxyuridine incorporation 
with click chemistry, an alternative to using 5-bromo-2'-deoxyuridine 
antibodies. Biotechniques 44:927-929. 
Bulley S, Neeb ZP, Burris SK, Bannister JP, Thomas-Gatewood CM, Jangsangthong 
W, Jaggar JH (2012) TMEM16A/ANO1 Channels Contribute to the Myogenic 
Response in Cerebral Arteries. Circulation Research 111:1027-1036. 
Burda Joshua E, Sofroniew Michael V (2014) Reactive Gliosis and the Multicellular 
Response to CNS Damage and Disease. Neuron 81:229-248. 
Burnstock G (2001) Purine-mediated signalling in pain and visceral perception. 
Trends in Pharmacological Sciences 22:182-188. 
Burnstock G (2006) Purinergic signalling. British Journal of Pharmacology 147:S172-
S181. 
Camprubí-Robles M, Mair N, Andratsch M, Benetti C, Beroukas D, Rukwied R, 
Langeslag M, Proia RL, Schmelz M, Ferrer Montiel AV, Haberberger RV, 
Kress M (2013) Sphingosine-1-Phosphate-Induced Nociceptor Excitation and 
Ongoing Pain Behavior in Mice and Humans Is Largely Mediated by S1P3 
Receptor. The Journal of Neuroscience 33:2582-2592. 
Campwala H, Sexton DW, Crossman DC, Fountain SJ (2014) P2Y6 receptor 
inhibition perturbs CCL2-evoked signalling in human monocytic and peripheral 
blood mononuclear cells. Journal of Cell Science 127:4964-4973. 
Capela A, Temple S (2002) LeX/ssea-1 Is Expressed by Adult Mouse CNS Stem 
Cells, Identifying Them as Nonependymal. Neuron 35:865-875. 
Castel M, Morris JF (2000) Morphological heterogeneity of the GABAergic network in 
the suprachiasmatic nucleus, the brain's circadian pacemaker. Journal of 
Anatomy 196:1-13. 
Cavanagh BL, Walker T, Norazit A, Meedeniya AC (2011) Thymidine analogues for 
tracking DNA synthesis. Molecules 16:7980-7993. 
195 
 
Cawsey T, Duflou J, Weickert CS, Gorrie CA (2015) Nestin-Positive Ependymal Cells 
Are Increased in the Human Spinal Cord after Traumatic Central Nervous 
System Injury. Journal of Neurotrauma 32:1393-1402. 
Ceruti S, Villa G, Genovese T, Mazzon E, Longhi R, Rosa P, Bramanti P, Cuzzocrea 
S, Abbracchio MP (2009) The P2Y-like receptor GPR17 as a sensor of 
damage and a new potential target in spinal cord injury. Brain 132:2206-2218. 
Ceruti S, Viganò F, Boda E, Ferrario S, Magni G, Boccazzi M, Rosa P, Buffo A, 
Abbracchio MP (2011) Expression of the new P2Y-like receptor GPR17 during 
oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced 
death. Glia 59:363-378. 
Chamma I, Chevy Q, Poncer JC, Lévi S (2012) Role of the neuronal K-Cl co-
transporter KCC2 in inhibitory and excitatory neurotransmission. Frontiers in 
Cellular Neuroscience 6:5. 
Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL 
(2010) Agonist and Antagonist Effects of Diadenosine Tetraphosphate, a 
Platelet Dense Granule Constituent, on Platelet P2Y(1), P2Y(12) and P2X(1) 
Receptors. Thrombosis Research 125:159-165. 
Chapman RJ, Lall VK, Maxeiner S, Willecke K, Deuchars J, King AE (2013) 
Localization of neurones expressing the gap junction protein Connexin45 
within the adult spinal dorsal horn: a study using Cx45-eGFP reporter mice. 
Brain Structure and Function 218:751-765. 
Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR (1996) Cloned 
and transfected P2Y4 receptors: characterization of a suramin and PPADS-
insensitive response to UTP. British Journal of Pharmacology 119:1301-1303. 
Chehrehasa F, Meedeniya ACB, Dwyer P, Abrahamsen G, Mackay-Sim A (2009) 
EdU, a new thymidine analogue for labelling proliferating cells in the nervous 
system. Journal of Neuroscience Methods 177:122-130. 
Chen C-C, Akopian AN, Sivilottit L, Colquhoun D, Burnstock G, Wood JN (1995) A 
P2X purinoceptor expressed by a subset of sensory neurons. Nature 377:428-
431. 
Chen Y, Li G-W, Wang C, Gu Y, Huang L-YM (2005) Mechanisms underlying 
enhanced P2X receptor-mediated responses in the neuropathic pain state. 
Pain 119:38-48. 
Cheriyan T, Ryan DJ, Weinreb JH, Cheriyan J, Paul JC, Lafage V, Kirsch T, Errico TJ 
(2014) Spinal cord injury models: a review. Spinal Cord 52:588-595. 
Chessell I, Simon J, Hibell A, Michel A, Barnard E, Humphrey P (1998) Cloning and 
functional characterisation of the mouse P2X7 receptor. FEBS Letters 439:26-
30. 
Chi L, Ke Y, Luo C, Li B, Gozal D, Kalyanaraman B, Liu R (2006) Motor Neuron 
Degeneration Promotes Neural Progenitor Cell Proliferation, Migration, and 
Neurogenesis in the Spinal Cords of Amyotrophic Lateral Sclerosis Mice. 
STEM CELLS 24:34-43. 
Chojnacki AK, Mak GK, Weiss S (2009) Identity crisis for adult periventricular neural 
stem cells: subventricular zone astrocytes, ependymal cells or both? Nature 
Reviews Neuroscience 10:153-163. 
Chopp M, Zhang XH, Li Y, Wang L, Chen J, Lu D, Lu M, Rosenblum M (2000) Spinal 
cord injury in rat: treatment with bone marrow stromal cell transplantation. 
Neuroreport 11:3001-3005. 
Chung K, Lee W (1988) Vasoactive intestinal polypeptide (VIP) immunoreactivity in 
the ependymal cells of the rat spinal cord. Neuroscience Letters 95:1-6. 
Cifuentes M, Rodríguez S, Pérez J, Grondona JM, Rodríguez EM, Fernández-Llebrez 
P (1994) Decreased cerebrospinal fluid flow through the central canal of the 
196 
 
spinal cord of rats immunologically deprived of Reissner's fibre. Experimental 
Brain Research 98:431-440. 
Cizkova D, Nagyova M, Slovinska L, Novotna I, Radonak J, Cizek M, Mechirova E, 
Tomori Z, Hlucilova J, Motlik J, Sulla I, Jr., Vanicky I (2009) Response of 
Ependymal Progenitors to Spinal Cord Injury or Enhanced Physical Activity in 
Adult Rat. Cell Mol Neurobiol 29:999-1013. 
Communi D, Motte S, Boeynaems JM, Pirotton S (1996) Pharmacological 
characterization of the human P(2Y4) receptor. European Journal of 
Pharmacology 317:383-389. 
Cook S, Rodland K, McCleskey E (1998) A memory for extracellular Ca2+ by 
speeding recovery of P2X receptors from desensitization. The Journal of 
Neuroscience 18:9238-9244. 
Corns LF (2012) Characterisation of cells in the postnatal neurogenic niche of the 
murine spinal cord. In: School of Biomedical Sciences: University of Leeds. 
Corns LF, Deuchars J, Deuchars SA (2013) GABAergic responses of mammalian 
ependymal cells in the central canal neurogenic niche of the postnatal spinal 
cord. Neuroscience Letters 553:57-62. 
Corns LF, Atkinson L, Daniel J, Edwards IJ, New L, Deuchars J, Deuchars SA (2015) 
Cholinergic Enhancement of Cell Proliferation in the Postnatal Neurogenic 
Niche of the Mammalian Spinal Cord. STEM CELLS 33:2864-2876. 
Coronel MF, Raggio MC, Adler NS, De Nicola AF, Labombarda F, González SL 
(2016) Progesterone modulates pro-inflammatory cytokine expression profile 
after spinal cord injury: Implications for neuropathic pain. Journal of 
Neuroimmunology 292:85-92. 
Cremer H, Chazal G, Lledo PM, Rougon G, Montaron MF, Mayo W, Le Moal M, 
Abrous DN (2000) PSA-NCAM: an important regulator of hippocampal 
plasticity. International Journal of Developmental Neuroscience 18:213-220. 
Criddle DN, de Moura RS, Greenwood IA, Large WA (1996) Effect of niflumic acid on 
noradrenaline-induced contractions of the rat aorta. British Journal of 
Pharmacology 118:1065-1071. 
Daniel J (2015) Characterising properites and responses of cells in the postnatal 
niche of the spinal cord. In: School of Biomedical Sciences: University of 
Leeds. 
Danilov AI, Covacu R, Moe MC, Langmoen IA, Johansson CB, Olsson T, Brundin L 
(2006) Neurogenesis in the adult spinal cord in an experimental model of 
multiple sclerosis. European Journal of Neuroscience 23:394. 
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, 
Gan W-B (2005) ATP mediates rapid microglial response to local brain injury 
in vivo. Nature Neuroscience 8:752-758. 
Davids E, Hevers W, Dämgen K, Zhang K, Tarazi FI, Lüddens H (2002) Organotypic 
rat cerebellar slice culture as a model to analyze the molecular pharmacology 
of GABAA receptors. European Neuropsychopharmacology 12:201-208. 
De Leener B, Taso M, Cohen-Adad J, Callot V (2016) Segmentation of the human 
spinal cord. Magnetic Resonance Materials in Physics, Biology and Medicine 
29:125-153. 
de Oliveira FM, Pelegrini-da-Silva A, Araldi D, Parada C, Tambeli C (2010) P2X3 and 
P2X2/3 receptors mediate mechanical hyperalgesia induced by bradykinin, 
but not by pro-inflammatory cytokines, PGE₂ or dopamine. European Journal 
of Pharmacology 649:177-182. 
de Rivero Vaccari JP, Bastien D, Yurcisin G, Pineau I, Dietrich WD, De Koninck Y, 
Keane RW, Lacroix S (2012) P2X4 Receptors Influence Inflammasome 
197 
 
Activation after Spinal Cord Injury. The Journal of Neuroscience 32:3058-
3066. 
Delmas P (2005) Polycystins: polymodal receptor/ion-channel cellular sensors. 
Pflugers Arch - Eur J Physiol 451:264-276. 
Dervan AG, Roberts BL (2003) Reaction of spinal cord central canal cells to cord 
transection and their contribution to cord regeneration. The Journal of 
Comparative Neurology 458:293-306. 
Deschênes‐Furry J, Perrone‐Bizzozero N, Jasmin BJ (2006) The RNA‐binding protein 
HuD: a regulator of neuronal differentiation, maintenance and plasticity. 
Bioessays 28:822-833. 
Deuchars SA, Brooke RE, Deuchars J (2001) Adenosine A1 Receptors Reduce 
Release from Excitatory But Not Inhibitory Synaptic Inputs onto Lateral Horn 
Neurons. The Journal of Neuroscience 21:6308-6320. 
Ding S, Sachs F (1999) Single Channel Properties of P2X2 Purinoceptors. The 
Journal of General Physiology 113:695-720. 
Djenoune L, Khabou H, Joubert F, Quan FB, Nunes Figueiredo S, Bodineau L, Del 
Bene F, Burcklé C, Tostivint H, Wyart C (2014) Investigation of spinal 
cerebrospinal fluid-contacting neurons expressing PKD2L1: evidence for a 
conserved system from fish to primates. Frontiers in Neuroanatomy 8. 
Doetsch F (2003) The glial identity of neural stem cells. Nature Neuroscience 6:1127-
1134. 
Doetsch F, Caille I, Lim DA, García-Verdugo JM, Alvarez-Buylla A (1999) 
Subventricular zone astrocytes are neural stem cells in the adult mammalian 
brain. Cell 97:703-716. 
Doetsch F, Petreanu L, Caille I, Garcia-Verdugo J-M, Alvarez-Buylla A (2002) EGF 
Converts Transit-Amplifying Neurogenic Precursors in the Adult Brain into 
Multipotent Stem Cells. Neuron 36:1021-1034. 
Doleski PH, Mendes RE, Leal D, Bottari NB, Piva MM, Da Silva ES, Gabriel ME, 
Lucca NJ, Schwertz CI, Giacomim P (2016) Seric and hepatic NTPDase and 
5'nucleotidase activities of rats experimentally infected by Fasciola hepatica. 
Parasitology 143:551-556. 
Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 
receptor pharmacology: comparison of recombinant mouse, rat and human 
P2X7 receptors. British Journal of Pharmacology 157:1203-1214. 
Dromard C, Guillon H, Rigau V, Ripoll C, Sabourin J-C, Perrin F, Scamps F, Bozza S, 
Sabatier P, Lonjon N (2008) Adult human spinal cord harbors neural precursor 
cells that generate neurons and glial cells in vitro. Journal of Neuroscience 
Research 86:1916-1926. 
Dupret D, Revest J-M, Koehl M, Ichas F, De Giorgi F, Costet P, Abrous DN, Piazza 
PV (2008) Spatial relational memory requires hippocampal adult 
neurogenesis. PLoS ONE 3:e1959. 
Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M (2005) A role 
for CXCR4 signaling in survival and migration of neural and oligodendrocyte 
precursors. Glia 50:258-269. 
Egan TM, Samways DSK, Li Z (2006) Biophysics of P2X receptors. Pflugers Arch - 
Eur J Physiol 452:501-512. 
Eickhorst AN, Berson A, Cockayne D, Lester HA, Khakh BS (2002) Control of P2X2 
channel permeability by the cytosolic domain. The Journal of General 
Physiology 120:119-131. 
Erb L, Liao Z, Seye CI, Weisman GA (2006) P2 receptors: intracellular signaling. 
Pflugers Arch - Eur J Physiol 452:552-562. 
198 
 
Erb L, Liu J, Ockerhausen J, Kong Q, Garrad RC, Griffin K, Neal C, Krugh B, 
Santiago-Pérez LI, González FA, Gresham HD, Turner JT, Weisman GA 
(2001) An Rgd Sequence in the P2y2 Receptor Interacts with αVβ3 Integrins 
and Is Required for Go-Mediated Signal Transduction. The Journal of Cell 
Biology 153:491-502. 
Evans RJ, Lewis C, Virginio C, Lundstrom K, Buell G, Surprenant A, North RA (1996) 
Ionic permeability of, and divalent cation effects on, two ATP-gated cation 
channels (P2X receptors) expressed in mammalian cells. The Journal of 
Physiology 497:413-422. 
Exintaris B, Lang R (1999) K+ channel blocker modulation of the refractory period in 
spontaneously active guinea-pig ureters. Urological Research 27:319-327. 
Fabel K, Kempermann G (2008) Physical activity and the regulation of neurogenesis 
in the adult and aging brain. Neuromolecular Medicine 10:59-66. 
Fahrenkrug J, De Muckadell OS, Fahrenkrug A (1977) Vasoactive intestinal 
polypeptide (VIP) in human cerebrospinal fluid. Brain Research 124:581-584. 
Fan J, Zeng H, Olson DP, Huber KM, Gibson JR, Takahashi JS (2015) Vasoactive 
Intestinal Polypeptide (VIP)-Expressing Neurons in the Suprachiasmatic 
Nucleus Provide Sparse GABAergic Outputs to Local Neurons with Circadian 
Regulation Occurring Distal to the Opening of Postsynaptic GABAA Ionotropic 
Receptors. The Journal of Neuroscience 35:1905-1920. 
Feng L, Hatten ME, Heintz N (1994) Brain lipid-binding protein (BLBP): A novel 
signaling system in the developing mammalian CNS. Neuron 12:895-908. 
Ferrari D, Gulinelli S, Salvestrini V, Lucchetti G, Zini R, Manfredini R, Caione L, 
Piacibello W, Ciciarello M, Rossi L, Idzko M, Ferrari S, Di Virgilio F, Lemoli 
RM (2011) Purinergic stimulation of human mesenchymal stem cells 
potentiates their chemotactic response to CXCL12 and increases the homing 
capacity and production of proinflammatory cytokines. Experimental 
Hematology 39:360-374.e365. 
Ferreira JM, Paes-de-Carvalho R (2001) Long-term activation of adenosine A 2a 
receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons. 
Brain Research 900:169-176. 
Ferreri DM, Vincent PA (2008) Signaling to and through the endothelial adherens 
junction. Cell Junctions: Adhesion, Development, and Disease:169-195. 
Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, Vezzani A, Ottolenghi S, 
Pandolfi PP, Sala M, DeBiasi S (2004) Sox2 deficiency causes 
neurodegeneration and impaired neurogenesis in the adult mouse brain. 
Development 131:3805-3819. 
Fidelin K, Djenoune L, Stokes C, Prendergast A, Gomez J, Baradel A, Del Bene F, 
Wyart C (2015) State-Dependent Modulation of Locomotion by GABAergic 
Spinal Sensory Neurons. Current Biology 25:3035-3047. 
Fields RD, Stevens B (2000) ATP: an extracellular signaling molecule between 
neurons and glia. Trends in Neurosciences 23:625-633. 
Fields RD, Stevens-Graham B (2002) New Insights into Neuron-Glia Communication. 
Science 298:556-562. 
Fields RD, Burnstock G (2006) Purinergic signalling in neuron-glia interactions. 
Nature reviews Neuroscience 7:423-436. 
Filippov AK, Simon J, Barnard EA, Brown DA (2003) Coupling of the nucleotide P2Y4 
receptor to neuronal ion channels. British Journal of Pharmacology 138:400-
406. 
Flores-Soto E, Reyes-García J, Sommer B, Chavez J, Barajas-López C, Montaño LM 
(2012) PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse 
199 
 
mode of the Na+/Ca2+ exchanger in guinea pig airway smooth muscle. 
European Journal of Pharmacology 674:439-444. 
Francius C, Harris A, Rucchin V, Hendricks TJ, Stam FJ, Barber M, Kurek D, 
Grosveld FG, Pierani A, Goulding M, Clotman F (2013) Identification of 
Multiple Subsets of Ventral Interneurons and Differential Distribution along the 
Rostrocaudal Axis of the Developing Spinal Cord. PLoS ONE 8:e70325. 
Franke H, Krügel U, Schmidt R, Grosche J, Reichenbach A, Illes P (2001) P2 
receptor-types involved in astrogliosis in vivo. British Journal of Pharmacology 
134:1180-1189. 
Franke H, Grummich B, Härtig W, Grosche J, Regenthal R, Edwards RH, Illes P, 
Krügel U (2006) Changes in purinergic signaling after cerebral injury – 
involvement of glutamatergic mechanisms? International Journal of 
Developmental Neuroscience 24:123-132. 
Friederike Knerlich-Lukoschus, Ropp-Brenner Bvd, Ralph Lucius, Hubertus 
Maximilian Mehdorn, Janka Held-Feindt (2011) Spatiotemporal CCR1, 
CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal 
cord injury model of posttraumatic neuropathic pain. Journal of Neurosurgery: 
Spine 14:583-597. 
Frisén J, Johansson CB, Török C, Risling M, Lendahl U (1995) Rapid, widespread, 
and longlasting induction of nestin contributes to the generation of glial scar 
tissue after CNS injury. The Journal of Cell Biology 131:453-464. 
Fuentes E, Palomo I (2015) Extracellular ATP metabolism on vascular endothelial 
cells: A pathway with pro-thrombotic and anti-thrombotic molecules. Vascular 
Pharmacology 75:1-6. 
Fujiwara Y, Kubo Y (2004) Density-dependent changes of the pore properties of the 
P2X2 receptor channel. The Journal of Physiology 558:31-43. 
Furlan JC, Kattail D, Fehlings MG (2009) The impact of co-morbidities on age-related 
differences in mortality after acute traumatic spinal cord injury. Journal of 
Neurotrauma 26:1361-1367. 
Gage FH (2000) Mammalian Neural Stem Cells. Science 287:1433-1438. 
Gao Z, Nissen JC, Legakis L, Tsirka SE (2015) Nicotine modulates neurogenesis in 
the central canal during EAE. Neuroscience 297:11-21. 
Garcia-Ovejero D, Arevalo-Martin A, Paniagua-Torija B, Sierra-Palomares Y, Molina-
Holgado E (2013) A cell population that strongly expresses the CB1 
cannabinoid receptor in the ependyma of the rat spinal cord. Journal of 
Comparative Neurology 521:233-251. 
Garcia-Ovejero D, Arevalo-Martin A, Paniagua-Torija B, Florensa-Vila J, Ferrer I, 
Grassner L, Molina-Holgado E (2015) The ependymal region of the adult 
human spinal cord differs from other species and shows ependymoma-like 
features. Brain 138:1583-1597. 
Garfia A, Mestres P, Rascher K (1979) Trinitrophenol lesions of the ventricular wall: a 
SEM-TEM study. Scanning Electron Microscopy:449-456. 
Gengatharan A, Bammann RR, Saghatelyan A (2016) The Role of Astrocytes in the 
Generation, Migration, and Integration of New Neurons in the Adult Olfactory 
Bulb. Frontiers in Neuroscience 10. 
Genzen JR, Platel J-C, Rubio ME, Bordey A (2009) Ependymal cells along the lateral 
ventricle express functional P2X7 receptors. Purinergic Signalling 5:299-307. 
Gibson SJ, Polak JM, Bloom SR, Wall PD (1981) The distribution of nine peptides in 
rat spinal cord with special emphasis on the substantia gelatinosa and on the 




Giniatullin R, Nistri A (2013) Desensitization properties of P2X3 receptors shaping 
pain signaling. Frontiers in Cellular Neuroscience 7. 
Gómez-Villafuertes R, Rodríguez-Jiménez FJ, Alastrue-Agudo A, Stojkovic M, Miras-
Portugal MT, Moreno-Manzano V (2015) Purinergic Receptors in Spinal Cord-
Derived Ependymal Stem/Progenitor Cells and Their Potential Role in Cell-
Based Therapy for Spinal Cord Injury. Cell Transplantation 24:1493-1509. 
Gratzner H (1982) Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new 
reagent for detection of DNA replication. Science 218:474-475. 
Graumann U, Ritz M-F, Gutierrez Rivero B, Hausmann O (2010) CD133 Expressing 
Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury. 
Current Neurovascular Research 7:144-154. 
Greenwood D, Jagger DJ, Huang L-C, Hoya N, Thorne PR, Wildman SS, King BF, 
Pak K, Ryan AF, Housley GD (2007) P2X receptor signaling inhibits BDNF-
mediated spiral ganglion neuron development in the neonatal rat cochlea. 
Development 134:1407-1417. 
Grillner S, Williams T, Lagerback P-A (1984) The edge cell, a possible intraspinal 
mechanoreceptor. Science 223:500-503. 
Grossman SD, Rosenberg LJ, Wrathall JR (2001) Temporal–Spatial Pattern of Acute 
Neuronal and Glial Loss after Spinal Cord Contusion. Experimental Neurology 
168:273-282. 
Guo R, Sakamoto H, Sugiura S, Ogawa M (2007) Endothelial cell motility is 
compatible with junctional integrity. Journal of Cellular Physiology 211:327-
335. 
Hamilton LK, Truong MKV, Bednarczyk MR, Aumont A, Fernandes KJL (2009) 
Cellular organization of the central canal ependymal zone, a niche of latent 
neural stem cells in the adult mammalian spinal cord. Neuroscience 
164:1044-1056. 
Hansen RR, Nasser A, Falk S, Baldvinsson SB, Ohlsson PH, Bahl JM, Jarvis MF, 
Ding M, Heegaard A-M (2012) Chronic administration of the selective P2X3, 
P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced 
bone pain in mice. European Journal of Pharmacology 688:27-34. 
Harden TK, Nicholas RA, Schachter JB, Lazarowski ER, Boyer JL (1998) 
Pharmacological selectivities of molecularly defined subtypes of P2Y 
receptors. In: The P2 nucleotide receptors, pp 109-134: Springer. 
Hargus NJ, Bertram EH, Patel MK (2009) Adenosine A1 receptors presynaptically 
modulate excitatory synaptic input onto subiculum neurons. Brain Research 
1280:60-68. 
Hatton G, Doran A, Salm A, Tweedle C (1980) Brain slice preparation: hypothalamus. 
Brain Research Bulletin 5:405-414. 
Heathcote RD, Chen A (1994) Morphogenesis of catecholaminergic interneurons in 
the frog spinal cord. The Journal of Comparative Neurology 342:57-68. 
Heine C, Heimrich B, Vogt J, Wegner A, Illes P, Franke H (2006) P2 receptor-
stimulation influences axonal outgrowth in the developing hippocampus in 
vitro. Neuroscience 138:303-311. 
Heine C, Sygnecka K, Scherf N, Grohmann M, Bräsigk A, Franke H (2015) P2Y1 
receptor mediated neuronal fibre outgrowth in organotypic brain slice co-
cultures. Neuropharmacology 93:252-266. 
Heyman NS, Burt JM (2008) Hindered Diffusion through an Aqueous Pore Describes 
Invariant Dye Selectivity of Cx43 Junctions. Biophysical Journal 94:840-854. 
Hockfield S, McKay RDG (1985) Identification of major cell classes in the developing 
mammalian nervous system. Journal of Neuroscience 5:3310-3328. 
201 
 
Hofstetter CP, Holmstrom NAV, Lilja JA, Schweinhardt P, Hao J, Spenger C, 
Wiesenfeld-Hallin Z, Kurpad SN, Frisen J, Olson L (2005) Allodynia limits the 
usefulness of intraspinal neural stem cell grafts; directed differentiation 
improves outcome. Nature Neuroscience 8:346-353. 
Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang R-B, 
Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet 
ADP receptor targeted by antithrombotic drugs. Nature 409:202-207. 
Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, Thal LJ, 
Gage FH (2000) Proliferation and differentiation of progenitor cells throughout 
the intact adult rat spinal cord. The Journal of Neuroscience 20:2218-2228. 
Hou M, Li Y, Paul DL (2013) A novel, highly sensitive method for assessing gap 
junctional coupling. Journal of Neuroscience Methods 220:18-23. 
Huang AL, Chen X, Hoon MA, Chandrashekar J, Guo W, Trankner D, Ryba NJP, 
Zuker CS (2006) The cells and logic for mammalian sour taste detection. 
Nature 442:934-938. 
Huang T, You Y, Spoor MS, Richer EJ, Kudva VV, Paige RC, Seiler MP, Liebler JM, 
Zabner J, Plopper CG, Brody SL (2003) Foxj1 is required for apical 
localization of ezrin in airway epithelial cells. Journal of Cell Science 
116:4935-4945. 
Hugel S, Schlichter R (2000) Presynaptic P2X Receptors Facilitate Inhibitory 
GABAergic Transmission between Cultured Rat Spinal Cord Dorsal Horn 
Neurons. The Journal of Neuroscience 20:2121-2130. 
Hugnot JP, Franzen R (2011) The spinal cord ependymal region: a stem cell niche in 
the caudal central nervous system. Frontiers in Bioscience 16:1044-1059. 
Hulsebosch CE (2002) Recent advances in Pathophysiology and Treatment of Spinal 
Cord Injury. Advances in Physiology Education 26:238-255. 
Hultman E, Greenhaff P (1991) Skeletal muscle energy metabolism and fatigue 
during intense exercise in man. Science Progress:361-370. 
Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD (2006) 
Astrocytes Promote Myelination in Response to Electrical Impulses. Neuron 
49:823-832. 
Iyer NR, Wilems TS, Sakiyama‐Elbert SE (2017) Stem cells for spinal cord injury: 
Strategies to inform differentiation and transplantation. Biotechnology and 
Bioengineering 114:245-259. 
Jacobson KA, Müller CE (2016) Medicinal chemistry of adenosine, P2Y and P2X 
receptors. Neuropharmacology 104:31-49. 
Jacobson KA, Balasubramanian R, Deflorian F, Gao Z-G (2012) G protein-coupled 
adenosine (P1) and P2Y receptors: ligand design and receptor interactions. 
Purinergic Signalling 8:419-436. 
Jaeger C, Teitelman G, Joh T, Albert V, Park D, Reis D (1983) Some neurons of the 
rat central nervous system contain aromatic-L-amino-acid decarboxylase but 
not monoamines. Science 219:1233-1235. 
Jaerve A, Bosse F, Müller HW (2012) SDF-1/CXCL12: Its role in spinal cord injury. 
The International Journal of Biochemistry and Cell Biology 44:452-456. 
Jaerve A, Schiwy N, Schmitz C, Mueller HW (2011) Differential effect of aging on 
axon sprouting and regenerative growth in spinal cord injury. Experimental 
Neurology 231:284-294. 
Jalalvand E, Robertson B, Wallén P, Hill RH, Grillner S (2014) Laterally projecting 
cerebrospinal fluid-contacting cells in the lamprey spinal cord are of two 
distinct types. Journal of Comparative Neurology 522:1753-1768. 
Jiang L-H, Hao Y, Mousawi F, Peng H, Yang X (2016) Expression of P2 Purinergic 
Receptors in Mesenchymal Stem Cells and Their Roles in Extracellular 
202 
 
Nucleotide Regulation of Cell Functions. Journal of Cellular Physiology 
232:287-297. 
Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD (2008) 
Multiplicity of cerebrospinal fluid functions: New challenges in health and 
disease. Cerebrospinal Fluid Research 5:1-32. 
Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisén J (1999) 
Identification of a neural stem cell in the adult mammalian central nervous 
system. Cell 96:25-34. 
Kahanovitch U, Tsemakhovich V, Berlin S, Rubinstein M, Styr B, Castel R, Peleg S, 
Tabak G, Dessauer CW, Ivanina T, Dascal N (2014) Recruitment of Gβγ 
controls the basal activity of G-protein coupled inwardly rectifying potassium 
(GIRK) channels: crucial role of distal C terminus of GIRK1. The Journal of 
Physiology 592:5373-5390. 
Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J (2014) Cation-chloride 
cotransporters in neuronal development, plasticity and disease. Nature 
Reviews Neuroscience 15:637-654. 
Kao GD, McKenna WG, Yen TJ (2001) Detection of repair activity during the DNA 
damage-induced G2 delay in human cancer cells. Oncogene 20:3486-3496. 
Keilani S, Sugaya K (2008) Reelin induces a radial glial phenotype in human neural 
progenitor cells by activation of Notch-1. BMC Developmental Biology 8:1. 
Kennedy C (2005) P2X receptors: targets for novel analgesics? The Neuroscientist 
11:345-356. 
Khadra A, Yan Z, Coddou C, Tomić M, Sherman A, Stojilkovic SS (2012) Gating 
properties of the P2X2a and P2X2b receptor channels: Experiments and 
mathematical modeling. The Journal of General Physiology 139:333-348. 
Khakh BS, Bao XR, Labarca C, Lester HA (1999) Neuronal P2X transmitter-gated 
cation channels change their ion selectivity in seconds. Nature Neuroscience 
2:322-330. 
Khakh BS, Smith WB, Chiu C-S, Ju D, Davidson N, Lester HA (2001) Activation-
dependent changes in receptor distribution and dendritic morphology in 
hippocampal neurons expressing P2X(2)-green fluorescent protein receptors. 
Proceedings of the National Academy of Sciences 98:5288-5293. 
Khallaf FG, Kehinde EO, Mostafa A (2016) Growth factors and cytokines in patients 
with long bone fractures and associated spinal cord injury. Journal of 
Orthopaedics 13:69-75. 
Khawaled R, Bruening-Wright A, Adelman JP, Maylie J (1999) Bicuculline block of 
small-conductance calcium-activated potassium channels. Pflugers Arch - Eur 
J Physiol 438:314-321. 
Khmyz V, Maximyuk O, Teslenko V, Verkhratsky A, Krishtal O (2008) P2X3 receptor 
gating near normal body temperature. Pflugers Arch - Eur J Physiol 456:339-
347. 
King BF, Wildman SS, Ziganshina LE, Pintor J, Burnstock G (1997) Effects of 
extracellular pH on agonism and antagonism at a recombinant P2X2 receptor. 
British Journal of Pharmacology 121:1445-1453. 
Kojima A, Tator CH (2000) Epidermal Growth Factor and Fibroblast Growth Factor 2 
Cause Proliferation of Ependymal Precursor Cells in the Adult Rat Spinal Cord 
In Vivo. Journal of Neuropathology and Experimental Neurology 59:687-697. 
Kojima A, Tator CH (2002) Intrathecal administration of epidermal growth factor and 
fibroblast growth factor 2 promotes ependymal proliferation and functional 




Köles L, Gerevich Z, Oliveira JF, Zadori ZS, Wirkner K, Illes P (2008) Interaction of 
P2 purinergic receptors with cellular macromolecules. Naunyn-
Schmiedeberg's Archives of Pharmacology 377:1-33. 
Kriegstein A, Alvarez-Buylla A (2009) The Glial Nature of Embryonic and Adult Neural 
Stem Cells. Annual Review of Neuroscience 32:149-184. 
Krityakiarana W, Zhao PM, Nguyen K, Gomez-Pinilla F, Kotchabhakdi N, de Vellis J, 
Espinosa-Jeffrey A (2016) Proof-of Concept that an Acute Trophic Factors 
Intervention After Spinal Cord Injury Provides an Adequate Niche for 
Neuroprotection, Recruitment of Nestin-Expressing Progenitors and 
Regeneration. Neurochemical Research 41:431-449. 
Kubo Y (1991) Properties of ionic currents induced by external ATP in a mouse 
mesodermal stem cell line. The Journal of Physiology 442:691-710. 
Kuhn HG, Peterson DA (2008) 3 Detection and Phenotypic Characterization of Adult 
Neurogenesis. Cold Spring Harbor Monograph Archive 52:25-47. 
Kunzelmann P, Schröder W, Traub O, Steinhäuser C, Dermietzel R, Willecke K 
(1999) Late onset and increasing expression of the gap junction protein 
connexin 30 in adult murine brain and long-term cultured astrocytes. Glia 
25:111-119. 
Kupitz Y, Atlas D (1993) A putative ATP-activated Na+ channel involved in sperm-
induced fertilization. Science 261:484-486. 
Kuriyama K, Hirouchi M, Nakayasu H (1993) Structure and function of cerebral GABA 
A and GABA B receptors. Neuroscience Research 17:91-99. 
Kuwajima T, Sitko AA, Bhansali P, Jurgens C, Guido W, Mason C (2013) Clear(T): a 
detergent- and solvent-free clearing method for neuronal and non-neuronal 
tissue. Development 140:1364-1368. 
Labombarda F, Ghoumari AM, Liere P, De Nicola AF, Schumacher M, Guennoun R 
(2013) Neuroprotection by steroids after neurotrauma in organotypic spinal 
cord cultures: A key role for progesterone receptors and steroidal modulators 
of GABAA receptors. Neuropharmacology 71:46-55. 
Lacroix S, Hamilton LK, Vaugeois A, Beaudoin S, Breault-Dugas C, Pineau I, 
Lévesque SA, Grégoire C-A, Fernandes KJL (2014) Central Canal Ependymal 
Cells Proliferate Extensively in Response to Traumatic Spinal Cord Injury but 
Not Demyelinating Lesions. PLoS ONE 9:e85916. 
Lahne M, Gale JE (2010) Damage-induced cell-cell communication in different 
cochlear cell types via two distinct ATP-dependent Ca waves. Purinergic 
Signalling 6:189-200. 
Lambrecht G (2000) Agonists and antagonists acting at P2X receptors: selectivity 
profiles and functional implications. Naunyn-Schmiedeberg's Archives of 
Pharmacology 362:340-350. 
Lamotte CC (1987) Vasoactive intestinal polypeptide cerebrospinal fluid‐contacting 
neurons of the monkey and cat spinal central canal. Journal of Comparative 
Neurology 258:527-541. 
Lang J, Maeda Y, Bannerman P, Xu J, Horiuchi M, Pleasure D, Guo F (2013) 
Adenomatous Polyposis Coli Regulates Oligodendroglial Development. The 
Journal of Neuroscience 33:3113-3130. 
Langer D, Ikehara Y, Takebayashi H, Hawkes R, Zimmermann H (2007) The 
ectonucleotidases alkaline phosphatase and nucleoside triphosphate 
diphosphohydrolase 2 are associated with subsets of progenitor cell 
populations in the mouse embryonic, postnatal and adult neurogenic zones. 
Neuroscience 150:863-879. 
Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, Harden TK (1995) 
Pharmacological selectivity of the cloned human P2U-purinoceptor: potent 
204 
 
activation by diadenosine tetraphosphate. British Journal of Pharmacology 
116:1619-1627. 
Lecca D, Ceruti S, Fumagalli M, Abbracchio MP (2012) Purinergic trophic signalling in 
glial cells: functional effects and modulation of cell proliferation, differentiation, 
and death. Purinergic Signalling 8:539-557. 
Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, Villa G, Verderio 
C, Grumelli C, Guerrini U, Tremoli E, Rosa P, Cuboni S, Martini C, Buffo A, 
Cimino M, Abbracchio MP (2008) The Recently Identified P2Y-Like Receptor 
GPR17 Is a Sensor of Brain Damage and a New Target for Brain Repair. 
PLoS ONE 3:e3579. 
Lechner SG, Boehm S (2004) Regulation of neuronal ion channels via P2Y receptors. 
Purinergic Signalling 1:31-41. 
Lee BB, Cripps RA, Fitzharris M, Wing PC (2014a) The global map for traumatic 
spinal cord injury epidemiology: update 2011, global incidence rate. Spinal 
Cord 52:110-116. 
Lee H, Koh BH, Peri LE, Sanders KM, Koh SD (2014b) Purinergic inhibitory 
regulation of murine detrusor muscles mediated by PDGFRα+ interstitial cells. 
The Journal of Physiology 592:1283-1293. 
Lee H, Koh BH, Yamasaki E, George NE, Sanders KM, Koh SD (2015) UTP activates 
small-conductance Ca2+-activated K+ channels in murine detrusor PDGFRα+ 
cells. American Journal of Physiology - Renal Physiology 309:F569-F574. 
Lee HJ, Wu J, Chung J, Wrathall JR (2013) SOX2 expression is upregulated in adult 
spinal cord after contusion injury in both oligodendrocyte lineage and 
ependymal cells. Journal of Neuroscience Research 91:196-210. 
Lee SH, Hao E, Levine F, Itkin-Ansari P (2011) Id3 upregulates BrdU incorporation 
associated with a DNA damage response, not replication, in human 
pancreatic β-cells. Islets 3:358-366. 
Lehtinen Maria K, Zappaterra Mauro W, Chen X, Yang Yawei J, Hill AD, Lun M, 
Maynard T, Gonzalez D, Kim S, Ye P, D'Ercole AJ, Wong Eric T, LaMantia 
Anthony S, Walsh Christopher A (2011) The Cerebrospinal Fluid Provides a 
Proliferative Niche for Neural Progenitor Cells. Neuron 69:893-905. 
Lerma J, Martín del Río R (1992) Chloride transport blockers prevent N-methyl-D-
aspartate receptor-channel complex activation. Molecular Pharmacology 
41:217-222. 
Li F, Liu X, Sampson JH, Bigner DD, Li C-Y (2016) Rapid reprogramming of primary 
human astrocytes into potent tumor initiating cells with defined genetic factors. 
Cancer Research 76:5143-5150. 
Li H, Chuang AZ, O’Brien J (2014) Regulation of photoreceptor gap junction 
phosphorylation by adenosine in zebrafish retina. Visual Neuroscience 
31:237. 
Li M, Toombes GES, Silberberg SD, Swartz KJ (2015) Physical basis of apparent 
pore dilation of ATP-activated P2X receptor channels. Nature Neuroscience 
18:1577-1583. 
Li X, Kang L, Li G, Zeng H, Zhang L, Ling X, Dong H, Liang S, Chen H (2013) 
Intrathecal leptin inhibits expression of the P2X2/3 receptors and alleviates 
neuropathic pain induced by chronic constriction sciatic nerve injury. 
Molecular Pain 9:1. 
Liu D-H, Huang X, Guo X, Meng X-M, Wu Y-S, Lu H-L, Zhang C-M, Kim Y-c, Xu W-X 
(2014) Voltage dependent potassium channel remodeling in murine intestinal 




Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Pérez LI, González FA, 
Seye CI, Weisman GA, Erb L (2004) Src Homology 3 Binding Sites in the 
P2Y2 Nucleotide Receptor Interact with Src and Regulate Activities of Src, 
Proline-rich Tyrosine Kinase 2, and Growth Factor Receptors. Journal of 
Biological Chemistry 279:8212-8218. 
Liu K, Wang Z, Wang H, Zhang Y (2002) Nestin expression and proliferation of 
ependymal cells in adult rat spinal cord after injury. Chinese Medical Journal 
115:339-341. 
Liu M, King BF, Dunn PM, Rong W, Townsend-Nicholson A, Burnstock G (2001) 
Coexpression of P2X3 and P2X2 Receptor Subunits in Varying Amounts 
Generates Heterogeneous Populations of P2X Receptors That Evoke a 
Spectrum of Agonist Responses Comparable to That Seen in Sensory 
Neurons. Journal of Pharmacology and Experimental Therapeutics 296:1043-
1050. 
Llorente IL, Landucci E, Pellegrini-Giampietro DE, Fernández-López A (2015) 
Glutamate receptor and transporter modifications in rat organotypic 
hippocampal slice cultures exposed to oxygen–glucose deprivation: The 
contribution of cyclooxygenase-2. Neuroscience 292:118-128. 
Lohr C, Grosche A, Reichenbach A, Hirnet D (2014) Purinergic neuron-glia 
interactions in sensory systems. Pflugers Arch - Eur J Physiol 466:1859-1872. 
Lu W-H, Wang C-Y, Chen P-S, Wang J-W, Chuang D-M, Yang C-S, Tzeng S-F 
(2013) Valproic acid attenuates microgliosis in injured spinal cord and 
purinergic P2X4 receptor expression in activated microglia. Journal of 
Neuroscience Research 91:694-705. 
Lukenda A, Dotlic S, Vukojevic N, Saric B, Vranic S, Zarkovic K (2016) Expression 
and prognostic value of putative cancer stem cell markers CD117 and CD15 
in choroidal and ciliary body melanoma. Journal of Clinical Pathology 69:234-
239. 
Ma B, Wynn G, Dunn PM, Burnstock G (2006) Increased 5-HT3-mediated signalling 
in pelvic afferent neurons from mice deficient in P2X2 and/or P2X3 receptor 
subunits. Purinergic Signalling 2:481-489. 
Mackenzie AB, Surprenant A, North AB (1999) Functional and Molecular Diversity of 
Purinergic Ion Channel Receptors. Annals of the New York Academy of 
Sciences 868:716-729. 
Magoul R, Onteniente B, Geffard M, Calas A (1987) Anatomical distribution and 
ultrastructural organization of the gabaergic system in the rat spinal cord. An 
immunocytochemical study using anti-GABA antibodies. Neuroscience 
20:1001-1009. 
Maillot C (1990) The perispinal spaces. Constitution, organization and relations with 
the cerebrospinal fluid (CSF). Journal of Neuroradiology 18:18-31. 
Mao Y, Mathews K, Gorrie CA (2016) Temporal Response of Endogenous Neural 
Progenitor Cells Following Injury to the Adult Rat Spinal Cord. Frontiers in 
Cellular Neuroscience 10. 
Margeta‐Mitrovic M, Mitrovic I, Riley RC, Jan LY, Basbaum AI (1999) 
Immunohistochemical localization of GABAB receptors in the rat central 
nervous system. Journal of Comparative Neurology 405:299-321. 
Marichal N, Fabbiani G, Trujillo-Cenóz O, Russo RE (2016) Purinergic signalling in a 
latent stem cell niche of the rat spinal cord. Purinergic Signalling:1-11. 
Marichal N, García G, Radmilovich M, Trujillo-Cenóz O, Russo RE (2009) Enigmatic 
Central Canal Contacting Cells: Immature Neurons in "Standby Mode"? The 
Journal of Neuroscience 29:10010-10024. 
206 
 
Marriott AS, Copeland NA, Cunningham R, Wilkinson MC, McLennan AG, Jones NJ 
(2015) Diadenosine 5′, 5′′′-P1,P4-tetraphosphate (Ap4A) is synthesized in 
response to DNA damage and inhibits the initiation of DNA replication. DNA 
Repair 33:90-100. 
Martens DJ, Seaberg RM, Van Der Kooy D (2002) In vivo infusions of exogenous 
growth factors into the fourth ventricle of the adult mouse brain increase the 
proliferation of neural progenitors around the fourth ventricle and the central 
canal of the spinal cord. European Journal of Neuroscience 16:1045-1057. 
Marusich MF, Furneaux HM, Henion PD, Weston JA (1994) Hu neuronal proteins are 
expressed in proliferating neurogenic cells. Journal of Neurobiology 25:143-
155. 
McLaren GJ, Kennedy C, Sneddon P (1995) The effects of suramin on purinergic and 
noradrenergic neurotransmission in the rat isolated tail artery. European 
Journal of Pharmacology 277:57-61. 
McLaughlin BJ, Barber R, Saito K, Roberts E, Wu JY (1975) Immunocytochemical 
localization of glutamate decarboxylase in rat spinal cord. Journal of 
Comparative Neurology 164:305-321. 
Mead TJ, Lefebvre V (2014) Proliferation Assays (BrdU and EdU) on Skeletal Tissue 
Sections. In: Skeletal Development and Repair: Methods and Protocols (Hilton 
JM, ed), pp 233-243. Totowa, NJ: Humana Press. 
Melani A, Turchi D, Vannucchi MG, Cipriani S, Gianfriddo M, Pedata F (2005) ATP 
extracellular concentrations are increased in the rat striatum during in vivo 
ischemia. Neurochemistry International 47:442-448. 
Meletis K, Barnabé-Heider F, Carlén M, Evergren E, Tomilin N, Shupliakov O, Frisén 
J (2008) Spinal cord injury reveals multilineage differentiation of ependymal 
cells. PLoS Biology 6:e182. 
Messemer N, Kunert C, Grohmann M, Sobottka H, Nieber K, Zimmermann H, Franke 
H, Nörenberg W, Straub I, Schaefer M, Riedel T, Illes P, Rubini P (2013) 
P2X7 receptors at adult neural progenitor cells of the mouse subventricular 
zone. Neuropharmacology 73:122-137. 
Migaud M, Butruille L, Duittoz A, Pillon D, Batailler M (2016) Adult neurogenesis and 
reproductive functions in mammals. Theriogenology 86:313-323. 
Milhorat TH, Kotzen RM, Anzil AP (1994) Stenosis of central canal of spinal cord in 
man: incidence and pathological findings in 232 autopsy cases. Journal of 
Neurosurgery 80:716-722. 
Mirzadeh Z, Merkle FT, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A 
(2008) Neural Stem Cells Confer Unique Pinwheel Architecture to the 
Ventricular Surface in Neurogenic Regions of the Adult Brain. Cell Stem Cell 
3:265-278. 
Mishra SK, Braun N, Shukla V, Füllgrabe M, Schomerus C, Korf H-W, Gachet C, 
Ikehara Y, Sévigny J, Robson SC, Zimmermann H (2006) Extracellular 
nucleotide signaling in adult neural stem cells: synergism with growth factor-
mediated cellular proliferation. Development 133:675-684. 
Mladinic M, Bianchetti E, Dekanic A, Mazzone GL, Nistri A (2014) ATF3 is a novel 
nuclear marker for migrating ependymal stem cells in the rat spinal cord. Stem 
Cell Research 12:815-827. 
Molander C, Xu Q, Grant G (1984) The cytoarchitectonic organization of the spinal 
cord in the rat. I. The lower thoracic and lumbosacral cord. Journal of 
Comparative Neurology 230:133-141. 
Momose-Sato Y, Honda Y, Sasaki H, Sato K (2005) Optical Imaging of Large-Scale 




Moore SA, Oglesbee MJ (2015) Spinal Cord Ependymal Responses to Naturally 
Occurring Traumatic Spinal Cord Injury in Dogs. Veterinary Pathology 
52:1108-1117. 
Moreno-Manzano V, Rodríguez-Jiménez FJ, García-Roselló M, Laínez S, Erceg S, 
Calvo MT, Ronaghi M, Lloret M, Planells-Cases R, Sánchez-Puelles JM, 
Stojkovic M (2009) Activated Spinal Cord Ependymal Stem Cells Rescue 
Neurological Function. STEM CELLS 27:733-743. 
Morgan C, Nadelhaft I, de Groat WC (1981) The distribution of visceral primary 
afferents from the pelvic nerve to Lissauer's tract and the spinal gray matter 
and its relationship to the sacral parasympathetic nucleus. The Journal of 
Comparative Neurology 201:415-440. 
Moriya T, Hassan A, Young W, Chesler M (1994) Dynamics of extracellular calcium 
activity following contusion of the rat spinal cord. Journal of Neurotrauma 
11:255-263. 
Morshead CM, Reynolds BA, Craig CG, McBurney MW, Staines WA, Morassutti D, 
Weiss S, van der Kooy D (1994) Neural stem cells in the adult mammalian 
forebrain: A relatively quiescent subpopulation of subependymal cells. Neuron 
13:1071-1082. 
Mortensen SP, Thaning P, Nyberg M, Saltin B, Hellsten Y (2011) Local release of 
ATP into the arterial inflow and venous drainage of human skeletal muscle: 
insight from ATP determination with the intravascular microdialysis technique. 
The Journal of Physiology 589:1847-1857. 
Mosbacher J, Maier R, Fakler Ba, Glatz A, Crespo J, Bilbe G (1998) P2Y receptor 
subtypes differentially couple to inwardly-rectifying potassium channels. FEBS 
letters 436:104-110. 
Mothe AJ, Tator CH (2005) Proliferation, migration, and differentiation of endogenous 
ependymal region stem/progenitor cells following minimal spinal cord injury in 
the adult rat. Neuroscience 131:177-187. 
Mothe AJ, Zahir T, Santaguida C, Cook D, Tator CH (2011) Neural stem/progenitor 
cells from the adult human spinal cord are multipotent and self-renewing and 
differentiate after transplantation. PLoS ONE 6:e27079. 
Mullen RJ, Buck CR, Smith AM (1992) NeuN, a neuronal specific nuclear protein in 
vertebrates. Development 116:201-211. 
Nacher J, Crespo C, McEwen BS (2001) Doublecortin expression in the adult rat 
telencephalon. European Journal of Neuroscience 14:629-644. 
Nacher J, Pham K, Gil-Fernandez V, McEwen BS (2004) Chronic restraint stress and 
chronic corticosterone treatment modulate differentially the expression of 
molecules related to structural plasticity in the adult rat piriform cortex. 
Neuroscience 126:503-509. 
Nagatsu I, Sakai M, Yoshida M, Nagatsu T (1988) Aromaticl-amino acid 
decarboxylase-immunoreactive neurons in and around the cerebrospinal fluid-
contacting neurons of the central canal do not contain dopamine or serotonin 
in the mouse and rat spinal cord. Brain Research 475:91-102. 
Nakayama Y (1976) The openings of the central canal in the filum terminale internum 
of some mammals. Journal of Neurocytology 5:531-544. 
Neary JT, Kang Y, Willoughby KA, Ellis EF (2003) Activation of Extracellular Signal-
Regulated Kinase by Stretch-Induced Injury in Astrocytes Involves 
Extracellular ATP and P2 Purinergic Receptors. The Journal of Neuroscience 
23:2348-2356. 
Neuhuber W (1982) The central projections of visceral primary afferent neurons of the 
inferior mesenteric plexus and hypogastric nerve and the location of the 
208 
 
related sensory and preganglionic sympathetic cell bodies in the rat. Anatomy 
and Embryology 164:413-425. 
Nicholls J, Saunders N (1996) Regeneration of immature mammalian spinal cord 
after injury. Trends in Neurosciences 19:229-234. 
Nilsson C, Lindvall-Axelsson M, Owman C (1992) Neuroendocrine regulatory 
mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Research 
Reviews 17:109-138. 
Noble K, Floyd R, Shmygol A, Shmygol A, Mobasheri A, Wray S (2010) Distribution, 
expression and functional effects of small conductance Ca-activated 
potassium (SK) channels in rat myometrium. Cell Calcium 47:47-54. 
Noraberg J, Kristensen BW, Zimmer J (1999) Markers for neuronal degeneration in 
organotypic slice cultures. Brain Research Protocols 3:278-290. 
North RA (2002) Molecular Physiology of P2X Receptors. Physiological Reviews 
82:1013-1067. 
North RA (2004) P2X3 receptors and peripheral pain mechanisms. The Journal of 
Physiology 554:301-308. 
North RA (2016) P2X receptors. Philosophical Transactions of the Royal Society of 
London B: Biological Sciences 371. 
North RA, Jarvis MF (2013) P2X Receptors as Drug Targets. Molecular 
Pharmacology 83:759-769. 
Ochalski PAY, Frankenstein UN, Hertzberg EL, Nagy JI (1996) Connexin-43 in rat 
spinal cord: localization in astrocytes and identification of heterotypic astro-
oligodendrocytic gap junctions. Neuroscience 76:931-945. 
Okano HJ, Darnell RB (1997) A hierarchy of Hu RNA binding proteins in developing 
and adult neurons. The Journal of Neuroscience 17:3024-3037. 
Orts-Del'Immagine A, Seddik R, Tell F, Airault C, Er-Raoui G, Najimi M, Trouslard J, 
Wanaverbecq N (2016) A single polycystic kidney disease 2-like 1 channel 
opening acts as a spike generator in cerebrospinal fluid-contacting neurons of 
adult mouse brainstem. Neuropharmacology 101:549-565. 
Oshio K, Watanabe H, Song Y, Verkman A, Manley GT (2005) Reduced 
cerebrospinal fluid production and intracranial pressure in mice lacking 
choroid plexus water channel Aquaporin-1. The FASEB Journal 19:76-78. 
Othman T, Yan H, Rivkees SA (2003) Oligodendrocytes express functional A1 
adenosine receptors that stimulate cellular migration. Glia 44:166-172. 
Paemeleire K, Leybaert L (2000) ATP-dependent astrocyte-endothelial calcium 
signaling following mechanical damage to a single astrocyte in astrocyte-
endothelial co-cultures. Journal of Neurotrauma 17:345-358. 
Parent JM (2007) Adult neurogenesis in the intact and epileptic dentate gyrus. 
Progress in Brain Research 163:529-817. 
Park J-S, Higashi H, Nagata K, Yoshimura M (1999) Bicuculline-resistant, Cl− 
dependent GABA response in the rat spinal dorsal horn. Neuroscience 
Research 33:261-268. 
Parr AM, Kulbatski I, Zahir T, Wang X, Yue C, Keating A, Tator CH (2008) 
Transplanted adult spinal cord–derived neural stem/progenitor cells promote 
early functional recovery after rat spinal cord injury. Neuroscience 155:760-
770. 
Pasternack SM, von Kugelgen I, Aboud KA, Lee Y-A, Ruschendorf F, Voss K, Hillmer 
AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz RC 
(2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in 
maintenance of human hair growth. Nature Genetics 40:329-334. 
Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian G-F, Goldman 
SA, Nedergaard M (2009) Systemic administration of an antagonist of the 
209 
 
ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. 
Proceedings of the National Academy of Sciences 106:12489-12493. 
Petracca YL, Sartoretti MM, Di Bella DJ, Marin-Burgin A, Carcagno AL, Schinder AF, 
Lanuza GM (2016) The late and dual origin of cerebrospinal fluid-contacting 
neurons in the mouse spinal cord. Development 143:880-891. 
Pintor J, King BF, Miras-Portugal MT, Burnstock G (1996) Selectivity and activity of 
adenine dinucleotides at recombinant P2x2 and P2Y1 purinoceptors. British 
Journal of Pharmacology 119:1006-1012. 
Pintor J, Dı́az-Hernández M, Gualix J, Gómez-Villafuertes R, Hernando F, Miras-
Portugal MT (2000) Diadenosine polyphosphate receptors: from rat and 
guinea-pig brain to human nervous system. Pharmacology and Therapeutics 
87:103-115. 
Ponce A, Larre I, Castillo A, García-Villegas R, Romero A, Flores-Maldonado C, 
Martinez-Rendón J, Contreras RG, Cereijido M (2014) Ouabain Increases 
Gap Junctional Communication in Epithelial Cells. Cellular Physiology and 
Biochemistry 34:2081-2090. 
Pratt EB, Brink TS, Bergson P, Voigt MM, Cook SP (2005) Use-Dependent Inhibition 
of P2X3 Receptors by Nanomolar Agonist. The Journal of Neuroscience 
25:7359-7365. 
Probert L, Hanley MR (1987) The immunocytochemical localisation of ‘substance-P-
degrading enzyme’ within the rat spinal cord. Neuroscience Letters 78:132-
137. 
Puchałowicz K, Tarnowski M, Baranowska-Bosiacka I, Chlubek D, Dziedziejko V 
(2014) P2X and P2Y Receptors—Role in the Pathophysiology of the Nervous 
System. International Journal of Molecular Sciences 15:23672-23704. 
Rabinovich-Nikitin I, Ezra A, Barbiro B, Rabinovich-Toidman P, Solomon B (2016) 
Chronic administration of AMD3100 increases survival and alleviates 
pathology in SOD1G93A mice model of ALS. Journal of Neuroinflammation 
13:1-11. 
Rafols JA, Goshgarian HG (1985) Spinal tanycytes in the adult rat : A correlative 
Golgi gold-toning study. The Anatomical Record 211:75-86. 
Rapaport E, Zamecnik PC (1976) Presence of diadenosine 5',5''' -P1, P4-
tetraphosphate (Ap4A) in mamalian cells in levels varying widely with 
proliferative activity of the tissue: a possible positive "pleiotypic activator". 
Proceedings of the National Academy of Sciences 73:3984-3988. 
Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A (1997) The 
Permeabilizing ATP Receptor, P2X7: Cloning and Expression of a Human 
cDNA. Journal of Biological Chemistry 272:5482-5486. 
Reali C, Fernández A, Radmilovich M, Trujillo-Cenóz O, Russo RE (2011) GABAergic 
signalling in a neurogenic niche of the turtle spinal cord. The Journal of 
Physiology 589:5633-5647. 
Reimer Michell M, Norris A, Ohnmacht J, Patani R, Zhong Z, Dias Tatyana B, Kuscha 
V, Scott Angela L, Chen Y-C, Rozov S, Frazer Sarah L, Wyatt C, Higashijima 
S-i, Patton EE, Panula P, Chandran S, Becker T, Becker Catherina G (2013) 
Dopamine from the Brain Promotes Spinal Motor Neuron Generation during 
Development and Adult Regeneration. Developmental Cell 25:478-491. 
Rene F, Poisbeau P, Egles C, Schlichter R, Felix J (1996) Co-culture of hypothalamic 
neurons and melanotrope cells: a model to study synaptogenesis between 
central neurons and endocrine cells. Neuroscience 76:203-214. 
Rexed B (1952) The cytoarchitectonic organization of the spinal cord in the cat. 
Journal of Comparative Neurology 96:415-495. 
210 
 
Roberts BL, Maslam S, Scholten G, Smit W (1995) Dopaminergic and GABAergic 
cerebrospinal fluid‐contacting neurons along the central canal of the spinal 
cord of the eel and trout. Journal of Comparative Neurology 354:423-437. 
Rodriguez-Jimenez FJ, Alastrue-Agudo A, Stojkovic M, Erceg S, Moreno-Manzano V 
(2015) Connexin 50 expression in ependymal stem progenitor cells after 
spinal cord injury activation. International Journal of Molecular Sciences 
16:26608-26618. 
Rodriguez-Jimenez FJ, Alastrue A, Stojkovic M, Erceg S, Moreno-Manzano V (2016) 
Connexin 50 modulates Sox2 expression in spinal-cord-derived ependymal 
stem/progenitor cells. Cell and Tissue Research 365:295-307. 
Rodríguez-Zayas AE, Torrado AI, Miranda JD (2010) P2Y2 receptor expression is 
altered in rats after spinal cord injury. International Journal of Developmental 
Neuroscience 28:413-421. 
Rodríguez-Zayas AE, Torrado AI, Rosas OR, Santiago JM, Figueroa JD, Miranda JD 
(2012) Blockade of P2 Nucleotide Receptors After Spinal Cord Injury Reduced 
the Gliotic Response and Spared Tissue. Journal of Molecular Neuroscience 
46:167-176. 
Rossi L, Manfredini R, Bertolini F, Ferrari D, Fogli M, Zini R, Salati S, Salvestrini V, 
Gulinelli S, Adinolfi E, Ferrari S, Di Virgilio F, Baccarani M, Lemoli RM (2007) 
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem 
cell migration. Blood 109:533-542. 
Rubenstein J (1989) Pathology of tumours of the nervous system. In: Taylor & 
Francis. 
Russi AE, Brown MA (2015) The meninges: new therapeutic targets for multiple 
sclerosis. Translational Research 165:255-269. 
Russo RE, Hounsgaard J (1999) Dynamics of intrinsic electrophysiological properties 
in spinal cord neurones. Progress in Biophysics and Molecular Biology 
72:329-365. 
Russo RE, Fernández A, Reali C, Radmilovich M, Trujillo‐Cenóz O (2004) Functional 
and molecular clues reveal precursor‐like cells and immature neurones in the 
turtle spinal cord. The Journal of Physiology 560:831-838. 
Sabelström H, Stenudd M, Réu P, Dias DO, Elfineh M, Zdunek S, Damberg P, Göritz 
C, Frisén J (2013) Resident Neural Stem Cells Restrict Tissue Damage and 
Neuronal Loss After Spinal Cord Injury in Mice. Science 342:637-640. 
Sabourin J-C, Ackema KB, Ohayon D, Guichet P-O, Perrin FE, Garces A, Ripoll C, 
Charité J, Simonneau L, Kettenmann H (2009) A Mesenchymal-Like ZEB1+ 
Niche Harbors Dorsal Radial Glial Fibrillary Acidic Protein-Positive Stem Cells 
in the Spinal Cord. STEM CELLS 27:2722-2733. 
Saleem H, Tovey SC, Molinski TF, Taylor CW (2014) Interactions of antagonists with 
subtypes of inositol 1,4,5-trisphosphate (IP3) receptor. British Journal of 
Pharmacology 171:3298-3312. 
Sawamoto K, Wichterle H, Gonzalez-Perez O, Cholfin JA, Yamada M, Spassky N, 
Murcia NS, Garcia-Verdugo JM, Marin O, Rubenstein JLR, Tessier-Lavigne 
M, Okano H, Alvarez-Buylla A (2006) New Neurons Follow the Flow of 
Cerebrospinal Fluid in the Adult Brain. Science 311:629-632. 
Saxe MD, Battaglia F, Wang J-W, Malleret G, David DJ, Monckton JE, Garcia ADR, 
Sofroniew MV, Kandel ER, Santarelli L, Hen R, Drew MR (2006) Ablation of 
hippocampal neurogenesis impairs contextual fear conditioning and synaptic 




Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK (1996) Second messenger 
cascade specificity and pharmacological selectivity of the human P2Y1-
purinoceptor. British Journal of Pharmacology 118:167-173. 
Schwab JM, Guo L, Schluesener HJ (2005) Spinal cord injury induces early and 
persistent lesional P2X 4 receptor expression. Journal of Neuroimmunology 
163:185-189. 
Seaberg RM, van der Kooy D (2002) Adult Rodent Neurogenic Regions: The 
Ventricular Subependyma Contains Neural Stem Cells, But the Dentate Gyrus 
Contains Restricted Progenitors. The Journal of Neuroscience 22:1784-1793. 
Sebastião AM, Ribeiro JA (2000) Fine-tuning neuromodulation by adenosine. Trends 
in Pharmacological Sciences 21:341-346. 
Seki T, Arai Y (1993) Highly polysialylated NCAM expression in the developing and 
adult rat spinal cord. Developmental Brain Research 73:141-145. 
Sellers LA, Simon J, Lundahl TS, Cousens DJ, Humphrey PPA, Barnard EA (2001) 
Adenosine Nucleotides Acting at the Human P2Y1Receptor Stimulate 
Mitogen-activated Protein Kinases and Induce Apoptosis. Journal of Biological 
Chemistry 276:16379-16390. 
Seye CI, Yu N, González FA, Erb L, Weisman GA (2004) The P2Y2 Nucleotide 
Receptor Mediates Vascular Cell Adhesion Molecule-1 Expression through 
Interaction with VEGF Receptor-2 (KDR/Flk-1). Journal of Biological 
Chemistry 279:35679-35686. 
Sharpless NS, Thal LJ, Perlow MJ, Tabaddor K, Waltz JM, Shapiro KN, Amin IM, 
Engel J, Crandall PH (1984) Vasoactive intestinal peptide in cerebrospinal 
fluid. Peptides 5:429-433. 
Shatarat A, Dunn WR, Ralevic V (2014) Raised tone reveals ATP as a sympathetic 
neurotransmitter in the porcine mesenteric arterial bed. Purinergic Signalling 
10:639-649. 
Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V (2014) Adenosine receptors: 
expression, function and regulation. International Journal of Molecular 
Sciences 15:2024-2052. 
Shibuya S, Miyamoto O, Auer R, Itano T, Mori S, Norimatsu H (2002) Embryonic 
intermediate filament, nestin, expression following traumatic spinal cord injury 
in adult rats. Neuroscience 114:905-916. 
Shieh C-C, Jarvis MF, Lee C-H, Perner RJ (2006) P2X receptor ligands and pain. 
Expert Opinion on Therapeutic Patents 16:1113-1127. 
Shihabuddin LS, Ray J, Gage FH (1997) FGF-2 is sufficient to isolate progenitors 
found in the adult mammalian spinal cord. Experimental Neurology 148:577-
586. 
Shihabuddin LS, Horner PJ, Ray J, Gage FH (2000) Adult Spinal Cord Stem Cells 
Generate Neurons after Transplantation in the Adult Dentate Gyrus. The 
Journal of Neuroscience 20:8727-8735. 
Shimosegawa T, Koizumi M, Toyota T, Goto Y, Yanaihara C, Yanaihara N (1986) An 
immunohistochemical study of methionine-enkephalin-Arg6-Gly7-Leu8-like 
immunoreactivity-containing liquor-contacting neurons (LCNs) in the rat spinal 
cord. Brain Research 379:1-9. 
Shukla V, Zimmermann H, Wang L, Kettenmann H, Raab S, Hammer K, Sévigny J, 
Robson SC, Braun N (2005) Functional expression of the ecto-ATPase 
NTPDase2 and of nucleotide receptors by neuronal progenitor cells in the 
adult murine hippocampus. Journal of Neuroscience Research 80:600-610. 
Shymanets A, Prajwal, Vadas O, Czupalla C, LoPiccolo J, Brenowitz M, Ghigo A, 
Hirsch E, Krause E, Wetzker R, Williams Roger L, Harteneck C, Nürnberg B 
(2015) Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-
212 
 
kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as 
a Gβγ-dependent regulator of PI3Kγ enzymatic activity. Biochemical Journal 
469:59-69. 
Siddall P, Loeser J (2001) Pain following spinal cord injury. Spinal Cord 39. 
Simon K, Hennen S, Merten N, Blättermann S, Gillard M, Kostenis E, Gomeza J 
(2016) The Orphan G Protein-coupled Receptor GPR17 Negatively Regulates 
Oligodendrocyte Differentiation via Gαi/o and Its Downstream Effector 
Molecules. Journal of Biological Chemistry 291:705-718. 
Sinkkonen ST, Mansikkamäki S, Möykkynen T, Lüddens H, Uusi-Oukari M, Korpi ER 
(2003) Receptor Subtype-Dependent Positive and Negative Modulation of 
GABAA Receptor Function by Niflumic Acid, a Nonsteroidal Anti-Inflammatory 
Drug. Molecular Pharmacology 64:753-763. 
Sokolova E, Skorinkin A, Fabbretti E, Masten L, Nistri A, Giniatullin R (2004) Agonist-
dependence of recovery from desensitization of P2X3 receptors provides a 
novel and sensitive approach for their rapid up or downregulation. British 
Journal of Pharmacology 141:1048-1058. 
Soltoff SP, Avraham H, Avraham S, Cantley LC (1998) Activation of P2Y2 Receptors 
by UTP and ATP Stimulates Mitogen-activated Kinase Activity through a 
Pathway That Involves Related Adhesion Focal Tyrosine Kinase and Protein 
Kinase C. Journal of Biological Chemistry 273:2653-2660. 
Spassky N, Merkle FT, Flames N, Tramontin AD, García-Verdugo JM, Alvarez-Buylla 
A (2005) Adult ependymal cells are postmitotic and are derived from radial 
glial cells during embryogenesis. The Journal of Neuroscience 25:10-18. 
Spector R, Robert Snodgrass S, Johanson CE (2015) A balanced view of the 
cerebrospinal fluid composition and functions: Focus on adult humans. 
Experimental Neurology 273:57-68. 
Stenudd M, Sabelström H, Frisén J (2015) Role of endogenous neural stem cells in 
spinal cord injury and repair. JAMA Neurology 72:235-237. 
Stoeckel M-E, Uhl-Bronner S, Hugel S, Veinante P, Klein M-J, Mutterer J, Freund-
Mercier M-J, Schlichter R (2003) Cerebrospinal fluid-contacting neurons in the 
rat spinal cord, a γ-aminobutyric acidergic system expressing the P2X2 
subunit of purinergic receptors, PSA-NCAM, and GAP-43 immunoreactivities: 
Light and electron microscopic study. The Journal of Comparative Neurology 
457:159-174. 
Stoop R, Surprenant A, North RA (1997) Different Sensitivities to pH of ATP-Induced 
Currents at Four Cloned P2X Receptors. Journal of Neurophysiology 78:1837-
1840. 
Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of 
nervous tissue. Journal of Neuroscience Methods 37:173-182. 
Street SE, Kramer NJ, Walsh PL, Taylor-Blake B, Yadav MC, King IF, Vihko P, 
Wightman RM, Millán JL, Zylka MJ (2013) Tissue-Nonspecific Alkaline 
Phosphatase Acts Redundantly with PAP and NT5E to Generate Adenosine 
in the Dorsal Spinal Cord. The Journal of Neuroscience 33:11314-11322. 
Studeny S, Torabi A, Vizzard MA (2005) P2X2 and P2X3 receptor expression in 
postnatal and adult rat urinary bladder and lumbosacral spinal cord. American 
Journal of Physiology-Regulatory, Integrative and Comparative Physiology 
289:1155-1168. 
Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996) The cytolytic 




Suyama S, Sunabori T, Kanki H, Sawamoto K, Gachet C, Koizumi S, Okano H (2012) 
Purinergic Signaling Promotes Proliferation of Adult Mouse Subventricular 
Zone Cells. The Journal of Neuroscience 32:9238-9247. 
Syková E, Jendelová P (2005) Magnetic resonance tracking of implanted adult and 
embryonic stem cells in injured brain and spinal cord. Annals of the New York 
Academy of Sciences 1049:146-160. 
Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, 
Eidsvoog K, Brem S (1994) Suramin, an anticancer and angiosuppressive 
agent, inhibits endothelial cell binding of basic fibroblast growth factor, 
migration, proliferation, and induction of urokinase-type plasminogen activator. 
Cancer Research 54:2654-2660. 
Takeshima T, Johnston JM, Commissiong JW (1994) Mesencephalic type 1 
astrocytes rescue dopaminergic neurons from death induced by serum 
deprivation. The Journal of Neuroscience 14:4769-4779. 
Takeuchi H, Natsume A, Wakabayashi T, Aoshima C, Shimato S, Ito M, Ishii J, 
Maeda Y, Hara M, Kim SU, Yoshida J (2007) Intravenously transplanted 
human neural stem cells migrate to the injured spinal cord in adult mice in an 
SDF-1- and HGF-dependent manner. Neuroscience Letters 426:69-74. 
Talbott JF, Loy DN, Liu Y, Qiu MS, Bunge MB, Rao MS, Whittemore SR (2005) 
Endogenous Nkx2. 2+/Olig2+ oligodendrocyte precursor cells fail to 
remyelinate the demyelinated adult rat spinal cord in the absence of 
astrocytes. Experimental Neurology 192:11-24. 
Tanaka EM, Ferretti P (2009) Considering the evolution of regeneration in the central 
nervous system. Nature Review Neuroscience 10:713-723. 
Tator CH, Fehlings MG (1991) Review of the secondary injury theory of acute spinal 
cord trauma with emphasis on vascular mechanisms. Journal of Neurosurgery 
75:15-26. 
Taupin P (2007) BrdU immunohistochemistry for studying adult neurogenesis: 
Paradigms, pitfalls, limitations, and validation. Brain Research Reviews 
53:198-214. 
Tavazoie M, Van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B, 
Garcia-Verdugo JM, Doetsch F (2008) A specialized vascular niche for adult 
neural stem cells. Cell Stem Cell 3:279-288. 
Theodosis DT, Bonfanti L, Olive S, Rougon G, Poulain DA (1994) Adhesion 
molecules and structural plasticity of the adult hypothalamo-neurohypophysial 
system. Psychoneuroendocrinology 19:455-462. 
Tohyama T, Lee VMY, Rorke LB, Marvin M, McKay RDG, Trojanowski JQ (1992) 
Nestin expression in embryonic human neuroepithelium and in human 
neuroepithelial tumor cells. Laboratory Investigation 66:303-313. 
Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K (2013) P2X4 receptors and 
neuropathic pain. Frontiers in Cellular Neuroscience 7. 
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, 
Inoue K (2003) P2X4 receptors induced in spinal microglia gate tactile 
allodynia after nerve injury. Nature 424:778-783. 
Tulke S, Williams P, Hellysaz A, Ilegems E, Wendel M, Broberger C (2016) 
Nucleobindin 1 (NUCB1) is a Golgi-resident marker of neurons. Neuroscience 
314:179-188. 
Tysseling VM, Mithal D, Sahni V, Birch D, Jung H, Miller RJ, Kessler JA (2011) SDF1 
in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal 
cord injury. Journal of Neuroinflammation 8:16-16. 
214 
 
Ulrich H, Abbracchio MP, Burnstock G (2012) Extrinsic Purinergic Regulation of 
Neural Stem/Progenitor Cells: Implications for CNS Development and Repair. 
Stem Cell Reviews and Reports 8:755-767. 
van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen 
LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G (2010) 
Optimization of chemically defined cell culture media – Replacing fetal bovine 
serum in mammalian in vitro methods. Toxicology in Vitro 24:1053-1063. 
Van Praag H, Kempermann G, Gage FH (2000) Neural consequences of 
enviromental enrichment. Nature Reviews Neuroscience 1:191-198. 
van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH (2002) 
Functional neurogenesis in the adult hippocampus. Nature 415:1030-1034. 
Veening JG, Barendregt HP (2010) The regulation of brain states by neuroactive 
substances distributed via the cerebrospinal fluid; a review. Cerebrospinal 
Fluid Research 7:1-16. 
Vigh-Teichmann I, Vigh B (1983) The system of cerebrospinal fluid-contacting 
neurons. Archivum Histologicum Japonicum 46:427-468. 
Vigh B, Vigh‐Teichmann I (1998) Actual problems of the cerebrospinal fluid‐
contacting neurons. Microscopy Research and Technique 41:57-83. 
Vigh B, Vigh-Teichmann I, Aros B (1977) Special dendritic and axonal endings 
formed by the cerebrospinal fluid contacting neurons of the spinal cord. Cell 
and Tissue Research 183:541-552. 
Vigh B, Frank C, Vincze C, Czirok S, Szabo A, Lukats A, Szel A (2004) The system of 
cerebrospinal fluid-contacting neurons. Its supposed role in the nonsynaptic 
signal transmission of the brain. Histology and Histopathology 19:607-628. 
Viitanen TM, Sukumaran P, Löf C, Törnquist K (2013) Functional coupling of TRPC2 
cation channels and the calcium-activated anion channels in rat thyroid cells: 
Implications for iodide homeostasis. Journal of Cellular Physiology 228:814-
823. 
Virginio C, North R, Surprenant A (1998) Calcium permeability and block at 
homomeric and heteromeric P2X2 and P2X3 receptors, and P2X receptors in 
rat nodose neurones. The Journal of Physiology 510:27-35. 
Virginio C, MacKenzie A, Rassendren FA, North RA, Surprenant A (1999) Pore 
dilation of neuronal P2X receptor channels. Nature Neuroscience 2:315-321. 
von Kügelgen I, Hoffmann K (2016) Pharmacology and structure of P2Y receptors. 
Neuropharmacology 104:50-61. 
Waldmeier PC, Hertz C, Wicki P, Grunenwald C, Baumann PA (1993) Autoreceptor-
mediated regulation of GABA release: role of uptake inhibition and effects of 
novel GABAB antagonists. Naunyn-Schmiedeberg's Archives of 
Pharmacology 347:514-520. 
Wang W-S, Tu W-Z, Cheng R-D, He R, Ruan L-H, Zhang L, Gong Y-S, Fan X-F, Hu 
J, Cheng B, Lai Y-P, Zou E-M, Jiang S-H (2014) Electroacupuncture and A-
317491 depress the transmission of pain on primary afferent mediated by the 
P2X3 receptor in rats with chronic neuropathic pain states. Journal of 
Neuroscience Research 92:1703-1713. 
Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS, Goldman 
SA, Nedergaard M (2004) P2X7 receptor inhibition improves recovery after 
spinal cord injury. Nature Medicine 10:821-827. 
Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Peterson AC, Reynolds BA 
(1996) Multipotent CNS stem cells are present in the adult mammalian spinal 
cord and ventricular neuroaxis. The Journal of Neuroscience 16:7599-7609. 
215 
 
Weissman TA, Riquelme PA, Ivic L, Flint AC, Kriegstein AR (2004) Calcium Waves 
Propagate through Radial Glial Cells and Modulate Proliferation in the 
Developing Neocortex. Neuron 43:647-661. 
Whedon JM, Glassey D (2009) Cerebrospinal fluid stasis and its clinical significance. 
Alternative Therapies in Health and Medicine 15:54. 
Whish S, Dziegielewska KM, Møllgård K, Noor NM, Liddelow SA, Habgood MD, 
Richardson SJ, Saunders NR (2015) The inner CSF–brain barrier: 
developmentally controlled access to the brain via intercellular junctions. 
Frontiers in Neuroscience 9:16. 
White PJ, Webb TE, Boarder MR (2003) Characterization of a Ca2+ Response to 
Both UTP and ATP at Human P2Y11 Receptors: Evidence for Agonist-
Specific Signaling. Molecular Pharmacology 63:1356-1363. 
Wildman SS, Unwin RJ, King BF (2003) Extended pharmacological profiles of rat 
P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+ and 
Zn2+ ions. British Journal of Pharmacology 140:1177-1186. 
Wildman SS, Brown SG, King BF, Burnstock G (1999) Selectivity of diadenosine 
polyphosphates for rat P2X receptor subunits. European Journal of 
Pharmacology 367:119-123. 
Winocur G, Wojtowicz JM, Sekeres M, Snyder JS, Wang S (2006) Inhibition of 
neurogenesis interferes with hippocampus-dependent memory function. 
Hippocampus 16:296-304. 
Wippold FJ, Perry A (2006) Neuropathology for the Neuroradiologist: Rosettes and 
Pseudorosettes. American Journal of Neuroradiology 27:488-492. 
Wirkner K, Günther A, Weber M, Guzman SJ, Krause T, Fuchs J, Köles L, Nörenberg 
W, Illes P (2007) Modulation of NMDA Receptor Current in Layer V Pyramidal 
Neurons of the Rat Prefrontal Cortex by P2Y Receptor Activation. Cerebral 
Cortex 17:621-631. 
Wyart C, Bene FD, Warp E, Scott EK, Trauner D, Baier H, Isacoff EY (2009) 
Optogenetic dissection of a behavioural module in the vertebrate spinal cord. 
Nature 461:407-410. 
Xu J, Chu KL, Brederson JD, Jarvis MF, McGaraughty S (2012) Spontaneous firing 
and evoked responses of spinal nociceptive neurons are attenuated by 
blockade of P2X3 and P2X2/3 receptors in inflamed rats. Journal of 
Neuroscience Research 90:1597-1606. 
Yamamoto S-i, Nagao M, Sugimori M, Kosako H, Nakatomi H, Yamamoto N, 
Takebayashi H, Nabeshima Y-i, Kitamura T, Weinmaster G (2001) 
Transcription factor expression and Notch-dependent regulation of neural 
progenitors in the adult rat spinal cord. The Journal of Neuroscience 21:9814-
9823. 
Yan S, Li P, Wang Y, Yu W, Qin A, Liu M, Xiang AP, Zhang W, Li W (2016) Nestin 
regulates neural stem cell migration via controlling the cell contractility. The 
International Journal of Biochemistry and Cell Biology 78:349-360. 
Yasui K, Hashizume Y, Yoshida M, Kameyama T, Sobue G (1999) Age-related 
morphologic changes of the central canal of the human spinal cord. Acta 
Neuropathologica 97:253-259. 
Yoshii Y, Furukawa T, Matsumoto H, Yoshimoto M, Kiyono Y, Zhang M-R, 
Fujibayashi Y, Saga T (2016) 64Cu-ATSM therapy targets regions with 
activated DNA repair and enrichment of CD133+ cells in an HT-29 tumor 




Yoshioka K, Saitoh O, Nakata H (2001) Heteromeric association creates a P2Y-like 
adenosine receptor. Proceedings of the National Academy of Sciences 
98:7617-7622. 
Yoshioka K, Saitoh O, Nakata H (2002) Agonist-promoted heteromeric 
oligomerization between adenosine A1 and P2Y1 receptors in living cells. 
FEBS Letters 523:147-151. 
Yu Y, Ugawa S, Ueda T, Ishida Y, Inoue K, Kyaw Nyunt A, Umemura A, Mase M, 
Yamada K, Shimada S (2008) Cellular localization of P2X7 receptor mRNA in 
the rat brain. Brain Research 1194:45-55. 
Zendedel A, Nobakht M, Bakhtiyari M, Beyer C, Kipp M, Baazm M, Joghataie MT 
(2012) Stromal cell-derived factor-1 alpha (SDF-1α) improves neural recovery 
after spinal cord contusion in rats. Brain Research 1473:214-226. 
Zetes DE, Steele CR (1997) Fluid–structure interaction of the stereocilia bundle in 
relation to mechanotransduction. The Journal of the Acoustical Society of 
America 101:3593-3601. 
Zhang X-F, Han P, Faltynek CR, Jarvis MF, Shieh C-C (2005) Functional expression 
of P2X7 receptors in non-neuronal cells of rat dorsal root ganglia. Brain 
Research 1052:63-70. 
Zhang Y, Qi X, Yao Y, Liu Z, Xia C (2013) Expression pattern of transcription factor 
SOX2 in reprogrammed oligodendrocyte precursor cells and microglias: 
Implications for glial neurogenesis. Acta neurobiologiae experimentalis 74:33-
43. 
Zhao C, Deng W, Gage FH (2008) Mechanisms and Functional Implications of Adult 
Neurogenesis. Cell 132:645-660. 
Zhou Y, Yamamoto M, Engel JD (2000) GATA2 is required for the generation of V2 
interneurons. Development 127:3829-3838. 
Zhou Y, Lu Y, Fang X, Zhang J, Li J, Li S, Deng X, Yu Y, Xu R (2015) An Astrocyte 
Regenerative Response from Vimentin-Containing Cells in the Spinal Cord of 
Amyotrophic Lateral Sclerosis's Disease-Like Transgenic (G93A SOD1) Mice. 
Neurodegenerative Diseases 15:1-12. 
Zhou Z, Hume RI (1998) Two mechanisms for inward rectification of current flow 
through the purinoceptor P2X2 class of ATP-gated channels. The Journal of 
Physiology 507:353-364. 
Zhu MH, Sung TS, O'Driscoll K, Koh SD, Sanders KM (2015) Intracellular Ca2+ 
release from endoplasmic reticulum regulates slow wave currents and 
pacemaker activity of interstitial cells of Cajal. American Journal of Physiology 
- Cell Physiology 308:C608-C620. 
Zimmermann H, Zebisch M, Sträter N (2012) Cellular function and molecular 
structure of ecto-nucleotidases. Purinergic Signalling 8:437-502. 
 
 
